<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Document</title>
    <link rel="stylesheet" href="style.css">
</head>
<body style="max-width: 1000px; margin: auto;">
    <div id="root"></div>
    
    <script>
        const data = [
    {
        "name": "Bronchitis",
        "tables": [
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-751\"></a>Table 4.1 – Pathogens most frequently associated with acute bronchitis (in descending order of frequency)</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Respiratory viruses</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Rhinovirus</p>\n<p class=\"box_p1\">Influenza virus (A and B)</p>\n<p class=\"box_p1\">Parainfluenza virus</p>\n<p class=\"box_p1\">Coronavirus (including SARS-CoV-2)</p>\n<p class=\"box_p1\">Respiratory syncytial virus</p>\n<p class=\"box_p1\">Metapneumovirus</p>\n<p class=\"box_p1\">Adenovirus</p>\n<p class=\"box_p1\">Other respiratory viruses</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\">\n<p class=\"legenda\">SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.</p>\n<p class=\"legenda\">Note. Nearly all cases of acute bronchitis have a viral origin. Only in a very small proportion of cases, are atypical pathogens (<em class=\"calibre10\">Mycoplasma pneumoniae</em>, <em class=\"calibre10\">Chlamydia pneumoniae</em>) involved. Atypical bacteria are intracellular and are colourless with Gram staining. They also have intrinsic resistance to beta-lactams either because they lack a cell wall (<em class=\"calibre10\">Mycoplasma</em>) and / or are intracellular pathogens (<em class=\"calibre10\">Chlamydia</em>).</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-94\" role=\"doc-pagebreak\" title=\"35\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-752\"></a>Table 4.2 – Medicines to consider for symptomatic treatment of acute bronchitis</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color1\" colspan=\"3\">\n<p class=\"box_tit1\"><img alt=\"Imagem\" class=\"calibre26\" src=\"images/000133.jpg\"/> <strong class=\"calibre5\">Important</strong></p>\n<p class=\"box_p1\">Medicines are listed in alphabetical order and they should all be considered equal treatment options.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Medicine</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Formulation</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Dose and frequency</strong></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Ibuprofen<sup class=\"calibre30\">a</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Oral liquid: 200 mg/5 mL</p>\n<p class=\"box_p1\">Tablet: 200 mg; 400 mg; 600 mg</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Adults</strong>: 200–400 mg given every 6 to 8 hours (maximum dose of 2.4 g a day)</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Children</strong>:</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">Pain control/antipyretic treatment: 5–10 mg/kg given every 6 to 8 hours</li>\n</ul>\n<p class=\"box_p1\">6–&lt; 10 kg: 50 mg given every 8 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 100 mg given every 8 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 150 mg given every 8 hours</p>\n<p class=\"box_p1\">20–&lt; 30 kg: 200 mg given every 8 hours</p>\n<p class=\"box_p1\">≥ 30 kg: use adult dose</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Paracetamol (acetaminophen)<sup class=\"calibre30\">b</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Oral liquid: 120 mg/5 mL; 125 mg/5 mL</p>\n<p class=\"box_p1\">Suppository: 100 mg</p>\n<p class=\"box_p1\">Tablet: 100 mg to 500 mg</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Adults</strong>: 500 mg–1 g given every 4 to 6 hours (maximum dose of 4 g a day)<sup class=\"calibre30\">c</sup></p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Children</strong>:</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">Pain control/antipyretic treatment: 10–15 mg/kg given every 6 hours</li>\n</ul>\n<p class=\"box_p1\">3–&lt; 6 kg: 60 mg given every 6 hours</p>\n<p class=\"box_p1\">6–&lt; 10 kg: 100 mg given every 6 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 150 mg given every 6 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 200 mg given every 6 hours</p>\n<p class=\"box_p1\">20–&lt; 30 kg: 300 mg given every 6 hours</p>\n<p class=\"box_p1\">≥ 30 kg: use adult dose</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> Not for children &lt; 3 months.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">b</sup> Not recommended for use as an anti-inflammatory as it has not been proven to have such an effect.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">c</sup> In patients with hepatic impairment or cirrhosis, maximum daily dose should be 2 g.</p>\n</td>\n</tr>\n</tfoot>\n</table>"
        ]
    },
    {
        "name": "Acute otitis media",
        "tables": [
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-753\"></a>Table 5.1 – Pathogens most frequently associated with acute otitis media (in descending order of frequency)</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Respiratory viruses (most cases)</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Bacteria (rarely)</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Respiratory syncytial virus</p>\n<p class=\"box_p1\">Rhinovirus</p>\n<p class=\"box_p1\">Coronavirus (including SARS-CoV-2)</p>\n<p class=\"box_p1\">Influenza virus (A and B)</p>\n<p class=\"box_p1\">Other respiratory viruses</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><em class=\"calibre10\">Streptococcus pneumoniae</em></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Haemophilus influenzae</em></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Moraxella catarrhalis</em></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Streptococcus pyogenes</em> (group A <em class=\"calibre10\">Streptococcus</em>)</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"2\">\n<p class=\"legenda\">SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-102\" role=\"doc-pagebreak\" title=\"43\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-755\"></a>Table 5.2 – Medicines to consider for pain control of acute otitis media</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color1\" colspan=\"3\">\n<p class=\"box_tit1\"><img alt=\"Imagem\" class=\"calibre26\" src=\"images/000133.jpg\"/> <strong class=\"calibre5\">Important</strong></p>\n<p class=\"box_p1\">Medicines are listed in alphabetical order and they should all be considered equal treatment options.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Medicine</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Formulation</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Dose and frequency</strong></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Ibuprofen<sup class=\"calibre30\">a</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Oral liquid: 200 mg/5 mL</p>\n<p class=\"box_p1\">Tablet: 200 mg; 400 mg; 600 mg</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Adults: 200–400 mg given every 6 to 8 hours (maximum dose of 2.4 g a day)</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Children</strong>:</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">Pain control/antipyretic treatment: 5–10 mg/kg given every 6 to 8 hours</li>\n</ul>\n<p class=\"box_p1\">6–&lt; 10 kg: 50 mg given every 8 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 100 mg given every 8 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 150 mg given every 8 hours</p>\n<p class=\"box_p1\">20–&lt; 30 kg: 200 mg given every 8 hours</p>\n<p class=\"box_p1\">≥ 30 kg: use adult dose</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Paracetamol (acetaminophen)<sup class=\"calibre30\">b</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Oral liquid: 120 mg/5 mL; 125 mg/5 mL</p>\n<p class=\"box_p1\">Suppository: 100 mg</p>\n<p class=\"box_p1\">Tablet: 100 mg to 500 mg</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Adults</strong>: 500 mg–1 g given every 4 to 6 hours (maximum dose of 4 g a day)<sup class=\"calibre30\">c</sup></p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Children</strong>:</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">Pain control/antipyretic treatment: 10–15 mg/kg given every 6 hours</li>\n</ul>\n<p class=\"box_p1\">3–&lt; 6 kg: 60 mg given every 6 hours</p>\n<p class=\"box_p1\">6–&lt; 10 kg: 100 mg given every 6 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 150 mg given every 6 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 200 mg given every 6 hours</p>\n<p class=\"box_p1\">20–&lt; 30 kg: 300 mg given every 6 hours</p>\n<p class=\"box_p1\">≥ 30 kg: use adult dose</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> Not for children &lt; 3 months.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">b</sup> Not recommended for use as an anti-inflammatory as it has not been proven to have such an effect.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">c</sup> In patients with hepatic impairment or cirrhosis, maximum daily dose should be 2 g.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-756\"></a>Table 5.3 – Empiric antibiotic treatment for acute bacterial otitis media</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color1\" colspan=\"4\">\n<p class=\"box_tit1\"><img alt=\"Imagem\" class=\"calibre26\" src=\"images/000133.jpg\"/> <strong class=\"calibre5\">Important</strong></p>\n<p class=\"box_p1\">Antibiotic treatment is not required in the great majority of cases (see Antibiotic treatment section)</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"colort\"></td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Adults</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Children</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Total treatment duration <em class=\"calibre10\">(49–51)</em></strong></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">First choice</strong></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_verde\">Amoxicillin</span>(oral): 500 mg given every 8 hours</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_verde\">Amoxicillin</span>(oral): 80–90 mg/kg/day</p>\n<p class=\"box_p1\">Oral weight bands:</p>\n<p class=\"box_p1\">3–6 kg: 250 mg given every 12 hours</p>\n<p class=\"box_p1\">6–&lt; 10 kg: 375 mg given every 12 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 500 mg given every 12 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 750 mg given every 12 hours</p>\n<p class=\"box_p1\">≥ 20 kg: 500 mg given every 8 hours or 1 g given every 12 hours</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">5 days</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"calibre6\" id=\"calibre_link-104\" role=\"doc-pagebreak\" title=\"45\" type=\"pagebreak\"></span><strong class=\"calibre5\">Second choice</strong></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_verde\">Amoxicillin+ clavulanic acid</span>(oral): 500 mg + 125 mg given every 8 hours</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_verde\">Amoxicillin+clavulanic acid</span><sup class=\"calibre30\">a</sup> (oral): 80–90 mg/kg/day of amoxicillin component</p>\n<p class=\"box_p1\">Oral weight bands:</p>\n<p class=\"box_p1\">3–&lt; 6 kg: 250 mg of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p1\">6–&lt; 10 kg: 375 mg of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 500 mg of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 750 mg of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p1\">≥ 20 kg: 500 mg of amoxicillin/dose given every 8 hours or 1 g of amoxicillin/dose given every 12 hours</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">5 days</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"4\">\n<p class=\"legenda\">Note. All dosages are for normal renal and hepatic function.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> Oral liquid formulations must be refrigerated after reconstitution as clavulanic acid is rapidly metabolized in high ambient temperatures.</p>\n<p class=\"legenda\">Legend: ACCESS antibiotics are indicated in green, WATCH antibiotics in orange and RESERVE antibiotics in red.</p>\n</td>\n</tr>\n</tfoot>\n</table>"
        ]
    },
    {
        "name": "Pharyngitis",
        "tables": [
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-757\"></a>Table 6.1 – Pathogens most frequently associated with pharyngitis (in descending order of frequency)</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Viruses (most cases)</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Bacteria (rarely)</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Respiratory syncytial virus</p>\n<p class=\"box_p1\">Rhinovirus</p>\n<p class=\"box_p1\">Coronavirus (including SARS-CoV-2)</p>\n<p class=\"box_p1\">Influenza virus (A and B)</p>\n<p class=\"box_p1\">Other respiratory viruses</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Other viruses (rarely)</strong></p>\n<p class=\"box_p1\">Epstein–Barr virus</p>\n<p class=\"box_p1\">HIV</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><em class=\"calibre10\">Streptococcus pyogenes</em> (group A <em class=\"calibre10\">Streptococcus</em>)</p>\n<p class=\"box_p1\">Group C <em class=\"calibre10\">Streptococcus</em></p>\n<p class=\"box_p1\">Group G <em class=\"calibre10\">Streptococcus</em></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Treponema pallidum</em></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Neisseria gonorrhoeae</em></p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"2\">\n<p class=\"legenda\">HIV: human immunodeficiency virus; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-758\"></a>Table 6.2 – Centor score for the clinical assessment of pharyngitis</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Relevant signs and symptoms</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Points</strong></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Fever &gt; 38.0 °C</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">1</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">No cough</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">1</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Tender anterior cervical lymphadenitis</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">1</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Tonsillar exudates</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">1</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"colort\">\n<p class=\"box_p3\"><strong class=\"calibre5\">Total score</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"box_p3\"><strong class=\"calibre5\">Likelihood of <em class=\"calibre10\">Streptococcus pyogenes</em> infection (%)</strong></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">0</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">1–2.5</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">1</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">5–10</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">2</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">11–17</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">3</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">28–35</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\"><span class=\"calibre6\" id=\"calibre_link-113\" role=\"doc-pagebreak\" title=\"54\" type=\"pagebreak\"></span>4</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">51–53</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Centor score 0 – 1 – 2</strong></p>\n</td>\n<td class=\"calibre29\">\n<ul class=\"tab\">\n<li class=\"box_li1\"><em class=\"calibre10\">Streptococcus pyogenes</em> pharyngitis unlikely</li>\n<li class=\"box_li1\">Give symptomatic treatment only</li>\n</ul>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p3\"><strong class=\"calibre5\">Centor score 3 – 4</strong></p>\n</td>\n<td class=\"color\">\n<ul class=\"tab\">\n<li class=\"box_li1\">Score suggestive of <em class=\"calibre10\">Streptococcus pyogenes</em> pharyngitis</li>\n<li class=\"box_li1\">In countries with a low prevalence of rheumatic fever, antibiotic treatment can be withheld even in cases of likely <em class=\"calibre10\">Streptococcus pyogenes</em> pharyngitis</li>\n<li class=\"box_li1\">In countries with medium to high prevalence of rheumatic fever, antibiotic treatment is recommended as it reduces the likelihood of developing rheumatic fever by around two thirds.</li>\n</ul>\n</td>\n</tr>\n</tbody>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-759\"></a>Table 6.3 – Microbiology tests that could be considered if available for the diagnosis of pharyngitis as indicated in the WHO EDL <em class=\"calibre10\">(6)</em></strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Diagnostic test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Purpose of the test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Settings where the test should be available</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Group A <em class=\"calibre10\">Streptococcus</em> antigen<sup class=\"calibre30\">a</sup> (RDT)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To aid in the diagnosis of Group A streptococcal pharyngitis</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Community settings and health facilities without laboratories<sup class=\"calibre30\">b</sup></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\"><span class=\"calibre6\" id=\"calibre_link-114\" role=\"doc-pagebreak\" title=\"55\" type=\"pagebreak\"></span>Throat culture</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">First step in detection and identification of bacterial species for selection of appropriate antibiotic regimens</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">EDL: Model List of Essential In Vitro Diagnostics; RDT: rapid diagnostic test.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> Possible specimens include: throat swabs.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">b</sup> <sup class=\"calibre30\"></sup> Community and health settings without laboratories are settings such as health posts and centres, doctors’ offices, outreach clinics, ambulatory care. These tests are also assumed to be available at health care facilities with laboratories.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-760\"></a>Table 6.4 – Medicines to consider for pain control of pharyngitis</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color1\" colspan=\"3\">\n<p class=\"box_tit1\"><img alt=\"Imagem\" class=\"calibre26\" src=\"images/000133.jpg\"/> <strong class=\"calibre5\">Important</strong></p>\n<p class=\"box_p1\">Medicines are listed in alphabetical order and they should all be considered equal treatment options.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Medicine</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Formulation</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Dose and frequency</strong></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Ibuprofen<sup class=\"calibre30\">a</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Oral liquid: 200 mg/5 mL</p>\n<p class=\"box_p1\">Tablet: 200 mg; 400 mg; 600 mg</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Adults</strong>: 200–400 mg given every 6 to 8 hours (maximum dose of 2.4 g a day)</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Children</strong>:</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">Pain control/antipyretic treatment: 5–10 mg/kg given every 6 to 8 hours</li>\n</ul>\n<p class=\"box_p1\">6–&lt; 10 kg: 50 mg given every 8 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 100 mg given every 8 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 150 mg given every 8 hours</p>\n<p class=\"box_p1\">20–&lt; 30 kg: 200 mg given every 8 hours</p>\n<p class=\"box_p1\">≥ 30 kg: use adult dose</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Paracetamol (acetaminophen)<sup class=\"calibre30\">b</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Oral liquid: 120 mg/5 mL; 125 mg/5 mL</p>\n<p class=\"box_p1\">Suppository: 100 mg</p>\n<p class=\"box_p1\">Tablet: 100 mg to 500 mg</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Adults</strong>: 500 mg–1 g given every 4 to 6 hours (maximum dose of 4 g a day)<sup class=\"calibre30\">c</sup></p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Children</strong>:</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">Pain control/antipyretic treatment: 10–15 mg/kg given every 6 hours</li>\n</ul>\n<p class=\"box_p1\">3–&lt; 6 kg: 60 mg given every 6 hours</p>\n<p class=\"box_p1\">6–&lt; 10 kg: 100 mg given every 6 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 150 mg given every 6 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 200 mg given every 6 hours</p>\n<p class=\"box_p1\">20–&lt; 30 kg: 300 mg given every 6 hours</p>\n<p class=\"box_p1\">≥ 30 kg: use adult dose</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> Not for children &lt; 3 months.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">b</sup> Not recommended for use as an anti-inflammatory as it has not been proven to have such an effect.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">c</sup> In patients with hepatic impairment or cirrhosis, maximum daily dose should be 2 g.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-117\" role=\"doc-pagebreak\" title=\"58\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-761\"></a>Table 6.5 – Empiric antibiotic treatment in patients with a high likelihood of <em class=\"calibre10\">Streptococcus pyogenes</em>pharyngitis</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color2\" colspan=\"4\">\n<p class=\"box_tit1\"><img alt=\"Imagem\" class=\"calibre26\" src=\"images/000166.jpg\"/> <strong class=\"calibre5\">Note</strong></p>\n<p class=\"box_p1\">The only clear indication for antibiotic treatment is to reduce the probability of developing rheumatic fever in endemic settings; however, after 21 years of age, the risk of rheumatic fever is lower.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color1\" colspan=\"4\">\n<p class=\"box_tit1\"><img alt=\"Imagem\" class=\"calibre26\" src=\"images/000133.jpg\"/> <strong class=\"calibre5\">Important</strong></p>\n<p class=\"box_p1\">Where more than one antibiotic is recommended for an infection, they are listed in alphabetical order and they should be considered equal treatment options, unless otherwise indicated.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"colort\"></td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Adults</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Children</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Total treatment duration <em class=\"calibre10\">(67,68)</em></strong></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">First choice</strong></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_verde\">Amoxicillin</span>(oral): 500 mg given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Phenoxymethylpenicillin </span> (oral): 500 mg (800 000 IU<sup class=\"calibre30\">a</sup> ) given every 6 hours</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_verde\">Amoxicillin</span>(oral): 80–90 mg/kg/day</p>\n<p class=\"box_p1\">Oral weight bands:</p>\n<p class=\"box_p1\">3–6 kg: 250 mg given every 12 hours</p>\n<p class=\"box_p1\">6–&lt; 10 kg: 375 mg given every 12 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 500 mg given every 12 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 750 mg given every 12 hours</p>\n<p class=\"box_p1\">≥ 20 kg: 500 mg given every 8 hours or 1 g given every 12 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Phenoxymethylpenicillin</span> (oral): 10–15 mg/kg/dose (16 000–24 000 IU/kg/dose<sup class=\"calibre30\">a</sup> ) given every 6 to 8 hours</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">5<sup class=\"calibre30\">b</sup> or 10<sup class=\"calibre30\">c</sup> days depending on the local prevalence or previous history of rheumatic fever</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"calibre6\" id=\"calibre_link-118\" role=\"doc-pagebreak\" title=\"59\" type=\"pagebreak\"></span><strong class=\"calibre5\">Second choice</strong></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_verde\">Cefalexin</span>(oral): 500 mg given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Clarithromycin</span><sup class=\"calibre30\">d</sup> (oral): 500 mg given every 12 hours</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_verde\">Cefalexin</span>(oral): 25 mg/kg/dose given every 12 hours</p>\n<p class=\"box_p1\">Oral weight bands:</p>\n<p class=\"box_p1\">3–&lt; 6 kg: 125 mg given every 12 hours</p>\n<p class=\"box_p1\">6–&lt; 10 kg: 250 mg given every 12 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 375 mg given every 12 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg 500 mg given every 12 hours</p>\n<p class=\"box_p1\">20–&lt; 30 kg: 625 mg given every 12 hours</p>\n<p class=\"box_p1\">≥ 30 kg: use adult dose</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Clarithromycin</span><sup class=\"calibre30\">d</sup> (oral): 7.5 mg/kg/dose given every 12 hours</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">5 days</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"4\">\n<p class=\"legenda\">IU: international units.</p>\n<p class=\"legenda\">Note. All dosages are for normal renal and hepatic function.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> Units of the potassium salt.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">b</sup> In settings with a low prevalence of rheumatic fever or in patients with no history of rheumatic fever or rheumatic heart disease.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">c</sup> In settings with a high prevalence of rheumatic fever or in patients with a history of rheumatic fever or rheumatic heart disease and who are aged between 3 and 21 years.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">d</sup> In settings with a high prevalence of macrolide resistance among <em class=\"calibre10\">Streptococcus pyogenes</em>, clarithromycin should not be recommended for the empiric treatment of <em class=\"calibre10\">Streptococcus pyogenes</em>pharyngitis. Azithromycin could be used as an alternative (e.g. when clarithromycin is not available) but there are increasing concerns about its potential for the emergence and spread of antibiotic resistance because of its long half-life.</p>\n<p class=\"legenda\">ACCESS antibiotics are highlighted in green, WATCH antibiotics in orange and RESERVE antibiotics in red.</p>\n</td>\n</tr>\n</tfoot>\n</table>"
        ]
    },
    {
        "name": "Acute sinusitis",
        "tables": [
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-762\"></a>Table 7.1 – Pathogens most frequently associated with acute sinusitis (in descending order of frequency)</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Respiratory viruses (most cases)</strong><sup class=\"calibre32\">a</sup></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Bacteria</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Influenza virus (A and B)</p>\n<p class=\"box_p1\">Respiratory syncytial virus</p>\n<p class=\"box_p1\">Parainfluenza virus</p>\n<p class=\"box_p1\">Rhinovirus</p>\n<p class=\"box_p1\">Coronavirus (including SARS-CoV-2)</p>\n<p class=\"box_p1\">Other respiratory viruses</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Rarely</strong></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Streptococcus pneumoniae</em></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Haemophilus influenzae</em></p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Very rarely</strong></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Moraxella catarrhalis</em></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Streptococcus pyogenes</em> (group A <em class=\"calibre10\">Streptococcus</em>)</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Staphylococcus aureus</em></p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"2\">\n<p class=\"legenda\">SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> About 98% of cases are caused by respiratory viruses.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-128\" role=\"doc-pagebreak\" title=\"69\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-763\"></a>Table 7.2 – Medicines to consider for symptomatic treatment of acute sinusitis</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color1\" colspan=\"3\">\n<p class=\"box_tit1\"><img alt=\"Imagem\" class=\"calibre26\" src=\"images/000133.jpg\"/> <strong class=\"calibre5\">Important</strong></p>\n<p class=\"box_p1\">Medicines are listed in alphabetical order and they should all be considered equal treatment options.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Medicine</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Formulation</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Dose and frequency</strong></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Ibuprofen<sup class=\"calibre30\">a</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Oral liquid: 200 mg/5 mL</p>\n<p class=\"box_p1\">Tablet: 200 mg; 400 mg; 600 mg</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Adults</strong>: 200–400 mg given every 6 to 8 hours (maximum dose of 2.4 g a day)</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Children</strong>:</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">Pain control/antipyretic treatment: 5–10 mg/kg given every 6 to 8 hours</li>\n</ul>\n<p class=\"box_p1\">6–&lt; 10 kg: 50 mg given every 8 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 100 mg given every 8 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 150 mg given every 8 hours</p>\n<p class=\"box_p1\">20–&lt; 30 kg: 200 mg given every 8 hours</p>\n<p class=\"box_p1\">≥ 30 kg: use adult dose</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Paracetamol (acetaminophen)<sup class=\"calibre30\">b</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Oral liquid: 120 mg/5 mL; 125 mg/5 mL</p>\n<p class=\"box_p1\">Suppository: 100 mg</p>\n<p class=\"box_p1\">Tablet: 100 mg to 500 mg</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Adults</strong>: 500 mg–1 g given every 4 to 6 hours (maximum dose of 4 g a day)<sup class=\"calibre30\">c</sup></p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Children</strong>:</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">Pain control/antipyretic treatment: 10–15 mg/kg given every 6 hours</li>\n</ul>\n<p class=\"box_p1\">3–&lt; 6 kg: 60 mg given every 6 hours</p>\n<p class=\"box_p1\">6–&lt; 10 kg: 100 mg given every 6 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 150 mg given every 6 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 200 mg given every 6 hours</p>\n<p class=\"box_p1\">20–&lt; 30 kg: 300 mg given every 6 hours</p>\n<p class=\"box_p1\">≥ 30 kg: use adult dose</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> Not for children &lt; 3 months.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">b</sup> Not recommended for use as an anti-inflammatory as it has not been proven to have such an effect.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">c</sup> In patients with hepatic impairment or cirrhosis, maximum daily dose should be 2 g.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-130\" role=\"doc-pagebreak\" title=\"71\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-764\"></a>Table 7.3 – Empiric antibiotic treatment for bacterial sinusitis</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color2\" colspan=\"3\">\n<p class=\"box_tit1\"><img alt=\"Imagem\" class=\"calibre26\" src=\"images/000166.jpg\"/> <strong class=\"calibre5\">Note</strong></p>\n<p class=\"box_p1\">Antibiotic treatment is not required in the great majority of cases: see Antibiotic treatment section.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color1\" colspan=\"3\">\n<p class=\"box_tit1\"><img alt=\"Imagem\" class=\"calibre26\" src=\"images/000133.jpg\"/> <strong class=\"calibre5\">Important</strong></p>\n<p class=\"box_p1\">Where more than one antibiotic is recommended for an infection, they are listed in alphabetical order and they should be considered equal treatment options, unless otherwise indicated.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Adults</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Children</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Total treatment duration <em class=\"calibre10\">(72)</em></strong></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_verde\">Amoxicillin</span>(oral): 1 g given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Amoxicillin+clavulanic acid</span> (oral): 500 mg + 125 mg given every 8 hours</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_verde\">Amoxicillin</span>(oral): 80–90 mg/kg/day</p>\n<p class=\"box_p1\">Oral weight bands:</p>\n<p class=\"box_p1\">3–&lt; 6 kg: 250 mg given every 12 hours</p>\n<p class=\"box_p1\">6–&lt; 10 kg: 375 mg given every 12 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 500 mg given every 12 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 750 mg given every 12 hours</p>\n<p class=\"box_p1\">≥ 20 kg: 500 mg given every 8 hours or 1 g given every 12 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Amoxicillin+clavulanic acid</span><sup class=\"calibre30\">a</sup> (oral): 80–90 mg/kg/day of amoxicillin component</p>\n<p class=\"box_p1\">Oral weight bands:</p>\n<p class=\"box_p1\">3–&lt; 6 kg: 250 mg of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p1\">6–&lt; 10 kg: 375 mg of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 500 mg of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 750 mg of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p1\">≥ 20 kg: 500 mg of amoxicillin/dose given every 8 hours or 1 g of amoxicillin/dose given every 12 hours</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">5 days</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">Note. All dosages are for normal renal and hepatic function.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> Oral liquid formulations must be refrigerated after reconstitution as clavulanic acid is rapidly metabolized in high ambient temperatures.</p>\n<p class=\"legenda\">Legend: ACCESS antibiotics are indicated in green, WATCH antibiotics in orange and RESERVE antibiotics in red.</p>\n</td>\n</tr>\n</tfoot>\n</table>"
        ]
    },
    {
        "name": "Oral and dental infections",
        "tables": [
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-766\"></a>Table 8.1 – Normal resident oral microbiota and pathogens most frequently associated with dental infections (in descending order of frequency)</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Normal resident oral microbiota</strong><sup class=\"calibre32\">a</sup></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Bacteria associated with caries</strong><sup class=\"calibre32\">b</sup></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Bacteria associated with periodontal disease</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><em class=\"calibre10\">Streptococcus</em> spp.</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Actinomyces</em> spp.</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Prevotella</em> spp.</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Veillonella</em> spp.</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><em class=\"calibre10\">Streptococcus</em> spp. (e.g. <em class=\"calibre10\">Streptococcus mutans</em>)</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Lactobacillus</em> spp.</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Actinomyces</em> spp.</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Anaerobes (most cases), e.g.:</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Prevotella</em> spp.</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Capnocytophaga</em> spp.</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Aggregatibacter</em> spp.</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Porphyromonas</em> spp.</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> A richly diverse group of pathogens, including both aerobic bacteria and anaerobes.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">b</sup> Mostly acidogenic bacteria</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-772\"></a>Table 8.2 – Medicines to control acute dental pain</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color1\" colspan=\"3\">\n<p class=\"box_tit1\"><img alt=\"Imagem\" class=\"calibre26\" src=\"images/000133.jpg\"/> <strong class=\"calibre5\">Important</strong></p>\n<p class=\"box_p1\">Medicines are listed in alphabetical order and they should all be considered equal treatment options.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Medicine</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Formulation</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Dose and frequency</strong></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Ibuprofen<sup class=\"calibre30\">a</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Oral liquid: 200 mg/5 mL</p>\n<p class=\"box_p1\">Tablet: 200 mg; 400 mg; 600 mg</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Adults</strong>: 200–400 mg given every 6 to 8 hours (maximum dose of 2.4 g a day)</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Children</strong>:</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">Pain control/antipyretic treatment: 5–10 mg/kg given every 6 to 8 hours</li>\n</ul>\n<p class=\"box_p1\">6–&lt; 10 kg: 50 mg given every 8 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 100 mg given every 8 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 150 mg given every 8 hours</p>\n<p class=\"box_p1\">20–&lt; 30 kg: 200 mg given every 8 hours</p>\n<p class=\"box_p1\">≥ 30 kg: use adult dose</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"calibre6\" id=\"calibre_link-149\" role=\"doc-pagebreak\" title=\"90\" type=\"pagebreak\"></span>Paracetamol (acetaminophen)<sup class=\"calibre30\">b</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Oral liquid: 120 mg/5 mL; 125 mg/5 mL</p>\n<p class=\"box_p1\">Suppository: 100 mg</p>\n<p class=\"box_p1\">Tablet: 100 mg to 500 mg</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Adults</strong>: 500 mg–1 g given every 4 to 6 hours (maximum dose of 4 g a day)<sup class=\"calibre30\">c</sup></p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Children</strong>:</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">Pain control/antipyretic treatment: 10–15 mg/kg given every 6 hours</li>\n</ul>\n<p class=\"box_p1\">3–&lt; 6 kg: 60 mg given every 6 hours</p>\n<p class=\"box_p1\">6–&lt; 10 kg: 100 mg given every 6 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 150 mg given every 6 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 200 mg given every 6 hours</p>\n<p class=\"box_p1\">20–&lt; 30 kg: 300 mg given every 6 hours</p>\n<p class=\"box_p1\">≥ 30 kg: use adult dose</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> Not for children &lt; 3 months, or for people with hypersensitivity to aspirin or any other NSAID (non-steroidal anti-inflammatory drug), or for people with a history of gastrointestinal bleeding or ulceration.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">b</sup> Not recommended for use as an anti-inflammatory as it has not been proven to have such an effect. Warning: overdose is relatively common among people with severe dental pain.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">c</sup> In patients with hepatic impairment or cirrhosis, maximum daily dose should be 2 g.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-150\" role=\"doc-pagebreak\" title=\"91\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-773\"></a>Table 8.3 – Commonly performed procedures for certain dental diseases</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Dental disease</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Procedure</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p3\"><strong class=\"calibre5\">Abscess</strong></p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">1. Apical abscess</p>\n<p class=\"box_p1\">Source control through:</p>\n<ul class=\"calibre22\">\n<li class=\"calibre13\">Tooth extraction</li>\n<li class=\"calibre13\">Pulp extirpation (drainage of pus and removal of necrotic pulp tissue by drilling through the tooth into the pulp) followed by root canal treatment</li>\n</ul>\n<p class=\"box_p1\"><strong class=\"calibre5\">OR</strong></p>\n<ul class=\"calibre22\">\n<li class=\"calibre13\">Soft tissue incision and drainage followed by tooth extraction or root canal treatment.</li>\n</ul>\n<p class=\"box_p1\">2. Periodontal abscess</p>\n<p class=\"box_p1\">Source control through:</p>\n<ul class=\"calibre22\">\n<li class=\"calibre13\">Tooth extraction</li>\n</ul>\n<p class=\"box_p1\"><strong class=\"calibre5\">OR</strong></p>\n<ul class=\"calibre22\">\n<li class=\"calibre13\">Drainage of any pus collection by professional cleaning of the periodontal tissues.</li>\n</ul>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Apical periodontitis/pulpal necrosis</strong></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Source control through:</p>\n<ul class=\"calibre22\">\n<li class=\"calibre13\">Tooth extraction</li>\n</ul>\n<p class=\"box_p1\"><strong class=\"calibre5\">OR</strong></p>\n<ul class=\"calibre22\">\n<li class=\"calibre13\">Pulp extirpation (drainage of pus and removal of necrotic pulp tissue by drilling through the tooth into the pulp) followed by root canal treatment</li>\n</ul>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p3\"><strong class=\"calibre5\">Dental caries (decay)/reversible pulpitis</strong></p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Removal of caries and restorative filling</p>\n<p class=\"box_p1\">Where access to dental care is not readily available or for people who are unable to accept a dental procedure (e.g. due to dental phobia), silver diamine fluoride may be appropriate to stop progression of the caries.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Dry socket (alveolar osteitis)</strong></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Reassurance that this is a common yet painful outcome</p>\n<p class=\"box_p1\">Irrigation of the socket with saline</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p3\"><strong class=\"calibre5\">Pericoronitis</strong></p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Source control through:</p>\n<ul class=\"calibre22\">\n<li class=\"calibre13\">Tooth extraction</li>\n</ul>\n<p class=\"box_p1\"><strong class=\"calibre5\">OR</strong></p>\n<ul class=\"calibre22\">\n<li class=\"calibre13\">Drainage of any pus collection by irrigation under the operculum (flap of gum over the erupting tooth) with saline</li>\n</ul>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"calibre6\" id=\"calibre_link-151\" role=\"doc-pagebreak\" title=\"92\" type=\"pagebreak\"></span><strong class=\"calibre5\">Pulpitis (when irreversible)</strong></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Source control through:</p>\n<ul class=\"calibre22\">\n<li class=\"calibre13\">Tooth extraction</li>\n</ul>\n<p class=\"box_p1\"><strong class=\"calibre5\">OR</strong></p>\n<ul class=\"calibre22\">\n<li class=\"calibre13\">Pulp extirpation (removal of the inflamed pulp and treatment of the root canal)</li>\n</ul>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p3\"><strong class=\"calibre5\">Necrotizing periodontal disease (previously known as necrotizing ulcerative gingivitis)</strong><sup class=\"calibre30\">a</sup></p>\n</td>\n<td class=\"color\">\n<ul class=\"tab\">\n<li class=\"box_li1\">Regular toothbrushing with a fluoride-containing toothpaste and use of an interdental brush or dental floss to remove plaque</li>\n<li class=\"box_li1\">Professional cleaning around the teeth and periodontal tissues to remove the mineralized material known as scale, tartar or calculus</li>\n<li class=\"box_li1\">Smoking cessation advice</li>\n</ul>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Noma</strong></p>\n</td>\n<td class=\"calibre29\">\n<ul class=\"tab\">\n<li class=\"box_li1\">Please refer to the WHO guidance for early detection and management of noma <em class=\"calibre10\">(77)</em></li>\n</ul>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"2\">\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> Necrotizing periodontal disease can often be resolved by procedures alone – antibiotics are often not required.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-153\" role=\"doc-pagebreak\" title=\"94\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-774\"></a>Table 8.4 – Empiric antibiotic treatment for selected cases of severe dental infections</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color2\" colspan=\"3\">\n<p class=\"box_tit1\"><img alt=\"Imagem\" class=\"calibre26\" src=\"images/000166.jpg\"/> <strong class=\"calibre5\">Note</strong></p>\n<p class=\"box_p1\">Antibiotic treatment is not required for most dental conditions. Dental procedures (e.g. drainage of an abscess and tooth extraction) are the main treatment.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color1\" colspan=\"3\">\n<p class=\"box_tit1\"><img alt=\"Imagem\" class=\"calibre26\" src=\"images/000133.jpg\"/> <strong class=\"calibre5\">Important</strong></p>\n<p class=\"box_p1\">Where more than one antibiotic is recommended for an infection, they are listed in alphabetical order and they should be considered equal treatment options, unless otherwise indicated.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Adults</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Children</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Total treatment duration</strong></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_verde\">Amoxicillin</span><sup class=\"calibre30\">a</sup> (oral): 500 mg given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Phenoxymethylpenicillin</span><sup class=\"calibre30\">a</sup> (oral): 500 mg (800 000 IU<sup class=\"calibre30\">b</sup> ) given every 6 hours</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_verde\">Amoxicillin</span><sup class=\"calibre30\">a</sup> (oral): 80–90 mg/kg/day</p>\n<p class=\"box_p1\">Oral weight bands:</p>\n<p class=\"box_p1\">3–&lt; 6 kg: 250 mg given every 12 hours</p>\n<p class=\"box_p1\">6–&lt; 10 kg: 375 mg given every 12 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 500 mg given every 12 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 750mg given every 12 hours</p>\n<p class=\"box_p1\">≥ 20 kg: 500 mg given every 8 hours or 1 g given every 12 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Phenoxymethylpenicillin</span><sup class=\"calibre30\">a</sup> (oral): 10–15 mg/kg/dose (16 000–24 000 IU/kg/dose<sup class=\"calibre30\">b</sup> ) given every 6 to 8 hours</p>\n<p class=\"box_p1\">≥ 30 kg: use adult dose</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">3 days, if adequate source control is achieved; otherwise 5 days<sup class=\"calibre30\">c</sup></p>\n<p class=\"box_p1\">Patients should be reassessed before the end of treatment to check the resolution of the infection.</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">IU: international units.</p>\n<p class=\"legenda\">Note. All dosages are for normal renal and hepatic function.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> For the treatment of infections of the dental soft tissues (e.g. pericoronitis or necrotizing periodontal disease), metronidazole is an option.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">b</sup> Units of the potassium salt.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">c</sup> If source control is not achieved or in cases where operative dental treatment is not available, often because of the unavailability of dentists in many low resource settings.</p>\n<p class=\"legenda\">Legend: ACCESS antibiotics are indicated in green, WATCH antibiotics in orange and RESERVE antibiotics in red.</p>\n</td>\n</tr>\n</tfoot>\n</table>"
        ]
    },
    {
        "name": "Localized acute bacterial lymphadenitis",
        "tables": [
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-160\" role=\"doc-pagebreak\" title=\"101\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-775\"></a>Table 9.1 – Pathogens most frequently associated with acute lymphadenitis (in descending order of frequency)</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Viruses</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Bacteria</strong></p>\n</td>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Most cases</strong></p>\n<p class=\"box_p1\">Epstein–Barr virus</p>\n<p class=\"box_p1\">Cytomegalovirus</p>\n<p class=\"box_p1\">Respiratory viruses</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">More rarely</strong></p>\n<p class=\"box_p1\">HIV</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Most cases</strong></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Staphylococcus aureus</em> (including MRSA)</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Streptococcus pyogenes</em> (group A <em class=\"calibre10\">Streptococcus</em>)</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">More rarely</strong><sup class=\"calibre30\">a</sup></p>\n<p class=\"box_p1\">Anaerobes</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Bartonella henselae</em> (mostly following cat bites or scratches)</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Chlamydia trachomatis</em> (serovars L<sub class=\"calibre36\">1</sub>, L<sub class=\"calibre36\">2</sub>and L<sub class=\"calibre36\">3</sub>which cause lymphogranuloma venereum)</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Corynebacterium diphtheriae</em></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Francisella tularensis</em></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Haemophilus ducreyi</em></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Neisseria gonorrhoeae</em></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Rickettsia</em> spp.</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Yersinia pestis</em></p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"2\">\n<p class=\"legenda\">MRSA: methicillin-resistant <em class=\"calibre10\">Staphylococcus aureus</em>.</p>\n<p class=\"legenda\">Note. Pathogens associated with chronic lymphadenitis such as mycobacteria (including non-tuberculous) are not included in the table.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> This is not a full list but aims to show the variety of bacteria associated with localized lymphadenitis. The bacteria are listed in alphabetical order. Sexually transmitted infections and zoonoses need to be considered in the differential diagnosis.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-162\" role=\"doc-pagebreak\" title=\"103\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-776\"></a>Table 9.2 – Empiric antibiotic treatment for bacterial lymphadenitis</strong><sup class=\"calibre30\">a</sup></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color1\" colspan=\"3\">\n<p class=\"box_tit1\"><img alt=\"Imagem\" class=\"calibre26\" src=\"images/000133.jpg\"/> <strong class=\"calibre5\">Important</strong></p>\n<p class=\"box_p1\">Where more than one antibiotic is recommended for an infection, they are listed in alphabetical order and they should be considered equal treatment options, unless otherwise indicated.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color2\" colspan=\"3\">\n<p class=\"box_tit1\"><img alt=\"Imagem\" class=\"calibre26\" src=\"images/000166.jpg\"/> <strong class=\"calibre5\">Note</strong></p>\n<p class=\"box_p1\">Cloxacillin and cefalexin have a narrower spectrum of antibacterial activity compared to amoxicillin+clavulanic acid and have good efficacy in mild skin and soft tissue infections. Therefore, from an antibiotic stewardship perspective, these two antibiotics are the preferred options whenever possible.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Adults</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Children</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Total treatment duration</strong></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_verde\">Amoxicillin+clavulanic acid</span></p>\n<p class=\"box_p1\">IV: 1 g + 200 mg given every 8 hours</p>\n<p class=\"box_p1\">Oral: 500 mg + 125 mg given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Cefalexin</span> (oral): 500 mg given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Cloxacillin</span><sup class=\"calibre30\">b</sup> IV: 2 g given every 6 hours</p>\n<p class=\"box_p1\">Oral: 500 mg given every 6 hours</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_verde\">Amoxicillin+clavulanic acid</span><sup class=\"calibre30\">c</sup> (IV/oral): 80–90 mg/kg/day of amoxicillin component</p>\n<p class=\"box_p1\">Oral weight bands:</p>\n<p class=\"box_p1\">3–&lt; 6 kg: 250 mg of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p1\">6–&lt; 10 kg: 375 mg of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 500 mg of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 750 mg of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p1\">≥ 20 kg: 500 mg of amoxicillin/dose given every 8 hours or 1 g of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<span class=\"calibre6\" id=\"calibre_link-163\" role=\"doc-pagebreak\" title=\"104\" type=\"pagebreak\"></span>\n<p class=\"box_p1\"><span class=\"back_verde\">Cefalexin</span> (oral): 25 mg/kg/dose given every 12 hours</p>\n<p class=\"box_p1\">Oral weight bands:</p>\n<p class=\"box_p1\">3–&lt; 6 kg: 125 mg given every 12 hours</p>\n<p class=\"box_p1\">6–&lt; 10 kg: 250 mg given every 12 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 375 mg given every 12 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 500 mg given every 12 hours</p>\n<p class=\"box_p1\">20–&lt; 30 kg: 625 mg given every 12 hours</p>\n<p class=\"box_p1\">≥ 30 kg: use adult dose</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Cloxacillin</span><sup class=\"calibre30\">b</sup></p>\n<p class=\"box_p1\">IV:</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">Neonates: 25–50 mg/kg/dose given every 12 hours</li>\n<li class=\"box_li1\">Children: 25 mg/kg/dose given every 6 hours</li>\n</ul>\n<p class=\"box_p1\">Oral: 15 mg/kg/dose given every 6 hours</p>\n<p class=\"box_p1\">Oral weight bands:</p>\n<p class=\"box_p1\">3–&lt; 6 kg: 62.5 mg given every 6 hours</p>\n<p class=\"box_p1\">6–&lt; 10 kg: 125 mg given every 6 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 250 mg given every 6 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 375 mg given every 6 hours</p>\n<p class=\"box_p1\">≥ 20 kg: 500 mg given every 6 hours</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">5 days</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">IV: intravenous.</p>\n<p class=\"legenda\">Note. All dosages are for normal renal and hepatic function.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> Patient history is key in order to adapt treatment if necessary; for example, lymphadenitis in the context of cat scratch fever caused by <em class=\"calibre10\">Bartonella henselae</em>would require a different antibiotic treatment.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">b</sup> If cloxacillin is unavailable, any other IV antistaphylococcal penicillin could be used. For oral administration, dicloxacillin and flucloxacillin are preferred options within the class as they have better oral bioavailability.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">c</sup> Oral liquid formulations must be refrigerated after reconstitution as clavulanic acid is rapidly metabolized in high ambient temperatures.</p>\n<p class=\"legenda\">Legend: ACCESS antibiotics are indicated in green, WATCH antibiotics in orange and RESERVE antibiotics in red.</p>\n</td>\n</tr>\n</tfoot>\n</table>"
        ]
    },
    {
        "name": "Bacterial eye infections (excluding trachoma)",
        "tables": [
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-177\" role=\"doc-pagebreak\" title=\"118\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-778\"></a>Table 10.1 – Pathogens most frequently associated with blepharitis (in descending order of frequency)</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Type of organism</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Pathogen</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Bacteria</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><em class=\"calibre10\">Staphylococcus aureus</em></p>\n<p class=\"box_p1\">Coagulase-negative <em class=\"calibre10\">Staphylococcus</em></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Mites</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><em class=\"calibre10\">Demodex folliculorum</em><sup class=\"calibre30\">a</sup></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Demodex brevis</em><sup class=\"calibre30\">b</sup></p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"2\">\n<p class=\"legenda\">Note. Blepharitis does not usually have an infectious origin.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> <em class=\"calibre10\">Demodex folliculorum</em>has been identified in 30% of patients with chronic anterior blepharitis but is also found with about the same prevalence in asymptomatic people. However, this organism is clearly a contributing factor in some patients as evidenced by the improvement seen in response to eradication therapy.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">b</sup> <em class=\"calibre10\">Demodex brevis</em>has been associated with posterior blepharitis.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-179\" role=\"doc-pagebreak\" title=\"120\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-779\"></a>Table 10.2 – Pathogens most frequently associated with conjunctivitis (in descending order of frequency)</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Type of organism</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Pathogen</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Viruses</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Most infectious cases are of viral origin</strong></p>\n<p class=\"box_p1\">Adenovirus (usually)</p>\n<p class=\"box_p1\">Herpes simplex virus (rarely)</p>\n<p class=\"box_p1\">Varicella-zoster virus (rarely)</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Bacteria <em class=\"calibre10\">(87)</em></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">In children</strong></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Staphylococcus aureus</em></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Streptococcus pneumoniae</em></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Haemophilus influenzae</em></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Moraxella catarrhalis</em></p>\n<p class=\"box_p3\"><strong class=\"calibre5\">In adults</strong></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Staphylococcus aureus</em></p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Consider</strong></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Chlamydia trachomatis</em> (serovars D–K) and <em class=\"calibre10\">Neisseria gonorrhoeae</em> in the context of sexually transmitted infections or in neonates after vaginal delivery from infected mothers.</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Chlamydia trachomatis</em> (serovars A–C) can cause trachoma. Trachoma is covered in a separate chapter.</p>\n</td>\n</tr>\n</tbody>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-181\" role=\"doc-pagebreak\" title=\"122\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-780\"></a>Table 10.3 – Empiric antibiotic treatment for bacterial conjunctivitis</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color1\" colspan=\"3\">\n<p class=\"box_tit1\"><img alt=\"Imagem\" class=\"calibre26\" src=\"images/000133.jpg\"/> <strong class=\"calibre5\">Important</strong></p>\n<p class=\"box_p1\">Where more than one antibiotic is recommended for an infection, they are listed in alphabetical order and they should be considered equal treatment options, unless otherwise indicated.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Type of eye infection</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Antibiotic treatment</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Total treatment duration</strong></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Bacterial conjunctivitis (children and adults)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\"><span class=\"back_verde\">Gentamicin</span>(eye drops): 0.3%, 1 drop in the affected eye every 6 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Ofloxacin</span> (eye drops): 0.3%, 1 drop in the affected eye every 6 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Tetracycline</span> (eye ointment): 1%, 1 cm in the affected eye every 6 hours</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">5 days</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Gonococcal conjunctivitis (adults, adolescents)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_amarelo\">Ceftriaxone</span> (IM)<sup class=\"calibre30\">a</sup> : 250 mg <strong class=\"calibre5\">AND</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Azithromycin</span> (oral): 1 g</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Single dose</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Gonococcal ophthalmia neonatorum (i.e. gonococcal conjunctivitis of the newborn)</p>\n<p class=\"box_p1\">Symptoms usually appear within 5 days of birth</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\"><span class=\"back_amarelo\">Ceftriaxone</span> (IM)<sup class=\"calibre30\">b</sup> : 50 mg/kg</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Single dose</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Chlamydial ophthalmia neonatorum (i.e. chlamydial conjunctivitis of the newborn)</p>\n<p class=\"box_p1\">Symptoms usually appear &gt; 5 days after birth</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_amarelo\">Azithromycin</span> (oral)<sup class=\"calibre30\">c</sup> : 20 mg/kg given once a day</p>\n<p class=\"box_p1\">Topical therapy alone is not effective.</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">3 days</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Ocular prophylaxis (topical treatment for the prevention of both gonococcal and chlamydial ophthalmia neonatorum)<sup class=\"calibre30\">d</sup></p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\"><span class=\"back_amarelo\">Erythromycin</span> (eye ointment): 0.5%</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Tetracycline</span> (eye ointment): 1%</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Antibiotic needs to be applied to both eyes soon after birth (single dose)</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\"><span class=\"calibre6\" id=\"calibre_link-182\" role=\"doc-pagebreak\" title=\"123\" type=\"pagebreak\"></span>IM: intramuscular.</p>\n<p class=\"legenda\">Note. All dosages are for normal renal and hepatic function.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> Concurrent treatment with azithromycin for chlamydial infection is usually recommended.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">b</sup> Ceftriaxone should not be administered in neonates receiving calcium-containing IV fluids and it should be avoided in infants with hyperbilirubinaemia. Cefotaxime can be used as an alternative. Alternatives to ceftriaxone indicated in the 2016 WHO guidelines but not included the EMLc for this indication are kanamycin (IM) 25 mg/kg or spectinomycin (IM) 25 mg/kg <em class=\"calibre10\">(89)</em>.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">c</sup> An alternative indicated in the 2016 WHO guidelines but not included in the EML for this indication is erythromycin (oral) 50 mg/kg per day divided in four doses for 14 days <em class=\"calibre10\">(89)</em>.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">d</sup> Alternatives indicated in the 2016 WHO guidelines but not included in the EML for this indication are: povidone–iodine (water-based solution; do not use alcohol-based solutions) 2.5%; silver nitrate (solution) 1%; chloramphenicol (eye ointment) 1% <em class=\"calibre10\">(89)</em>.</p>\n<p class=\"legenda\">Legend: ACCESS antibiotics are indicated in green, WATCH antibiotics in orange and RESERVE antibiotics in red.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-183\" role=\"doc-pagebreak\" title=\"124\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-781\"></a>Table 10.4 – Pathogens most frequently associated with endophthalmitis</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Type of endophthalmitis</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Most common causative pathogens (in descending order of frequency)</strong></p>\n</td>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Exogenous – most cases</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Bacteria</strong></p>\n<p class=\"box_p3\"><strong class=\"calibre5\"><em class=\"calibre10\">Most cases</em></strong></p>\n<p class=\"box_p1\">Coagulase-negative staphylococci</p>\n<p class=\"box_p3\"><strong class=\"calibre5\"><em class=\"calibre10\">Less frequently</em></strong></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Staphylococcus aureus (93)</em></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Streptococcus</em> spp.<sup class=\"calibre30\">a</sup></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Klebsiella</em> spp. (more frequent in Asia ; often in conjunction with liver abscess)</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Bacillus cereus</em> (mostly in cases of penetrating trauma)</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Fungi</strong><sup class=\"calibre30\">b</sup></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Fusarium</em> spp.</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Aspergillus</em> spp.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Endogenous – rare</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Bacteria:</strong> same as above</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Fungi</strong><sup class=\"calibre30\">c</sup></p>\n<p class=\"box_p1\">Mostly <em class=\"calibre10\">Candida albicans</em></p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"2\">\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> <em class=\"calibre10\">Streptococcus viridans</em>is more frequently encountered in case of post-intravitreal injection endophthalmitis compared to post-cataract endophthalmitis <em class=\"calibre10\">(94)</em>.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">b</sup> In tropical regions, fungal endophthalmitis is often due to molds and is usually exogenous in origin.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">c</sup> In temperate climates, fungal endophthalmitis is usually endogenous and caused by <em class=\"calibre10\">Candida</em>spp.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-184\" role=\"doc-pagebreak\" title=\"125\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-782\"></a>Table 10.5 – Microbiology tests to consider when endophthalmitis is suspected as indicated in the WHO EDL <em class=\"calibre10\">(6)</em></strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Diagnostic test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Purpose of the test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Settings where the test should be available</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Microscopy (Gram stain) and culture of aqueous or vitreous humour aspirate</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Microbial morphology and detection and identification of bacterial and fungal species for selection of appropriate antimicrobial regimens</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Blood cultures and antimicrobial susceptibility testing</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To detect bacterial and fungal bloodstream infections in patients with suspected endogenous endophthalmitis</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">EDL: WHO Model List of Essential In Vitro Diagnostics.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-783\"></a>Table 10.6 – Empiric antibiotic treatment for bacterial endophthalmitis</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Type of bacterial endophthalmitis</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Antibiotic treatment</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Total treatment duration</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Exogenous</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Intravitreal injection</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Vancomycin</span>1 mg <strong class=\"calibre5\">AND</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Ceftazidime</span> 2.25 mg</p>\n<p class=\"box_p1\">Systemic antibiotics alone are not effective in treating bacterial exogenous endophthalmitis. Whether systemic antibiotics provide any benefit in these cases as adjunctive therapy to intravitreal antibiotics is still debatable.</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Intravitreal antibiotics: single dose. If no clinical improvement after 48 hours, the intravitreal injection can be repeated.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Endogenous</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">ADD</strong></p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Systemic treatment</strong></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Adults</em></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Ceftriaxone</span> (IV): 2g given once a day <strong class=\"calibre5\">AND</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Vancomycin</span> (IV): 15–20 mg/kg given every 12 hours</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Neonates and children</em></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Ceftriaxone</span> (IV): 80 mg/kg/dose given once a day</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">AND</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Vancomycin</span> (IV):</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">Neonates: 15 mg/kg/ dose given every 12 hours</li>\n<li class=\"box_li1\">Children: 15 mg/kg/dose given every 8 hours</li>\n</ul>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Duration of systemic antibiotics should be determined by the need to treat the underlying source of bacteraemia (e.g. 6 weeks in many cases of endocarditis).</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">IV: intravenous.</p>\n<p class=\"legenda\">Note. All dosages are for normal renal and hepatic function.</p>\n<p class=\"legenda\">Legend: ACCESS antibiotics are indicated in green, WATCH antibiotics in orange and RESERVE antibiotics in red.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-784\"></a>Table 10.7 – Pathogens most frequently associated with keratitis</strong><sup class=\"calibre30\">a</sup> <strong class=\"calibre5\">(in descending order of frequency)</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Type of organism</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Pathogen</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\"><em class=\"calibre10\">Fungi</em></p>\n</td>\n<td class=\"color\">\n<p class=\"box_p3\"><strong class=\"calibre5\">Mostly</strong></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Fusarium</em> spp.</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Aspergillus</em> spp.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Bacteria</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><em class=\"calibre10\">Pseudomonas</em> spp. (contact lenses)</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Staphylococcus epidermidis</em></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Staphylococcus aureus</em></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Streptococcus pneumoniae</em></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Viruses</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p3\"><strong class=\"calibre5\">Mostly</strong></p>\n<p class=\"box_p1\">Herpes simplex virus (usually type 1)</p>\n<p class=\"box_p1\">Varicella zoster virus</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Parasites</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><em class=\"calibre10\">Acanthamoeba</em> (contact lenses)</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"2\">\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> Bacteria and viruses are the most common causes of keratitis in high-income countries, while fungi predominate in low- and middle-income countries. Global variations in etiology largely reflect patient-based risk factors such as population demographic, occupation, contact lens use, concomitant ocular and systemic illness, as well as environmental factors such as geographical location, climate and virulence of causative organisms. For example, <em class=\"calibre10\">Pseudomonas</em>spp. and <em class=\"calibre10\">Acanthamoeba</em> spp. are often associated with the use of contact lenses and fungal keratitis must be considered after any traumatic corneal injury, notably from vegetable matter. In the paediatric population, there appears to be a higher incidence of atypical infections, for example, due to <em class=\"calibre10\">Acanthamoeba</em> <em class=\"calibre10\">(97)</em>.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-785\"></a>Table 10.8 – Microbiology tests to consider when keratitis is suspected as indicated in the WHO EDL <em class=\"calibre10\">(6)</em></strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Diagnostic test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Purpose of the test</strong></p>\n</th>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Settings where the test should be available</strong></p>\n</td>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Microscopy (Gram stain) and culture of corneal scrapings or corneal biopsy material</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Microbial morphology and detection and identification of bacterial and fungal species for selection of appropriate antimicrobial regimens</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">EDL: WHO Model List of Essential In Vitro Diagnostics.</p>\n<p class=\"legenda\">Note. Nucleic acid amplification testing (i.e. polymerase chain reaction) for viral etiology (e.g. herpes simplex virus) could be considered based on clinical presentation and individual risk factors.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-786\"></a>Table 10.9 – Empiric antibiotic treatment for bacterial keratitis</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Antibiotic treatment</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Total treatment duration</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Children and adults</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Ofloxacin</span><sup class=\"calibre30\">a</sup> (eye drops): 0.3%, 1 drop in the affected eye every hour for 48 hours then every 4 hours until healed</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">2 weeks but duration is often personalized to the individual based on clinical improvement.</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"2\">\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> A fluoroquinolone is usually given to patients who wear contact lenses because <em class=\"calibre10\">Pseudomonas aeruginosa</em>is often the causative pathogen. For most patients, hourly treatment is indicated for the first 24 to 48 hours. Drops are preferred because ointments have poor corneal penetration. However, ointments may be used at bedtime to allow the patient to sleep through the night, but only after a positive response has been demonstrated to the initial intensive eyedrop treatment.</p>\n<p class=\"legenda\">Legend: ACCESS antibiotics are indicated in green, WATCH antibiotics in orange and RESERVE antibiotics in red.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-787\"></a>Table 10.10 – Pathogens most frequently associated with orbital cellulitis (in descending order of frequency)</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Type of organism</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Pathogen</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Bacteria</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">In adults</strong></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Staphylococcus aureus</em></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Streptococcus</em> spp.</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Bacteroides</em> spp.</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">In children</strong></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Haemophilus influenzae</em> (rare in vaccinated children <em class=\"calibre10\">(100)</em>)</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Following eye trauma</strong></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Pseudomonas aeruginosa</em></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Escherichia coli</em></p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Following a dental abscess</strong></p>\n<p class=\"box_p1\">Polymicrobial infection (including anaerobes)</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Fungi<sup class=\"calibre30\">a</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Mostly in immunocompromised patients, such as those with diabetes, receiving chemotherapy and with HIV infection</strong></p>\n<p class=\"box_p1\">Zygomycetes (e.g. <em class=\"calibre10\">Mucor</em>)</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Aspergillus</em> spp.</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"2\">\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> Fungal infections are rare but they should be considered in immunocompromised patients including patients with poorly controlled diabetes.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-788\"></a>Table 10.11 – Microbiology tests to consider when orbital cellulitis is suspected as indicated in the WHO EDL <em class=\"calibre10\">(6)</em></strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Diagnostic test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Purpose of the test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Settings where the test should be available</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Microscopy (Gram stain), culture and antimicrobial susceptibility testing of abscess material</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Microbial morphology and detection and identification of bacterial and fungal species for selection of appropriate antimicrobial regimens</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Blood cultures and antimicrobial susceptibility testing</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To detect bacterial and fungal bloodstream infections</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">EDL: WHO Model List of Essential In Vitro Diagnostics.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-192\" role=\"doc-pagebreak\" title=\"133\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-789\"></a>Table 10.12 – Pathogens most frequently associated with periorbital (or preseptal) cellulitis (in descending order of frequency)</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Type of organism</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Pathogen</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Bacteria</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><em class=\"calibre10\">Staphylococcus aureus</em> (including MRSA)</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Streptococcus pneumoniae</em></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Haemophilus influenzae</em> (rare in vaccinated children <em class=\"calibre10\">(100)</em>)</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Moraxella catarrhalis</em></p>\n<p class=\"box_p1\">Anaerobes (suspect if there is a history of animal or human bite or if necrosis is present)</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Viruses</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">If the infection is associated with a vesicular skin rash, suspect:</p>\n<p class=\"box_p1\">Herpes simplex virus</p>\n<p class=\"box_p1\">Varicella-zoster virus</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"2\">\n<p class=\"legenda\">MRSA: methicillin-resistant <em class=\"calibre10\">Staphylococcus aureus</em>.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-194\" role=\"doc-pagebreak\" title=\"135\" type=\"pagebreak\"></span><strong class=\"calibre5\">Table 10.13 – Empiric antibiotic treatment for periorbital (or preseptal) cellulitis</strong><sup class=\"calibre30\">a</sup></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color1\" colspan=\"3\">\n<p class=\"box_tit1\"><img alt=\"Imagem\" class=\"calibre26\" src=\"images/000133.jpg\"/> <strong class=\"calibre5\">Important</strong></p>\n<p class=\"box_p1\">Where more than one antibiotic is recommended for an infection, they are listed in alphabetical order and they should be considered equal treatment options, unless otherwise indicated.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color2\" colspan=\"3\">\n<p class=\"box_tit1\"><img alt=\"Imagem\" class=\"calibre26\" src=\"images/000166.jpg\"/> <strong class=\"calibre5\">Note</strong></p>\n<p class=\"box_p1\">Cloxacillin has a narrower spectrum of antibacterial activity than amoxicillin+clavulanic acid and cefalexin with limited coverage of Gram-negative bacteria from the upper respiratory tract that may cause periorbital (or preseptal) cellulitis (e.g. <em class=\"calibre10\">Haemophilus influenzae</em>, <em class=\"calibre10\">Moraxella catarrhalis</em>). Therefore, when this infection is suspected, amoxicillin+clavulanic acid or cefalexin are the preferred options.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Adults</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Children</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Total treatment duration</strong></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_verde\">Amoxicillin+clavulanic acid</span> IV: 1 g + 200 mg given every 8 hours</p>\n<p class=\"box_p1\">Oral: 500 mg + 125 mg given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Cefalexin</span> (oral): 500 mg given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Cloxacillin</span><sup class=\"calibre30\">b</sup> IV: 2 g given every 6 hours</p>\n<p class=\"box_p1\">Oral: 500 mg given every 6 hours</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_verde\">Amoxicillin+clavulanic acid</span><sup class=\"calibre30\">c</sup></p>\n<p class=\"box_p1\">IV:</p>\n<p class=\"box_p1\">First week of life: 50 mg/kg of amoxicillin/dose given every 12 hours Beyond first week of life: 50 mg/kg of amoxicillin/dose given every 8 hours</p>\n<p class=\"box_p1\">Oral: 80–90 mg/kg/day of amoxicillin component</p>\n<p class=\"box_p1\">Oral weight bands:</p>\n<p class=\"box_p1\">3–&lt; 6 kg: 250 mg of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p1\">6–&lt; 10 kg: 375 mg of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 500 mg of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 750 mg of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p1\">≥ 20 kg: 500 mg of amoxicillin/dose given every 8 hours or 1 g of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<span class=\"calibre6\" id=\"calibre_link-195\" role=\"doc-pagebreak\" title=\"136\" type=\"pagebreak\"></span>\n<p class=\"box_p1\"><span class=\"back_verde\">Cefalexin</span> (oral): 25 mg/kg/dose given every 12 hours</p>\n<p class=\"box_p1\">Oral weight bands:</p>\n<p class=\"box_p1\">3–&lt; 6 kg: 125 mg given every 12 hours</p>\n<p class=\"box_p1\">6–&lt; 10 kg: 250 mg given every 12 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 375 mg given every 12 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 500 mg given every 12 hours</p>\n<p class=\"box_p1\">20–&lt; 30 kg: 625 mg given every 12 hours</p>\n<p class=\"box_p1\">≥ 30 kg: use adult dose</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Cloxacillin</span><sup class=\"calibre30\">b</sup></p>\n<p class=\"box_p1\">IV:</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">Neonates: 25–50 mg/kg/dose given every 12 hours</li>\n<li class=\"box_li1\">Children: 25 mg/kg/dose given every 6 hours</li>\n</ul>\n<p class=\"box_p1\">Oral: 15 mg/kg/dose given every 6 hours</p>\n<p class=\"box_p1\">Oral weight bands:</p>\n<p class=\"box_p1\">3–&lt; 6 kg: 62.5 mg given every 6 hours</p>\n<p class=\"box_p1\">6–&lt; 10 kg: 125 mg given every 6 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 250 mg given every 6 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 375 mg given every 6 hours</p>\n<p class=\"box_p1\">≥ 20 kg: 500 mg given every 6 hours</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">10–14 days (depending on the severity)</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">IV: intravenous.</p>\n<p class=\"legenda\">Note. All dosages are for normal renal and hepatic function.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> It should be noted that these specific recommendations are not included in the EML and EMLc <em class=\"calibre10\">(8,9)</em>. The options presented are based on what is recommended for mild skin and soft tissues infections.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">b</sup> If cloxacillin is unavailable, any other IV antistaphylococcal penicillin could be used. For oral administration; dicloxacillin and flucloxacillin are preferred options within the class as they have better oral bioavailability.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">c</sup> Oral liquid formulations must be refrigerated after reconstitution as clavulanic acid is rapidly metabolized in high ambient temperatures.</p>\n<p class=\"legenda\">Legend: ACCESS antibiotics are indicated in green, WATCH antibiotics in orange and RESERVE antibiotics in red.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-790\"></a>Table 10.14 – Pathogens most frequently associated with uveitis</strong><sup class=\"calibre30\">a</sup> <strong class=\"calibre5\">(in alphabetical order)</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Type of organism</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Pathogen</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Bacteria</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\"><em class=\"calibre10\">Bartonella henselae</em> (with cat-scratch disease)</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Mycobacterium tuberculosis</em><sup class=\"calibre30\">b</sup></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Treponema pallidum</em> (with neurosyphilis)</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Parasites</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><em class=\"calibre10\">Toxoplasma gondii</em></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Viruses</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Cytomegalovirus</p>\n<p class=\"box_p1\">Herpes simplex virus</p>\n<p class=\"box_p1\">Varicella-zoster virus</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"2\">\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> Usually in the context of infectious or autoimmune or inflammatory systemic conditions. Therefore consider individual risk factors and presentation to identify the most likely causative pathogen.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">b</sup> Ocular tuberculosis usually results from haematogenous dissemination of the infection from pulmonary or extra-pulmonary sites.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-791\"></a>Table 10.15 – Microbiology tests to consider when uveitis is suspected as indicated in the WHO EDL <em class=\"calibre10\">(6)</em></strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Diagnostic test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Purpose of the test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Settings where the test should be available</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Microscopy (Gram stain) and culture<sup class=\"calibre30\">a</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Microbial morphology and detection and identification of bacterial species for selection of appropriate antibiotic regimens</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">EDL: Model List of Essential In Vitro Diagnostics.</p>\n<p class=\"legenda\">Note. Nucleic acid amplification testing (i.e. polymerase chain reaction) for viral etiology (e.g. herpes simplex virus) could be considered based on clinical presentation and individual risk factors.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> Depending on the type of infection, consider conjunctival swabs, corneal scrapings or corneal biopsy, aqueous or vitreous humour aspirate.</p>\n</td>\n</tr>\n</tfoot>\n</table>"
        ]
    },
    {
        "name": "Trachoma",
        "tables": [
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-793\"></a>Table 11.1 – Microbiology tests to consider if trachoma is suspected as indicated in the WHO EDL <em class=\"calibre10\">(6)</em></strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Diagnostic test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Purpose of the test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Settings where the test should be available</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Qualitative test for <em class=\"calibre10\">Chlamydia trachomatis</em> (i.e. nucleic acid amplification test)<sup class=\"calibre30\">a</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To diagnose chlamydial infection</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Microscopy (Gram stain) and culture<sup class=\"calibre30\">a</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Initial step to detect and identify bacterial species for selection of appropriate antibiotic regimens</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">EDL: Model List of Essential In Vitro Diagnostics.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> Possible specimens: conjunctival swabs.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-794\"></a>Table 11.2 – Empiric antibiotic treatment for trachoma</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Adults and children</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Total treatment duration</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_amarelo\">Azithromycin</span> (oral): 20 mg/kg (maximum 1 g (adults); 500 mg (children))</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Azithromycin</span> (eye drops)<sup class=\"calibre30\">a</sup> : 1.5%, 1 drop administered to both eyes every 12 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Tetracycline</span>(eye ointment): 1% 1 cm administered to both eyes every 12 hours</p>\n<p class=\"box_p1\">Topical treatment is used in areas where oral azithromycin is not readily available.</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Single dose (azithromycin)</p>\n<p class=\"box_p1\">3 days (topical treatment with azithromycin)</p>\n<p class=\"box_p1\">6 weeks (topical treatment with tetracycline)</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"2\">\n<p class=\"legenda\">Note. Antibiotic treatment is mostly given once a year for at least 3 years as part of mass administration programmes in endemic areas.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> Azithromycin eye drops may be as effective as oral azithromycin <em class=\"calibre10\">(117)</em>.</p>\n<p class=\"legenda\">Legend: ACCESS antibiotics are indicated in green, WATCH antibiotics in orange and RESERVE antibiotics in red.</p>\n</td>\n</tr>\n</tfoot>\n</table>"
        ]
    },
    {
        "name": "Community-acquired pneumonia – mild",
        "tables": [
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-795\"></a>Table 12.1 – Pathogens most frequently associated with community-acquired pneumonia (in descending order of frequency)</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Typical bacteria</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Atypical bacteria</strong><sup class=\"calibre32\">b</sup></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Respiratory viruses</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Other pathogens to consider in specific settings</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><em class=\"calibre10\">Streptococcus pneumoniae</em><sup class=\"calibre30\">a</sup></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Haemophilus influenzae</em></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Moraxella catarrhalis</em></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Staphylococcus aureus</em></p>\n<p class=\"box_p1\">Enterobacterales (e.g. <em class=\"calibre10\">Escherichia coli</em>, <em class=\"calibre10\">Klebsiella pneumoniae</em>)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><em class=\"calibre10\">Mycoplasma pneumoniae</em><sup class=\"calibre30\">b</sup></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Chlamydia pneumoniae</em><sup class=\"calibre30\">b</sup> and <em class=\"calibre10\">Chlamydia psittaci</em><sup class=\"calibre30\">b</sup></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Legionella</em> spp.</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Coxiella burnetii</em></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Influenza virus (A and B)</p>\n<p class=\"box_p1\">Respiratory syncytial virus<sup class=\"calibre30\">c</sup></p>\n<p class=\"box_p1\">Metapneumovirus</p>\n<p class=\"box_p1\">Parainfluenza virus</p>\n<p class=\"box_p1\">Coronavirus (including SARS-CoV-2)</p>\n<p class=\"box_p1\">Adenovirus</p>\n<p class=\"box_p1\">Rhinovirus</p>\n<p class=\"box_p1\">Other respiratory viruses</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><em class=\"calibre10\">Burkholderia pseudomallei</em> (South-East Asia, Australia)</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Mycobacterium tuberculosis</em></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Pneumocystis jirovecii</em> (in people with HIV or other types of cellular immunosuppression)</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"4\">\n<p class=\"legenda\">HIV: human immunodeficiency virus; SARS-CoV-2: severe acute respiratory syndrome coronavirus-2.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> The most common bacterial cause of community acquired pneumonia in all age groups (beyond the first week of life) is <em class=\"calibre10\">Streptococcus pneumoniae</em>.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">b</sup> Atypical bacteria remain colourless with Gram staining. They also have intrinsic resistance to beta-lactams. <em class=\"calibre10\">Mycoplasma pneumoniae</em>and <em class=\"calibre10\">Chlamydia</em> spp. are more frequent in children &gt; 5 years (compared with younger children) and in young adults. Risk factors for <em class=\"calibre10\">Chlamydia psittaci</em> include exposure to birds.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">c</sup> Up to 50% of cases of pneumonia in children &lt; 5 years are caused by a virus, most commonly respiratory syncytial virus.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-796\"></a>Table 12.2 – CURB-65 criteria and scoring, and treatment decisions for community-acquired pneumonia</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<th class=\"colort1\">\n<p class=\"table_head\"><strong class=\"calibre5\">Criterion</strong></p>\n</th>\n<th class=\"colort1\">\n<p class=\"table_head\"><strong class=\"calibre5\">Points</strong></p>\n</th>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Presence of confusion (new onset)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">1</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Urea &gt; 19 mg/dL (or &gt; 7 mmol/L)<sup class=\"calibre30\">a</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">1</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Respiratory rate &gt; 30 breaths/min</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">1</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Systolic blood pressure &lt; 90 mmHg (&lt; 12 kPa) or diastolic blood pressure ≤ 60 mmHg (≤ 8 kPa)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">1</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Age ≥ 65 years</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">1</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"colort\">\n<p class=\"box_p3\"><strong class=\"calibre5\">CURB-65 score/CRB-65 score</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"box_p3\"><strong class=\"calibre5\">Where to treat</strong></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">0–1</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p3\"><strong class=\"calibre5\">Candidate for outpatient treatment</strong></p>\n<p class=\"box_p1\">Low 30-day mortality risk (&lt; 1.5%)</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">2</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Consider inpatient treatment</strong></p>\n<p class=\"box_p1\">30-day mortality risk ≈ 10%</p>\n<p class=\"box_p1\">Consider adding clarithromycin (see Community-acquired pneumonia – severe)</p>\n<p class=\"box_p1\">If tests are available, consider testing for atypical pathogens (e.g. <em class=\"calibre10\">Legionella</em> spp., <em class=\"calibre10\">Mycoplasma</em> spp.)</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\"><span class=\"calibre6\" id=\"calibre_link-217\" role=\"doc-pagebreak\" title=\"158\" type=\"pagebreak\"></span>≥ 3</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p3\"><strong class=\"calibre5\">Inpatient treatment (consider admission to intensive care)</strong></p>\n<p class=\"box_p1\">High 30-day mortality risk (≈ 20%)</p>\n<p class=\"box_p1\">Consider adding clarithromycin (see Community-acquired pneumonia – severe)</p>\n<p class=\"box_p1\">Consider testing for atypical pathogens (e.g. <em class=\"calibre10\">Legionella</em> spp., <em class=\"calibre10\">Mycoplasma</em> spp.)</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"2\">\n<p class=\"legenda\">Note. The CURB-65 score is not validated in low-and middle-income countries.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> Urea is not required for the calculation of the CRB-65 score, a modification of the CURB-65 score that does not require laboratory tests.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-218\" role=\"doc-pagebreak\" title=\"159\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-797\"></a>Table 12.3 – Medicines to consider for symptomatic treatment of community-acquired pneumonia</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color1\" colspan=\"3\">\n<p class=\"box_tit1\"><img alt=\"Imagem\" class=\"calibre26\" src=\"images/000133.jpg\"/> <strong class=\"calibre5\">Important</strong></p>\n<p class=\"box_p1\">Medicines are listed in alphabetical order and they should all be considered equal treatment options.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Medicine</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Formulation</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Dose and frequency</strong></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Ibuprofen<sup class=\"calibre30\">a</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Oral liquid: 200 mg/5 mL</p>\n<p class=\"box_p1\">Tablet: 200 mg; 400 mg; 600 mg</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Adults</strong>: 200–400 mg given every 6 to 8 hours (maximum dose of 2.4 g a day)</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Children</strong>:</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">Pain control/antipyretic treatment: 5–10 mg/kg given every 6 to 8 hours</li>\n</ul>\n<p class=\"box_p1\">6–&lt; 10 kg: 50 mg given every 8 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 100 mg given every 8 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 150 mg given every 8 hours</p>\n<p class=\"box_p1\">20–&lt; 30 kg: 200 mg given every 8 hours</p>\n<p class=\"box_p1\">≥ 30 kg: use adult dose</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Paracetamol (acetaminophen)<sup class=\"calibre30\">b</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Oral liquid: 120 mg/5 mL; 125 mg/5 mL</p>\n<p class=\"box_p1\">Suppository: 100 mg</p>\n<p class=\"box_p1\">Tablet: 100 mg to 500 mg</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Adults</strong>: 500 mg–1 g given every 4 to 6 hours (maximum dose of 4 g a day)<sup class=\"calibre30\">c</sup></p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Children</strong>:</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">Pain control/antipyretic treatment: 10–15 mg/kg given every 6 hours</li>\n</ul>\n<p class=\"box_p1\">3–&lt; 6 kg: 60 mg given every 6 hours</p>\n<p class=\"box_p1\">6–&lt; 10 kg: 100 mg given every 6 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 150 mg given every 6 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 200 mg given every 6 hours</p>\n<p class=\"box_p1\">20–&lt; 30 kg: 300 mg given every 6 hours</p>\n<p class=\"box_p1\">≥ 30 kg: use adult dose</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> Not for children &lt; 3 months.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">b</sup> Not recommended for use as an anti-inflammatory as it has not been proven to have such an effect.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">c</sup> In patients with hepatic impairment or cirrhosis, maximum daily dose should be 2 g.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-798\"></a>Table 12.4 – Empiric antibiotic treatment for mild cases of community-acquired pneumonia in adults</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color1\" colspan=\"3\">\n<p class=\"box_tit1\"><img alt=\"Imagem\" class=\"calibre26\" src=\"images/000133.jpg\"/> <strong class=\"calibre5\">Important</strong></p>\n<p class=\"box_p1\">Where more than one antibiotic is recommended for an infection, they are listed in alphabetical order and they should be considered equal treatment options, unless otherwise indicated.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"colort\"></td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Adults</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Total treatment duration <em class=\"calibre10\">(130,131)</em></strong></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">First choice</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_verde\">Amoxicillin</span> (oral): 1 g given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Phenoxymethylpenicillin</span> (oral): 500 mg (800 000 IU<sup class=\"calibre30\">a</sup> ) given every 6 hours</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">5 days</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Second choice</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_verde\">Amoxicillin+clavulanic acid</span> (oral): 875 mg + 125 mg given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Doxycycline</span> (oral): 100 mg given every 12 hours</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">5 days</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">IU: international units.</p>\n<p class=\"legenda\">Note. All dosages are for normal renal and hepatic function.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> Units of the potassium salt.</p>\n<p class=\"legenda\">Legend: ACCESS antibiotics are indicated in green, WATCH antibiotics in orange and RESERVE antibiotics in red.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-220\" role=\"doc-pagebreak\" title=\"161\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-799\"></a>Table 12.5 – Empiric antibiotic treatment for mild cases of community-acquired pneumonia in children</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\"></th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Children</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Total treatment duration</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Pneumonia (fast breathing and/or chest indrawing) – treat at home with oral antibiotic</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_verde\">Amoxicillin</span> (oral): 80–90 mg/kg/day</p>\n<p class=\"box_p1\">Oral weight bands:</p>\n<p class=\"box_p1\">3–&lt; 6 kg: 250 mg given every 12 hours</p>\n<p class=\"box_p1\">6–&lt; 10 kg: 375 mg given every 12 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 500 mg given every 12 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 750 mg given every 12 hours</p>\n<p class=\"box_p1\">≥ 20 kg: 500 mg given every 8 hours or 1 g given every 12 hours</p>\n<p class=\"box_p1\">Children with fast-breathing pneumonia who fail to respond to first-line treatment with amoxicillin should have the option of referral to a facility where there is appropriate second-line treatment.</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">3 days for children in areas of low HIV prevalence and no chest indrawing</p>\n<p class=\"box_p1\">5 days if the child has chest indrawing or lives in region of higher HIV prevalence</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">HIV: human immunodeficiency virus.</p>\n<p class=\"legenda\">Note: All dosages are for normal renal and hepatic function.</p>\n<p class=\"legenda\">Legend: ACCESS antibiotics are indicated in green, WATCH antibiotics in orange and RESERVE antibiotics in red.</p>\n</td>\n</tr>\n</tfoot>\n</table>"
        ]
    },
    {
        "name": "Exacerbation of chronic obstructive pulmonary disease",
        "tables": [
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-800\"></a>Table 13.1 – Pathogens most frequently associated with exacerbations of chronic obstructive pulmonary disease (in descending order of frequency)</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Respiratory viruses (most cases)</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Bacteria (less frequently)</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Influenza virus (A and B)</p>\n<p class=\"box_p1\">Respiratory syncytial virus</p>\n<p class=\"box_p1\">Parainfluenza virus</p>\n<p class=\"box_p1\">Rhinovirus</p>\n<p class=\"box_p1\">Coronavirus (including SARS-CoV-2)</p>\n<p class=\"box_p1\">Other respiratory viruses</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><em class=\"calibre10\">Haemophilus influenzae</em></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Moraxella catarrhalis</em></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Streptococcus pneumoniae</em></p>\n<p class=\"box_p1\">Gram-negative bacteria, including <em class=\"calibre10\">Pseudomonas aeruginosa</em> (including multidrug-resistant strains such as those producing ESBL and carbapenemases)</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"2\">\n<p class=\"legenda\">ESBL: extended-spectrum beta-lactamases; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-227\" role=\"doc-pagebreak\" title=\"168\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-801\"></a>Table 13.2 – Empiric antibiotic treatment for exacerbation of chronic obstructive pulmonary disease</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color1\" colspan=\"4\">\n<p class=\"box_tit1\"><img alt=\"Imagem\" class=\"calibre26\" src=\"images/000133.jpg\"/> <strong class=\"calibre5\">Important</strong></p>\n<p class=\"box_p1\">Where more than one antibiotic is recommended for an infection, they are listed in alphabetical order and they should be considered equal treatment options, unless otherwise indicated.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Severity</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">First choice</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Second choice</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Total treatment duration</strong></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Mild to moderate cases</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_verde\">Amoxicillin</span>(oral): 500 mg given every 8 hours</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_verde\">Cefalexin</span>(oral): 500 mg given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Doxycycline</span> (oral): 100 mg given every 12 hours</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">5 days</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Severe cases</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_verde\">Amoxicillin+clavulanic acid</span>(oral): 500 mg + 125 mg given every 8 hours</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">–</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">5 days</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"4\">\n<p class=\"legenda\">Note. All dosages are for normal renal and hepatic function.</p>\n<p class=\"legenda\">Legend: ACCESS antibiotics are indicated in green, WATCH antibiotics in orange and RESERVE antibiotics in red.</p>\n</td>\n</tr>\n</tfoot>\n</table>"
        ]
    },
    {
        "name": "Acute infectious diarrhoea/gastroenteritis",
        "tables": [
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-235\" role=\"doc-pagebreak\" title=\"176\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-802\"></a>Table 14.1 – Pathogens most frequently associated with acute infectious diarrhoea in children (in descending order of frequency)</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Setting</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Viruses (most cases)</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Bacteria</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Parasites</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Low income</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Rotavirus</p>\n<p class=\"box_p1\">Measles virus<sup class=\"calibre30\">a</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><em class=\"calibre10\">Escherichia coli</em></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Shigella</em> spp.</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><em class=\"calibre10\">Cryptosporidium</em> spp.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">High income</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Norovirus</p>\n<p class=\"box_p1\">Rotavirus</p>\n<p class=\"box_p1\">Adenovirus</p>\n<p class=\"box_p1\">Measles virus<sup class=\"calibre30\">a</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Intestinal/non-invasive/diarrhoeal non-typhoidal <em class=\"calibre10\">Salmonella</em></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Campylobacter</em> spp.</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">–</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"4\">\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> Diarrhoea is the most common complication in measles.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-803\"></a>Table 14.2 – Pathogens most frequently associated with acute infectious diarrhoea in adults (in descending order of frequency)</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Setting</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Viruses (most cases)</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Bacteria</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Low income</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Norovirus</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><em class=\"calibre10\">Campylobacter</em> spp.</p>\n<p class=\"box_p1\">Intestinal/non-invasive/diarrhoeal non-typhoidal <em class=\"calibre10\">Salmonella</em></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Shigella</em> spp.</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Escherichia coli</em></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">High income</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Norovirus</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Intestinal/non-invasive/diarrhoeal non-typhoidal <em class=\"calibre10\">Salmonella</em></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Campylobacter</em> spp.</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Escherichia coli</em></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Shigella</em> spp.</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Listeria monocytogenes</em></p>\n</td>\n</tr>\n</tbody>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-236\" role=\"doc-pagebreak\" title=\"177\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-804\"></a>Table 14.3 – Pathogens most frequently associated with persistent (14–29 days) or chronic (&gt; 30 days) infectious diarrhoea in people living with HIV</strong><sup class=\"calibre30\">a</sup> <strong class=\"calibre5\">(in descending order of frequency)</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Parasites</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Viruses</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Fungi (rarely)</strong><sup class=\"calibre32\">b</sup></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><em class=\"calibre10\">Cryptosporidium</em> spp.</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Microsporidium</em> spp.</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Cystoisospora belli</em></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><em class=\"calibre10\">Cytomegalovirus</em></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><em class=\"calibre10\">Histoplasma capsulatum</em></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Coccidioides</em> spp.</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Penicillium</em> spp.</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">HIV: human immunodeficiency virus.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> It should be noted that in these cases, patients often receive unnecessary antibiotic treatment.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">b</sup> Rarely in the context of disseminated infections in patients with low CD4 count.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-805\"></a>Table 14.4 – Classification of dehydration</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Severity of dehydration</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Signs</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Severe dehydration: at least two signs from the list on the right must be present</p>\n</td>\n<td class=\"color\">\n<ul class=\"tab\">\n<li class=\"box_li1\">Lethargy and/or unconsciousness</li>\n<li class=\"box_li1\">Sunken eyes</li>\n<li class=\"box_li1\">Inability to drink</li>\n<li class=\"box_li1\">Skin pinch goes back very slowly (≥ 2 seconds)</li>\n</ul>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Some dehydration: at least two signs from the list on the right must be present</p>\n</td>\n<td class=\"calibre29\">\n<ul class=\"tab\">\n<li class=\"box_li1\">Restlessness, irritability</li>\n<li class=\"box_li1\">Sunken eyes</li>\n<li class=\"box_li1\">Drinks eagerly, is thirsty</li>\n</ul>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">No dehydration</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Too few signs to classify as some or severe dehydration</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"2\">\n<p class=\"legenda\">Source: WHO Pocket book of hospital care for children <em class=\"calibre10\">(31)</em>.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-806\"></a>Table 14.5 – Microbiology tests to consider in certain cases of diarrhoeal disease as indicated in the WHO EDL <em class=\"calibre10\">(6)</em></strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Diagnostic test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Purpose of the test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Setting where the test should be available</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Stool culture and antimicrobial susceptibility testing</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To detect and identify bacterial species for selection of appropriate antibiotic regimens</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Stool microscopy</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To detect and identify parasites and their ova (eggs) or cysts</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\"><em class=\"calibre10\">Vibrio cholerae</em> antigen<sup class=\"calibre30\">a</sup> (RDT)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To detect or exclude a cholera outbreak (not for use in case management)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Community settings and health facilities without laboratories</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">EDL: Model List of Essential In Vitro Diagnostics; RDT: rapid diagnostic test.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> Possible specimens include stool and rectal swab.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-807\"></a>Table 14.6 – Empiric antibiotic treatment for selected cases of infectious acute diarrhoea</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color1\" colspan=\"4\">\n<p class=\"box_tit1\"><img alt=\"Imagem\" class=\"calibre26\" src=\"images/000133.jpg\"/> <strong class=\"calibre5\">Important</strong></p>\n<p class=\"box_p1\">Where more than one antibiotic is recommended for an infection, they are listed in alphabetical order and they should be considered equal treatment options, unless otherwise indicated.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"colort\"></td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Adults</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Children</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Total treatment duration</strong></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">First choice</strong></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_amarelo\">Ciprofloxacin</span><sup class=\"calibre30\">a,b</sup> (oral): 500 mg given every 12 hours</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_amarelo\">Ciprofloxacin</span><sup class=\"calibre30\">a</sup> (oral): 15 mg/kg/dose given every 12 hours</p>\n<p class=\"box_p1\">Oral weight bands:</p>\n<p class=\"box_p1\">3–&lt; 6 kg: 50 mg given every 12 hours</p>\n<p class=\"box_p1\">6–&lt; 10 kg: 100 mg given every 12 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 150 mg given every 12 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 200 mg given every 12 hours</p>\n<p class=\"box_p1\">20–&lt; 30 kg: 300 mg given every 12 hours</p>\n<p class=\"box_p1\">≥ 30 kg: use adult dose</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">3 days</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"calibre6\" id=\"calibre_link-241\" role=\"doc-pagebreak\" title=\"182\" type=\"pagebreak\"></span><strong class=\"calibre5\">Second choice</strong></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Oral options</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Azithromycin</span><sup class=\"calibre30\">c</sup> (oral): 500 mg given once a day (on day 1) followed by 250 mg given once a day for 3 days</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Cefixime</span><sup class=\"calibre30\">d</sup> (oral):400 mg given once a day</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Sulfamethoxazole+ trimethoprim</span><sup class=\"calibre30\">d,e</sup> (oral): 800 mg + 160 mg given every 12 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Parenteral option</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Ceftriaxone</span><sup class=\"calibre30\">d</sup> (IV/IM): 1 g given once a day</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Oral options</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Azithromycin</span><sup class=\"calibre30\">c</sup> (oral): 10 mg/kg/dose given once a day</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Cefixime</span><sup class=\"calibre30\">d</sup> (oral): 10 mg/kg/dose given once a day</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Sulfamethoxazole+ trimethoprim</span><sup class=\"calibre30\">d,e</sup> (oral):20 mg/kg + 4 mg/kg given every 12 hours</p>\n<p class=\"box_p1\">Oral weight bands (mg of the sulfamethoxazole/trimethoprim component):</p>\n<p class=\"box_p1\">3–&lt; 6 kg: 100 mg/20 mg given every 12 hours</p>\n<p class=\"box_p1\">6–&lt; 10 kg: 200 mg/40 mg given every 12 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 400 mg/80 mg given every 12 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 400 mg/80 mg given every 12 hours</p>\n<p class=\"box_p1\">20–&lt; 30 kg: 400 mg/80 mg given every 12 hours</p>\n<p class=\"box_p1\">≥ 30 kg: use adult dose</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Parenteral option</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Ceftriaxone</span><sup class=\"calibre30\">d</sup> (IV/IM): 80 mg/kg/dose given once a day</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_amarelo\">Azithromycin</span>: 4 days</p>\n<p class=\"calibre24\"> </p>\n<p class=\"calibre24\"> </p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Cefixime</span>:</p>\n<p class=\"box_p1\">3 days (adults)</p>\n<p class=\"box_p1\">5 days (children)</p>\n<p class=\"box_p1\"><span class=\"back_verde\">Sulfamethoxazole+ trimethoprim</span>: 5 days</p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Ceftriaxone</span>: 3 days</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"4\">\n<p class=\"legenda\">IM: intramuscular; IV: intravenous.</p>\n<p class=\"legenda\">Note. All dosages are for normal renal and hepatic function.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> If symptoms do not resolve within 24–48 hours of treatment, consider <em class=\"calibre10\">Entamoeba histolytica</em>or <em class=\"calibre10\">Giardia intestinalis</em> as possible causes and provide appropriate treatment.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">b</sup> The use of fluoroquinolones (such as ciprofloxacin) can be associated with important side-effects including: (i) mental health disturbances such as disorientation, agitation, nervousness, memory impairment and delirium; (ii) serious blood sugar disturbances such as hypoglycaemic coma; (iii) increased risk of tendinitis and tendon rupture; (iv) worsening symptoms in those with myasthenia gravis; and (v) potential irreversible neuropathy (serious nerve damage).</p>\n<p class=\"legenda\"><span class=\"calibre6\" id=\"calibre_link-242\" role=\"doc-pagebreak\" title=\"183\" type=\"pagebreak\"></span><sup class=\"calibre30\">c</sup> Azithromycin is preferred in cases of high prevalence of ciprofloxacin resistance among bacteria frequently associated with acute infectious diarrhoea (e.g. Intestinal/non-invasive/diarrhoeal non-typhoidal <em class=\"calibre10\">Salmonella</em>, <em class=\"calibre10\">Shigella</em>spp.). Of note azithromycin can cause abnormal changes in the electrical activity of the heart leading to a potentially fatal irregular heart rhythm, especially in patients with known risk factors such as long QT interval or arrhythmias.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">d</sup> Cefixime, ceftriaxone and sulfamethoxazole+trimethoprim are not active against <em class=\"calibre10\">Campylobacter</em>spp.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">e</sup> Ideally, sulfamethoxazole+trimethoprim should only be used if local data suggest susceptibility or if the isolated strain is susceptible. As per WHO 2005 guidelines, this antibiotic should not be used empirically when shigellosis is suspected <em class=\"calibre10\">(145)</em>. In patients taking sulfamethoxazole+trimethoprim for prophylaxis, a different antibiotic should be used for treatment unless susceptibility is confirmed.</p>\n<p class=\"legenda\">Legend: ACCESS antibiotics are indicated in green, WATCH antibiotics in orange and RESERVE antibiotics in red.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-808\"></a>Table 14.7 – Empiric antibiotic treatment for cholera</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color2\" colspan=\"2\">\n<p class=\"box_tit1\"><img alt=\"Imagem\" class=\"calibre26\" src=\"images/000166.jpg\"/> <strong class=\"calibre5\">Note</strong></p>\n<p class=\"box_p1\">For indications for antibiotic use, please refer to the technical note on the use of antibiotics for the treatment and control of cholera from the Global Task Force on Cholera Control <em class=\"calibre10\">(148)</em>.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color1\" colspan=\"2\">\n<p class=\"box_tit1\"><img alt=\"Imagem\" class=\"calibre26\" src=\"images/000133.jpg\"/> <strong class=\"calibre5\">Important</strong></p>\n<p class=\"box_p1\">Where more than one antibiotic is recommended for an infection, they are listed in alphabetical order and they should be considered equal treatment options, unless otherwise indicated.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Adults</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Children</strong></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">First choice</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Azithromycin</span><sup class=\"calibre30\">a</sup> (oral): 1 g, single dose</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Doxycycline</span> (oral): 300 mg, single dose (or 100 mg given every 12 hours for 3 days if single dose is not tolerated)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">First choice</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Azithromycin</span><sup class=\"calibre30\">a</sup> (oral): 20 mg/kg, single dose</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Second choice</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Ciprofloxacin</span> (oral): 1 g, single dose</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Second choice</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Ciprofloxacin</span> (oral): 15 mg/kg, single dose</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Doxycycline</span> (oral)</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">&lt; 45 kg (&lt; 12 years): 2 to 4 mg/kg, single dose</li>\n<li class=\"box_li1\">&gt; 45 kg (&gt; 12 years): 300 mg, single dose</li>\n</ul>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"2\">\n<p class=\"legenda\">Note. All dosages are for normal renal and hepatic function.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> Azithromycin is preferred because of the decreasing susceptibility of cholera to tetracyclines and fluoroquinolones. Because of the long half-life of azithromycin, it should only be recommended for outbreak situations, where single-dose treatment is especially useful.</p>\n<p class=\"legenda\">Legend: ACCESS antibiotics are indicated in green, WATCH antibiotics in orange and RESERVE antibiotics in red.</p>\n</td>\n</tr>\n</tfoot>\n</table>"
        ]
    },
    {
        "name": "Enteric fever",
        "tables": [
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-809\"></a>Table 15.1 – Microbiology tests to consider when enteric fever is suspected as indicated in the WHO EDL <em class=\"calibre10\">(6)</em></strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Diagnostic test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Purpose of the test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Setting where the test should be available</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Blood cultures<sup class=\"calibre30\">a</sup> and antimicrobial susceptibility testing</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To detect bacterial and fungal bloodstream infections (sepsis)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Bone marrow culture<sup class=\"calibre30\">b</sup> and antimicrobial susceptibility testing</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Initial step in detection and identification of bacterial and fungal species for selection of appropriate antimicrobial regimens</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Stool culture<sup class=\"calibre30\">c</sup> and antimicrobial susceptibility testing</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Initial step in detection and identification of bacterial species for selection of appropriate antibiotic regimens</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">EDL: Model List of Essential In Vitro Diagnostics.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> Often the mainstay of diagnosis. Without antibiotic treatment, blood cultures are often positive (5–7 out of 10 patients) however sensitivity is low, if antibiotics have already been started.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">b</sup> The gold standard for diagnosis but it is often not feasible to do.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">c</sup> Low sensitivity and not useful in the early phase (first week) of disease when the test is often negative.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-810\"></a>Table 15.2 – Empiric antibiotic treatment for enteric fever</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Risk of fluoroquinolone resistance</strong><sup class=\"calibre32\">a</sup></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Adults</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Children</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Total treatment duration</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Low</strong></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_amarelo\">Ciprofloxacin</span><sup class=\"calibre30\">b</sup> (oral): 500 mg given every 12 hours</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_amarelo\">Ciprofloxacin</span> (oral): 15 mg/kg/dose given every 12 hours</p>\n<p class=\"box_p1\">Oral weight bands:</p>\n<p class=\"box_p1\">3–&lt; 6 kg: 50 mg given every 12 hours</p>\n<p class=\"box_p1\">6–&lt; 10 kg: 100 mg given every 12 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 150 mg given every 12 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 200 mg given every 12 hours</p>\n<p class=\"box_p1\">20–&lt; 30 kg: 300 mg given every 12 hours</p>\n<p class=\"box_p1\">≥ 30 kg: use adult dose</p>\n</td>\n<td class=\"calibre29\" rowspan=\"2\">\n<p class=\"box_p1\">Mild cases: 7 days</p>\n<p class=\"box_p1\">Severe cases: 10 days if the patient is clinically improving and without a fever for 48 hours</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">High</strong></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Mild cases</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Azithromycin</span><sup class=\"calibre30\">c</sup> (oral): 1 g given once a day (on day one) followed by 500 mg given once a day</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Severe cases</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Ceftriaxone</span><sup class=\"calibre30\">d</sup> (IV):2 g given once a day</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Mild cases</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Azithromycin</span> (oral):20 mg/kg/dose given once a day</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Severe cases</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Ceftriaxone</span><sup class=\"calibre30\">d</sup> (IV): 80 mg/kg/ dose given once a day</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"4\">\n<p class=\"legenda\">IV: intravenous.</p>\n<p class=\"legenda\">Note. All dosages are for normal renal and hepatic function.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> It should be noted that there is no clearly defined prevalence of resistance in a certain setting that defines low versus high risk of fluoroquinolone resistance.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">b</sup> The use of fluoroquinolones (such as ciprofloxacin) can be associated with important side-effects including: (i) mental health disturbances such as disorientation, agitation, nervousness, memory impairment and delirium; (ii) serious blood sugar disturbances such as hypoglycaemic coma; (iii) increased risk of tendinitis and tendon rupture; (iv) worsening symptoms in those with myasthenia gravis; and (v) potential irreversible neuropathy (serious nerve damage).</p>\n<p class=\"legenda\"><sup class=\"calibre30\">c</sup> Azithromycin can cause abnormal changes in the electrical activity of the heart leading to a potentially fatal irregular heart rhythm especially in patients with known risk factors such as long QT interval or arrhythmias.</p>\n<p class=\"legenda\"><span class=\"calibre6\" id=\"calibre_link-251\" role=\"doc-pagebreak\" title=\"192\" type=\"pagebreak\"></span><sup class=\"calibre30\">d</sup> In settings where ceftriaxone-resistance is increasing, azithromycin should be prioritized. Outbreaks of enteric fever caused by extensively antibiotic-resistant <em class=\"calibre10\">Salmonella</em>Typhi have been reported, for example, in Pakistan since 2016 <em class=\"calibre10\">(159)</em> and in travel-related cases across the world <em class=\"calibre10\">(162–164)</em>. In general, when ceftriaxone is used, changing to oral treatment could be considered when there is symptomatic improvement. If available, the choice of oral options to use could be guided by results of susceptibility testing, including the possibility of using certain first-choice options that were used in the past.</p>\n<p class=\"legenda\">Legend: ACCESS antibiotics are indicated in green, WATCH antibiotics in orange and RESERVE antibiotics in red.</p>\n</td>\n</tr>\n</tfoot>\n</table>"
        ]
    },
    {
        "name": "Skin and soft tissue infections – mild bacterial impetigo, erysipelas and cellulitis",
        "tables": [
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-812\"></a>Table 16.1 – Pathogens most frequently associated with skin infections (in descending order of frequency)</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Most cases</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">More rarely (e.g. in immunocompromised and/or diabetic patients, traumatic skin lesions)</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Cases with specific environmental exposures</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><em class=\"calibre10\">Streptococcus pyogenes</em> (group A <em class=\"calibre10\">Streptococcus</em>), especially in the case of erysipelas</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Staphylococcus aureus</em> (including MRSA)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Enterobacterales (including multidrug-resistant strains such as those producing ESBL and carbapenemases)</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Pseudomonas aeruginosa</em> (including multidrug-resistant strains such as those producing ESBL and carbapenemases)</p>\n<p class=\"box_p1\">Anaerobes</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><em class=\"calibre10\">Aeromonas hydrophila</em> (exposure to fresh water)</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Erysipelothrix rhusiopathiae</em> (contact with animals colonized with the organism, mostly pigs and fish)</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Vibrio vulnificus</em> (exposure to seawater)</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">ESBL: extended-spectrum beta-lactamases; MRSA: methicillin-resistant <em class=\"calibre10\">Staphylococcus aureus</em>.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-813\"></a>Table 16.2 – Morphology of skin lesions</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Type of skin lesion</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Morphology</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Bulla</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Larger (&gt; 10 mm) fluid-filled blister</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Papule</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Small (&lt; 10 mm), elevated lesion that can be palpated</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Pustule</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Small (&lt; 10 mm) vesicle containing pus</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Vesicle</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Small (&lt; 10 mm) fluid-filled blister</p>\n</td>\n</tr>\n</tbody>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-262\" role=\"doc-pagebreak\" title=\"203\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-818\"></a>Table 16.3 – Microbiology tests to consider for the diagnosis of skin infections in certain cases as indicated in the WHO EDL <em class=\"calibre10\">(6)</em></strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Diagnostic test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Purpose of the test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Setting where the test should be available</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Tissue swab culture and antimicrobial susceptibility testing</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Initial step to detect and identify bacterial and fungal species for selection of appropriate antimicrobial regimens</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">EDL: Model List of Essential In Vitro Diagnostics.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-819\"></a>Table 16.4 – Empiric antibiotic treatment for mild skin infections</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color1\" colspan=\"3\">\n<p class=\"box_tit1\"><img alt=\"Imagem\" class=\"calibre26\" src=\"images/000133.jpg\"/> <strong class=\"calibre5\">Important</strong></p>\n<p class=\"box_p1\">Where more than one antibiotic is recommended for an infection, they are listed in alphabetical order and they should be considered equal treatment options, unless otherwise indicated.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color2\" colspan=\"3\">\n<p class=\"box_tit1\"><img alt=\"Imagem\" class=\"calibre26\" src=\"images/000166.jpg\"/> <strong class=\"calibre5\">Note</strong></p>\n<p class=\"box_p1\">Cloxacillin and cefalexin have a narrower spectrum of antibacterial activity compared to amoxicillin+clavulanic acid with good efficacy in mild skin and soft tissue infections. Therefore, from an antibiotic stewardship perspective, these two antibiotics are the preferred options whenever possible.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Adults</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Children</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Total treatment duration</strong></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_verde\">Amoxicillin+clavulanic acid</span> (oral): 500 mg + 125 mg given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Cefalexin</span>(oral): 500 mg given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Cloxacillin</span><sup class=\"calibre30\">a</sup> (oral): 500 mg given every 6 hours</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_verde\">Amoxicillin+clavulanic acid</span><sup class=\"calibre30\">b</sup> (oral):80–90 mg/kg/day of amoxicillin component</p>\n<p class=\"box_p1\">Oral weight bands:</p>\n<p class=\"box_p1\">3–&lt; 6 kg: 250 mg of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p1\">6–&lt; 10 kg: 375 mg of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 500 mg of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 750 mg of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p1\">≥ 20kg: 500 mg of amoxicillin/dose given every 8 hours or 1 g of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<span class=\"calibre6\" id=\"calibre_link-264\" role=\"doc-pagebreak\" title=\"205\" type=\"pagebreak\"></span>\n<p class=\"box_p1\"><span class=\"back_verde\">Cefalexin</span> (oral): 25 mg/kg/dose given every 12 hours</p>\n<p class=\"box_p1\">Oral weight bands:</p>\n<p class=\"box_p1\">3–&lt; 6 kg: 125 mg given every 12 hours</p>\n<p class=\"box_p1\">6–&lt; 10 kg: 250 mg given every 12 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 375 mg given every 12 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 500 mg given every 12 hours</p>\n<p class=\"box_p1\">20–&lt; 30 kg: 625 mg given every 12 hours</p>\n<p class=\"box_p1\">≥ 30 kg: use adult dose</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Cloxacillin</span><sup class=\"calibre30\">a,c</sup> (oral): 15 mg/kg/dose given every 6 hours</p>\n<p class=\"box_p1\">Oral weight bands:</p>\n<p class=\"box_p1\">3–&lt; 6 kg: 62.5 mg given every 6 hours</p>\n<p class=\"box_p1\">6–&lt; 10 kg: 125 mg given every 6 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 250 mg given every 6 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 375 mg given every 6 hours</p>\n<p class=\"box_p1\">≥ 20 kg: 500 mg given every 6 hours</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">5 days<sup class=\"calibre30\">d</sup></p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">Note. All dosages are for normal renal and hepatic function.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> If cloxacillin is unavailable, dicloxacillin or flucloxacillin could be used.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">b</sup> Oral liquid formulations must be refrigerated after reconstitution as clavulanic acid is rapidly metabolized in high ambient temperatures.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">c</sup> The WHO <em class=\"calibre10\">Pocket book of hospital care for children (31)</em>suggests amoxicillin plus cloxacillin. However, cloxacillin can be safely used as a single antibiotic option because it has good activity against both methicillin-susceptible <em class=\"calibre10\">Staphylococcus aureus</em> and <em class=\"calibre10\">Streptococcus pyogenes</em> (often referred to as group A <em class=\"calibre10\">Streptococcus</em>). Amoxicillin alone is not suitable because it has variable activity against methicillin-susceptible <em class=\"calibre10\">Staphylococcus aureus</em>.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">d</sup> The optimal duration of antibiotic treatment is not known <em class=\"calibre10\">(169)</em>; duration is often individualized based on clinical response.</p>\n<p class=\"legenda\">Legend: ACCESS antibiotics are indicated in green, WATCH antibiotics in orange and RESERVE antibiotics in red.</p>\n</td>\n</tr>\n</tfoot>\n</table>"
        ]
    },
    {
        "name": "Burn wound-related infections",
        "tables": [
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\">Table 17.1 – Pathogens most frequently associated with infected burn wounds (in descending order of frequency)</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Time infection acquired</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Bacteria</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Fungi</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Soon after the injury</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><em class=\"calibre10\">Streptococcus</em> spp.</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Staphylococcus aureus</em> (including MRSA)</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Staphylococcus</em> spp. other than <em class=\"calibre10\">Staphylococcus aureus</em></p>\n<p class=\"box_p1\">Enterobacterales (including multidrug-resistant strains such as those producing ESBL and carbapenemases)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Infrequent</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"calibre6\" id=\"calibre_link-270\" role=\"doc-pagebreak\" title=\"211\" type=\"pagebreak\"></span>Additionally, during hospitalization</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><em class=\"calibre10\">Pseudomonas aeruginosa</em></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Acinetobacter baumannii</em></p>\n<p class=\"box_p1\">(including multidrug-resistant strains such as those producing ESBL and carbapenemases)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><em class=\"calibre10\">Candida</em> spp.</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">ESBL: extended-spectrum beta-lactamases; MRSA: methicillin-resistant <em class=\"calibre10\">Staphylococcus aureus</em>.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-820\"></a>Table 17.2 – Empiric antibiotic treatment for mild burn wound infections</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color1\" colspan=\"3\">\n<p class=\"box_tit1\"><img alt=\"Imagem\" class=\"calibre26\" src=\"images/000133.jpg\"/> <strong class=\"calibre5\">Important</strong></p>\n<p class=\"box_p1\">Where more than one antibiotic is recommended for an infection, they are listed in alphabetical order and they should be considered equal treatment options, unless otherwise indicated.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color2\" colspan=\"3\">\n<p class=\"box_tit1\"><img alt=\"Imagem\" class=\"calibre26\" src=\"images/000166.jpg\"/> <strong class=\"calibre5\">Note</strong></p>\n<p class=\"box_p1\">Cloxacillin and cefalexin have a narrower spectrum of antibacterial activity compared to amoxicillin+clavulanic acid with good efficacy in mild skin and soft tissue infections. Therefore, from an antibiotic stewardship perspective, these two antibiotics are the preferred options whenever possible.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Adults</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Children</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Total treatment duration</strong></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_verde\">Amoxicillin+clavulanic acid</span> (oral): 500 mg + 125 mg given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Cefalexin</span> (oral): 500 mg given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Cloxacillin</span><sup class=\"calibre30\">a</sup> (oral): 500 mg given every 6 hours</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_verde\">Amoxicillin+clavulanic acid</span><sup class=\"calibre30\">b</sup> (oral): 80–90 mg/kg/day of amoxicillin component</p>\n<p class=\"box_p1\">Oral weight bands:</p>\n<p class=\"box_p1\">3–&lt; 6 kg: 250 mg of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p1\">6–&lt; 10 kg: 375 mg of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 500 mg of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 750 mg of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p1\">≥ 20 kg: 500 mg of amoxicillin/dose given every 8 hours or 1 g of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<span class=\"calibre6\" id=\"calibre_link-273\" role=\"doc-pagebreak\" title=\"214\" type=\"pagebreak\"></span>\n<p class=\"box_p1\"><span class=\"back_verde\">Cefalexin</span> (oral): 25 mg/kg/dose given every 12 hours</p>\n<p class=\"box_p1\">Oral weight bands:</p>\n<p class=\"box_p1\">3–&lt; 6 kg: 125 mg given every 12 hours</p>\n<p class=\"box_p1\">6–&lt; 10 kg: 250 mg given every 12 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 375 mg given every 12 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 500 mg given every 12 hours</p>\n<p class=\"box_p1\">20–&lt; 30 kg: 625 mg given every 12 hours</p>\n<p class=\"box_p1\">≥ 30 kg: use adult dose</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Cloxacillin</span><sup class=\"calibre30\">a,c</sup> (oral): 15 mg/kg/dose given every 6 hours</p>\n<p class=\"box_p1\">Oral weight bands:</p>\n<p class=\"box_p1\">3–&lt; 6 kg: 62.5 mg given every 6 hours</p>\n<p class=\"box_p1\">6–&lt; 10 kg: 125 mg given every 6 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 250 mg given every 6 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 375 mg given every 6 hours</p>\n<p class=\"box_p1\">≥ 20 kg: 500 mg given every 6 hours</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">5 days</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">Note. All dosages are for normal renal and hepatic function.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> If cloxacillin is unavailable, dicloxacillin or flucloxacillin could be used.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">b</sup> Oral liquid formulations must be refrigerated after reconstitution as clavulanic acid is rapidly metabolized in high ambient temperatures.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">c</sup> The WHO <em class=\"calibre10\">Pocket book of hospital care for children</em>suggests amoxicillin plus cloxacillin; however, cloxacillin can be safely used as a single antibiotic option since it has good activity against both methicillin-susceptible <em class=\"calibre10\">Staphylococcus aureus</em> and <em class=\"calibre10\">Streptococcus pyogenes</em>. Amoxicillin alone is not suitable because it has variable activity against methicillin-susceptible <em class=\"calibre10\">Staphylococcus aureus</em>.</p>\n<p class=\"legenda\">Legend: ACCESS antibiotics are indicated in green, WATCH antibiotics in orange and RESERVE antibiotics in red.</p>\n</td>\n</tr>\n</tfoot>\n</table>"
        ]
    },
    {
        "name": "Wound and bite-related infections",
        "tables": [
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-821\"></a>Table 18.1 – Pathogens most frequently associated with traumatic skin wounds (in descending order of frequency), except bites, see Table 18.2</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Most cases</strong><sup class=\"calibre32\">a</sup></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">More rarely</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><em class=\"calibre10\">Streptococcus</em> spp.</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Staphylococcus aureus</em> (including MRSA)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Anaerobes</p>\n<p class=\"box_p1\">Enterobacterales</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Enterococcus</em> spp.</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Clostridium tetani</em> (soil contaminant)</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"2\">\n<p class=\"legenda\">MRSA: methicillin-resistant <em class=\"calibre10\">Staphylococcus aureus</em>.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> Mostly Gram-positive pathogens from the skin microbiota.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Species causing the bite</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Pathogens</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Human</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Common bacterial pathogens</strong></p>\n<p class=\"box_p1\">Anaerobes from the oral microbiota such as <em class=\"calibre10\">Prevotella</em> and <em class=\"calibre10\">Fusobacterium</em> spp.</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Streptococcus</em> spp.</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Staphylococcus aureus</em></p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Non-bacterial pathogens</strong></p>\n<p class=\"box_p1\">Hepatitis B virus</p>\n<p class=\"box_p1\">Hepatitis C virus</p>\n<p class=\"box_p1\">HIV</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Cat</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Common bacterial pathogens</strong></p>\n<p class=\"box_p1\">Anaerobes such as <em class=\"calibre10\">Bacteroides</em> spp., <em class=\"calibre10\">Cutibacterium</em> spp., <em class=\"calibre10\">Fusobacterium</em> spp., <em class=\"calibre10\">Peptostreptococcus</em> spp. and <em class=\"calibre10\">Prevotella</em> spp.</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Pasteurella multocida</em></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Staphylococcus aureus</em></p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Other bacterial pathogens</strong></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Bartonella henselae</em> (agent of cat-scratch disease)</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Francisella tularensis</em> (agent of tularaemia)</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Non-bacterial pathogens</strong></p>\n<p class=\"box_p1\">Rabies virus</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Soil contaminants</strong></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Clostridium tetani</em> (agent of tetanus)</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Dog</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Common bacterial pathogens</strong></p>\n<p class=\"box_p1\">Anaerobes such as <em class=\"calibre10\">Bacteroides</em> spp., <em class=\"calibre10\">Cutibacterium</em> spp., <em class=\"calibre10\">Fusobacterium</em> spp., <em class=\"calibre10\">Peptostreptococcus</em> spp. and <em class=\"calibre10\">Prevotella</em> spp.</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Capnocytophaga canimorsus</em></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Pasteurella multocida</em></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Staphylococcus aureus</em></p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Other bacterial pathogens</strong></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Francisella tularensis</em> (agent of tularaemia)</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Leptospira</em> spp. (agent of leptospirosis)</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Non-bacterial pathogens</strong></p>\n<p class=\"box_p1\">Rabies virus</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Soil contaminants</strong></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Clostridium tetani</em> (agent of tetanus)</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"calibre6\" id=\"calibre_link-283\" role=\"doc-pagebreak\" title=\"224\" type=\"pagebreak\"></span>Monkey</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Bacterial pathogens</strong></p>\n<p class=\"box_p1\">Anaerobes such as <em class=\"calibre10\">Bacteroides</em> spp., <em class=\"calibre10\">Cutibacterium</em> spp., <em class=\"calibre10\">Fusobacterium</em> spp., <em class=\"calibre10\">Peptostreptococcus</em> spp. and <em class=\"calibre10\">Prevotella</em> spp.</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Streptococcus</em> spp.</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Staphylococcus aureus</em></p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Non-bacterial pathogens</strong></p>\n<p class=\"box_p1\">Hepatitis B virus (macaques)</p>\n<p class=\"box_p1\">Herpes B virus</p>\n<p class=\"box_p1\">Monkeypox virus</p>\n<p class=\"box_p1\">Rabies virus</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Soil contaminants</strong></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Clostridium tetani</em> (agent of tetanus)</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Rodent (e.g. mice, rats)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Bacterial pathogens</strong></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Francisella tularensis</em> (agent of tularaemia)</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Leptospira</em> spp. (agent of leptospirosis)</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Pasteurella multocida</em></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Spirillum minor</em> (agent of rat-bite fever in Asia)</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Streptobacillus moniliformis</em> (agent of rat-bite fever in North America)</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Non-bacterial pathogens</strong></p>\n<p class=\"box_p1\">Rabies virus</p>\n<p class=\"box_p1\">Monkeypox virus</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Soil contaminants</strong></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Clostridium tetani</em> (agent of tetanus)</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Reptile (e.g. crocodiles, lizards, snakes, turtles)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Bacterial pathogens</strong></p>\n<p class=\"box_p1\">Anaerobes such as <em class=\"calibre10\">Prevotella</em> and <em class=\"calibre10\">Fusobacterium</em> spp.</p>\n<p class=\"box_p1\">Enterobacterales</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Pseudomonas aeruginosa</em></p>\n<p class=\"box_p1\">Non-typhoidal <em class=\"calibre10\">Salmonella</em> spp.</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Soil contaminants</strong></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Clostridium tetani</em> (agent of tetanus)</p>\n</td>\n</tr>\n</tbody>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-822\"></a>Table 18.3 – Risk of rabies exposure according to the type of contact with the animal suspected of having rabies <em class=\"calibre10\">(179)</em></strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Category</strong><sup class=\"calibre32\">a</sup></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Type of contact</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Risk of exposure</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">I</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Touching or feeding animals, animal licks on intact skin</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">No exposure</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">II</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Nibbling of uncovered skin, minor scratches or abrasions without bleeding</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Exposure</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">III</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Single or multiple transdermal bites or scratches, contamination of mucous membrane or broken skin with saliva from animal licks, exposures due to direct contact with bats</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Severe exposure</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> The category of exposure determines the indicated post-exposure prophylaxis procedure.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-287\" role=\"doc-pagebreak\" title=\"228\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-823\"></a>Table 18.4 – Empiric antibiotic treatment for mild infections from traumatic wounds and bites</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color1\" colspan=\"3\">\n<p class=\"box_tit1\"><img alt=\"Imagem\" class=\"calibre26\" src=\"images/000133.jpg\"/> <strong class=\"calibre5\">Important</strong></p>\n<p class=\"box_p1\">Where more than one antibiotic is recommended for an infection, they are listed in alphabetical order and they should be considered equal treatment options, unless otherwise indicated.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color2\" colspan=\"3\">\n<p class=\"box_tit1\"><img alt=\"Imagem\" class=\"calibre26\" src=\"images/000166.jpg\"/> <strong class=\"calibre5\">Note</strong></p>\n<p class=\"box_p1\">Amoxicillin+clavulanic acid is the preferred treatment option for <strong class=\"calibre5\">bite wound infections</strong> because of its activity against anaerobic bacteria.</p>\n<p class=\"box_p1\">Cloxacillin and cefalexin have a narrower spectrum of antibacterial activity compared to amoxicillin+clavulanic acid with good efficacy in <strong class=\"calibre5\">other</strong> cases of mild skin and soft tissue infections. Therefore, from an antibiotic stewardship perspective, these would be the preferred options whenever possible, except for bite wounds.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Adults</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Children</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Total treatment duration</strong></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_verde\">Amoxicillin+clavulanic acid</span> (oral): 500 mg + 125 mg given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Cefalexin</span> (oral): 500 mg given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Cloxacillin</span><sup class=\"calibre30\">a</sup> (oral): 500 mg given every 6 hours</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_verde\">Amoxicillin+clavulanic acid</span><sup class=\"calibre30\">b</sup> (oral): 80–90 mg/kg/day of amoxicillin component</p>\n<p class=\"box_p1\">Oral weight bands:</p>\n<p class=\"box_p1\">3–&lt; 6 kg: 250 mg of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p1\">6–&lt; 10 kg: 375 mg of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 500 mg of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 750 mg of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p1\">≥ 20 kg: 500 mg of amoxicillin/dose given every 8 hours or 1 g of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<span class=\"calibre6\" id=\"calibre_link-288\" role=\"doc-pagebreak\" title=\"229\" type=\"pagebreak\"></span>\n<p class=\"box_p1\"><span class=\"back_verde\">Cefalexin</span>(oral): 25 mg/kg/dose given every 12 hours</p>\n<p class=\"box_p1\">Oral weight bands:</p>\n<p class=\"box_p1\">3–&lt; 6 kg: 125 mg given every 12 hours</p>\n<p class=\"box_p1\">6–&lt; 10 kg: 250 mg given every 12 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 375 mg given every 12 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 500 mg given every 12 hours</p>\n<p class=\"box_p1\">20–&lt; 30 kg: 625 mg given every 12 hours</p>\n<p class=\"box_p1\">≥ 30 kg: use adult dose</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Cloxacillin</span><sup class=\"calibre30\">a</sup> (oral): 15 mg/kg/dose given every 6 hours</p>\n<p class=\"box_p1\">Oral weight bands:</p>\n<p class=\"box_p1\">3–&lt; 6 kg: 62.5 mg given every 6 hours</p>\n<p class=\"box_p1\">6–&lt; 10 kg: 125 mg given every 6 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 250 mg given every 6 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 375 mg given every 6 hours</p>\n<p class=\"box_p1\">≥ 20 kg: 500 mg given every 6 hours</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">3 days (preventive treatment of wounds at high risk of infection)</p>\n<p class=\"box_p1\">5 days (treatment of infected wounds)</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">Note. All dosages are for normal renal and hepatic function.</p>\n<p class=\"legenda\">a If cloxacillin is unavailable, dicloxacillin or flucloxacillin could be used.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">b</sup> Oral liquid formulations must be refrigerated after reconstitution as clavulanic acid is rapidly metabolized in high ambient temperatures.</p>\n<p class=\"legenda\">Legend: ACCESS antibiotics are indicated in green, WATCH antibiotics in orange and RESERVE antibiotics in red.</p>\n</td>\n</tr>\n</tfoot>\n</table>"
        ]
    },
    {
        "name": "Sexually transmitted infections – chlamydial urogenital infection",
        "tables": [
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-294\" role=\"doc-pagebreak\" title=\"235\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-824\"></a>Table 19.1 – Microbiology tests to consider when chlamydial infection is suspected as indicated in the WHO EDL <em class=\"calibre10\">(6)</em></strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Diagnostic test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Purpose of the test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Settings where the test should be available</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Qualitative test for <em class=\"calibre10\">Chlamydia trachomatis</em> and <em class=\"calibre10\">Neisseria gonorrhoeae</em> infections (i.e. nucleic acid amplification test)<sup class=\"calibre30\">a,b</sup></p>\n<p class=\"box_p3\"><strong class=\"calibre5\">This is the recommended reference standard</strong></p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To diagnose chlamydial and/or gonorrhoeal urogenital disease and extragenital infection</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Microscopy (Gram stain)<sup class=\"calibre30\">c</sup></p>\n<p class=\"box_p1\">Gram stain of vaginal and urethral discharge will usually show the presence of leukocytes (&gt; 10 leukocytes/high power field for urethral discharge and &gt; 20 leukocytes/high power field for vaginal discharge) but this finding is not specific for chlamydial infections. If carried out by an experienced person, a Gram stain negative for intracellular diplococci (<em class=\"calibre10\">Neisseria gonorrhoeae</em> is an intracellular diplococcus) with the presence of &gt; 5 leukocytes/high power field in the context of urethral discharge in a man can be presumed to suggest non-gonococcal urethritis.</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To assess microbial morphology, and presence or absence of white blood cells</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Culture<sup class=\"calibre30\">c,d</sup> and antimicrobial susceptibility testing (rarely performed)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Initial step to detect and identify bacterial species for selection of appropriate antibiotic regimens</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">EDL: Model List of Essential In Vitro Diagnostics.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> Usually chlamydial and gonococcal infections are tested at the same time since their clinical presentations are very similar.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">b</sup> Possible specimens among women, are a vulvovaginal specimen, which may be self-collected. An endocervical swab can also be an alternative but requires a speculum. First-catch urine is another option, but the sensitivity and specificity tend to be lower in women. Among men, possible specimens are first-catch urine or urethral swabs. Anorectal and pharyngeal samples are also adequate. For anorectal samples among men who have sex with men, <em class=\"calibre10\">Chlamydia</em>genovar testing for lymphogranuloma venereum should be done to guide the appropriate treatment regimen for this condition.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">c</sup> Possible specimens are urethral swabs, endocervical swabs, vaginal swabs, rectal swabs, oropharyngeal swabs and conjunctival swabs. Note. Urine samples are not good specimens for microscopy and culture.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">d</sup> Consider culture if symptoms persist despite adequate treatment: note, urine samples are not good specimens for culture. Processing <em class=\"calibre10\">Chlamydia trachomatis</em> for culture requires highly experienced laboratories and technicians and is too complex, laborious and time-consuming to be of economic value. It is rarely performed in middle- or high-income countries nowadays except for special purposes.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-295\" role=\"doc-pagebreak\" title=\"236\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-825\"></a>Table 19.2 – Additional tests for other sexually transmitted infections to consider in patients with confirmed or suspected chlamydial urogenital infection as indicated in the WHO EDL <em class=\"calibre10\">(6)</em></strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Infection</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Diagnostic test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Purpose of the test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Settings where the test should be available</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Gonorrhoea</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\"><em class=\"calibre10\">Neisseria gonorrhoeae</em> NAAT</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To diagnose gonorrhoeal urogenital disease and extragenital infection</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">HIV</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Anti-HIV-1 and -HIV-2 antibody (RDT)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Self-testing to screen for HIV</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Community settings and health facilities without laboratories<sup class=\"calibre30\">a</sup></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">HIV</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Anti-HIV-1 and -HIV-2 antibody (RDT and immunoassay)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To screen for HIV infection</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Community settings and health facilities without laboratories<sup class=\"calibre30\">a</sup> (RDT)</p>\n<p class=\"box_p1\">Health care facilities with clinical laboratories (immunoassay)</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">HIV</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Combined anti-HIV-1/HIV-2 antibody and p24 antigen (RDT and immunoassay)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To screen for HIV infection</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Community settings and health facilities without laboratories<sup class=\"calibre30\">a</sup> (RDT)</p>\n<p class=\"box_p1\">Health care facilities with clinical laboratories (immunoassay)</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Hepatitis B</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Hepatitis B virus surface antigen (RDT, immunoassay)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To screen for acute and chronic hepatitis B virus infection in people aged &gt; 12 months</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Community settings and health facilities without laboratories<sup class=\"calibre30\">a</sup> (RDT)</p>\n<p class=\"box_p1\">Health care facilities with clinical laboratories (immunoassay)</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"calibre6\" id=\"calibre_link-296\" role=\"doc-pagebreak\" title=\"237\" type=\"pagebreak\"></span>Hepatitis B</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">IgM-specific antibodies to hepatitis B core antigen (immunoassay)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To aid in the diagnosis of acute HBV infection in the context of outbreak investigation</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories (immunoassay)</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Hepatitis C</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Anti-hepatitis C antibody (RDT, immunoassay)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To screen for hepatitis C virus infection in people aged &gt; 18 months</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Community settings and health facilities without laboratories<sup class=\"calibre30\">a</sup> (RDT)</p>\n<p class=\"box_p1\">Health care facilities with clinical laboratories (immunoassay)</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Syphilis</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Antibodies to <em class=\"calibre10\">Treponema pallidum</em><sup class=\"calibre30\">b</sup> (RDT)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To diagnose or help to diagnose <em class=\"calibre10\">Treponema pallidum</em></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Community settings and health facilities without laboratories<sup class=\"calibre30\">a</sup></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Syphilis and HIV (combined test)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Combined antibodies to <em class=\"calibre10\">Treponema pallidum</em> and to HIV-1 and HIV-2 (RDT)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To diagnose or help to diagnose HIV and/or <em class=\"calibre10\">Treponema pallidum</em></p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Community settings and health facilities without laboratories<sup class=\"calibre30\">a</sup></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Trichomoniasis</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Microscopy</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To assess microbial morphology, and presence or absence of white blood cells</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"4\">\n<p class=\"legenda\">EDL: Model List of Essential In Vitro Diagnostics; HIV: human immunodeficiency virus; NAAT: nucleic acid amplification test; RDT: rapid diagnostic test.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> Community and health settings without laboratories are facilities such as health posts and centres, doctors’ offices, outreach clinics and ambulatory care. These tests are assumed to be available at health care facilities with laboratories.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">b</sup> Usually, a non-treponemal test (e.g. rapid plasma reagin, Venereal Disease Research Laboratory test) is used for screening. Please refer to the chapter on syphilis for more details on testing.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-298\" role=\"doc-pagebreak\" title=\"239\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-826\"></a>Table 19.3 – Antibiotic treatment for chlamydial urogenital infections as indicated in the most recent WHO guidelines <em class=\"calibre10\">(190,191)</em> <br class=\"calibre7\"/>Please check the WHO website regularly for possible updates</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Type of chlamydial infection</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Treatment</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Total treatment duration</strong></p>\n</td>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Uncomplicated urogenital infection<sup class=\"calibre30\">a</sup></p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\"><span class=\"back_verde\">Doxycycline</span><sup class=\"calibre30\">b</sup> (oral): 100 mg given every 12 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Azithromycin</span> (oral): 1g</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">7 days (doxycycline)</p>\n<p class=\"box_p3\"> </p>\n<p class=\"box_p1\">Single dose (azithromycin)</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Anorectal infection<sup class=\"calibre30\">c</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_verde\">Doxycycline</span> (oral): 100 mg given every 12 hours</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">7 days</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Infection in pregnant women<sup class=\"calibre30\">d</sup></p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\"><span class=\"back_amarelo\">Azithromycin</span> (oral): 1g</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Single dose</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Lymphogranuloma venereum<sup class=\"calibre30\">e</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_verde\">Doxycycline</span> (oral): 100 mg given every 12 hours</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">21 days</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Ophthalmia neonatorum<sup class=\"calibre30\">f</sup> (i.e. chlamydial conjunctivitis)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\"><span class=\"back_amarelo\">Azithromycin</span> (oral): 20 mg/kg given once a day</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">3 days</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Ocular prophylaxis<sup class=\"calibre30\">g</sup> (topical treatment for the prevention of both gonococcal and chlamydial ophthalmia neonatorum)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_amarelo\">Erythromycin</span> (eye ointment): 0.5%</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Antibiotic needs to be applied to both eyes soon after birth (single dose)</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">EML: Model List of Essential Medicines; EMLc: Model List of Essential Medicines for children.</p>\n<p class=\"legenda\">Note. All dosages are for normal renal and hepatic function.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> Alternatives indicated in the 2021 WHO guidelines but not included the WHO EML for this indication are: erythromycin (oral): 500 mg every 6 hours; ofloxacin (oral): 200–400 mg every 12 hours. The recommended duration of treatment is 7 days for both options.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">b</sup> According to recent data, doxycycline is more effective than azithromycin and could be given priority if adherence to treatment is not a concern <em class=\"calibre10\">(198–200)</em>. The 2021 WHO guidelines for the management of symptomatic sexually transmitted infections recommend doxycycline as the first-line option and azithromycin as an effective substitute <em class=\"calibre10\">(191)</em>. Therefore, exceptionally in this case, alternative antibiotic options are not presented in alphabetical order and doxycycline is mentioned first in the Table.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">c</sup> Alternatives indicated in the 2021 WHO guidelines but not included in the EML for this indication are: erythromycin (oral): 500 mg every 6 hours. The recommended duration of treatment is 14 days.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">d</sup> Alternatives indicated in the 2021 WHO guidelines but not included in the EML for this indication are: erythromycin (oral): 500 mg every 6 hours. The recommended duration of treatment is 7 days.</p>\n<p class=\"legenda\"><span class=\"calibre6\" id=\"calibre_link-299\" role=\"doc-pagebreak\" title=\"240\" type=\"pagebreak\"></span><sup class=\"calibre30\">e</sup> Alternatives indicated in the 2021 WHO guidelines but not included in the EML for this indication are: erythromycin (oral): 500 mg every 6 hours. The recommended duration of treatment is 21 days.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">f</sup> Alternatives indicated in the 2016 WHO guidelines but not included in the EMLc for this indication are: erythromycin (oral): 50 mg/kg per day divided in 4 doses for 14 days.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">g</sup> Alternatives indicated in the 2016 WHO guidelines but not included the EMLc for this indication are: tetracycline hydrochloride (eye ointment) 1%; povidone–iodine (water-based solution. Do not use alcohol-based solutions) 2.5%; silver nitrate (solution) 1%; chloramphenicol (eye ointment) 1%.</p>\n<p class=\"legenda\">Legend: ACCESS antibiotics are indicated in green, WATCH antibiotics in orange and RESERVE antibiotics in red.</p>\n</td>\n</tr>\n</tfoot>\n</table>"
        ]
    },
    {
        "name": "Sexually transmitted infections – gonococcal infection",
        "tables": [
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-827\"></a>Table 20.1 – Microbiology tests to consider when gonococcal infection is suspected as indicated in the WHO EDL <em class=\"calibre10\">(6)</em></strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Diagnostic test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Purpose of the test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Settings where the test should be available</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Qualitative test for <em class=\"calibre10\">Neisseria gonorrhoeae</em> and <em class=\"calibre10\">Chlamydia trachomatis</em> infections (i.e. nucleic acid amplification test)<sup class=\"calibre30\">a,b</sup></p>\n<p class=\"box_p3\"><strong class=\"calibre5\">This is the recommended reference standard</strong></p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To diagnose gonorrhoeal and/or chlamydial urogenital disease and extragenital infection</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Microscopy (Gram stain)<sup class=\"calibre30\">c</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To assess microbial morphology, and presence or absence of white blood cells</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\"><span class=\"calibre6\" id=\"calibre_link-307\" role=\"doc-pagebreak\" title=\"248\" type=\"pagebreak\"></span>Culture<sup class=\"calibre30\">d</sup> and antimicrobial susceptibility testing</p>\n<p class=\"box_p1\">Consider if symptoms persist despite adequate treatment and for surveillance purposes.</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Initial step to detect and identify bacterial species for selection of appropriate antibiotic regimens</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Blood cultures</p>\n<p class=\"box_p1\">Consider if disseminated infection is suspected.</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To detect bacterial bloodstream infections (sepsis)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">EDL: Model List of Essential In Vitro Diagnostics.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> Usually gonococcal and chlamydial infections are tested at the same time since their clinical presentations are very similar.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">b</sup> Possible specimens among women include a vulvovaginal specimen, which may be self-collected. An endocervical swab can be an alternative but requires a speculum. First-catch urine is another option, but the sensitivity and specificity tend to be lower in women. Among men, first-catch urine or urethral swabs are appropriate. Anorectal and pharyngeal samples are also adequate. Nucleic acid amplification tests also perform well for pharyngeal and anorectal samples.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">c</sup> Possible specimens are: urethral swabs, endocervical swabs and conjunctival swabs. Note. Urine samples are not good specimens for microscopy.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">d</sup> Possible specimens are: urethral swabs, endocervical swabs, vaginal swabs, rectal swabs, oropharyngeal swabs and conjunctival swabs. Note. Urine samples are not good specimens for culture. Culture is the standard method for performing antibiotic susceptibility testing.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-828\"></a>Table 20.2 – Additional tests for other sexually transmitted infections to consider in patients with confirmed or suspected gonococcal infection as indicated in the WHO EDL <em class=\"calibre10\">(6)</em></strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Infection</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Diagnostic test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Purpose of the test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Settings where the test should be available</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Chlamydial urogenital infection</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\"><em class=\"calibre10\">Chlamydia trachomatis</em> NAAT</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To diagnose chlamydial urogenital disease and extragenital infection</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">HIV</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Anti-HIV-1 and -HIV-2 antibody (RDT)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Self-testing to screen for HIV</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Community settings and health facilities without laboratories<sup class=\"calibre30\">a</sup></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\"><span class=\"calibre6\" id=\"calibre_link-308\" role=\"doc-pagebreak\" title=\"249\" type=\"pagebreak\"></span>HIV</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Anti-HIV-1 and -HIV-2 antibody (RDT and immunoassay)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To screen for HIV infection</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Community settings and health facilities without laboratories<sup class=\"calibre30\">a</sup> (RDT)</p>\n<p class=\"box_p1\">Health care facilities with clinical laboratories (immunoassay)</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">HIV</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Combined anti-HIV-1/HIV-2 antibody and p24 antigen (RDT and immunoassay)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To screen for HIV infection</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Community settings and health facilities without laboratories<sup class=\"calibre30\">a</sup> (RDT)</p>\n<p class=\"box_p1\">Health care facilities with clinical laboratories (immunoassay)</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Hepatitis B</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Hepatitis B virus surface antigen (RDT, immunoassay)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To screen for acute and chronic hepatitis B virus infection in people aged &gt; 12 months</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Community settings and health facilities without laboratories<sup class=\"calibre30\">a</sup> (RDT)</p>\n<p class=\"box_p1\">Health care facilities with clinical laboratories (immunoassay)</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Hepatitis B</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">IgM-specific antibodies to hepatitis B core antigen (immunoassay)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To aid in the diagnosis of acute HBV infection in the context of outbreak investigation</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Hepatitis C</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Anti-hepatitis C antibody (RDT, immunoassay)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To screen for hepatitis C virus infection in people aged &gt; 18 months</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Community settings and health facilities without laboratories<sup class=\"calibre30\">a</sup> (RDT)</p>\n<p class=\"box_p1\">Health care facilities with clinical laboratories (immunoassay)</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"calibre6\" id=\"calibre_link-309\" role=\"doc-pagebreak\" title=\"250\" type=\"pagebreak\"></span>Syphilis</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Antibodies to <em class=\"calibre10\">Treponema pallidum</em><sup class=\"calibre30\">b</sup> (RDT)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To diagnose or help to diagnose <em class=\"calibre10\">Treponema pallidum</em></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Community settings and health facilities without laboratories<sup class=\"calibre30\">a</sup></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Syphilis and HIV (combined test)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Combined antibodies to <em class=\"calibre10\">Treponema pallidum</em> and to HIV-1 and HIV-2 (RDT)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To diagnose or help to diagnose HIV and/or <em class=\"calibre10\">Treponema pallidum</em></p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Community settings and health facilities without laboratories<sup class=\"calibre30\">a</sup></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Trichomoniasis</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Microscopy</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To assess microbial morphology, and presence or absence of white blood cells</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"4\">\n<p class=\"legenda\">EDL: Model List of Essential In Vitro Diagnostics; HIV: human immunodeficiency virus; NAAT: nucleic acid amplification test; RDT: rapid diagnostic test.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> Community and health settings without laboratories are defined as community and health facilities such as health posts and centres, doctors’ offices, outreach clinics and ambulatory care. These tests are also assumed to be available at health care facilities with laboratories.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">b</sup> Usually a non-treponemal test (e.g. rapid plasma reagin, Venereal Disease Research Laboratory test) is used for screening. Please refer to the chapter on syphilis for more details on testing.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-829\"></a>Table 20.3 – Antibiotic treatment for gonococcal infection as indicated in the 2016 WHO guidelines for the treatment of gonorrhoea <em class=\"calibre10\">(89)</em></strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color1\" colspan=\"3\">\n<p class=\"box_tit1\"><img alt=\"Imagem\" class=\"calibre26\" src=\"images/000133.jpg\"/> <strong class=\"calibre5\">Important</strong></p>\n<p class=\"box_p1\">WHO is currently revising treatment recommendations and dosages (please check the WHO website regularly for possible updates).</p>\n<p class=\"box_p1\">Where more than one antibiotic is recommended for an infection, they are listed in alphabetical order and they should be considered equal treatment options, unless otherwise indicated.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Type of gonococcal infection</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Treatment</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Total treatment duration</strong></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Genital and anorectal infections (<strong class=\"calibre5\">dual therapy</strong><sup class=\"calibre30\">a</sup> )</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\"><strong class=\"calibre5\">First choice</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Ceftriaxone</span> (IM): 250 mg <strong class=\"calibre5\">AND</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Azithromycin</span> (oral): 1 g</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Second choice</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Cefixime</span> (oral): 400 mg <strong class=\"calibre5\">AND</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Azithromycin</span> (oral): 1 g</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Single dose</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Genital and anorectal infections (<strong class=\"calibre5\">single therapy</strong>), if local resistance data confirm susceptibility to the antibiotic</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_amarelo\">Cefixime</span> (oral): 400 mg</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Ceftriaxone</span> (IM): 250 mg<sup class=\"calibre30\">b</sup></p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Spectinomycin</span> (IM): 2 g</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Single dose</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\"><span class=\"calibre6\" id=\"calibre_link-311\" role=\"doc-pagebreak\" title=\"252\" type=\"pagebreak\"></span>Oropharyngeal infections<sup class=\"calibre30\">c</sup> (<strong class=\"calibre5\">dual therapy</strong><sup class=\"calibre30\">a</sup> )</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\"><strong class=\"calibre5\">First choice</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Ceftriaxone</span> (IM): 250 mg <strong class=\"calibre5\">AND</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Azithromycin</span> (oral): 1 g</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Second choice</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Cefixime</span> (oral): 400 mg <strong class=\"calibre5\">AND</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Azithromycin</span> (oral): 1 g</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Single dose</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Oropharyngeal infections<sup class=\"calibre30\">c</sup> (<strong class=\"calibre5\">single therapy</strong>), if local resistance data confirm susceptibility to the antibiotic</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_amarelo\">Ceftriaxone</span> (IM): 250 mg<sup class=\"calibre30\">b</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Single dose</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Gonococcal ophthalmia neonatorum (i.e. gonococcal conjunctivitis)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\"><span class=\"back_amarelo\">Ceftriaxone</span><sup class=\"calibre30\">d</sup> (IM): 50mg/kg</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Single dose</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Ocular prophylaxis<sup class=\"calibre30\">e</sup> (topical treatment for the prevention of both chlamydial and gonococcal ophthalmia neonatorum)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_amarelo\">Erythromycin</span> (eye ointment): 0.5%</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Antibiotic needs to be applied to both eyes soon after birth (single dose)</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Retreatment after treatment failure</p>\n<p class=\"box_p1\">Consider treatment failure if symptoms persist after 5 days of adequate treatment</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\"><span class=\"back_amarelo\">Cefixime</span> (oral): 800 mg <strong class=\"calibre5\">AND</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Azithromycin</span> (oral): 2 g</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Ceftriaxone</span> (IM): 500 mg <strong class=\"calibre5\">AND</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Azithromycin</span> (oral): 2 g</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Gentamicin</span> (IM): 240 mg <strong class=\"calibre5\">AND</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Azithromycin</span> (oral): 2 g</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Spectinomycin</span><sup class=\"calibre30\">c</sup> (IM): 2 g <strong class=\"calibre5\">AND</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Azithromycin</span> (oral): 2 g</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Single dose</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">IM: intramuscular.</p>\n<p class=\"legenda\">Note. All dosages are for normal renal and hepatic function.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> Dual therapy should be given if no reliable local data on resistance are available.</p>\n<p class=\"legenda\"><span class=\"calibre6\" id=\"calibre_link-312\" role=\"doc-pagebreak\" title=\"253\" type=\"pagebreak\"></span><sup class=\"calibre30\">b</sup> A single dose of 500 mg or 1 g of ceftriaxone (IM) is recommended in some international guidelines <em class=\"calibre10\">(207–209)</em>.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">c</sup> Do not use spectinomycin to treat cases of oropharyngeal infection.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">d</sup> Ceftriaxone should not be administered in neonates receiving calcium-containing intravenous fluids and it should be avoided in infants with hyperbilirubinaemia. Cefotaxime can be used as an alternative. Alternatives to ceftriaxone indicated in the 2016 WHO guidelines include kanamycin (IM) 25mg/kg or spectinomycin (IM) 25mg/kg <em class=\"calibre10\">(89)</em>.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">e</sup> Alternatives indicated in the 2016 WHO guidelines include tetracycline hydrochloride (eye ointment) 1%; povidone–iodine (water-based solution. Do not use alcohol-based solutions) 2.5%; silver nitrate (solution) 1%; chloramphenicol (eye ointment) 1%.</p>\n<p class=\"legenda\">Legend: ACCESS antibiotics are indicated in green, WATCH antibiotics in orange and RESERVE antibiotics in red.</p>\n</td>\n</tr>\n</tfoot>\n</table>"
        ]
    },
    {
        "name": "Sexually transmitted infections – syphilis",
        "tables": [
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-321\" role=\"doc-pagebreak\" title=\"262\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-830\"></a>Table 21.1 – Microbiology tests to consider when syphilis is suspected as indicated in the WHO EDL <em class=\"calibre10\">(6)</em></strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Diagnostic test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Purpose of the test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Settings where the test should be available</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Microscopy of specimens obtained from skin and tissues lesions<sup class=\"calibre30\">a</sup></p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To assess microbial morphology</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Antibodies to <em class=\"calibre10\">Treponema pallidum</em> (RDT)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To diagnose or help to diagnose <em class=\"calibre10\">Treponema pallidum</em></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Community settings and health facilities without laboratories<sup class=\"calibre30\">b</sup></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Combined antibodies to <em class=\"calibre10\">Treponema pallidum</em> and to HIV-1 and HIV-2 (RDT)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To diagnose or help to diagnose HIV and/or <em class=\"calibre10\">Treponema pallidum</em></p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Community settings and health facilities without laboratories<sup class=\"calibre30\">b</sup></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Non-treponemal test: rapid plasma reagin</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To screen for syphilis and monitor effectiveness of treatment</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Non-treponemal test: VDLR test<sup class=\"calibre30\">c</sup></p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To screen for syphilis and monitor effectiveness of treatment and also to screen for, diagnose and confirm neurosyphilis<sup class=\"calibre30\">c</sup></p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Treponemal test: TPHA test<sup class=\"calibre30\">d</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To confirm syphilis and diagnose early and late syphilis</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Treponemal test: TPPA test<sup class=\"calibre30\">d</sup></p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To confirm syphilis and diagnose early and late syphilis</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">EDL: Model List of Essential In Vitro Diagnostics; HIV: human immunodeficiency virus; RDT: rapid diagnostic test; TPHA: <em class=\"calibre10\">Treponema pallidum</em> haemagglutination; TPPA: <em class=\"calibre10\">Treponema pallidum</em> particle agglutination; VDRL: Venereal Disease Research Laboratory.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> Nucleic acid amplification tests (e.g. polymerase chain reaction) of specimens obtained from skin and tissues lesions could also be considered if available.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">b</sup> Community and health settings without laboratories are defined as community and health facilities such as health posts and centres, doctors’ offices, outreach clinics and ambulatory care. These tests are also assumed to be available at health care facilities with laboratories.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">c</sup> If neurosyphilis is suspected (this can occur at any stage of infection including in the first few months), the VDRL test can also be used on the cerebrospinal fluid in the presence of a positive syphilis serology. The test has a high specificity (i.e. few false-positive results) but a low sensitivity (i.e. many false-negative results). Examination of the cerebrospinal fluid is recommended where there is clinical evidence of neurological involvement. It is also highly desirable in all patients with syphilis of more than 2 years duration or of uncertain duration in order to evaluate the possible presence of asymptomatic neurosyphilis <em class=\"calibre10\">(219)</em>.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">d</sup> Treponemal tests usually remain positive after the infection has been cleared.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-323\" role=\"doc-pagebreak\" title=\"264\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-833\"></a>Table 21.2 – Possible interpretation of combinations of non-treponemal and treponemal test results</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Non-treponemal test (RPR or VDRL)</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Treponemal test (FTA-ABS, TPPA, TPHA, RDT)</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Interpretation</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Positive</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Positive</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">This supports the diagnosis of syphilis (the stage of disease and need for treatment should be determined on a case-by-case basis).</p>\n<p class=\"box_p1\">Note. These cases should be notified to the local authority according to national guidance for disease notification.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Negative</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Positive</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Usually this can occur as a result of a successfully treated previous infection because treponemal tests tend to remain positive. Otherwise it could be a very early (or late) phase of the infection.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Positive</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Negative</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Usually this can be considered a false positive result (e.g. during pregnancy).</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Negative</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Negative</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Usually the diagnosis of syphilis can be excluded.</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">FTA-ABS: fluorescent treponemal antibody absorption; RDT: rapid diagnostic test; RPR: rapid plasma reagin; TPHA: <em class=\"calibre10\">Treponema pallidum</em> haemagglutination assay; TPPA: <em class=\"calibre10\">Treponema pallidum</em> particle agglutination; VDRL: Venereal Disease Research Laboratory.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-834\"></a>Table 21.3 – Additional tests for other sexually transmitted infections to consider in patients with confirmed or suspected syphilis as indicated in the WHO EDL <em class=\"calibre10\">(6)</em></strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Infection</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Diagnostic test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Purpose of the test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Settings where the test should be available</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Chlamydial urogenital infection and gonococcal infection</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Qualitative test for <em class=\"calibre10\">Chlamydia trachomatis</em> and <em class=\"calibre10\">Neisseria gonorrhoeae</em> infections (NAAT)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To diagnose chlamydial and/or gonorrhoeal urogenital disease and extragenital infection</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"calibre6\" id=\"calibre_link-324\" role=\"doc-pagebreak\" title=\"265\" type=\"pagebreak\"></span>HIV</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Anti-HIV-1 and -HIV-2 antibody (RDT)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Self-testing to screen for HIV</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Community settings and health facilities without laboratories<sup class=\"calibre30\">a</sup></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">HIV</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Anti-HIV-1 and -HIV-2 antibody (RDT and immunoassay)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To screen for HIV infection</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Community settings and health facilities without laboratories<sup class=\"calibre30\">a</sup> (RDT)</p>\n<p class=\"box_p1\">Health care facilities with clinical laboratories (immunoassay)</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">HIV</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Combined anti-HIV-1/HIV-2 antibody and p24 antigen (RDT and immunoassay)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To screen for HIV infection</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Community settings and health facilities without laboratories<sup class=\"calibre30\">a</sup> (RDT)</p>\n<p class=\"box_p1\">Health care facilities with clinical laboratories (immunoassay)</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Hepatitis B</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Hepatitis B virus surface antigen (RDT, immunoassay</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To screen for acute and chronic hepatitis B virus infection in people older than 12 months</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Community settings and health facilities without laboratories<sup class=\"calibre30\">a</sup> (RDT)</p>\n<p class=\"box_p1\">Health care facilities with clinical laboratories (immunoassay)</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Hepatitis B</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">IgM-specific antibodies to hepatitis B core antigen (immunoassay)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To aid in the diagnosis of acute HBV infection in the context of outbreak investigation</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Hepatitis C</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Anti-hepatitis C antibody (RDT, immunoassay)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To screen for hepatitis C virus infection in people older than 18 months</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Community settings and health facilities without laboratories<sup class=\"calibre30\">a</sup> (RDT)</p>\n<p class=\"box_p1\">Health care facilities with clinical laboratories (immunoassay)</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"calibre6\" id=\"calibre_link-325\" role=\"doc-pagebreak\" title=\"266\" type=\"pagebreak\"></span>Trichomoniasis</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Microscopy</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To assess microbial morphology, and presence or absence of white blood cells</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"4\">\n<p class=\"legenda\">EDL: Model List of Essential In Vitro Diagnostics; HIV: human immunodeficiency virus; NAAT: nucleic acid amplification test; RDT: rapid diagnostic test.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> Community and health settings without laboratories are defined as community and health facilities such as health posts and centres, doctors’ offices, outreach clinics and ambulatory care. These tests are also assumed to be available at health care facilities with laboratories.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-835\"></a>Table 21.4 – Laboratory tests (other than microbiology) to consider when late syphilis is suspected as indicated in the WHO EDL <em class=\"calibre10\">(6)</em></strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Diagnostic test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Purpose of the test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Settings where the test should be available</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Basic CSF profile: CSF leukocyte count<sup class=\"calibre30\">a</sup> , CSF differential leukocyte count and CSF protein<sup class=\"calibre30\">b</sup> and glucose<sup class=\"calibre30\">c</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To aid in the diagnosis of neurosyphilis</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">CSF: cerebrospinal fluid; EDL: Model List of Essential In Vitro Diagnostics.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> CSF leukocyte count: usually &gt; 5 white blood cell/μL (&gt; 0.005 × 10<sup class=\"calibre30\">9</sup> /L), or a higher cut-off &gt; 20 cell/μL (&gt; 0.02 × 10<sup class=\"calibre30\">9</sup> /L) in HIV-positive patients even though these are not specific findings of neurosyphilis.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">b</sup> CSF protein levels: protein concentration is usually increased (&gt; 45 mg/dL or &gt; 0.45 g/L) but not a specific finding of neurosyphilis.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">c</sup> CSF glucose levels: glucose concentrations are usually decreased but not a specific finding of neurosyphilis.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-836\"></a>Table 21.5 – Antibiotic treatment for syphilis by stage of the disease as indicated in the most recent WHO guidelines for the treatment of syphilis <em class=\"calibre10\">(210)</em></strong> <br class=\"calibre7\"/><strong class=\"calibre5\">Please check the WHO website regularly for possible updates</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Type of infection</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Treatment</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Total treatment duration</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Early syphilis (adults and adolescents)</p>\n<p class=\"box_p1\">Early syphilis includes primary, secondary and early latent syphilis of no more than 2 years duration</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\"><strong class=\"calibre5\">First choice</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Benzathine benzylpenicillin</span><sup class=\"calibre30\">a</sup> (IM): 2.4 million IU (≈ 1.8 g)</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Second choice</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Procaine benzylpenicillin</span> (IM):1.2 million IU (1.2 g) given once a day</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Benzathine benzylpenicillin: single dose</p>\n<p class=\"box_p3\"> </p>\n<p class=\"box_p1\">Procaine benzylpenicillin: 10–14 days</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"calibre6\" id=\"calibre_link-327\" role=\"doc-pagebreak\" title=\"268\" type=\"pagebreak\"></span>Late syphilis or unknown stage (adults and adolescents)</p>\n<p class=\"box_p1\">This includes infection of more than 2 years duration without evidence of treponemal infection (i.e. asymptomatic infection)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">First choice</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Benzathine benzylpenicillin</span><sup class=\"calibre30\">b</sup> (IM): 2.4 million IU (≈ 1.8 g)</p>\n<p class=\"box_p3\"> </p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Second choice</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Procaine benzylpenicillin</span> (IM):1.2 million IU (1.2 g) given once a day</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Benzathine benzylpenicillin: one dose per week for 3 consecutive weeks (e.g. on days 1, 8 and 15)</p>\n<p class=\"box_p1\">The interval between doses should not exceed 14 days</p>\n<p class=\"box_p1\">Procaine benzylpenicillin: 20 days</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Congenital syphilis</p>\n<p class=\"box_p1\">Infants with confirmed disease or infants who are clinically normal but whose mother had untreated or inadequately treated syphilis<sup class=\"calibre30\">c</sup></p>\n<p class=\"box_p1\">Inadequate treatment refers to treatment received &lt; 30 days before delivery and/or treatment with a non-penicillin regimen</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\"><span class=\"back_verde\">Benzylpenicillin</span> (IV): 50 000–75 000 IU/kg/dose (30–45 mg/kg/dose) given every 12 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Procaine benzylpenicillin</span> (IM):50 000 IU/kg (50 mg/kg) given once a day</p>\n<p class=\"box_p1\">If IV access is available, benzylpenicillin is preferred over procaine benzylpenicillin.</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">10–15 days</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Neurosyphilis<sup class=\"calibre30\">d</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_verde\">Benzylpenicillin</span><sup class=\"calibre30\">e</sup> (IV): 2–4 million IU (1.2–2.4 g) given every 4 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Procaine benzylpenicillin</span><sup class=\"calibre30\">f</sup> (IM): 1.2 million IU (1.2 g) given once a day <strong class=\"calibre5\">AND</strong> Probenecid (oral): 500 mg given every 6 hours</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">14 days</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\"><span class=\"calibre6\" id=\"calibre_link-328\" role=\"doc-pagebreak\" title=\"269\" type=\"pagebreak\"></span>Syphilis in pregnancy</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Early syphilis</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Benzathine benzylpenicillin</span> (IM): 2.4 million IU (≈ 1.8 g)</p>\n<p class=\"box_p1\">Alternative options (not in the EML) in case of allergy to penicillin (or stock-outs):</p>\n<p class=\"box_p1\">Ceftriaxone 1 g for 10–14 days</p>\n<p class=\"box_p1\">Azithromycin (2 g single dose) or erythromycin (500 mg every 6 hours for 14 days) can also be used but neither of them crosses the placental barrier completely, therefore only the mother is treated, not the fetus.</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Late syphilis or unknown stage</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Benzathine benzylpenicillin</span> (IM):2.4 million IU (≈ 1.8 g)</p>\n<p class=\"box_p1\">Alternative option (not in the EML) in case of allergy to penicillin (or stock-outs): Erythromycin 500 mg every 6 hours for 30 days, but this does not treat the fetus since erythromycin does not cross the placental barrier completely, therefore only the mother is treated.</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Early syphilis</strong></p>\n<p class=\"box_p1\">Single dose</p>\n<p class=\"box_p3\"> </p>\n<p class=\"box_p3\"> </p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Late syphilis or unknown stage</strong></p>\n<p class=\"box_p1\">One dose per week for 3 consecutive weeks (e.g. on days 1, 8 and 15).</p>\n<p class=\"box_p1\">The interval between doses should not exceed 14 days.</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">EML: Model List of Essential Medicines; IM: intramuscular; IU: international units; IV: intravenous;</p>\n<p class=\"legenda\">Note. All dosages are for normal renal and hepatic function.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> Alternative options in case of allergy to penicillin or stock-outs are indicated in the 2016 WHO guidelines but these are not included in the EML for this indication. These alternatives are doxycycline (oral) 100 mg every 12 hours (except in pregnant women) for 14 days, or ceftriaxone 1 g (IM) for 10–14 days <em class=\"calibre10\">(210)</em>. In special circumstances (i.e. when susceptibility is likely, based on local epidemiology) azithromycin 2 g (oral) as a single dose can be given. If penicillin cannot be used, doxycycline is the preferred choice (except in pregnant women) because of its lower cost and oral administration <em class=\"calibre10\">(210)</em>.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">b</sup> An alternative option, in case of allergy to penicillin or stock-outs, is indicated in the 2016 WHO guidelines but this option is not included in the EML for this indication. This option is doxycycline (oral) 100 mg every 12 hours (except in pregnant women) for 30 days <em class=\"calibre10\">(210)</em>.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">c</sup> If the mother was adequately treated and the infant is clinically normal, close monitoring of the infant is suggested. If treatment is provided, the 2016 WHO guidelines indicate benzathine benzylpenicillin (IM) 50 000 IU/kg (37.5 mg/kg) per day single dose as an option.</p>\n<p class=\"legenda\"><span class=\"calibre6\" id=\"calibre_link-329\" role=\"doc-pagebreak\" title=\"270\" type=\"pagebreak\"></span><sup class=\"calibre30\">d</sup> From the 2003 WHO guidelines on management of sexually transmitted infections <em class=\"calibre10\">(219)</em>.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">e</sup> Alternative options are indicated in the 2003 WHO guidelines for non-pregnant patients allergic to penicillin but they are not included in the EML. These options are: doxycycline (oral) 200 mg every 12 hours; and tetracycline (oral) 500 mg every 6 hours. Treatment duration is 30 days in both cases.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">f</sup> Some authorities recommend adding benzathine benzylpenicillin 2.4 million IU (≈ 1.8 g) by IM injection, in three consecutive doses once weekly after completing this regimen, but there are no data to support this approach. Benzathine benzylpenicillin 2.4 million IU (≈ 1.8 g) by IM injection does not give adequate therapeutic levels in the cerebrospinal fluid <em class=\"calibre10\">(210)</em>.</p>\n<p class=\"legenda\">Legend: ACCESS antibiotics are indicated in green, WATCH antibiotics in orange and RESERVE antibiotics in red.</p>\n</td>\n</tr>\n</tfoot>\n</table>"
        ]
    },
    {
        "name": "Sexually transmitted infections – trichomoniasis",
        "tables": [
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-837\"></a>Table 22.1 – Microbiology tests to consider when trichomoniasis is suspected as indicated in the WHO EDL <em class=\"calibre10\">(6)</em></strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Diagnostic test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Purpose of the test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Settings where the test should be available</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Microscopy<sup class=\"calibre30\">a,b</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To assess microbial morphology and presence or absence of white blood cells</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Culture<sup class=\"calibre30\">b</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Initial step to detect and identify bacterial species for selection of appropriate antibiotic regimens</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">EDL: Model List of Essential In Vitro Diagnostics.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> If available, nucleic acid amplification tests for <em class=\"calibre10\">Trichomonas vaginalis</em>could be considered, especially if the microscopy examination is negative. Nucleic acid tests for trichomoniasis are not listed in the third version of the EDL.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">b</sup> Possible specimens are urethral swabs, endocervical swabs and vaginal swabs.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-334\" role=\"doc-pagebreak\" title=\"275\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-838\"></a>Table 22.2 – Additional tests for other sexually transmitted infections to consider in patients with confirmed or suspected trichomoniasis as indicated in the WHO EDL <em class=\"calibre10\">(6)</em></strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Infection</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Diagnostic test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Purpose of the test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Settings where the test should be available</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Chlamydial urogenital infection and gonococcal infection</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Qualitative test for <em class=\"calibre10\">Chlamydia trachomatis</em> and <em class=\"calibre10\">Neisseria gonorrhoeae</em> infections (NAAT)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To diagnose chlamydial and/or gonorrhoeal urogenital disease and extragenital infection</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">HIV</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Anti-HIV-1 and -HIV-2 antibody (RDT)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Self-testing to screen for HIV</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Community settings and health facilities without laboratories<sup class=\"calibre30\">a</sup></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">HIV</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Anti-HIV-1 and -HIV-2 antibody (RDT and immunoassay)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To screen for HIV infection</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Community settings and health facilities without laboratories<sup class=\"calibre30\">a</sup> (RDT)</p>\n<p class=\"box_p1\">Health care facilities with clinical laboratories (immunoassay)</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">HIV</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Combined anti-HIV-1/HIV-2 antibody and p24 antigen (RDT and immunoassay)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To screen for HIV infection</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Community settings and health facilities without laboratories<sup class=\"calibre30\">a</sup> (RDT)</p>\n<p class=\"box_p1\">Health care facilities with clinical laboratories (immunoassay)</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Hepatitis B</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Hepatitis B virus surface antigen (RDT, immunoassay)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To screen for acute and chronic hepatitis B virus infection in people &gt; 12 months</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Community settings and health facilities without laboratories<sup class=\"calibre30\">a</sup> (RDT)</p>\n<p class=\"box_p1\">Health care facilities with clinical laboratories (immunoassay)</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Hepatitis B</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">IgM-specific antibodies to hepatitis B core antigen (immunoassay)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To aid in the diagnosis of acute HBV infection in the context of outbreak investigation</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\"><span class=\"calibre6\" id=\"calibre_link-335\" role=\"doc-pagebreak\" title=\"276\" type=\"pagebreak\"></span>Hepatitis C</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Anti-hepatitis C antibody (RDT, immunoassay)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To screen for hepatitis C virus infection in people &gt; 18 months</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Community settings and health facilities without laboratories<sup class=\"calibre30\">a</sup> (RDT)</p>\n<p class=\"box_p1\">Health care facilities with clinical laboratories (immunoassay)</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Syphilis</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Antibodies to <em class=\"calibre10\">Treponema pallidum</em><sup class=\"calibre30\">b</sup> (RDT)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To diagnose or help to diagnose <em class=\"calibre10\">Treponema pallidum</em></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Community settings and health facilities without laboratories<sup class=\"calibre30\">a</sup></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Syphilis and HIV combined test</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Combined antibodies to <em class=\"calibre10\">Treponema pallidum</em> and HIV-1/HIV-2 (RDT)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To diagnose or help to diagnose HIV and/or <em class=\"calibre10\">Treponema pallidum</em></p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Community settings and health facilities without laboratories<sup class=\"calibre30\">a</sup></p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"4\">\n<p class=\"legenda\">EDL: Model List of Essential In Vitro Diagnostics; HIV: human immunodeficiency virus; NAAT: nucleic acid amplification test; RDT: rapid diagnostic test.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> Community and health settings without laboratories are facilities such as health posts and centres, doctors’ offices, outreach clinics, ambulatory care and home-based and self-testing. These tests are also assumed to be available at health care facilities with laboratories.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">b</sup> Usually a non-treponemal test, such as rapid plasma reagin, Venereal Disease Research Laboratory test, is used for screening. Please refer to the chapter on syphilis for more details on testing.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-336\" role=\"doc-pagebreak\" title=\"277\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-839\"></a>Table 22.3 – Antibiotic treatment for trichomoniasis as indicated in the 2021 WHO guidelines for the management of symptomatic sexually transmitted infections <em class=\"calibre10\">(191)</em></strong> <br class=\"calibre7\"/><strong class=\"calibre5\">Please check the WHO website regularly for possible updates</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Treatment</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Total treatment duration</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_verde\">Metronidazole</span> (oral): 2 g</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Metronidazole</span> (oral): 400 or 500 mg given every 12 hours<sup class=\"calibre30\">a</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Single dose</p>\n<p class=\"box_p3\"> </p>\n<p class=\"box_p1\">7 days</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"2\">\n<p class=\"legenda\">Note. All dosages are for normal renal and hepatic function.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> If compliance is not a problem, consider giving 500 mg (oral) every 12 hours for 7 days. Evidence supports better cure rates with a 7-day course of treatment compared with a single dose <em class=\"calibre10\">(221)</em>.</p>\n<p class=\"legenda\">Legend: ACCESS antibiotics are indicated in green, WATCH antibiotics in orange and RESERVE antibiotics in red.</p>\n</td>\n</tr>\n</tfoot>\n</table>"
        ]
    },
    {
        "name": "Lower urinary tract infection",
        "tables": [
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-344\" role=\"doc-pagebreak\" title=\"285\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-841\"></a>Table 23.1 – Pathogens most frequently associated with urinary tract infections (in descending order of frequency)</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Bacteria</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Enterobacterales (including multidrug-resistant strains such as those producing ESBL)</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\"><em class=\"calibre10\">Escherichia coli</em> (responsible for &gt; 80% of cases)</li>\n<li class=\"box_li1\"><em class=\"calibre10\">Klebsiella pneumoniae</em></li>\n<li class=\"box_li1\"><em class=\"calibre10\">Proteus mirabilis</em></li>\n</ul>\n<p class=\"box_p1\">Coagulase-negative staphylococci</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\"><em class=\"calibre10\">Staphylococcus saprophyticus</em> (in young women)</li>\n</ul>\n<p class=\"box_p1\"><em class=\"calibre10\">Streptococcus agalactiae</em> (group B <em class=\"calibre10\">Streptococcus</em>)</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Enterococcus</em> spp.</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Pseudomonas aeruginosa</em><sup class=\"calibre30\">a</sup> (including multidrug-resistant strains)</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Acinetobacter baumannii</em><sup class=\"calibre30\">a</sup> (including multidrug-resistant strains)</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\">\n<p class=\"legenda\">ESBL: extended-spectrum beta-lactamases.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> Especially in patients with recent antibiotic exposure.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-842\"></a>Table 23.2 – Microbiology tests to consider for diagnosis of lower urinary tract infections as indicated in the WHO EDL <em class=\"calibre10\">(6)</em></strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Diagnostic test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Purpose of the test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Settings where the test should be available</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Urine culture<sup class=\"calibre30\">a</sup> and antimicrobial susceptibility testing</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Initial step to detect and identify bacterial and fungal species for selection of appropriate antimicrobial regimens</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">EDL: Model List of Essential In Vitro Diagnostics.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> <strong class=\"calibre5\">A positive urine culture in an asymptomatic patient indicates bacterial colonization and does not require treatment except in pregnant women or in patients undergoing urological procedures in which bleeding is anticipated</strong>. Bacterial colonization of the urine is a common finding, especially in women, the elderly (both sexes) and individuals with underlying urological abnormalities. Of note, the absence of urine leukocytes has a good negative predictive value but the positive predictive value of leukocyturia is poor.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-843\"></a>Table 23.3 – Laboratory tests to consider for diagnosis of lower urinary tract infections as indicated in the WHO EDL <em class=\"calibre10\">(6)</em></strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Diagnostic test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Purpose of the test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Settings where the test should be available</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Urinalysis test strips</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To detect urinary tract infections</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Community settings and health facilities without laboratories<sup class=\"calibre30\">a</sup></p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">EDL: Model List of Essential In Vitro Diagnostics.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> Community and health settings without laboratories are settings such as health posts and centres, doctors’ offices, outreach clinics and ambulatory care. These tests are also assumed to be available at health care facilities with laboratories.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-347\" role=\"doc-pagebreak\" title=\"288\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-844\"></a>Table 23.4 – Medicines to consider for pain control of lower urinary tract infections</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color1\" colspan=\"3\">\n<p class=\"box_tit1\"><img alt=\"Imagem\" class=\"calibre26\" src=\"images/000133.jpg\"/> <strong class=\"calibre5\">Important</strong></p>\n<p class=\"box_p1\">Medicines are listed in alphabetical order and they should all be considered equal treatment options.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Medicine</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Formulation</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Dose and frequency</strong></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Ibuprofen<sup class=\"calibre30\">a</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Oral liquid: 200 mg/5 mL</p>\n<p class=\"box_p1\">Tablet: 200 mg; 400 mg; 600 mg</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Adults</strong>: 200–400 mg given every 6 to 8 hours (maximum dose of 2.4 g a day)</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Children</strong>:</p>\n<p class=\"box_p1\">Pain control/antipyretic treatment: 5–10 mg/kg given every 6 to 8 hours</p>\n<p class=\"box_p1\">Weight bands:</p>\n<p class=\"box_p1\">6–&lt; 10 kg: 50 mg given every 8 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 100 mg given every 8 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 150 mg given every 8 hours</p>\n<p class=\"box_p1\">20–&lt; 30 kg: 200 mg given every 8 hours</p>\n<p class=\"box_p1\">≥ 30 kg: use adult dose</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Paracetamol (acetaminophen)<sup class=\"calibre30\">b</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Oral liquid: 120 mg/5 mL; 125 mg/5 mL</p>\n<p class=\"box_p1\">Suppository: 100 mg</p>\n<p class=\"box_p1\">Tablet: 100 mg to 500 mg</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Adults</strong>: 500 mg–1 g given every 4 to 6 hours (maximum dose of 4 g a day)<sup class=\"calibre30\">c</sup></p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Children</strong>:</p>\n<p class=\"box_p1\">Pain control/antipyretic treatment: 10–15 mg/kg given every 6 hours</p>\n<p class=\"box_p1\">Weight bands:</p>\n<p class=\"box_p1\">3–&lt; 6 kg: 60 mg given every 6 hours</p>\n<p class=\"box_p1\">6–&lt; 10 kg: 100 mg given every 6 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 150 mg given every 6 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 200 mg given every 6 hours</p>\n<p class=\"box_p1\">20–&lt; 30 kg: 300 mg given every 6 hours</p>\n<p class=\"box_p1\">≥ 30 kg: use adult dose</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> Not for children &lt; 3 months.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">b</sup> Not recommended for use as an anti-inflammatory as it has not been proven to have such an effect.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">c</sup> In patients with hepatic impairment or cirrhosis, maximum daily dose should be 2 g.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-349\" role=\"doc-pagebreak\" title=\"290\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-845\"></a>Table 23.5 – Empiric antibiotic treatment for lower urinary tract infections</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color1\" colspan=\"3\">\n<p class=\"box_tit1\"><img alt=\"Imagem\" class=\"calibre26\" src=\"images/000133.jpg\"/> <strong class=\"calibre5\">Important</strong></p>\n<p class=\"box_p1\">Where more than one antibiotic is recommended for an infection, they are listed in alphabetical order and they should be considered equal treatment options, unless otherwise indicated.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Adults</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Children</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Total treatment duration</strong><sup class=\"calibre32\">d</sup></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\"><span class=\"back_verde\">Amoxicillin+clavulanic acid</span><sup class=\"calibre30\">a</sup> (oral): 500 mg + 125 mg given every 8 hours</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\"><span class=\"back_verde\">Amoxicillin+clavulanic acid</span><sup class=\"calibre30\">a,c</sup> (oral): 80–90 mg/kg/day of amoxicillin component</p>\n<p class=\"box_p1\">Oral weight bands:</p>\n<p class=\"box_p1\">3–&lt; 6 kg: 250 mg of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p1\">6–&lt; 10 kg: 375 mg of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 500 mg of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 750 mg of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p1\">≥ 20 kg: 500 mg of amoxicillin/dose given every 8 hours or 1 g of amoxicillin/dose given every 12 hours</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">3–5 days</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_verde\">Nitrofurantoin</span> (oral):</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">100 mg given every 12 hours (modified-release formulation)</li>\n<li class=\"box_li1\">50 mg given every 6 hours (immediate-release formulation)</li>\n</ul>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_verde\">Nitrofurantoin</span> (oral):</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">2 mg/kg/dose given every 12 hours</li>\n<li class=\"box_li1\">1 mg/kg/dose given every 6 hours (immediate release formulation)</li>\n</ul>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">5 days</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\"><span class=\"calibre6\" id=\"calibre_link-350\" role=\"doc-pagebreak\" title=\"291\" type=\"pagebreak\"></span><span class=\"back_verde\">Sulfamethoxazole+ trimethoprim</span><sup class=\"calibre30\">b</sup> (oral): 800 mg + 160 mg given every 12 hours</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\"><span class=\"back_verde\">Sulfamethoxazole+ trimethoprim</span> (oral): 4 mg/kg (of trimethoprim component), every 12 hours</p>\n<p class=\"box_p1\">Oral weight bands:</p>\n<p class=\"box_p1\">mg of sulfamethoxazole/trimethoprim component</p>\n<p class=\"box_p1\">3–&lt; 6 kg: 100 mg/20 mg given every 12 hours</p>\n<p class=\"box_p1\">6–&lt; 10 kg: 200 mg/40 mg given every 12 hours</p>\n<p class=\"box_p1\">10–&lt; 30 kg: 400 mg/80 mg given every 12 hours</p>\n<p class=\"box_p1\">≥ 30 kg: use adult dose</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">3 days</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_verde\">Trimethoprim</span> (oral): 200 mg given every 12 hours</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_verde\">Trimethoprim</span> (oral): 4 mg/kg, every 12 hours</p>\n<p class=\"box_p1\">Oral weight bands:</p>\n<p class=\"box_p1\">3–&lt; 6 kg: 20 mg given every 12 hours</p>\n<p class=\"box_p1\">6–&lt; 10 kg: 40 mg given every 12 hours</p>\n<p class=\"box_p1\">10–&lt; 30 kg: 80 mg given every 12 hours</p>\n<p class=\"box_p1\">≥ 30 kg: use adult dose</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">3 days</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">Note. All dosages are for normal renal and hepatic function.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> Amoxicillin+clavulanic acid: <em class=\"calibre10\">Escherichia coli</em>resistance rates to amoxicillin+clavulanic acid are lower than to amoxicillin alone. This combination still has activity against some extended-spectrum beta-lactamase-producing isolates and it can be considered an acceptable option, particularly in young children.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">b</sup> Resistance to sulfamethoxazole+trimethoprim is high in many settings <em class=\"calibre10\">(232,233)</em>. It is ineffective against most isolates producing extended-spectrum beta-lactamases. It is not recommended in the first trimester of pregnancy.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">c</sup> Oral liquid formulations must be refrigerated after reconstitution as clavulanic acid is rapidly metabolized in high ambient temperatures.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">d</sup> In general, shorter treatments are indicated for children or non-pregnant women (3–5 days depending on the antibiotic), while longer treatments are indicated for pregnant women (usually 5 days) or men (usually 7 days).</p>\n<p class=\"legenda\">Legend: ACCESS antibiotics are indicated in green, WATCH antibiotics in orange and RESERVE antibiotics in red.</p>\n</td>\n</tr>\n</tfoot>\n</table>"
        ]
    },
    {
        "name": "Sepsis in adults (including septic shock)",
        "tables": [
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-355\" role=\"doc-pagebreak\" title=\"298\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-848\"></a>Table 24.1 – Sequential Organ Failure Assessment (SOFA) score</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\" rowspan=\"2\">\n<p class=\"table_head\"><strong class=\"calibre5\">Parameter</strong></p>\n</th>\n<th class=\"calibre28\" colspan=\"5\">\n<p class=\"table_headc\"><strong class=\"calibre5\">Score</strong></p>\n</th>\n</tr>\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_headc\"><strong class=\"calibre5\">0</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_headc\"><strong class=\"calibre5\">1</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_headc\"><strong class=\"calibre5\">2</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_headc\"><strong class=\"calibre5\">3</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_headc\"><strong class=\"calibre5\">4</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">PaO<sub class=\"calibre36\">2</sub>/FiO<sub class=\"calibre36\">2</sub>, mmHg (kPa)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">≥ 400</p>\n<p class=\"box_p1\">(53.3)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">300 - 399</p>\n<p class=\"box_p1\">(40.0 - 53.2)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">200 - 299</p>\n<p class=\"box_p1\">(26.7 - 39.9)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">100 - 199</p>\n<p class=\"box_p1\">(13.3 - 26.6)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">&lt; 100</p>\n<p class=\"box_p1\">(13.3)</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">MAP mmHg (kPa) and catecholamine doses needed, µg/kg/min for ≥ 1 h</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">MAP: ≥ 70 (9.3)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">MAP: &lt; 70 (9.3)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Dopamine: &lt; 5</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\">Dobutamine any dose</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Dopamine: 5.1–15</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\">Epinephrine /norepinephrine: ≤ 0.1</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Dopamine: &gt; 15</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\">Epinephrine /norepinephrine: &gt; 0.1</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Platelets, x 10<sup class=\"calibre30\">3</sup> /µL (or x 10<sup class=\"calibre30\">9</sup> /L)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">≥ 150</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">100 - 149</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">50 - 99</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">20 - 49</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">&lt; 20</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Bilirubin, mg/dL (µmol/L)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">&lt; 1.2</p>\n<p class=\"box_p1\">(20)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">1.2–1.9</p>\n<p class=\"box_p1\">(20–32)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">2–5.9</p>\n<p class=\"box_p1\">(33–101)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">6.0–11.9</p>\n<p class=\"box_p1\">(102–204)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">&gt; 12.0</p>\n<p class=\"box_p1\">(204)</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Glasgow coma scale<sup class=\"calibre30\">a</sup></p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">15</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">13–14</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">10–12</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">6–9</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">&lt; 6</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Creatinine, mg/dL (µmol/L)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">&lt; 1.2</p>\n<p class=\"box_p1\">(110)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">1.2–1.9</p>\n<p class=\"box_p1\">(110–170)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">2.0–3.4</p>\n<p class=\"box_p1\">(171–299)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">3.5–4.9</p>\n<p class=\"box_p1\">(300–440)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">&gt; 5.0</p>\n<p class=\"box_p1\">(440)</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Urine output, mL/day</p>\n</td>\n<td class=\"color\"></td>\n<td class=\"color\"></td>\n<td class=\"color\"></td>\n<td class=\"color\">\n<p class=\"box_p1\">&lt; 500</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">&lt; 200</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"6\">\n<p class=\"legenda\">FIO<sub class=\"calibre36\">2</sub>: fractional inspired oxygen; MAP: mean arterial pressure; PaO<sub class=\"calibre36\">2</sub>: arterial oxygen partial pressure.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> The Glasgow come scale is a clinical scale used to measure a person’s level of consciousness based on the assessment of three parameters: eye opening response (maximum 4 points assigned), best verbal response (maximum 5 points assigned) and best motor response (maximum 6 points assigned). The total score can range from 3 (completely unresponsive) to 15 (responsive). Scores lower than 8 usually indicate a comatose state. To calculate the Glasgow coma scale, several online calculators exist.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-849\"></a>Table 24.2 – Quick Sequential Organ Failure Assessment (qSOFA) score</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Parameter</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Value</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Respiratory rate</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">≥ 22 breaths/min</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Altered mental status</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Glasgow coma scale &lt; 15<sup class=\"calibre30\">a</sup></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Systolic blood pressure</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">≤ 100 mmHg (≤ 13.3 kPa)</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"2\">\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> The Glasgow come scale is a clinical scale used to measure a person’s level of consciousness based on the assessment of three parameters: eye opening response (maximum 4 points assigned), best verbal response (maximum 5 points assigned) and best motor response (maximum 6 points assigned). The total score can range from 3 (completely unresponsive) to 15 (responsive). Scores lower than 8 usually indicate a comatose state. To calculate the Glasgow coma scale, several online calculators exist.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-363\" role=\"doc-pagebreak\" title=\"306\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-850\"></a>Table 24.3 – Bacteria most frequently identified in blood cultures in patients with sepsis (also refer to Box 24.1 on bacteraemia)</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Setting of acquisition of the infection</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Bacteria (in alphabetical order)</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Community</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Enterobacterales<sup class=\"calibre30\">a</sup> (<em class=\"calibre10\">Escherichia coli</em>, <em class=\"calibre10\">Klebsiella pneumoniae</em> and others)</p>\n<p class=\"box_p1\">Invasive non-typhoidal <em class=\"calibre10\">Salmonella</em> (elderly patients and patients living with HIV)</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Salmonella</em> Typhi and Paratyphi (causative agent of enteric fever)</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Staphylococcus aureus</em> (including MRSA)</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Streptococcus pneumoniae</em> (including penicillin non-susceptible strains)</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Streptococcus pyogenes</em> (group A <em class=\"calibre10\">Streptococcus</em>)</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Other pathogens to consider</strong></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Burkholderia pseudomallei</em> (causative agent of melioidosis which is endemic in South-East Asia and Australia)</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Neisseria meningitidis</em> (including strains resistant to third-generation cephalosporins)</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Hospital</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><em class=\"calibre10\">Acinetobacter baumannii</em><sup class=\"calibre30\">a</sup></p>\n<p class=\"box_p1\">Enterobacterales<sup class=\"calibre30\">a</sup> (<em class=\"calibre10\">Escherichia coli</em>, <em class=\"calibre10\">Klebsiella pneumoniae</em> and others)</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Pseudomonas aeuroginosa</em><sup class=\"calibre30\">a</sup></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Staphylococcus aureus</em> (including MRSA)</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Maternal sepsis (additional pathogens to consider)<sup class=\"calibre30\">b</sup></p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\"><em class=\"calibre10\">Listeria monocytogenes</em></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Streptococcus agalactiae</em> (group B <em class=\"calibre10\">Streptococcus</em>)</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"2\">\n<p class=\"legenda\">HIV: human immunodeficiency virus; MRSA: methicillin-resistant <em class=\"calibre10\">Staphylococcus aureus</em>.</p>\n<p class=\"legenda\">Note. Most data on the pathogens associated with sepsis come from high-income settings.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> Including multidrug-resistant strains such as those producing extended-spectrum beta-lactamases and carbapenemases.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">b</sup> In cases of maternal sepsis, however, the urinary tract represents the main source of infection (see epidemiology section).</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-851\"></a>Table 24.4 – Microbiology tests to consider when sepsis of bacterial origin in suspected depending on the most likely source of infection as indicated in the WHO EDL <em class=\"calibre10\">(6)</em></strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Suspected underlying infection</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Diagnostic test</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Purpose of the test</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Settings where the test should be available</strong></p>\n</td>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">All cases where sepsis is suspected</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Blood cultures and antimicrobial susceptibility testing</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To detect bacterial bloodstream infections</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Lower respiratory tract infection</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Sputum microscopy (Gram stain)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To assess microbial morphology and adequacy of the specimen for culture by identifying white blood cells and squamous epithelial cells</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\"><span class=\"calibre6\" id=\"calibre_link-366\" role=\"doc-pagebreak\" title=\"309\" type=\"pagebreak\"></span>Lower respiratory tract infection</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Sputum culture and antimicrobial susceptibility testing</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Initial step to detect and identify bacterial and fungal species for selection of appropriate antimicrobial regimens</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Meningitis</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Cerebrospinal fluid Gram stain, bacterial culture and antimicrobial susceptibility testing</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Initial step to detect and identify bacterial and fungal species for selection of appropriate antimicrobial regimens</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Meningitis</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Cerebrospinal fluid microscopy</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To assess microbial morphology, number of white blood cells and red blood cells</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Diarrhoeal disease, enteric fever<sup class=\"calibre30\">a</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Stool culture and antimicrobial susceptibility testing</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Initial step to detect and identify bacterial species for selection of appropriate antibiotic regimens</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Abscess (e.g. in the context of intra-abdominal infections, skin and soft-tissue infections and dental infections)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Culture and antimicrobial susceptibility testing of abscess and/or fluid collections that can be drained</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Initial step to detect and identify bacterial and fungal species for selection of appropriate antimicrobial regimens</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Urinary tract infection</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Urine culture and antimicrobial susceptibility testing</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Initial step to detect and identify bacterial and fungal species for selection of appropriate antimicrobial regimens</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"4\">\n<p class=\"legenda\">EDL: Model List of Essential In Vitro Diagnostics.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> If enteric fever is suspected, note that stool cultures have a low sensitivity and are not useful in the early phase (first week) of the disease when the test is often negative.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-852\"></a>Table 24.5 – Laboratory tests (other than microbiology) to consider when sepsis in suspected to identify a bacterial infection as indicated in the WHO EDL <em class=\"calibre10\">(6)</em></strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Diagnostic test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Purpose of the test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Settings where the test should be available</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">White blood count</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To help in the diagnosis of infections</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories but also in primary care settings</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">C-reactive protein<sup class=\"calibre30\">a</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To detect inflammation as an indicator of various conditions (e.g. sepsis)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Procalcitonin<sup class=\"calibre30\">a</sup></p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To guide antibiotic therapy or discontinuation in sepsis</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Only in tertiary health care facilities</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">EDL: Model List of Essential In Vitro Diagnostics.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> Biomarkers C-reactive protein and procalcitonin may help determine whether an infection is caused by bacteria. Regular serial measurement of these biomarkers can also help decide when antibiotic therapy can be stopped <em class=\"calibre10\">(250–252)</em>. It is important to note that the probability of sepsis based on the patient’s initial clinical assessment before testing (pre-test probability) needs to be considered. If the pre-test probability is high, inflammatory markers in the normal range do not rule out sepsis.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-853\"></a>Table 24.6 – Laboratory tests (other than microbiology) to consider when sepsis in suspected to identify organ dysfunction as indicated in the WHO EDL <em class=\"calibre10\">(6)</em></strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Diagnostic test</strong><sup class=\"calibre32\">a</sup></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Purpose of the test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Settings where the test should be available</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Bilirubin</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To detect or monitor liver disease, bile duct disorders and red cell destruction</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Required for SOFA score calculation</strong></p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Community settings and health facilities without laboratories<sup class=\"calibre30\">b</sup></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Blood pH and gases</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To assess lung function and metabolic or kidney disorders, and monitor oxygen therapy</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Required for SOFA score calculation</strong> (for PaO<sub class=\"calibre36\">2</sub>/FiO<sub class=\"calibre36\">2</sub>)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\"><span class=\"calibre6\" id=\"calibre_link-368\" role=\"doc-pagebreak\" title=\"311\" type=\"pagebreak\"></span>Blood urea nitrogen</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To assess kidney function</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Required for CURB-65 score calculation</strong> (if pneumonia is suspected<sup class=\"calibre30\">c</sup> )</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Complete blood count</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To detect a wide range of disorders, including infections</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Creatinine</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To monitor kidney function for management of severe infections (i.e. sepsis) and to adjust antimicrobial regimen</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Required for SOFA score calculation</strong></p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Electrolytes</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To monitor fluid, electrolyte and acid–base balance</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Glucose</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To diagnose intermediate hyperglycaemia and hypoglycaemia</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Community settings and health facilities without laboratories<sup class=\"calibre30\">b</sup></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Haemoglobin</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To diagnose and monitor anaemia</p>\n<p class=\"box_p1\">This is a clinical marker for some severe infections (e.g. malaria and viral haemorrhagic fevers)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Community settings and health facilities without laboratories<sup class=\"calibre30\">b</sup></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Platelet count</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To diagnose thrombocytopenia or thrombocytosis.</p>\n<p class=\"box_p1\">This is a marker to manage severe infections associated with sepsis (e.g. viral haemorrhagic fever and meningococcaemia)</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Required for SOFA score calculation</strong></p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">White blood cell count</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To aid in the diagnosis of infections</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Whole blood lactate</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To assess metabolic acidosis, sepsis and dehydration</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Community settings and health facilities without laboratories<sup class=\"calibre30\">b</sup></p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">EDL: Model List of Essential In Vitro Diagnostics; FiO<sub class=\"calibre36\">2</sub>: fractional inspired oxygen; PaO<sub class=\"calibre36\">2</sub>: arterial oxygen partial pressure; SOFA: Sequential Organ Failure Assessment.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> The tests are listed in alphabetical order.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">b</sup> Community and health settings without laboratories are facilities such as health posts and centres, doctors’ offices, outreach clinics, ambulatory care. These tests are assumed to be available at health care facilities with laboratories.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">c</sup> See the chapter on community-acquired pneumonia for more information.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-371\" role=\"doc-pagebreak\" title=\"314\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-854\"></a>Table 24.7 – Empiric antibiotic treatment for community-acquired sepsis of bacterial origin in adults</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color1\" colspan=\"3\">\n<p class=\"box_tit1\"><img alt=\"Imagem\" class=\"calibre26\" src=\"images/000133.jpg\"/> <strong class=\"calibre5\">Important</strong></p>\n<p class=\"box_p1\">Where more than one antibiotic is recommended for an infection, they are listed in alphabetical order and they should be considered equal treatment options, unless otherwise indicated.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Most probable source of infection</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Empiric antibiotic treatment</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Total treatment duration (may vary also based on degree of immunosuppression)</strong></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Clinical sepsis of unknown origin<sup class=\"calibre30\">a</sup></p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\"><span class=\"back_amarelo\">Cefotaxime</span><sup class=\"calibre30\">b</sup> (IV): 2 g given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Ceftriaxone</span><sup class=\"calibre30\">b</sup> (IV): 2 g given once a day</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">COMBINED WITH</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Amikacin</span><sup class=\"calibre30\">c</sup> (IV): 15 mg/kg given once a day</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Gentamicin</span><sup class=\"calibre30\">c</sup> (IV): 5 mg/kg given once a day</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">7 days</p>\n<p class=\"box_p1\">But duration depends on the patient’s underlying disease, the degree of immunosuppression, the causative pathogen (if any identified later on) and clinical progression)</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Enteric fever</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_amarelo\">Ceftriaxone</span><sup class=\"calibre30\">d</sup> (IV): 2 g given once a day</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">10 days</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Intra-abdominal infection</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\"><strong class=\"calibre5\">First choice</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Cefotaxime</span> (IV): 2 g given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">AND</strong> <span class=\"back_verde\">Metronidazole</span> (IV): 500 mg given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Ceftriaxone</span> (IV): 2 g given once a day <strong class=\"calibre5\">AND</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Metronidazole</span> (IV): 500 mg given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Piperacillin+tazobactam</span><sup class=\"calibre30\">e</sup> (IV):4 g + 500 mg given every 6 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Second choice</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Meropenem</span><sup class=\"calibre30\">f</sup> (IV): 2 g given every 8 hours</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Generally 7 days.</p>\n<p class=\"box_p1\">Duration depends on type of infection, whether adequate surgical source control was achieved, the degree of immunosuppression and on clinical recovery.</p>\n<p class=\"box_p1\">Please refer to specific chapters of the AWaRe book based on the suspected underlying infection</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\"><span class=\"calibre6\" id=\"calibre_link-372\" role=\"doc-pagebreak\" title=\"315\" type=\"pagebreak\"></span>Meningitis</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\"><strong class=\"calibre5\">First choice</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Cefotaxime</span> (IV): 2 g given every 6 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Ceftriaxone</span> (IV): 2 g given every 12 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Second choice (only when first choice options are not available)</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Amoxicillin</span> (IV): 2 g given every 4 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Ampicillin</span> (IV): 2 g given every 4 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Benzylpenicillin</span> (IV): 4 million IU (2.4 g) given every 4 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Chloramphenicol</span><sup class=\"calibre30\">g</sup> (IV): 1 g given every 6 hours</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">10 days<sup class=\"calibre30\">h</sup></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Lower respiratory tract infection</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_amarelo\">Cefotaxime</span> (IV): 2 g given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">AND</strong> <span class=\"back_amarelo\">Clarithromycin</span> (IV): 500 mg given every 12 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Ceftriaxone</span> (IV): 2 g given once a day <strong class=\"calibre5\">AND</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Clarithromycin</span> (IV): 500 mg given every 12 hours</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">5 days</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\"><span class=\"calibre6\" id=\"calibre_link-373\" role=\"doc-pagebreak\" title=\"316\" type=\"pagebreak\"></span>Skin and soft tissues infection</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\"><span class=\"back_amarelo\">Ceftriaxone</span><sup class=\"calibre30\">i</sup> (IV): 2 g given once a day</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">AND</strong> <span class=\"back_verde\">Metronidazole</span><sup class=\"calibre30\">i</sup> (IV): 500 mg given every 8 hours</p>\n<p class=\"box_p1\">(In case of necrotizing fasciitis, use this treatment option only If <em class=\"calibre10\">Streptococcus pyogenes</em> infection has been excluded first)</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">If MRSA is suspected, ADD</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Vancomycin</span> (IV): 15–20 mg/kg given every 12 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Piperacillin+tazobactam</span><sup class=\"calibre30\">j</sup> (IV):4 g + 500 mg given every 6 hours <strong class=\"calibre5\">AND</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Clindamycin</span> (IV): 900 mg given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">If MRSA is suspected, ADD</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Vancomycin</span> (IV): 15–20 mg/kg given every 12 hours</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Generally 7 days.</p>\n<p class=\"box_p1\">Duration depends on type of infection, whether adequate surgical source control was achieved, the degree of immunosuppression, and clinical recovery.</p>\n<p class=\"box_p1\">Please refer to specific chapters of the AWaRe book based on the suspected underlying infection</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Urinary tract infection</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_amarelo\">Cefotaxime</span><sup class=\"calibre30\">l</sup> (IV): 2 g given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">AND</strong> <span class=\"back_verde\">Amikacin</span><sup class=\"calibre30\">k</sup> (IV): 15 mg/kg given once a day</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Ceftriaxone</span><sup class=\"calibre30\">l</sup> (IV): 2 g given once a day</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">AND</strong> <span class=\"back_verde\">Amikacin</span><sup class=\"calibre30\">k</sup> (IV): 15 mg/kg given once a day</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">7 days</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">AWaRe: Access, Watch and Reserve; ESBL: extended-spectrum beta-lactamases; IU: international units; IV: intravenous; MRSA: methicillin-resistant <em class=\"calibre10\">Staphylococcus aureus</em>.</p>\n<p class=\"legenda\">Note. All dosages are for normal renal and hepatic function. Dose adjustments may be required in patients with septic shock.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> If the source of the infection is determined please follow infection-specific guidance.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">b</sup> Ceftriaxone or cefotaxime are alternative options. The choice can be made based on local availabilities.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">c</sup> Gentamicin and amikacin are alternative options. The choice can be made based on local availabilities. In addition, amikacin (and to a lesser extent gentamicin) is still effective against many isolates producing ESBL and is considered an appropriate carbapenem-sparing option in settings where ESBL-producing isolates are very prevalent.</p>\n<p class=\"legenda\"><span class=\"calibre6\" id=\"calibre_link-374\" role=\"doc-pagebreak\" title=\"317\" type=\"pagebreak\"></span><sup class=\"calibre30\">d</sup> Some countries may have problems of increasing ceftriaxone resistance.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">e</sup> In patients considered at risk of infections with ESBL-producing Enterobacterales, piperacillin+tazobactam does not provide adequate activity against many ESBL-producing isolates. In these cases, meropenem can be considered.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">f</sup> Meropenem should be considered only in settings with a high prevalence of ESBL-producing Enterobacterales.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">g</sup> Use chloramphenicol only when no other choice is available.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">h</sup> Duration differs in the context of epidemics as indicated by WHO <em class=\"calibre10\">(257)</em>and also depending on the pathogen identified.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">i</sup> Ceftriaxone and metronidazole is the preferred option if the suspected source of infection is polymicrobial (type 1) necrotizing fasciitis but it is also an adequate option in case of severe cellulitis.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">j</sup> Piperacillin+tazobactam (or penicillin) and clindamycin is the preferred option if the suspected source of infection is necrotizing fasciitis caused by <em class=\"calibre10\">Streptococcus pyogenes</em>but it is also an adequate option in case of severe cellulitis.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">k</sup> Amikacin is still effective against ESBL-producing isolates and is considered an appropriate carbapenem-sparing option in settings where ESBL-producing isolates are prevalent.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">l</sup> Alternative antibiotics to consider based on local resistance data are piperacillin+tazobactam and carbapenems.</p>\n<p class=\"legenda\">Legend: ACCESS antibiotics are indicated in green, WATCH antibiotics in orange and RESERVE antibiotics in red.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-855\"></a>Table 24.8 – Vaccinations to consider for prevention of certain infections</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Vaccination</strong><sup class=\"calibre32\">a</sup></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Population where the vaccine should be considered</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Meningococcal vaccination <em class=\"calibre10\">(236)</em></p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Countries with high (&gt; 10 cases per 100 000 population/year) or intermediate (2–10 cases per 100 000 population/year) incidence of meningococcal disease or with frequent epidemics. All individuals aged 1–29 years (including pregnant women) should be vaccinated with the meningococcal A conjugate vaccine.</p>\n<p class=\"box_p1\">Countries with low incidence of meningococcal disease (&lt; 2 cases per 100 000 population/year). Vaccination is advised only for defined high-risk groups such as children and young adults or individuals with immunodeficiency. The choice of the recommended vaccine depends on the local prevalence of the meningococcal serogroups.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"calibre6\" id=\"calibre_link-375\" role=\"doc-pagebreak\" title=\"318\" type=\"pagebreak\"></span>Pneumococcal vaccination <em class=\"calibre10\">(35)</em></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">All children should be vaccinated with pneumococcal conjugate vaccines. In adults, the vaccine is recommended in many countries for elderly people (&gt; 65 years) and for high-risk groups (e.g. patients with chronic pulmonary disease or who have had a splenectomy).</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\"><em class=\"calibre10\">Salmonella</em> Typhi vaccination <em class=\"calibre10\">(154)</em></p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Individuals living in countries with a high burden of enteric fever or antibiotic-resistant <em class=\"calibre10\">Salmonella</em> Typhi should be vaccinated with typhoid conjugate vaccines. Vaccination should also be offered during outbreaks.</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"2\">\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> References cited are to WHO position papers that support the evidence for vaccination.</p>\n</td>\n</tr>\n</tfoot>\n</table>"
        ]
    },
    {
        "name": "Sepsis in neonates (< 28 days) and children (28 days–12 years)",
        "tables": [
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-380\" role=\"doc-pagebreak\" title=\"323\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-858\"></a>Table 25.1 – Paediatric Sequential Organ Failure Assessment (pSOFA) score</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\" rowspan=\"2\">\n<p class=\"table_head\"><strong class=\"calibre5\">Parameter</strong></p>\n</th>\n<th class=\"calibre28\" colspan=\"5\">\n<p class=\"table_headc\"><strong class=\"calibre5\">Score</strong></p>\n</th>\n</tr>\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_headc\"><strong class=\"calibre5\">0</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_headc\"><strong class=\"calibre5\">1</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_headc\"><strong class=\"calibre5\">2</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_headc\"><strong class=\"calibre5\">3</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_headc\"><strong class=\"calibre5\">4</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">PaO<sub class=\"calibre36\">2</sub>/FiO<sub class=\"calibre36\">2</sub>, mmHg (kPa)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">≥ 400</p>\n<p class=\"box_p1\">(53.3)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">300 - 399</p>\n<p class=\"box_p1\">(40.0 - 53.2)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">200 - 299</p>\n<p class=\"box_p1\">(26.7 - 39.9)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">100 - 199</p>\n<p class=\"box_p1\">(13.3 - 26.6)</p>\n<p class=\"box_p1\">with respiratory support</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">&lt; 100</p>\n<p class=\"box_p1\">(13.3)</p>\n<p class=\"box_p1\">with respiratory support</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">MAP, mmHg (kPa)</p>\n<p class=\"box_p1\">by age group (in months) and catecholamine doses needed (µg/kg/min for ≥ 1 h)</p>\n</td>\n<td class=\"calibre29\"></td>\n<td class=\"calibre29\"></td>\n<td class=\"calibre29\"></td>\n<td class=\"calibre29\"></td>\n<td class=\"calibre29\"></td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">&lt; 1</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">≥ 46 (6.1)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">&lt; 46 (6.1)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Dopamine &lt; 5</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\">Dobutamine any dose</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Dopamine 5.1–15</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\">Epinephrine /norepinephrine ≤ 0.1</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Dopamine &gt;15</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\">Epinephrine /norepinephrine &gt; 0.1</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">1–11</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">≥ 55 (7.3)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">&lt; 55 (7.3)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">As above</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">As above</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">As above</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">12–23 (1–2 years)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">≥ 60 (8)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">&lt; 60 (8)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">As above</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">As above</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">As above</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">24–59 (2–5 years)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">≥ 62 (8.2)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">&lt; 62 (8.2)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">As above</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">As above</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">As above</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">60–143 (6–11 years)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">≥ 65 (8.6)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">&lt; 65 (8.6)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">As above</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">As above</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">As above</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">144–216 (12–18 years)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">≥ 67 (8.9)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">&lt; 67 (8.9)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">As above</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">As above</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">As above</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\"><span class=\"calibre6\" id=\"calibre_link-381\" role=\"doc-pagebreak\" title=\"324\" type=\"pagebreak\"></span>Platelets, x 10<sup class=\"calibre30\">3</sup> /µL (or x 10<sup class=\"calibre30\">9</sup> /L)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">≥ 150</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">100 - 149</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">50 - 99</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">20 - 49</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">&lt; 20</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Bilirubin, mg/dL (µmol/L)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">&lt; 1.2 (20)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">1.2–1.9 (20–32)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">2–5.9 (33–101)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">6.0–11.9 102–204)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">&gt; 12.0 (204)</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Glasgow coma scale<sup class=\"calibre30\">a</sup></p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">15</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">13–14</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">10–12</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">6–9</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">&lt; 6</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Creatinine, mg/dL (µmol/L) by age group (months)</p>\n</td>\n<td class=\"calibre29\"></td>\n<td class=\"calibre29\"></td>\n<td class=\"calibre29\"></td>\n<td class=\"calibre29\"></td>\n<td class=\"calibre29\"></td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">&lt; 1</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">&lt; 0.8 (71)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">0.8–0.9 (71–80)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">1.0–1.1 (88–97)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">1.2–1.5 (110–133)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">≥ 1.6 (141)</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">1–11</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">&lt; 0.3 (26)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">0.3–0.4 (26–35)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">0.5–0.7 (44–62)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">0.8–1.1 (71–97)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">≥ 1.2 (110)</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">12–23 (1–2 years)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">&lt; 0.4 (35)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">0.4–0.5 (35–44)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">0.6–1.0 (53–88)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">1.1–1.4 (97–124)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">≥ 1.5 (133)</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">24–59 (2-5 years)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">&lt; 0.6 (53)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">0.6–0.8 (53–71)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">0.9–1.5 (79–133)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">1.6–2.2 (141–195)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">≥ 2.3 (203)</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">60–143 (6–11 years)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">&lt; 0.7 (62)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">0.7–1.0 (62–88)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">1.1–1.7 (97–150)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">1.8–2.5 (159–221)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">≥ 2.6 (230)</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">144–216 (12–18 years)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">&lt; 1.0 (88)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">1.0–1.6 (88–141)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">1.7–2.8 (150–247)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">2.9–4.1 (256–362)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">≥ 4.2 (371)</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"6\">\n<p class=\"legenda\">FIO<sub class=\"calibre36\">2</sub>: fractional inspired oxygen; MAP: mean arterial pressure; PaO<sub class=\"calibre36\">2</sub>: arterial oxygen partial pressure.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> The Glasgow come scale is a clinical scale used to measure a person’s level of consciousness based on the assessment of three parameters: eye opening response (maximum 4 points assigned), best verbal response (maximum 5 points assigned) and best motor response (maximum 6 points assigned). The total score can range from 3 (completely unresponsive) to 15 (responsive). Scores lower than 8 usually indicate a comatose state. To calculate the Glasgow coma scale, several online calculators exist.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\">Table 1 – Age-specific criteria for suspected bloodstream infection</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"table_head\"><strong class=\"calibre5\">Age group</strong></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"table_head\"><strong class=\"calibre5\">Heart rate (beats/min)</strong></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"table_head\"><strong class=\"calibre5\">Respiratory rate (breaths/min)</strong></p>\n</td>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">1 month–1 year</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">&gt; 180 or &lt; 90</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">&gt; 34</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">2–5 years</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">&gt; 140</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">&gt; 22</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">6–12 years</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">&gt; 130</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">&gt; 18</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">13–18 years</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">&gt; 110</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">&gt; 14</p>\n</td>\n</tr>\n</tbody>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-860\"></a>Table 25.2 – Bacteria most frequently identified in blood cultures in neonates 28 days or younger with sepsis (also refer to Box 25.3 on bacteraemia)</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Setting</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Infection acquired in the community</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Infection acquired in hospital</strong></p>\n</td>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Low and middle income</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Most common</strong></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Escherichia coli</em> (including multidrug-resistant strains such as those producing ESBL)</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Staphylococcus aureus</em> (including MRSA)</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Klebsiella</em> spp. (including multidrug-resistant strains)</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Streptococcus agalactiae</em> (group B <em class=\"calibre10\">Streptococcus</em>)</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">More rarely</strong></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Staphylococcus</em> spp. (other than <em class=\"calibre10\">Staphylococcus aureus</em>)</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Acinetobacter</em> spp. (including multidrug-resistant strains)</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Streptococcus pyogenes</em> (group A <em class=\"calibre10\">Streptococcus</em>)</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Streptococcus pneumoniae</em></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Listeria monocytogenes</em></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Haemophilus influenzae</em></p>\n<p class=\"box_p1\">Gram-negative bacteria other than <em class=\"calibre10\">Escherichia coli</em>, <em class=\"calibre10\">Klebsiella</em> spp. and <em class=\"calibre10\">Acinetobacter</em> spp.</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Enterococcus</em> spp.</p>\n<p class=\"box_p1\">Invasive non-typhoidal <em class=\"calibre10\">Salmonella</em></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><em class=\"calibre10\">Klebsiella</em> spp.</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Escherichia coli</em></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Acinetobacter</em> spp. (including multidrug-resistant strains)</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Staphylococcus aureus</em> (including MRSA)</p>\n<p class=\"box_p1\">Gram-negative bacteria other than <em class=\"calibre10\">Escherichia coli</em> and <em class=\"calibre10\">Klebsiella</em> spp. and <em class=\"calibre10\">Acinetobacter</em> spp.</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Enterococcus</em> spp.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"calibre6\" id=\"calibre_link-391\" role=\"doc-pagebreak\" title=\"334\" type=\"pagebreak\"></span>High income</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Most common</strong></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Escherichia coli</em> (including multidrug-resistant strains such as those producing ESBL)</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Staphylococcus aureus</em> (including MRSA)</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Streptococcus agalactiae</em> (group B <em class=\"calibre10\">Streptococcus</em>)</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">More rarely</strong></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Staphylococcus</em> spp. (other than <em class=\"calibre10\">Staphylococcus aureus</em>)</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Listeria monocytogenes</em></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Haemophilus influenzae</em></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><em class=\"calibre10\">Escherichia coli</em> (including multidrug-resistant strains such as those producing ESBL)</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Klebsiella</em> spp. (including multidrug-resistant strains such as those producing ESBL and carbapenemases)</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Staphylococcus aureus</em> (including MRSA)</p>\n<p class=\"box_p1\">Gram-negative bacteria other than <em class=\"calibre10\">Escherichia coli</em> and <em class=\"calibre10\">Klebsiella</em> spp.</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Enterococcus</em> spp.</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">ESBL: extended-spectrum beta-lactamases; MRSA: methicillin-resistant <em class=\"calibre10\">Staphylococcus aureus</em>.</p>\n<p class=\"legenda\">Note. As indicated in the definition section, the distinction between neonatal sepsis acquired in the community and in the hospital is usually used in low- and middle-income settings, but neonatal sepsis can also be classified as early or late onset based on the time of onset of sepsis (counting days after delivery). The purpose of both classifications is to help identify the most likely causative pathogens, however, overlap may exist in some settings; for example, <em class=\"calibre10\">Acinetobacter</em> spp. is associated with early-onset sepsis in some settings.</p>\n<p class=\"legenda\">Hospital-acquired infections have a higher risk of being caused by multidrug-resistant organisms.</p>\n<p class=\"legenda\">Only bacteria are listed in the table. Other pathogens to consider are viruses (mostly herpes simplex virus and enteroviruses) and fungi (mostly <em class=\"calibre10\">Candida</em> spp.).</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-392\" role=\"doc-pagebreak\" title=\"335\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-861\"></a>Table 25.3 – Bacteria most frequently identified in blood cultures in children older than 28 days with sepsis (also refer to Box 25.3 on bacteraemia)</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Setting</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Infection acquired in the community</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Infection acquired in hospital</strong></p>\n</td>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Low and middle income</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Gram-negative bacteria (mostly <em class=\"calibre10\">Escherichia coli</em>, <em class=\"calibre10\">Klebsiella</em> spp. including multidrug-resistant strains such as those producing ESBL and carbapenemases)</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Salmonella</em> Typhi and Paratyphi (causing enteric fever)</p>\n<p class=\"box_p1\">Invasive non-typhoidal <em class=\"calibre10\">Salmonella</em> (mainly in sub-Saharan Africa in children &lt; 5 years with recent/acute <em class=\"calibre10\">Plasmodium falciparum</em> malaria, anaemia, malnutrition, or HIV)</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Streptococcus pneumoniae</em></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Streptococcus pyogenes</em> (group A Streptococcus<em class=\"calibre10\">)</em></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Staphylococcus aureus</em></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Neisseria meningitidis</em></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Haemophilus influenzae</em> type b</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><em class=\"calibre10\">Klebsiella</em> spp. (including multidrug-resistant strains such as those producing ESBL and carbapenemases)</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Escherichia coli</em> (including multidrug-resistant strains such as those producing ESBL and carbapenemases)</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Staphylococcus aureus</em> (including MRSA)</p>\n<p class=\"box_p1\">Gram-negative bacteria other than <em class=\"calibre10\">Escherichia</em> coli and <em class=\"calibre10\">Klebsiella</em> spp. (including multidrug-resistant strains such as those producing ESBL and carbapenemases)</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Enterococcus</em> spp.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">High income</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><em class=\"calibre10\">Streptococcus pneumoniae</em></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Streptococcus pyogenes</em> (group A <em class=\"calibre10\">Streptococcus</em>)</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Staphylococcus aureus</em></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Neisseria meningitidis</em></p>\n<p class=\"box_p1\">Gram-negative bacteria (mostly <em class=\"calibre10\">Escherichia coli</em>, <em class=\"calibre10\">Klebsiella</em> spp. including multidrug-resistant strains such as those producing ESBL and carbapenemases)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><em class=\"calibre10\">Klebsiella</em> spp.</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Escherichia coli</em></p>\n<p class=\"box_p1\">(including multidrug-resistant strains such as those producing ESBL and carbapenemases)</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Staphylococcus aureus</em> (including MRSA)</p>\n<p class=\"box_p1\">Gram-negative bacteria other than <em class=\"calibre10\">Escherichia coli</em> and <em class=\"calibre10\">Klebsiella</em> spp. (including multidrug-resistant strains such as those producing ESBL and carbapenemases)</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Enterococcus</em> spp.</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">ESBL: extended-spectrum beta-lactamases; MRSA: methicillin-resistant <em class=\"calibre10\">Staphylococcus aureus</em>.</p>\n<p class=\"legenda\">Note. Hospital-acquired infections have a higher risk of being caused by multidrug-resistant organisms.</p>\n<p class=\"legenda\">Only bacteria are listed in the table. Other pathogens to consider are viruses (mostly herpes simplex virus and enteroviruses) and fungi (mostly <em class=\"calibre10\">Candida</em> spp.).</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\">Table 25.4 – Microbiology tests to consider when sepsis in suspected depending on the most likely source of infection as indicated in the WHO EDL <em class=\"calibre10\">(6)</em></strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Suspected underlying infection</strong><sup class=\"calibre32\">a</sup></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Diagnostic test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Purpose of the test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Settings where the test should be available</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">All cases where sepsis is suspected</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Blood culture and antimicrobial susceptibility testing</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To detect bacterial bloodstream infections</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Urinary tract infection</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Urine culture and antimicrobial susceptibility testing</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Initial step to detect and identify bacterial and fungal species for selection of appropriate antimicrobial regimens</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Meningitis</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Cerebrospinal fluid: Gram stain, bacterial culture<sup class=\"calibre30\">b</sup> and antimicrobial susceptibility testing</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Initial step to detect and identify bacterial and fungal species for selection of appropriate antimicrobial regimens</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"calibre6\" id=\"calibre_link-395\" role=\"doc-pagebreak\" title=\"338\" type=\"pagebreak\"></span>Diarrhoeal disease, enteric fever<sup class=\"calibre30\">c</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Stool culture and antimicrobial susceptibility testing</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Initial step to detect and identify bacterial species for selection of appropriate antibiotic regimens</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Abscess (e.g. in the context of intra-abdominal infections, skin and soft-tissue infections, dental infections)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Culture and antimicrobial susceptibility testing of abscess and/or fluid collections that can be drained</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Initial step to detect and identify bacterial and fungal species for selection of appropriate antimicrobial regimens</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"4\">\n<p class=\"legenda\">EDL: Model List of Essential In Vitro Diagnostics.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> Additional tests may be considered in endemic settings or after travel to endemic settings (e.g. malaria, viruses causing viral haemorrhagic fevers).</p>\n<p class=\"legenda\"><sup class=\"calibre30\">b</sup> Even though cerebrospinal fluid culture is rarely done, it is a very important test to perform.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">c</sup> If enteric fever is suspected, note that stool cultures have a low sensitivity and are not useful in the early phase (first week) of disease when the test is often negative.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-863\"></a>Table 25.5 – Laboratory tests (other than microbiology) to consider when sepsis in suspected to identify a bacterial infection as indicated in the WHO EDL <em class=\"calibre10\">(6)</em></strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Diagnostic test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Purpose of the test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Settings where the test should be available</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">White blood count</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To help in the diagnosis of infections</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories and also in primary care settings</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"calibre6\" id=\"calibre_link-396\" role=\"doc-pagebreak\" title=\"339\" type=\"pagebreak\"></span>C-reactive protein</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To detect inflammation as an indicator of various conditions (e.g. sepsis)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Procalcitonin<sup class=\"calibre30\">a</sup></p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To guide antibiotic therapy or discontinuation in sepsis</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Only in tertiary and higher health care facilities</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">EDL: Model List of Essential In Vitro Diagnostics.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> Procalcitonin is not widely available and has only moderate accuracy for the diagnosis of sepsis in neonates with suspected sepsis at the cut-off of 2.0–2.5 ng/mL; different cut-offs in neonates with early- versus late-onset sepsis may be necessary <em class=\"calibre10\">(270)</em>. Procalcitonin may possibly have a higher sensitivity and specificity than C-reactive protein, <em class=\"calibre10\">(271)</em>. A combination of both tests may improve the accuracy of diagnosis of neonatal sepsis <em class=\"calibre10\">(272)</em>.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-864\"></a>Table 25.6 – Laboratory tests (other than microbiology) to consider when sepsis in suspected to identify organ dysfunction as indicated in the WHO EDL <em class=\"calibre10\">(6)</em></strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Diagnostic test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Purpose of the test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Settings where the test should be available</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Bilirubin</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To detect or monitor liver disease, bile duct disorders and red cell destruction</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Blood pH and gases</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To assess lung function, metabolic or kidney disorders and monitor oxygen therapy</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Blood urea nitrogen</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To assess kidney function</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Creatinine</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To monitor kidney function for management of severe infections (i.e. sepsis,) and to adjust antimicrobial regimen</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Electrolytes</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To monitor fluid, electrolyte and acid–base balance</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Glucose</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To diagnose intermediate hyperglycaemia and hypoglycaemia</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories and also in primary care settings</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\"><span class=\"calibre6\" id=\"calibre_link-397\" role=\"doc-pagebreak\" title=\"340\" type=\"pagebreak\"></span>Platelet count</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To diagnose thrombocytopenia or thrombocytosis.</p>\n<p class=\"box_p1\">This is a marker to manage severe infections associated with sepsis (e.g. viral haemorrhagic fever, meningococcaemia)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Whole blood lactate</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To assess metabolic acidosis</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">EDL: Model List of Essential In Vitro Diagnostics.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-399\" role=\"doc-pagebreak\" title=\"342\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-865\"></a>Table 25.7 – Empiric antibiotic treatment for community-acquired sepsis of bacterial origin in neonates and children</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color2\" colspan=\"4\">\n<p class=\"box_tit1\"><img alt=\"Imagem\" class=\"calibre26\" src=\"images/000166.jpg\"/> <strong class=\"calibre5\">Note</strong></p>\n<p class=\"box_p1\">An update of WHO guidelines for the treatment of neonatal sepsis is ongoing at the date of publication of the AWaRe book. Please regularly check the WHO website for news on this topic.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color1\" colspan=\"4\">\n<p class=\"box_tit1\"><img alt=\"Imagem\" class=\"calibre26\" src=\"images/000133.jpg\"/> <strong class=\"calibre5\">Important</strong></p>\n<p class=\"box_p1\">Where more than one antibiotic is recommended for an infection, they are listed in alphabetical order and they should be considered equal treatment options, unless otherwise indicated.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"colort\"></td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Referral to hospital possible</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Referral to hospital not possible <em class=\"calibre10\">(262)</em></strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Total treatment duration</strong></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">First choice</strong><sup class=\"calibre30\">a</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_verde\">Ampicillin</span> (IV): 50 mg/kg/dose:</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">Given every 12 hours (first week of life)</li>\n<li class=\"box_li1\">Given every 8 hours (&gt; first week of life)</li>\n</ul>\n<p class=\"box_p3\"><strong class=\"calibre5\">AND</strong> <span class=\"back_verde\">Gentamicin</span> (IV):</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">Neonates: 5 mg/kg/dose given once a day</li>\n<li class=\"box_li1\">Children: 7.5 mg/kg/dose given once a day</li>\n</ul>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Benzylpenicillin</span> (IV): 50 000 IU/kg/dose (30 mg/kg/dose) given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">AND</strong> <span class=\"back_verde\">Gentamicin</span> (IV):</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">Neonates: 5 mg/kg/dose given once a day</li>\n<li class=\"box_li1\">Children: 7.5 mg/kg/dose given once a day</li>\n</ul>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_verde\">Amoxicillin</span> (oral): 50 mg/kg/dose:</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">Given every 12 hours (infants 0-2 months)</li>\n<li class=\"box_li1\">Given every 8 hours (&gt; 2 months)</li>\n</ul>\n<p class=\"box_p3\"><strong class=\"calibre5\">AND</strong> <span class=\"back_verde\">Gentamicin</span> (IM):</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">Neonates: 5 mg/kg/dose given once a day</li>\n<li class=\"box_li1\">Children: 7.5 mg/kg/dose given once a day</li>\n</ul>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">7 days (14 days in case of meningitis)</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"calibre6\" id=\"calibre_link-400\" role=\"doc-pagebreak\" title=\"343\" type=\"pagebreak\"></span><strong class=\"calibre5\">Second choice</strong><sup class=\"calibre30\">b</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_amarelo\">Cefotaxime</span><sup class=\"calibre30\">b</sup> (IV): 50 mg/kg/dose given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Ceftriaxone</span><sup class=\"calibre30\">b,c</sup> (IV): 80 mg/kg/dose given once a day</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Cloxacillin</span><sup class=\"calibre30\">d,e</sup> (IV):</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">Neonates: 25–50 mg/kg/dose given every 12 hours</li>\n<li class=\"box_li1\">Children: 25 mg/kg/dose given every 6 hours</li>\n</ul>\n<p class=\"box_p3\"><strong class=\"calibre5\">AND</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Amikacin</span><sup class=\"calibre30\">f</sup> (IV): 15 mg/kg/dose given once a day</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">No specific option is indicated in the EML and EMLc as second choice option when referral to hospital is not possible.</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">7 days</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"4\">\n<p class=\"legenda\">EML: Model List of Essential Medicines; EMLc: Model List of Essential Medicines for children; IM: intramuscular; IU: international units; IV: intravenous; MRSA: methicillin-resistant <em class=\"calibre10\">Staphylococcus aureus</em>.</p>\n<p class=\"legenda\">Note. All dosages are for normal renal and hepatic function.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> To cover for <em class=\"calibre10\">Listeria monocytogenes</em>and Gram-negative bacteria.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">b</sup> In settings with high resistance, particularly for suspected health care-associated infections, a broad-spectrum antibiotic with activity against Gram-negative bacteria should also be considered (e.g. piperacillin+tazobactam). Of note, empiric treatment with third-generation cephalosporins (ceftriaxone/cefotaxime) may be more appropriate in settings where invasive non-typhoidal <em class=\"calibre10\">Salmonella</em>are a major cause of bloodstream infection. The reason is that (i) &gt; 85% of non-typhoidal <em class=\"calibre10\">Salmonella</em> are multidrug-resistant, which includes ampicillin resistance and (ii) aminoglycosides have reduced clinical effectiveness in invasive non-typhoidal <em class=\"calibre10\">Salmonella</em> infections.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">c</sup> Ceftriaxone should not be used in neonates with hyperbilirubinaemia and should not be administered with calcium. Age restriction: use only in neonates of &gt; 41 weeks corrected gestational age.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">d</sup> Cloxacillin is a useful second-choice option when an infection caused by <em class=\"calibre10\">Staphylococcus aureus</em>is suspected; the presence of extensive skin pustules, abscess or omphalitis (i.e. infection of the umbilicus and/or surrounding tissues) may suggest a staphylococcal infection. Of note, in community setting with high prevalence of MRSA, vancomycin should be considered instead of cloxacillin.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">e</sup> If cloxacillin is unavailable, any other IV antistaphylococcal penicillin could be used.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">f</sup> Gentamicin can be used when amikacin is not available. Amikacin (or gentamicin) would mostly be used as a treatment for infections caused by Gram-negative bacteria and when antibiotic-resistant bacteria are suspected.</p>\n<p class=\"legenda\">Legend: ACCESS antibiotics are indicated in green, WATCH antibiotics in orange and RESERVE antibiotics in red.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-866\"></a>Table 25.8 – Vaccinations to consider to prevent certain infections</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Vaccination</strong><sup class=\"calibre32\">a</sup></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Population where the vaccine should be considered</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\"><em class=\"calibre10\">Haemophilus influenzae</em> type b vaccination <em class=\"calibre10\">(36)</em></p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">All children should be vaccinated with <em class=\"calibre10\">Haemophilus influenzae</em> type b conjugate vaccines.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Meningococcal vaccination <em class=\"calibre10\">(36,236)</em></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Countries with high (&gt; 10 cases per 100 000 population/year) or intermediate (2–10 cases per 100 000 population/year) incidence of meningococcal disease or with frequent epidemics: all individuals aged 1–29 years (including pregnant women) should be vaccinated with the meningococcal A conjugate vaccine.</p>\n<p class=\"box_p1\">Countries with low incidence of meningococcal disease (&lt; 2 cases per 100 000 population/year): vaccination only for defined high-risk groups such as children and young adults or individuals with immunodeficiency.</p>\n<p class=\"box_p1\">The choice of the recommended vaccine depends on the local prevalence of the meningococcal serogroups.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Pneumococcal vaccination <em class=\"calibre10\">(35)</em></p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">All children should be vaccinated with pneumococcal conjugate vaccines.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><em class=\"calibre10\">Salmonella</em> Typhi vaccination <em class=\"calibre10\">(154)</em></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Individuals living in countries with a high burden of enteric fever or a high burden of antibiotic-resistant <em class=\"calibre10\">Salmonella</em> Typhi should be vaccinated with typhoid conjugate vaccines; vaccination should also be offered during outbreaks.</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"2\">\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> References cited are to WHO position papers that support the evidence for vaccination.</p>\n</td>\n</tr>\n</tfoot>\n</table>"
        ]
    },
    {
        "name": "Bacterial meningitis",
        "tables": [
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-409\" role=\"doc-pagebreak\" title=\"352\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-867\"></a>Table 26.1 – Pathogens most frequently associated with bacterial meningitis (in descending order of frequency)</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Neonates (0–1 month)</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Children and adolescents</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Non-immunocompromised adults</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Immunocompromised adults or all adults &gt; 50 years</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Other</strong></p>\n</td>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><em class=\"calibre10\">Streptococcus agalactiae</em> (group B <em class=\"calibre10\">Streptococcus</em>)</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Escherichia coli</em></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Listeria monocytogenes</em></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Streptococcus pneumoniae</em></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><em class=\"calibre10\">Streptococcus pneumoniae</em></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Neisseria meningitidis</em></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Haemophilus influenzae</em> type b and non-typeable strains</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Mycobacterium tuberculosis</em><sup class=\"calibre30\">a</sup></p>\n<p class=\"box_p1\">Invasive non-typhoidal <em class=\"calibre10\">Salmonella</em><sup class=\"calibre30\">b</sup></p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Rare</strong></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Salmonella</em> Typhi</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><em class=\"calibre10\">Streptococcus pneumoniae</em></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Neisseria meningitidis</em></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><em class=\"calibre10\">Streptococcus pneumoniae</em></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Neisseria meningitidis</em></p>\n<p class=\"box_p3\"><strong class=\"calibre5\">In addition to the above also consider:</strong></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Listeria monocytogenes</em><sup class=\"calibre30\">c</sup></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Mycobacterium tuberculosis</em><sup class=\"calibre30\">a</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><em class=\"calibre10\">Streptococcus suis</em><sup class=\"calibre30\">d</sup></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Mycobacterium tuberculosis</em><sup class=\"calibre30\">a</sup></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Staphylococcus aureus</em> or Gram-negative bacteria<sup class=\"calibre30\">e</sup> (including multidrug-resistant strains after neurosurgical interventions)</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Non-bacterial causes of meningitis</strong></p>\n<p class=\"box_p1\">Viral infections (especially Enteroviruses, Herpesviridae and Arboviruses)</p>\n<p class=\"box_p1\">Cryptococcal meningitis and cerebral toxoplasmosis in severely immunocompromised patients (e.g. with HIV)</p>\n<p class=\"box_p1\">Cerebral malaria (in patients living in or travelling to endemic settings)</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"5\">\n<p class=\"legenda\">HIV: human immunodeficiency virus.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> Mostly in settings where tuberculosis is endemic and/or in patients positive for HIV.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">b</sup> Mainly in sub-Saharan Africa in children living with HIV and/or sickle cell disease.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">c</sup> Pregnant women also have an increased risk of <em class=\"calibre10\">Listeria monocytogenes</em> infection.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">d</sup> Consider if exposure to pigs.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">e</sup> Gram-negative bacterial meningitis can also occur as a consequence of <em class=\"calibre10\">Strongyloides</em> hyperinfection syndrome, which is a rare but fatal condition that can occur in immunocompromised people infected with <em class=\"calibre10\">Strongyloides stercoralis</em>.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-869\"></a>Table 26.2 – Microbiology tests to consider for the diagnosis of meningitis as indicated in the WHO EDL <em class=\"calibre10\">(6)</em></strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Diagnostic test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Purpose of the test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Settings where the test should be available</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Blood cultures<sup class=\"calibre30\">a</sup> and antimicrobial susceptibility testing</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To detect bacterial and fungal bloodstream infections</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">CSF microscopy (Gram stain)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To assess microbial morphology, number of white blood cells and red blood cells</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">CSF culture and antimicrobial susceptibility testing</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Initial step to detect and identify bacterial and fungal species for selection of appropriate antimicrobial regimens</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Cryptococcal antigen test (CSF, blood)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To screen and diagnose cryptococcal meningitis in people living with advanced HIV disease</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories and also in primary care settings</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\"><span class=\"calibre6\" id=\"calibre_link-412\" role=\"doc-pagebreak\" title=\"355\" type=\"pagebreak\"></span><em class=\"calibre10\">Mycobacterium tuberculosis</em> DNA (CSF)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To diagnose active tuberculosis and simultaneously or sequentially detect rifampicin resistance</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">CSF: cerebrospinal fluid; EDL: Model List of Essential In Vitro Diagnostics; HIV: human immunodeficiency virus.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> If blood is taken before starting antibiotic treatment, blood cultures are often positive in cases of bacterial meningitis (up to 75% of cases) <em class=\"calibre10\">(281,282)</em>.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-870\"></a>Table 26.3 – Laboratory tests that could be considered for the diagnosis of meningitis as indicated in the WHO EDL <em class=\"calibre10\">(6)</em></strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Diagnostic test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Purpose of the test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Settings where the test should be available</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Basic CSF profile (CSF leukocyte count, CSF differential leukocyte count and CSF protein and glucose)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To aid in the diagnosis of bacterial, mycobacterial, fungal and viral meningitis</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Complete blood count</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To detect a wide range of disorders, including infections</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Blood glucose</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To diagnose hyperglycaemia/hypoglycaemia</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories but also in primary care settings</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">C-reactive protein</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To detect inflammation as an indicator of various conditions (e.g. sepsis)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Procalcitonin</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To guide antibiotic therapy or discontinuation in sepsis</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Only in tertiary health care facilities</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Whole blood lactate</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To assess metabolic acidosis, sepsis and dehydration</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Community settings and health facilities without laboratories</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">CSF: cerebrospinal fluid; EDL: Model List of Essential In Vitro Diagnostics.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-415\" role=\"doc-pagebreak\" title=\"358\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-871\"></a>Table 26.4 – Empiric antibiotic treatment for bacterial meningitis</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color1\" colspan=\"5\">\n<p class=\"box_tit1\"><img alt=\"Imagem\" class=\"calibre26\" src=\"images/000133.jpg\"/> <strong class=\"calibre5\">Important</strong></p>\n<p class=\"box_p1\">Where more than one antibiotic is recommended for an infection, they are listed in alphabetical order and they should be considered equal treatment options, unless otherwise indicated.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"colort\"></td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Adults</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Children (not neonates)</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Neonates (&lt; 1 month)</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Total treatment duration</strong></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">First choice</strong></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_amarelo\">Cefotaxime</span> (IV): 2 g given every 6 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Ceftriaxone</span> (IV): 2 g given every 12 hours</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_amarelo\">Cefotaxime</span> (IV): 50 mg/kg/dose given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Ceftriaxone</span> (IV): 100 mg/kg given once a day</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_verde\">Ampicillin</span> (IV):</p>\n<p class=\"box_p1\">50 mg/kg/dose given every 12 hours (first week of life)</p>\n<p class=\"box_p1\">50 mg/kg/dose given every 8 hours (&gt; first week of life)</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">AND</strong> <span class=\"back_verde\">Gentamicin</span> (IV):</p>\n<p class=\"box_p1\">5 mg/kg given once a day (first week of life)</p>\n<p class=\"box_p1\">7.5 mg/kg given once a day (&gt; first week of life)</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Cefotaxime</span> (IV):</p>\n<p class=\"box_p1\">50 mg/kg/dose given every 12 hours (first week of life)</p>\n<p class=\"box_p1\">50 mg/kg/dose given every 6 hours (&gt; first week of life)</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">AND</strong> <span class=\"back_verde\">Gentamicin</span> (IV):</p>\n<p class=\"box_p1\">5 mg/kg given once a day (first week of life)</p>\n<p class=\"box_p1\">7.5 mg/kg given once a day (&gt; first week of life)</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Ceftriaxone</span> (IV): 100 mg/kg given once a day</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">AND</strong> <span class=\"back_verde\">Gentamicin</span> (IV):</p>\n<p class=\"box_p1\">5 mg/kg given once a day (first week of life)</p>\n<p class=\"box_p1\">7.5 mg/kg given once a day (&gt; first week of life)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Unknown pathogen</strong></p>\n<p class=\"box_p1\">10 days (adults and children)</p>\n<p class=\"box_p1\">3 weeks (neonates)</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Confirmed pneumococcal meningitis</strong></p>\n<p class=\"box_p1\">10–14 days</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Confirmed meningococcal meningitis</strong></p>\n<p class=\"box_p1\">5–7 days</p>\n<p class=\"box_p1\">In epidemics, specific WHO recommendations on duration apply <em class=\"calibre10\">(257)</em></p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Confirmed <em class=\"calibre10\">Listeria</em> meningitis</strong></p>\n<p class=\"box_p1\">21 days</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"calibre6\" id=\"calibre_link-416\" role=\"doc-pagebreak\" title=\"359\" type=\"pagebreak\"></span><strong class=\"calibre5\">Second choice</strong><sup class=\"calibre30\">a</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_verde\">Amoxicillin</span><sup class=\"calibre30\">b</sup> <strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Ampicillin</span><sup class=\"calibre30\">b</sup> (IV): 2 g given every 4 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Benzylpenicillin</span> (IV): 4 million IU (2.4 g) given every 4 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Chloramphenicol</span><sup class=\"calibre30\">c</sup> (IV): 1 g given every 6 hours</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_verde\">Amoxicillin</span> (IV): 50 mg/kg/dose given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Ampicillin</span> (IV): 50 mg/kg/dose given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Benzylpenicillin</span> (IV): 100 000 IU/kg/dose (60 mg/kg/dose) given every 6 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Chloramphenicol</span><sup class=\"calibre30\">c</sup> (IV: 25 mg/kg/dose given every 6 hours</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_amarelo\">Meropenem</span> (IV): 40 mg/kg/dose given every 8 hours</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Same as above</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"5\">\n<p class=\"legenda\">IU: international units; IV: intravenous.</p>\n<p class=\"legenda\">Note: All dosages are for normal renal and hepatic function.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> In adults and in children beyond neonatal age, consider second choice options only when first choice options are not available. In neonates, consider meropenem (second choice) only where resistant Gram-negative organisms are the suspected causative agents.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">b</sup> Ampicillin (or IV amoxicillin) in adults should be added to ceftriaxone/cefotaxime if risk factors for <em class=\"calibre10\">Listeria monocytogenes</em> are present (e.g. patients ≥ 50 years, pregnant women).</p>\n<p class=\"legenda\"><sup class=\"calibre30\">c</sup> Chloramphenicol should only be used when no other option is available because of toxicity (the most serious adverse event is bone marrow depression).</p>\n<p class=\"legenda\">Legend: ACCESS antibiotics are indicated in green, WATCH antibiotics in orange and RESERVE antibiotics in red.</p>\n</td>\n</tr>\n</tfoot>\n</table>"
        ]
    },
    {
        "name": "Community-acquired pneumonia – severe",
        "tables": [
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-426\" role=\"doc-pagebreak\" title=\"369\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-872\"></a>Table 27.1 – Pathogens most frequently associated with community-acquired pneumonia (in descending order of frequency)</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">“Typical” bacteria</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">“Atypical” bacteria</strong><sup class=\"calibre32\">a</sup></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Respiratory viruses</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Other pathogens to consider in specific settings</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><em class=\"calibre10\">Streptococcus pneumoniae</em><sup class=\"calibre30\">b</sup></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Haemophilus influenzae</em></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Moraxella catarrhalis</em></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Staphylococcus aureus</em></p>\n<p class=\"box_p1\">Enterobacterales (e.g. <em class=\"calibre10\">Escherichia coli</em>, <em class=\"calibre10\">Klebsiella pneumoniae</em>)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><em class=\"calibre10\">Mycoplasma pneumoniae</em><sup class=\"calibre30\">c</sup></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Chlamydia pneumoniae</em><sup class=\"calibre30\">c</sup> and <em class=\"calibre10\">Chlamydia psittaci</em><sup class=\"calibre30\">c</sup></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Legionella</em> spp.</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Coxiella burnetii</em></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Influenza virus (A and B)</p>\n<p class=\"box_p1\">Respiratory syncytial virus<sup class=\"calibre30\">d</sup></p>\n<p class=\"box_p1\">Metapneumovirus</p>\n<p class=\"box_p1\">Parainfluenza virus</p>\n<p class=\"box_p1\">Coronavirus (including SARS-CoV-2)</p>\n<p class=\"box_p1\">Adenovirus</p>\n<p class=\"box_p1\">Rhinovirus</p>\n<p class=\"box_p1\">Other respiratory viruses</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><em class=\"calibre10\">Burkholderia pseudomallei</em> (South-East Asia, Australia)</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Mycobacterium tuberculosis</em></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Pneumocystis jirovecii</em> (in people with HIV or other types of cellular immunosuppression)</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"4\">\n<p class=\"legenda\">HIV: human immunodeficiency virus; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.</p>\n<p class=\"legenda\">a Atypical bacteria remain colourless with Gram staining. They also have intrinsic resistance to beta-lactams.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">b</sup> The most common bacterial cause of community-acquired pneumonia in all age groups (beyond the first week of life) is <em class=\"calibre10\">Streptococcus pneumoniae</em>.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">c</sup> <em class=\"calibre10\">Mycoplasma pneumoniae</em> and <em class=\"calibre10\">Chlamydia</em> spp. are more frequent in children &gt; 5 years (compared with younger children) and in young adults.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">d</sup> Up to 50% of cases of pneumonia in children &lt; 5 years are caused by a virus (most commonly respiratory syncytial virus).</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-873\"></a>Table 27.2 – Microbiology tests to consider if community-acquired pneumonia is suspected as indicated in the WHO EDL <em class=\"calibre10\">(6)</em></strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Diagnostic test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Purpose of test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Setting where the test should be available</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Comment</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Blood cultures and antimicrobial susceptibility testing</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To detect bacterial bloodstream infection</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Not routinely needed but suggested in severe cases<sup class=\"calibre30\">a</sup></p>\n<p class=\"box_p1\">Some guidelines suggest blood culture also in cases of recent antibiotic exposure (&lt; 3 months) or if MRSA or <em class=\"calibre10\">Pseudomonas aeruginosa</em> infection is suspected</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Sputum microscopy (Gram stain)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To assess microbial morphology and adequacy of the specimen for culture by identifying white blood cells and squamous epithelial cells</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Not routinely needed but suggested in severe cases<sup class=\"calibre30\">a</sup></p>\n<p class=\"box_p1\">Some guidelines suggest sputum microscopy also in cases of recent antibiotic exposure (&lt; 3 months) or if MRSA or <em class=\"calibre10\">Pseudomonas aeruginosa</em> infection is suspected</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Sputum culture and antimicrobial susceptibility testing</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Initial step to detect and identify bacterial and fungal species for selection of appropriate antimicrobial regimens</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Not routinely needed but suggested in severe cases<sup class=\"calibre30\">a</sup></p>\n<p class=\"box_p1\">Some guidelines suggest sputum culture also in cases of recent antibiotic exposure (&lt; 3 months) or if MRSA or <em class=\"calibre10\">Pseudomonas aeruginosa</em> infection is suspected</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"calibre6\" id=\"calibre_link-429\" role=\"doc-pagebreak\" title=\"372\" type=\"pagebreak\"></span>Sputum rapid molecular test for <em class=\"calibre10\">Mycobacterium tuberculosis</em></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To diagnose active tuberculosis and detect rifampicin resistance</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">If <em class=\"calibre10\">Mycobacterium tuberculosis</em> infection is suspected</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Urinary antigens for <em class=\"calibre10\">Legionella pneumophila</em> and <em class=\"calibre10\">Streptococcus pneumoniae</em></p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To diagnose legionellosis and pneumococcal pneumonia</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">–<sup class=\"calibre30\">b</sup></p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Not routinely needed but suggested in severe cases<sup class=\"calibre30\">a</sup> . It is often difficult or impossible to obtain high-quality sputum (e.g. from elderly people and children)</p>\n<p class=\"box_p1\">Some guidelines also recommend urinary antigens in case of an outbreak of legionellosis or recent travel</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Nasopharyngeal swab for NAAT for influenza viruses</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To diagnose seasonal influenza infection</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories but also in primary care settings</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Not routinely needed but suggested during the influenza season</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">SARS-CoV-2 antigen</p>\n<p class=\"box_p1\">Upper respiratory specimens (e.g. nasopharyngeal or nasal swab)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To diagnose COVID-19</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Community settings and health facilities without laboratories<sup class=\"calibre30\">c</sup></p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Not routinely needed but suggested depending on the epidemiologic situation</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">SARS-CoV-2 NAAT</p>\n<p class=\"box_p1\">Upper respiratory specimens (e.g. nasopharyngeal and oropharyngeal) and lower respiratory specimens (e.g. BAL)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To diagnose COVID-19</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Not routinely needed but suggested depending on the epidemiologic situation</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\"><span class=\"calibre6\" id=\"calibre_link-430\" role=\"doc-pagebreak\" title=\"373\" type=\"pagebreak\"></span>Nasopharyngeal swab for NAAT for respiratory viruses other than influenza viruses or SARS-CoV-2 (e.g. respiratory syncytial virus, adenovirus)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To diagnose respiratory viruses other than influenza or SARS-CoV-2</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">–<sup class=\"calibre30\">b</sup></p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Not routinely needed but suggested in severe cases<sup class=\"calibre30\">a</sup></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Anti-HIV-1 and -HIV-2 antibody (RDT)</p>\n<p class=\"box_p1\">or</p>\n<p class=\"box_p1\">Combined anti-HIV-1/HIV-2 antibody and p24 antigen (RDT)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To diagnose HIV infection</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Community settings and health facilities without laboratories<sup class=\"calibre30\">c</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Please consult the WHO consolidated guidelines on HIV testing services <em class=\"calibre10\">(286)</em>.</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"4\">\n<p class=\"legenda\">BAL: bronchoalveolar lavage; COVID-19: coronavirus disease 2019; EDL: Model List of Essential In Vitro Diagnostics; HIV: human immunodeficiency virus; MRSA: methicillin-resistant <em class=\"calibre10\">Staphylococcus aureus</em>; NAAT: nucleic acid amplification test; RDT: rapid diagnostic test; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> Severe cases are those with CURB-65 ≥ 2 (adults); for children, refer to the section: Scores to determine disease severity and guide treatment decisions.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">b</sup> This test is not in the WHO EDL <em class=\"calibre10\">(6)</em>.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">c</sup> Community and health settings without laboratories are defined as community and health facilities such as health posts and centres, doctors’ offices, outreach clinics and ambulatory care. These tests are also assumed to be available at health care facilities with laboratories.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-431\" role=\"doc-pagebreak\" title=\"374\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-874\"></a>Table 27.3 – Laboratory tests to consider if community-acquired pneumonia is suspected as indicated in the WHO EDL <em class=\"calibre10\">(6)</em></strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Diagnostic test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Purpose of the test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Settings where the test should be available</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Blood urea nitrogen</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To assess kidney function<sup class=\"calibre30\">a</sup></p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">White blood cell count</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To help in the diagnosis of infection</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Blood pH and gases</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To assess lung function and metabolic or kidney disorders, and monitor oxygen therapy</p>\n<p class=\"box_p1\">To measure blood pH, oxygen and carbon dioxide, serum bicarbonate and anion gap</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">C-reactive protein</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To detect inflammation as an indicator of various conditions</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Procalcitonin</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To guide antibiotic therapy or discontinuation in sepsis and lower respiratory tract infection</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Only in tertiary care facilities</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">EDL: Model List of Essential In Vitro Diagnostics.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> Required for the CURB-65 score calculation.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-875\"></a>Table 27.4 – CURB-65 criteria and scoring, and treatment decisions</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Criterion</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Points</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Presence of confusion (new onset)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">1</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Urea &gt; 19 mg/dL (or &gt; 7 mmol/L)<sup class=\"calibre30\">a</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">1</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Respiratory rate &gt; 30 breaths/min</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">1</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"calibre6\" id=\"calibre_link-433\" role=\"doc-pagebreak\" title=\"376\" type=\"pagebreak\"></span>Systolic blood pressure &lt; 90 mmHg (&lt; 12 kPa) or diastolic blood pressure ≤ 60 mmHg (≤ 8 kPa)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">1</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Age ≥ 65 years</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">1</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"colort\">\n<p class=\"box_p1\"><strong class=\"calibre5\">CURB-65 score/CRB-65 score</strong><sup class=\"calibre30\">a</sup></p>\n</td>\n<td class=\"colort\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Where to treat</strong></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">0–1</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Candidate for outpatient treatment</strong></p>\n<p class=\"box_p1\">Low 30-day mortality risk (&lt; 1.5%)</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">2</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Consider inpatient treatment</strong></p>\n<p class=\"box_p1\">30-day mortality risk ≈ 10%</p>\n<p class=\"box_p1\">Consider adding clarithromycin (see Table 27.5)</p>\n<p class=\"box_p1\">If tests are available, consider testing for atypical pathogens (e.g. <em class=\"calibre10\">Legionella</em> spp., <em class=\"calibre10\">Mycoplasma</em> spp.)</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">≥ 3</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Inpatient treatment (consider admission to intensive care)</strong></p>\n<p class=\"box_p1\">High 30-day mortality risk (≈ 20%)</p>\n<p class=\"box_p1\">Consider adding clarithromycin (see Table 27.5)</p>\n<p class=\"box_p1\">Consider testing for atypical pathogens (e.g. <em class=\"calibre10\">Legionella</em> spp., <em class=\"calibre10\">Mycoplasma</em> spp.)</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"2\">\n<p class=\"legenda\">Note. The CURB score is not validated in low-and middle-income countries.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> Urea is not required for the calculation of the CRB-65 score, a modification of the CURB-65 score that does not require laboratory tests.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-435\" role=\"doc-pagebreak\" title=\"378\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-876\"></a>Table 27.5 – Empiric antibiotic treatment for severe cases of community-acquired pneumonia in adults</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color1\" colspan=\"3\">\n<p class=\"box_tit1\"><img alt=\"Imagem\" class=\"calibre26\" src=\"images/000133.jpg\"/> <strong class=\"calibre5\">Important</strong></p>\n<p class=\"box_p1\">Where more than one antibiotic is recommended for an infection, they are listed in alphabetical order and they should be considered equal treatment options, unless otherwise indicated.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"colort\"></td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Adults</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Total treatment duration <em class=\"calibre10\">(130,131)</em></strong></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">First choice</strong></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_amarelo\">Cefotaxime</span> (IV/IM): 2 g given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Ceftriaxone</span> (IV/IM): 2 g given once a day (IV), 1 g given once a day (IM)<sup class=\"calibre30\">a</sup></p>\n<p class=\"box_p3\"><strong class=\"calibre5\">If CURB-65 ≥ 2, CONSIDER ADDING</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Clarithromycin</span><sup class=\"calibre30\">b</sup> (oral or IV): 500 mg given every 12 hours</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">5 days</p>\n<p class=\"box_p1\">Consider longer treatment and/or investigate for complications if the patient is not clinically stable at day 5</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Second choice</strong></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_verde\">Amoxicillin+clavulanic acid</span> (IV): 1 g + 200 mg given every 8 hours (a higher dose could be considered: 1 g + 200 mg given every 6 hours)</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">If CURB-65 ≥ 2, CONSIDER ADDING</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Clarithromycin</span><sup class=\"calibre30\">b</sup> (oral or IV): 500 mg given every 12 hours</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">5 days</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">IM: intramuscular; IU: international units; IV: intravenous.</p>\n<p class=\"legenda\">Note. All dosages are for normal renal and hepatic function.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> The reason for giving a lower dose when the ceftriaxone is given IM (rather than IV) is that a larger volume would be painful to give as intramuscular injection.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">b</sup> The rationale of adding clarithromycin to beta-lactam is to cover for possible atypical bacteria. Azithromycin could be used as an alternative when clarithromycin is not available but there are increasing concerns about its potential for the emergence and spread of antibiotic resistance because of its long half-life. Erythromycin could also be considered but it is associated with higher toxicity (diarrhoea is frequently associated with its use). Macrolides have good bioavailability and there is no need to use the intravenous route if the patient has a functioning gastrointestinal tract.</p>\n<p class=\"legenda\">Legend: ACCESS antibiotics are indicated in green, WATCH antibiotics in orange and RESERVE antibiotics in red.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-436\" role=\"doc-pagebreak\" title=\"379\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-877\"></a>Table 27.6 – Empiric antibiotic treatment for severe cases of community-acquired pneumonia in children (from the Revised WHO classification and treatment of childhood pneumonia at health facilities) <em class=\"calibre10\">(118)</em></strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color1\" colspan=\"3\">\n<p class=\"box_tit1\"><img alt=\"Imagem\" class=\"calibre26\" src=\"images/000133.jpg\"/> <strong class=\"calibre5\">Important</strong></p>\n<p class=\"box_p1\">Where more than one antibiotic is recommended for an infection, they are listed in alphabetical order and they should be considered equal treatment options, unless otherwise indicated.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"colort\"></td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Children</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Total treatment duration</strong></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Severe pneumonia</strong> (pneumonia with any danger sign<sup class=\"calibre30\">a</sup> , which requires referral to facility/hospital, admission and injectable therapy)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_verde\">Amoxicillin</span> <strong class=\"calibre5\">OR</strong> <span class=\"back_verde\">Ampicillin</span> (IV/IM):</p>\n<p class=\"box_p1\">50 mg/kg/dose given every 12 hours (first week of life)</p>\n<p class=\"box_p1\">50 mg/kg/dose given every 8 hours (&gt;first week of life)</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">AND</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Gentamicin</span> (IV/IM):</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">Neonates: 5 mg/kg/dose given once a day</li>\n<li class=\"box_li1\">Children: 7.5 mg/kg/dose given once a day</li>\n</ul>\n<p class=\"box_p3\"><strong class=\"calibre5\">Amoxicillin/ampicillin can be replaced by</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Benzylpenicillin</span> (IV): 50 000 IU/kg/dose (30 mg/kg/dose) given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">If no clinical response to ampicillin AND gentamicin after 48–72 hours, change to:</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Cefotaxime</span> (IV/IM): 50mg/kg/dose given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Ceftriaxone</span> (IV/IM): 80 mg/kg/dose given once a day</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Note</strong></p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">if HIV-positive and older than 1 month, <em class=\"calibre10\">Pneumocystis jirovecii</em> pneumonia is a risk so add empiric sulfamethoxazole+trimethoprim: 8 mg/kg trimethoprim and 40 mg/kg sulfamethoxazole, given every 8 hours for 3 weeks</li>\n<li class=\"box_li1\">Severe pneumonia, particularly in school-aged children, may rarely be caused by <em class=\"calibre10\">Mycoplasma pneumoniae</em>, which is unresponsive to beta-lactams and would be usually treated with macrolides (e.g. clarithromycin)</li>\n</ul>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">5 days</p>\n<p class=\"box_p1\">(consider longer treatment if the patient is not clinically stable at day 5)</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\"><span class=\"calibre6\" id=\"calibre_link-437\" role=\"doc-pagebreak\" title=\"380\" type=\"pagebreak\"></span>HIV: human immunodeficiency virus; IM: intramuscular; IU: international units; IV: intravenous.</p>\n<p class=\"legenda\">Note. All dosages are for normal renal and hepatic function.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> Not able to drink, persistent vomiting, convulsions, lethargic or unconscious, stridor in a calm child or severe malnutrition.</p>\n<p class=\"legenda\">Legend: ACCESS antibiotics are indicated in green, WATCH antibiotics in orange and RESERVE antibiotics in red.</p>\n</td>\n</tr>\n</tfoot>\n</table>"
        ]
    },
    {
        "name": "Hospital-acquired pneumonia",
        "tables": [
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-878\"></a>Table 28.1 – Pathogens most frequently associated with hospital-acquired pneumonia (in descending order of frequency)</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Bacteria</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Viruses</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Fungi</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Gram-negative bacteria including <em class=\"calibre10\">Pseudomonas aeruginosa</em>, <em class=\"calibre10\">Acinetobacter baumannii</em> and Enterobacterales such as <em class=\"calibre10\">Klebsiella pneumoniae</em> (including multidrug-resistant strains such as those producing ESBL and carbapenemases)</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Streptococcus pneumoniae</em></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Haemophilus influenzae</em></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Staphylococcus aureus</em> (including MRSA)</p>\n<p class=\"box_p1\">Anaerobes (mostly associated with aspiration of a large amount of secretions)</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Legionella pneumophila</em></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Influenza virus (A and B)</p>\n<p class=\"box_p1\">Other respiratory viruses (including SARS-CoV-2)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Mostly <em class=\"calibre10\">Aspergillus</em> spp. in severely immunocompromised patients or ventilated patients with influenza</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">ESBL: extended spectrum beta-lactamase; MRSA: methicillin-resistant <em class=\"calibre10\">Staphylococcus aureus</em>; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-879\"></a>Table 28.2 – Microbiology tests to consider if hospital-acquired pneumonia is suspected as indicated in the WHO EDL <em class=\"calibre10\">(6)</em></strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Diagnostic test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Purpose of the test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Settings where the test should be available</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Blood cultures and antimicrobial susceptibility testing</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To detect bacterial bloodstream infection</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Respiratory sample microscopy<sup class=\"calibre30\">a</sup> (Gram stain)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To assess microbial morphology and adequacy of the specimen for culture by identifying white blood cells and squamous epithelial cells</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Respiratory sample culture<sup class=\"calibre30\">a</sup> and antimicrobial susceptibility testing</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Initial step to detect and identify bacterial and fungal species for selection of appropriate antimicrobial regimens</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"calibre6\" id=\"calibre_link-446\" role=\"doc-pagebreak\" title=\"389\" type=\"pagebreak\"></span>Urinary antigens for <em class=\"calibre10\">Legionella pneumophila</em> and <em class=\"calibre10\">Streptococcus pneumoniae</em></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To diagnose legionellosis and pneumococcal pneumonia</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">–<sup class=\"calibre30\">b</sup></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Nasopharyngeal swab for NAAT for influenza<sup class=\"calibre30\">c</sup></p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To diagnose seasonal influenza infection</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories but also in primary care settings</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Nasopharyngeal swab for NAAT or antigen test for SARS-CoV-2<sup class=\"calibre30\">d</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To diagnose COVID-19</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories (NAAT) and primary care settings (antigen test)</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Nasopharyngeal swab for NAAT for respiratory viruses other than influenza or SARS-CoV-2 (e.g. respiratory syncytial virus)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To diagnose respiratory viruses other than influenza or SARS-CoV-2</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">–<sup class=\"calibre30\">b</sup></p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">COVID-19: coronavirus disease 2019; EDL: Model List of Essential In Vitro Diagnostics; NAAT: nucleic acid amplification test; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> Respiratory sampling can be done using invasive or non-invasive methods depending on the patient’s condition (e.g. if the patient is mechanically ventilated or not) and local availability. Invasive methods include bronchoalveolar lavage and blind bronchial sampling (usually called mini- bronchoalveolar lavage), while non-invasive methods include spontaneous expectoration, sputum induction, nasotracheal suctioning or endotracheal aspiration.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">b</sup> This test is not in the current WHO Model List of Essential In Vitro Diagnostics <em class=\"calibre10\">(6)</em>.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">c</sup> To help decide on antiviral treatment and for infection prevention and control purposes, for example, to prevent transmission to other patients.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">d</sup> Depending on the current epidemiology.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-447\" role=\"doc-pagebreak\" title=\"390\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-880\"></a>Table 28.3 – Laboratory tests to consider if hospital-acquired pneumonia is suspected as indicated in the WHO EDL <em class=\"calibre10\">(6)</em></strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Diagnostic test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Purpose of the test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Settings where the test should be available</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">White blood cell count</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To help in the diagnosis of infection</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Blood pH and gases</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To assess lung function and metabolic or kidney disorders, and monitor oxygen therapy</p>\n<p class=\"box_p1\">To measure blood pH, oxygen and carbon dioxide, serum bicarbonate and anion gap</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">C-reactive protein</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To detect inflammation as an indicator of various conditions (e.g. sepsis)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Procalcitonin</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To guide antibiotic therapy or discontinuation in sepsis and lower respiratory tract infection</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Only in tertiary care facilities</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">EDL: Model List of Essential In Vitro Diagnostics.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-450\" role=\"doc-pagebreak\" title=\"393\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-881\"></a>Table 28.4 – Empiric antibiotic treatment for hospital-acquired pneumonia (not for ventilator-associated pneumonia)</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color1\" colspan=\"3\">\n<p class=\"box_tit1\"><img alt=\"Imagem\" class=\"calibre26\" src=\"images/000133.jpg\"/> <strong class=\"calibre5\">Important</strong></p>\n<p class=\"box_p1\">Where more than one antibiotic is recommended for an infection, they are listed in alphabetical order and they should be considered equal treatment options, unless otherwise indicated.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Adults</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Children</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Total treatment duration</strong></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_verde\">Amoxicillin+clavulanic acid</span><sup class=\"calibre30\">a</sup> (IV/oral)</p>\n<p class=\"box_p1\">IV: 1 g + 200 mg given every 8 hours</p>\n<p class=\"box_p1\">Oral: 875 mg + 125 mg given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Cefotaxime</span> (IV/IM): 2 g given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Ceftriaxone</span><sup class=\"calibre30\">b</sup> (IV/IM)</p>\n<p class=\"box_p1\">IV: 2 g given once a day</p>\n<p class=\"box_p1\">IM: 1 g given once a day</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Piperacillin+tazobactam</span><sup class=\"calibre30\">c</sup> (IV): 4 g + 500 mg given every 6 hours</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_verde\">Amoxicillin+clavulanic acid</span><sup class=\"calibre30\">a,d</sup></p>\n<p class=\"box_p1\">IV:</p>\n<p class=\"box_p1\">First week of life: 50 mg/kg of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p1\">Beyond first week of life: 50 mg/kg of amoxicillin/dose given every 8 hours</p>\n<p class=\"box_p1\">Oral: 80–90 mg/kg/day of amoxicillin component</p>\n<p class=\"box_p1\">Oral weight bands:</p>\n<p class=\"box_p1\">3–&lt; 6 kg: 250 mg of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p1\">6–&lt; 10 kg: 375 mg of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 500 mg of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 750 mg of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p1\">≥ 20 kg: 500 mg of amoxicillin/dose given every 8 hours or 1 g of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Cefotaxime</span> (IV/IM): 50mg/kg/dose given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"calibre6\" id=\"calibre_link-451\" role=\"doc-pagebreak\" title=\"394\" type=\"pagebreak\"></span><span class=\"back_amarelo\">Ceftriaxone</span> (IV/IM): 80 mg/kg/dose given once a day</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Piperacillin+tazobactam</span><sup class=\"calibre30\">c</sup> (IV): 100 mg/kg/dose of piperacillin component given every 8 hours</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">7 days</p>\n<p class=\"box_p1\">Reassess the diagnosis and consider longer treatment if the patient is not clinically stable at day 7</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">IM: intramuscular; IV: intravenous.</p>\n<p class=\"legenda\">Note: All dosages are for normal renal and hepatic function.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> Amoxicillin+clavulanic acid can be used in certain circumstances with low-risk of multidrug-resistant infections (e.g. short hospitalization before symptom onset and if no prior antibiotic exposure).</p>\n<p class=\"legenda\"><sup class=\"calibre30\">b</sup> The reason for giving a lower dose when ceftriaxone is given IM (rather than IV) is that a larger volume would be painful to give as intramuscular injection.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">c</sup> Piperacillin+tazobactam offers anti-<em class=\"calibre10\">Pseudomonas</em> coverage, which the other options do not. Risk of <em class=\"calibre10\">Pseudomonas aeruginosa</em> is higher in patients with recent antibiotic exposure and especially in patients with known previous respiratory colonization by <em class=\"calibre10\">Pseudomonas aeruginosa</em> and underlying lung diseases.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">d</sup> Oral liquid formulations must be refrigerated after reconstitution as clavulanic acid is rapidly metabolized in high ambient temperatures.</p>\n<p class=\"legenda\">Legend: ACCESS antibiotics are indicated in green, WATCH antibiotics in orange and RESERVE antibiotics in red.</p>\n</td>\n</tr>\n</tfoot>\n</table>"
        ]
    },
    {
        "name": "Intra-abdominal infections – acute cholecystitis and cholangitis",
        "tables": [
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-460\" role=\"doc-pagebreak\" title=\"403\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-882\"></a>Table 29.1 – Pathogens most frequently associated with acute cholecystitis and cholangitis (in descending order of frequency)</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Bacteria</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Fungi</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Enterobacterales (mostly <em class=\"calibre10\">Escherichia coli</em>) and other Gram-negative bacteria such as <em class=\"calibre10\">Pseudomonas aeruginosa</em> and <em class=\"calibre10\">Acinetobacter baumannii</em> (including multidrug-resistant strains such as those producing ESBL and carbapenemases)</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Streptococcus</em> spp. (e.g. of the <em class=\"calibre10\">Streptococcus anginosus</em> group – old name: <em class=\"calibre10\">Streptococcus milleri</em>)</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Enterococcus</em> spp.</p>\n<p class=\"box_p1\">Anaerobes (mostly <em class=\"calibre10\">Bacteroides</em> spp.)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Mostly <em class=\"calibre10\">Candida albicans</em></p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"2\">\n<p class=\"legenda\">ESBL: extended-spectrum beta-lactamases.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-461\" role=\"doc-pagebreak\" title=\"404\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-883\"></a>Table 29.2 – Microbiology tests to consider in severe cases of acute cholecystitis or cholangitis as indicated in the WHO EDL <em class=\"calibre10\">(6)</em></strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Diagnostic test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Purpose of the test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Settings where the test should be available</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Blood cultures and antimicrobial susceptibility testing</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To detect bacterial bloodstream infections</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Microscopy, culture and antimicrobial susceptibility testing of fluid material or bile when these can be drained</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Initial step to detect and identify bacterial and fungal species for selection of appropriate antimicrobial regimens</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">EDL: Model List of Essential In Vitro Diagnostics.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-884\"></a>Table 29.3 – Laboratory tests (other than microbiology) that may help assess the severity of disease and identify a bacterial infection as indicated in the WHO EDL <em class=\"calibre10\">(6)</em></strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Diagnostic test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Purpose of the test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Settings where the test should be available</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">White blood cell count</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To help in the diagnosis of infections</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Aspartate aminotransferase</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To assess liver function</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Bilirubin</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To detect or monitor liver disease, bile duct disorders and red cell destruction</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Alkaline phosphatase</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To aid in diagnosis of hepatobiliary diseases</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\"><span class=\"calibre6\" id=\"calibre_link-462\" role=\"doc-pagebreak\" title=\"405\" type=\"pagebreak\"></span>C-reactive protein</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To detect inflammation as an indicator of various conditions (e.g. sepsis)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Procalcitonin</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To guide antibiotic therapy or discontinuation in sepsis</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Only in tertiary care facilities</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">EDL: Model List of Essential In Vitro Diagnostics.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-464\" role=\"doc-pagebreak\" title=\"407\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-885\"></a>Table 29.4 – Empiric antibiotic treatment for acute cholecystitis or cholangitis</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color2\" colspan=\"4\">\n<p class=\"box_tit1\"><img alt=\"Imagem\" class=\"calibre26\" src=\"images/000166.jpg\"/> <strong class=\"calibre5\">Note</strong></p>\n<p class=\"box_p1\">Mild cases are defined as patients who are not critically ill with no signs of sepsis or septic shock.</p>\n<p class=\"box_p1\">Severe cases are defined as patients who are critically ill with signs of sepsis or septic shock.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color1\" colspan=\"4\">\n<p class=\"box_tit1\"><img alt=\"Imagem\" class=\"calibre26\" src=\"images/000133.jpg\"/> <strong class=\"calibre5\">Important</strong></p>\n<p class=\"box_p1\">Where more than one antibiotic is recommended for an infection, they are listed in alphabetical order and they should be considered equal treatment options, unless otherwise indicated.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Severity</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Adults</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Children</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Total treatment duration</strong></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Mild cases</strong></p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\"><strong class=\"calibre5\">First choice</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Amoxicillin+clavulanic acid</span></p>\n<p class=\"box_p1\">IV: 1g + 200 mg given every 8 hours</p>\n<p class=\"box_p1\">Oral: 875 + 125 mg given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Cefotaxime</span> (IV): 2 g given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">AND</strong> <span class=\"back_verde\">Metronidazole</span> (IV/oral): 500 mg given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Ceftriaxone</span> (IV): 2 g given once a day</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">AND</strong> <span class=\"back_verde\">Metronidazole</span> (IV/oral): 500 mg given every 8 hours</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\"><span class=\"back_verde\">Amoxicillin+clavulanic acid</span><sup class=\"calibre30\">b</sup></p>\n<p class=\"box_p1\">IV:</p>\n<p class=\"box_p1\">First week of life: 50 mg/kg of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p1\">Beyond first week of life: 50 mg/kg of amoxicillin/dose given every 8 hours</p>\n<p class=\"box_p1\">Oral: 80–90 mg/kg/day of amoxicillin component</p>\n<p class=\"box_p1\">Oral weight bands</p>\n<p class=\"box_p1\">3–&lt; 6 kg: 250 mg of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p1\">6–&lt; 10 kg: 375 mg of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 500 mg of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 750 mg of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p1\">≥ 20kg: 500 mg of amoxicillin/dose given every 8 hours or 1 g of amoxicillin/dose given every 12 hours</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Uncomplicated cases treated with cholecystectomy: stop antibiotic after surgery if adequate control of the source of infection has been achieved and symptoms have resolved.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\"><span class=\"calibre6\" id=\"calibre_link-465\" role=\"doc-pagebreak\" title=\"408\" type=\"pagebreak\"></span><strong class=\"calibre5\">Mild cases</strong></p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Second choice</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Ciprofloxacin</span><sup class=\"calibre30\">a</sup> (oral): 500 mg given</p>\n<p class=\"box_p1\">every 12 hours <strong class=\"calibre5\">AND</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Metronidazole</span> (IV/oral): 500 mg given every 8 hours</p>\n<p class=\"box_p1\">(Ciprofloxacin and metronidazole have excellent oral bioavailability and the IV route should be reserved for patients with impaired gastrointestinal function.)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Ampicillin</span> (IV):</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">First week of life: 50 mg/kg/dose given every 12 hours</li>\n<li class=\"box_li1\">Beyond first week of life: 50 mg/kg/dose given every 8 hours</li>\n</ul>\n<p class=\"box_p3\"><strong class=\"calibre5\">AND</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Gentamicin</span> (IV):</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">Neonates: 5 mg/kg given once daily</li>\n<li class=\"box_li1\">Children: 7.5 mg/kg given once daily</li>\n</ul>\n<p class=\"box_p3\"><strong class=\"calibre5\">AND</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Metronidazole</span> (IV/oral):</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">Neonates: 7.5 mg/kg/dose given every 12 hours (for IV starting with a loading dose of 15 mg/kg)</li>\n<li class=\"box_li1\">Children: 7.5 mg/kg/dose given every 8 hours</li>\n</ul>\n<p class=\"box_p1\">Oral weight bands</p>\n<p class=\"box_p1\">3–&lt; 6 kg: 30 mg given every 8 hours</p>\n<p class=\"box_p1\">6–&lt; 10 kg: 50 mg given every 8 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 100 mg given every 8 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 150 mg given every 8 hours</p>\n<p class=\"box_p1\">20–&lt; 30 kg: 200 mg given every 8 hours</p>\n<p class=\"box_p1\">≥ 30 kg: use adult dose</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n</td>\n<td class=\"color\"></td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\"><span class=\"calibre6\" id=\"calibre_link-466\" role=\"doc-pagebreak\" title=\"409\" type=\"pagebreak\"></span><strong class=\"calibre5\">Mild cases</strong></p>\n</td>\n<td class=\"color\"></td>\n<td class=\"color\">\n<p class=\"box_p1\"><span class=\"back_amarelo\">Cefotaxime</span> (IV): 50 mg/kg/dose given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">AND</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Metronidazole</span> (IV/oral):</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">Neonates: 7.5 mg/kg/dose given every 12 hours (for IV starting with a loading dose of 15 mg/kg)</li>\n<li class=\"box_li1\">Children: 7.5 mg/kg/dose given every 8 hours</li>\n</ul>\n<p class=\"box_p1\">Oral weight bands</p>\n<p class=\"box_p1\">3–&lt; 6 kg: 30 mg given every 8 hours</p>\n<p class=\"box_p1\">6–&lt; 10 kg: 50 mg given every 8 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 100 mg given every 8 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 150 mg given every 8 hours</p>\n<p class=\"box_p1\">20–&lt; 30 kg: 200 mg given every 8 hours</p>\n<p class=\"box_p1\">≥ 30 kg: use adult dose</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n</td>\n<td class=\"color\"></td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\"><span class=\"calibre6\" id=\"calibre_link-467\" role=\"doc-pagebreak\" title=\"410\" type=\"pagebreak\"></span><strong class=\"calibre5\">Mild cases</strong></p>\n</td>\n<td class=\"color\"></td>\n<td class=\"color\">\n<p class=\"box_p1\"><span class=\"back_amarelo\">Ceftriaxone</span> (IV): 80 mg/kg/dose given once a day</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">AND</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Metronidazole</span> (IV/oral):</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">Neonates: 7.5 mg/kg/dose given every 12 hours (for IV starting with a loading dose of 15 mg/kg)</li>\n<li class=\"box_li1\">Children: 7.5 mg/kg/dose given every 8 hours</li>\n</ul>\n<p class=\"box_p1\">Oral weight bands</p>\n<p class=\"box_p1\">3–&lt; 6 kg: 30 mg given every 8 hours</p>\n<p class=\"box_p1\">6–&lt; 10 kg: 50 mg given every 8 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 100 mg given every 8 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 150 mg given every 8 hours</p>\n<p class=\"box_p1\">20–&lt; 30 kg: 200 mg given every 8 hours</p>\n<p class=\"box_p1\">≥ 30 kg: use adult dose</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Second choice</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Ciprofloxacin</span> (IV/oral): 15 mg/kg/dose, given every 12 hours</p>\n</td>\n<td class=\"color\"></td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\"><span class=\"calibre6\" id=\"calibre_link-468\" role=\"doc-pagebreak\" title=\"411\" type=\"pagebreak\"></span><strong class=\"calibre5\">Mild cases</strong></p>\n</td>\n<td class=\"color\"></td>\n<td class=\"color\">\n<p class=\"box_p1\">Oral weight bands</p>\n<p class=\"box_p1\">3–&lt; 6 kg: 50 mg given every 12 hours</p>\n<p class=\"box_p1\">6–&lt; 10 kg: 100 mg given every 12 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 150 mg given every 12 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 200 mg given every 12 hours</p>\n<p class=\"box_p1\">20–&lt; 30 kg: 300 mg given every 12 hours</p>\n<p class=\"box_p1\">≥ 30 kg: use adult dose</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">AND</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Metronidazole</span> (IV/oral):</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">Neonates: 7.5 mg/kg/dose given every 12 hours (for IV starting with a loading dose of 15 mg/kg)</li>\n<li class=\"box_li1\">Children: 7.5 mg/kg/dose given every 8 hours</li>\n</ul>\n<p class=\"box_p1\">Oral weight bands</p>\n<p class=\"box_p1\">3–&lt; 6 kg: 30 mg given every 8 hours</p>\n<p class=\"box_p1\">6–&lt; 10 kg: 50 mg given every 8 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 100 mg given every 8 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 150 mg given every 8 hours</p>\n<p class=\"box_p1\">20–&lt; 30 kg: 200 mg given every 8 hours</p>\n<p class=\"box_p1\">≥ 30 kg: use adult dose</p>\n<p class=\"box_p1\">(Ciprofloxacin and metronidazole have excellent oral bioavailability and the IV route should be reserved for patients with impaired gastrointestinal function)</p>\n</td>\n<td class=\"color\"></td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"calibre6\" id=\"calibre_link-469\" role=\"doc-pagebreak\" title=\"412\" type=\"pagebreak\"></span><strong class=\"calibre5\">Severe cases</strong></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">First choice</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Cefotaxime</span> (IV): 2 g given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">AND</strong> <span class=\"back_verde\">Metronidazole</span> (IV/oral): 500 mg given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Ceftriaxone</span> (IV): 2 g given once a day</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">AND</strong> <span class=\"back_verde\">Metronidazole</span> (IV/oral): 500 mg given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Piperacillin+tazobactam</span><sup class=\"calibre30\">c</sup> (IV): 4 g + 500 mg given every 6 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Second choice</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Meropenem</span><sup class=\"calibre30\">d</sup> (IV): 1 g given every 8 hours</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">First choice</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Ampicillin</span> (IV):</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">First week of life: 50 mg/kg/dose given every 12 hours</li>\n<li class=\"box_li1\">Beyond first week of life: 50 mg/kg/dose given every 8 hours</li>\n</ul>\n<p class=\"box_p3\"><strong class=\"calibre5\">AND</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Gentamicin</span> (IV):</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">Neonates: 5 mg/kg given once daily</li>\n<li class=\"box_li1\">Children: 7.5 mg/kg given once daily</li>\n</ul>\n<p class=\"box_p3\"><strong class=\"calibre5\">AND</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Metronidazole</span> (oral/IV):</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">Neonates: 7.5 mg/kg/dose given every 12 hours (for IV starting with a loading dose of 15 mg/kg)</li>\n<li class=\"box_li1\">Children: 7.5 mg/kg/dose given every 8 hours</li>\n</ul>\n<p class=\"box_p1\">Oral weight bands</p>\n<p class=\"box_p1\">3–&lt; 6 kg: 30 mg given every 8 hours</p>\n<p class=\"box_p1\">6–&lt; 10 kg: 50 mg given every 8 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 100 mg given every 8 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 150 mg given every 8 hours</p>\n<p class=\"box_p1\">20–&lt; 30 kg: 200 mg given every 8 hours</p>\n<p class=\"box_p1\">≥ 30 kg: use adult dose</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Acute cholecystitis</strong>: 5 days in total if adequate control of the source of infection has been achieved with surgery and symptoms have resolved.</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Acute cholangitis</strong>: continue antibiotic treatment for a total of 5 days once control of the source of infection has been achieved with biliary drainage and symptoms have resolved.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"calibre6\" id=\"calibre_link-470\" role=\"doc-pagebreak\" title=\"413\" type=\"pagebreak\"></span><strong class=\"calibre5\">Severe cases</strong></p>\n</td>\n<td class=\"calibre29\"></td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_amarelo\">Piperacillin+tazobactam</span> (IV): 100 mg/kg/dose of piperacillin component given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Second choice</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Meropenem</span><sup class=\"calibre30\">d</sup> (IV): 20 mg/kg/dose given every 8 hours</p>\n</td>\n<td class=\"calibre29\"></td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"4\">\n<p class=\"legenda\">IV: intravenous.</p>\n<p class=\"legenda\">Note: All dosages are for normal renal and hepatic function.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> The use of fluoroquinolones (such as ciprofloxacin) can be associated with important side-effects including: (i) mental health disturbances such as disorientation, agitation, nervousness, memory impairment and delirium; (ii) serious blood sugar disturbances such as hypoglycaemic coma; (iii) increased risk of tendinitis and tendon rupture; (iv) worsening symptoms in those with myasthenia gravis; and (v) potential irreversible neuropathy (serious nerve damage).</p>\n<p class=\"legenda\"><sup class=\"calibre30\">b</sup> Oral liquid formulations must be refrigerated after reconstitution as clavulanic acid is rapidly metabolized in high ambient temperatures.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">c</sup> Of note, piperacillin+tazobactam offers anti-<em class=\"calibre10\">Enterococcus</em> coverage, which the other options listed for adults do not. Ampicillin would be another appropriate option, but it was not listed in this table as it is not currently in the EML for this indication, while it is listed for children.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">d</sup> Meropenem should not be considered for routine use for all severe cases but only in complicated cases (i.e. abscess and/or peritonitis) in settings with a high prevalence of extended-spectrum beta-lactamase-producing Enterobacterales or in patients with known prior colonization, treated with multiple antibiotic courses or at risk of infections with pathogens resistant to the first-choice option. Empiric use of a Reserve antibiotic could be considered exceptionally in very select cases of seriously ill patient: who are failing to respond to carbapenems; or who have previously been treated for infections caused by carbapenem-resistant pathogens; or who are known to be colonized with multidrug-resistant Gram-negative bacteria that are known to be susceptible to the selected Reserve antibiotic. Please refer to the chapter on Reserve antibiotics for the definition and list of Reserve antibiotics included in the EML and EMLc.</p>\n<p class=\"legenda\">Legend: ACCESS antibiotics are indicated in green, WATCH antibiotics in orange and RESERVE antibiotics in red.</p>\n</td>\n</tr>\n</tfoot>\n</table>"
        ]
    },
    {
        "name": "Intra-abdominal infections – pyogenic liver abscess",
        "tables": [
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-478\" role=\"doc-pagebreak\" title=\"421\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-886\"></a>Table 30.1 – Pathogens most frequently associated with liver abscess (in descending order of frequency)</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Bacteria</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Parasites</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Fungi</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Enterobacterales (mostly <em class=\"calibre10\">Escherichia coli</em>, <em class=\"calibre10\">Klebsiella pneumoniae</em><sup class=\"calibre30\">a</sup> , <em class=\"calibre10\">Enterobacter</em>spp.) including multidrug-resistant strains such as those producing ESBL and carbapenemases</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Staphylococcus</em> spp.</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Streptococcus</em> spp. (e.g. of the <em class=\"calibre10\">Streptococcus anginosus</em> group – old name: <em class=\"calibre10\">Streptococcus milleri</em>)</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Enterococcus</em> spp.</p>\n<p class=\"box_p1\">Anaerobes (mostly <em class=\"calibre10\">Bacteroides</em> spp.)</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">In endemic settings consider</strong></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Burkholderia pseudomallei</em><sup class=\"calibre30\">b</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><em class=\"calibre10\">Entamoeba histolytica</em><sup class=\"calibre30\">c</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><em class=\"calibre10\">Candida</em> spp.<sup class=\"calibre30\">d</sup></p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">ESBL: extended-spectrum beta-lactamases.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> In Asia, <em class=\"calibre10\">Klebsiella pneumoniae</em> is currently the main cause of liver abscess.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">b</sup> <em class=\"calibre10\">Burkholderia pseudomallei</em> is an important cause of liver abscess in South-East Asia and northern Australia.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">c</sup> This pathogen is not a cause of pyogenic abscess but needs to be considered in the differential diagnosis, especially in patients who live in or have travelled to settings where <em class=\"calibre10\">Entamoeba histolytica</em> is endemic.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">d</sup> This pathogen is not a cause of pyogenic abscess and is infrequent in immunocompetent individuals but should be considered in the context of immunosuppression. Often it is in combination with bacteria.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-479\" role=\"doc-pagebreak\" title=\"422\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-887\"></a>Table 30.2 – Microbiology tests to consider when a liver abscess is suspected (including testing for <em class=\"calibre10\">Entamoeba histolytica</em>) as indicated in the WHO EDL <em class=\"calibre10\">(6)</em></strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Diagnostic test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Purpose of the test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Settings where the test should be available</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Blood cultures and antimicrobial susceptibility testing</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To detect bacterial bloodstream infections</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Microscopy, culture and antimicrobial susceptibility testing of abscess or pus aspirate</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Initial step to detect and identify bacterial and fungal species for selection of appropriate antimicrobial regimens</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Microscopy of stool sample for <em class=\"calibre10\">Entamoeba histolytica</em></p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To diagnose <em class=\"calibre10\">Entamoeba histolytica</em><sup class=\"calibre30\">a</sup></p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Antigen or nucleic acid amplification test (i.e. polymerase chain reaction<sup class=\"calibre30\">b</sup>) of abscess aspirate material for <em class=\"calibre10\">Entamoeba histolytica</em></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To diagnose <em class=\"calibre10\">Entamoeba histolytica</em><sup class=\"calibre30\">a</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">–<sup class=\"calibre30\">c</sup></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Serology for <em class=\"calibre10\">Entamoeba histolytica</em><sup class=\"calibre30\">d</sup></p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To diagnose <em class=\"calibre10\">Entamoeba histolytica</em><sup class=\"calibre30\">a</sup></p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">–<sup class=\"calibre30\">c</sup></p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">EDL: Model List of Essential In Vitro Diagnostics.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> <em class=\"calibre10\">Entamoeba histolytica</em> is not a cause of pyogenic abscess but a cause of liver abscess that needs to be considered in the differential diagnosis in endemic settings. However, patients with amoebic liver abscess usually have no bowel symptoms; therefore, stool testing (microscopy or antigen) has a low sensitivity and is of limited usefulness for diagnosis.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">b</sup> Antigen or nucleic acid amplification testing of abscess aspirate material for <em class=\"calibre10\">Entamoeba histolytica</em> could be considered where available. Diagnosis is often difficult in low- and middle-income countries due to limited laboratory resources and the fact that most patients present after a failed course of antibiotic treatment for pyogenic abscess; therefore the yield of any microbiology tests is lower <em class=\"calibre10\">(311,312)</em>.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">c</sup> This test is not in the WHO EDL <em class=\"calibre10\">(6)</em>.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">d</sup> Serology is a useful test in the diagnosis of invasive amoebiasis and is positive in more than 90% of patients with the disease. A positive serology combined with a compatible clinical presentation suggests active disease. However, in endemic settings, a positive result is more difficult to interpret since serology can remain positive for months and even years after resolution of the infection. Therefore, past and current infections become difficult to distinguish. With negative results, if the clinical suspicion of invasive amoebiasis is still strong, serology could be repeated after 1 week.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-480\" role=\"doc-pagebreak\" title=\"423\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-888\"></a>Table 30.3 – Laboratory tests (other than microbiology) to consider if pyogenic liver abscess is suspected as indicated in the WHO EDL <em class=\"calibre10\">(6)</em></strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Diagnostic test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Purpose of the test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Settings where the test should be available</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">White blood count</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To help in the diagnosis of infections</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Aspartate aminotransferase</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To assess liver function</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Alanine aminotransferase</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To assess liver function</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Bilirubin</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To detect or monitor liver disease</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Community settings and health facilities without laboratories<sup class=\"calibre30\">a</sup></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Direct and indirect bilirubin</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To detect or monitor liver disease, bile duct disorders and haemolytic anaemia, and to differentiate between these causes of jaundice</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Alkaline phosphatase</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To aid in the diagnosis of hepatobiliary diseases</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">EDL: Model List of Essential In Vitro Diagnostics.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> Community and health settings without laboratories are settings such as health posts and centres, doctors’ offices, outreach clinics and ambulatory care. These tests are also assumed to be available at health care facilities with laboratories.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-483\" role=\"doc-pagebreak\" title=\"426\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-889\"></a>Table 30.4 – Empiric antibiotic treatment for pyogenic or amoebic liver abscess</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color2\" colspan=\"4\">\n<p class=\"box_tit1\"><img alt=\"Imagem\" class=\"calibre26\" src=\"images/000166.jpg\"/> <strong class=\"calibre5\">Note</strong></p>\n<p class=\"box_p1\">In clinically stable patients, targeted treatment based on the results of microbiology tests is preferred.</p>\n<p class=\"box_p1\">Mild cases are defined as patients who are not critically ill with no signs of sepsis or septic shock.</p>\n<p class=\"box_p1\">Severe cases are defined as patients who are critically ill with signs of sepsis or septic shock.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color1\" colspan=\"4\">\n<p class=\"box_tit1\"><img alt=\"Imagem\" class=\"calibre26\" src=\"images/000133.jpg\"/> <strong class=\"calibre5\">Important</strong></p>\n<p class=\"box_p1\">Where more than one antibiotic is recommended for an infection, they are listed in alphabetical order and they should be considered equal treatment options, unless otherwise indicated.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Condition</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Adults</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Children</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Total treatment duration</strong></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Mild cases of pyogenic liver abscess</strong></p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\"><strong class=\"calibre5\">First choice</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Amoxicillin+clavulanic acid</span></p>\n<p class=\"box_p1\">IV: 1g + 200 mg given every 8 hours</p>\n<p class=\"box_p1\">Oral: 875 + 125 mg given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Cefotaxime</span> (IV): 2 g given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">AND</strong> <span class=\"back_verde\">Metronidazole</span> (IV/oral): 500 mg given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Ceftriaxone</span> (IV): 2 g given once a day</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">AND</strong> <span class=\"back_verde\">Metronidazole</span> (IV/oral): 500 mg given every 8 hours</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\"><span class=\"back_verde\">Amoxicillin+clavulanic acid</span><sup class=\"calibre30\">b</sup> :</p>\n<p class=\"box_p1\">IV:</p>\n<p class=\"box_p1\">First week of life: 50 mg/kg of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p1\">Beyond first week of life: 50 mg/kg of amoxicillin/dose given every 8 hours</p>\n<p class=\"box_p1\">Oral: 80–90 mg/kg/day of amoxicillin component</p>\n<p class=\"box_p1\">Oral weight bands</p>\n<p class=\"box_p1\">3–&lt; 6 kg: 250 mg of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p1\">6–&lt; 10 kg: 375 mg of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 500 mg of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 750 mg of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p1\">≥ 20 kg: 500 mg of amoxicillin/dose given every 8 hours or 1 g of amoxicillin/dose given every 12 hours</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">At least 4 weeks if adequate control of the source of infection is achieved (follow-up imaging is usually performed to guide treatment duration)</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\"><span class=\"calibre6\" id=\"calibre_link-484\" role=\"doc-pagebreak\" title=\"427\" type=\"pagebreak\"></span><strong class=\"calibre5\">Mild cases of pyogenic liver abscess</strong></p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Second choice</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Ciprofloxacin</span><sup class=\"calibre30\">a</sup> (oral): 500 mg given</p>\n<p class=\"box_p1\">every 12 hours <strong class=\"calibre5\">AND</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Metronidazole</span> (IV/oral): 500 mg given every 8 hours</p>\n<p class=\"box_p1\">(Ciprofloxacin and metronidazole have excellent oral bioavailability and the IV route should be reserved for patients with impaired gastrointestinal function)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Ampicillin</span> (IV):</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">First week of life: 50 mg/kg/dose given every 12 hours</li>\n<li class=\"box_li1\">Beyond first week of life: 50 mg/kg/dose given every 8 hours</li>\n</ul>\n<p class=\"box_p3\"><strong class=\"calibre5\">AND</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Gentamicin</span> (IV):</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">Neonates: 5 mg/kg given once daily</li>\n<li class=\"box_li1\">Children: 7.5 mg/kg given once daily</li>\n</ul>\n<p class=\"box_p3\"><strong class=\"calibre5\">AND</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Metronidazole</span> (IV/oral):</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">Neonates: 7.5 mg/kg/dose given every 12 hours (for IV starting with a loading dose of 15 mg/kg)</li>\n<li class=\"box_li1\">Children: 7.5 mg/kg/dose given every 8 hours</li>\n</ul>\n<p class=\"box_p1\">Oral weight bands</p>\n<p class=\"box_p1\">3–&lt; 6 kg: 30 mg given every 8 hours</p>\n<p class=\"box_p1\">6–&lt; 10 kg: 50 mg given every 8 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 100 mg given every 8 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 150 mg given every 8 hours</p>\n<p class=\"box_p1\">20–&lt; 30 kg: 200 mg given every 8 hours</p>\n<p class=\"box_p1\">≥ 30 kg: use adult dose</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n</td>\n<td class=\"color\"></td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\"><span class=\"calibre6\" id=\"calibre_link-485\" role=\"doc-pagebreak\" title=\"428\" type=\"pagebreak\"></span><strong class=\"calibre5\">Mild cases of pyogenic liver abscess</strong></p>\n</td>\n<td class=\"color\"></td>\n<td class=\"color\">\n<p class=\"box_p1\"><span class=\"back_amarelo\">Cefotaxime</span> (IV): 50 mg/kg/dose given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">AND</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Metronidazole</span> (IV/oral):</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">Neonates: 7.5 mg/kg/dose given every 12 hours (for IV starting with a loading dose of 15 mg/kg)</li>\n<li class=\"box_li1\">Children: 7.5 mg/kg/dose given every 8 hours</li>\n</ul>\n<p class=\"box_p1\">Oral weight bands</p>\n<p class=\"box_p1\">3–&lt; 6 kg: 30 mg given every 8 hours</p>\n<p class=\"box_p1\">6–&lt; 10 kg: 50 mg given every 8 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 100 mg given every 8 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 150 mg given every 8 hours</p>\n<p class=\"box_p1\">20–&lt; 30 kg: 200 mg given every 8 hours</p>\n<p class=\"box_p1\">≥ 30 kg: use adult dose</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n</td>\n<td class=\"color\"></td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\"><span class=\"calibre6\" id=\"calibre_link-486\" role=\"doc-pagebreak\" title=\"429\" type=\"pagebreak\"></span><strong class=\"calibre5\">Mild cases of pyogenic liver abscess</strong></p>\n</td>\n<td class=\"color\"></td>\n<td class=\"color\">\n<p class=\"box_p1\"><span class=\"back_amarelo\">Ceftriaxone</span> (IV): 80 mg/kg/dose given once a day</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">AND</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Metronidazole</span> (IV/oral):</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">Neonates: 7.5 mg/kg/dose given every 12 hours (for IV starting with a loading dose of 15 mg/kg)</li>\n<li class=\"box_li1\">Children: 7.5 mg/kg/dose given every 8 hours</li>\n</ul>\n<p class=\"box_p1\">Oral weight bands</p>\n<p class=\"box_p1\">3–&lt; 6 kg: 30 mg given every 8 hours</p>\n<p class=\"box_p1\">6–&lt; 10 kg: 50 mg given every 8 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 100 mg given every 8 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 150 mg given every 8 hours</p>\n<p class=\"box_p1\">20–&lt; 30 kg: 200 mg given every 8 hours</p>\n<p class=\"box_p1\">≥ 30 kg: use adult dose</p>\n</td>\n<td class=\"color\"></td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\"><span class=\"calibre6\" id=\"calibre_link-487\" role=\"doc-pagebreak\" title=\"430\" type=\"pagebreak\"></span><strong class=\"calibre5\">Mild cases of pyogenic liver abscess</strong></p>\n</td>\n<td class=\"color\"></td>\n<td class=\"color\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Second choice</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Ciprofloxacin</span> (IV/oral): 15 mg/kg/dose, given every 12 hours</p>\n<p class=\"box_p1\">Oral weight bands</p>\n<p class=\"box_p1\">3–&lt; 6 kg: 50 mg given every 12 hours</p>\n<p class=\"box_p1\">6–&lt; 10 kg: 100 mg given every 12 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 150 mg given every 12 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 200 mg given every 12 hours</p>\n<p class=\"box_p1\">20–&lt; 30 kg: 300 mg given every 12 hours</p>\n<p class=\"box_p1\">≥ 30 kg: use adult dose</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">AND</strong></p>\n</td>\n<td class=\"color\"></td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\"><span class=\"calibre6\" id=\"calibre_link-488\" role=\"doc-pagebreak\" title=\"431\" type=\"pagebreak\"></span><strong class=\"calibre5\">Mild cases of pyogenic liver abscess</strong></p>\n</td>\n<td class=\"color\"></td>\n<td class=\"color\">\n<p class=\"box_p1\"><span class=\"back_verde\">Metronidazole</span> (IV/oral):</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">Neonates: 7.5 mg/kg/dose given every 12 hours (for IV starting with a loading dose of 15 mg/kg)</li>\n<li class=\"box_li1\">Children: 7.5 mg/kg/dose given every 8 hours</li>\n</ul>\n<p class=\"box_p1\">Oral weight bands</p>\n<p class=\"box_p1\">3–&lt; 6 kg: 30 mg given every 8 hours</p>\n<p class=\"box_p1\">6–&lt; 10 kg: 50 mg given every 8 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 100 mg given every 8 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 150 mg given every 8 hours</p>\n<p class=\"box_p1\">20–&lt; 30 kg: 200 mg given every 8 hours</p>\n<p class=\"box_p1\">≥ 30 kg: use adult dose</p>\n<p class=\"box_p1\">(Ciprofloxacin and metronidazole have excellent oral bioavailability and the IV route should be reserved for patients with impaired gastrointestinal function)</p>\n</td>\n<td class=\"color\"></td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"calibre6\" id=\"calibre_link-489\" role=\"doc-pagebreak\" title=\"432\" type=\"pagebreak\"></span><strong class=\"calibre5\">Severe cases of pyogenic liver abscess</strong></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">First choice</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Cefotaxime</span> (IV): 2 g given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">AND</strong> <span class=\"back_verde\">Metronidazole</span> (IV/oral): 500 mg given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Ceftriaxone</span> (IV): 2 g given once a day</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">AND</strong> <span class=\"back_verde\">Metronidazole</span> (IV/oral): 500 mg given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Piperacillin+tazobactam</span><sup class=\"calibre30\">c</sup> (IV):4 g + 500 mg given every 6 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Second choice</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Meropenem</span><sup class=\"calibre30\">d</sup> (IV): 1 g given every 8 hours</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">First choice</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Ampicillin</span> (IV):</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">First week of life: 50 mg/kg/dose given every 12 hours</li>\n<li class=\"box_li1\">Beyond first week of life: 50 mg/kg/dose given every 8 hours</li>\n</ul>\n<p class=\"box_p3\"><strong class=\"calibre5\">AND</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Gentamicin</span> (IV):</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">Neonates: 5 mg/kg given once daily</li>\n<li class=\"box_li1\">Children: 7.5 mg/kg given once daily</li>\n</ul>\n<p class=\"box_p3\"><strong class=\"calibre5\">AND</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Metronidazole</span> (IV/oral)</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">Neonates: 7.5 mg/kg/dose given every 12 hours (for IV starting with a loading dose of 15 mg/kg)</li>\n<li class=\"box_li1\">Children: 7.5 mg/kg/dose given every 8 hours</li>\n</ul>\n<p class=\"box_p1\">Oral weight bands</p>\n<p class=\"box_p1\">3–&lt; 6 kg: 30 mg given every 8 hours</p>\n<p class=\"box_p1\">6–&lt; 10 kg: 50 mg given every 8 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 100 mg given every 8 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 150 mg given every 8 hours</p>\n<p class=\"box_p1\">20–&lt; 30 kg: 200 mg given every 8 hours</p>\n<p class=\"box_p1\">≥ 30 kg: use adult dose</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">At least 4 weeks if adequate control of the source of infection is achieved (follow-up imaging is usually performed to guide treatment duration)</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"calibre6\" id=\"calibre_link-490\" role=\"doc-pagebreak\" title=\"433\" type=\"pagebreak\"></span><strong class=\"calibre5\">Severe cases of pyogenic liver abscess</strong></p>\n</td>\n<td class=\"calibre29\"></td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_amarelo\">Piperacillin+tazobactam</span> (IV): 100 mg/kg/dose of piperacillin component given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Second choice</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Meropenem</span><sup class=\"calibre30\">d</sup> (IV): 20 mg/kg/dose given every 8 hours</p>\n</td>\n<td class=\"calibre29\"></td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Amoebic liver abscess</strong></p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\"><span class=\"back_verde\">Metronidazole</span> (oral<sup class=\"calibre30\">e</sup> ): 750 mg given every 8 hours, followed by paromomycin (oral): 25–35 mg/kg divided in 3 doses (to eradicate colonic colonization)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\"><span class=\"back_verde\">Metronidazole</span> (oral<sup class=\"calibre30\">e</sup> ): 10–15 mg/kg/dose given every 8 hours</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">10 days of metronidazole, followed by 7 days of paromomycin</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"4\">\n<p class=\"legenda\">EML: Model List of Essential Medicines; EMLc: Model List of Essential Medicines for children; IV: intravenous.</p>\n<p class=\"legenda\">Note. All dosages are for normal renal and hepatic function.</p>\n<p class=\"legenda\">The EML and EMLc currently does not have specific recommendations for antibiotic treatment of pyogenic or amoebic liver abscess; therefore the options presented in the table are extrapolated from the recommended treatment for complicated intra-abdominal infections.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> The use of fluoroquinolones (such as ciprofloxacin) can be associated with important side-effects including: (i) mental health disturbances such as disorientation, agitation; nervousness, memory impairment and delirium; (ii) serious blood sugar disturbances such as hypoglycaemic coma; (iii) increased risk of tendinitis and tendon rupture; (iv) worsening symptoms in those with myasthenia gravis; and (v) potential irreversible neuropathy (serious nerve damage).</p>\n<p class=\"legenda\"><sup class=\"calibre30\">b</sup> Oral liquid formulations must be refrigerated after reconstitution as clavulanic acid is rapidly metabolized in high ambient temperatures.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">c</sup> Of note, piperacillin+tazobactam offers anti-<em class=\"calibre10\">Enterococcus</em> coverage, which the other options listed for adults do not. Ampicillin would be another appropriate option, but it was not listed in this table as it is not currently in the EML for this indication, while it is listed for children.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">d</sup> Meropenem should not be considered for routine use in all severe cases but only in complicated cases in settings with a high prevalence of extended-spectrum beta-lactamase-producing Enterobacterales or in patients with known prior colonization, treated with multiple antibiotic courses or at risk of infections with pathogens resistant to the first choice option. Empiric use of a Reserve antibiotic could be considered exceptionally in very select cases of seriously ill patients failing to respond to carbapenems or who have previously been treated for infections caused by carbapenem-resistant pathogens or who are known to be colonized with multidrug-resistant Gram-negative bacteria known to be susceptible to the selected Reserve antibiotic. Please refer to the chapter on Reserve antibiotics for the definition and list of Reserve antibiotics included in the EML and EMLc. When <em class=\"calibre10\">Burkholderia pseudomallei</em> is suspected, empiric use of meropenem or imipenem could be considered, although the preferred option is ceftazidime.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">e</sup> If the patient is unable to tolerate oral treatment or in severe infections, IV metronidazole should be given: dose in adults: 500 mg every 8 hours.</p>\n<p class=\"legenda\">Legend: ACCESS antibiotics are indicated in green, WATCH antibiotics in orange and RESERVE antibiotics in red.</p>\n</td>\n</tr>\n</tfoot>\n</table>"
        ]
    },
    {
        "name": "Intra-abdominal infections – acute appendicitis",
        "tables": [
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-498\" role=\"doc-pagebreak\" title=\"441\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-890\"></a>Table 31.1 – Pathogens most frequently associated with complicated acute appendicitis (in descending order of frequency)</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Bacteria</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Fungi</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Parasites</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Enterobacterales (mostly <em class=\"calibre10\">Escherichia coli</em>) and other Gram-negative bacteria such as <em class=\"calibre10\">Pseudomonas aeruginosa</em> and <em class=\"calibre10\">Acinetobacter baumannii</em>, including multidrug-resistant strains such as those producing ESBL and carbapenemases</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Streptococcus</em> spp. (e.g. of the <em class=\"calibre10\">Streptococcus anginosus</em> group – old name: <em class=\"calibre10\">Streptococcus milleri</em>)</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Enterococcus</em> spp.</p>\n<p class=\"box_p1\">Anaerobes (mostly <em class=\"calibre10\">Bacteroides</em> spp.)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Mostly <em class=\"calibre10\">Candida albicans</em></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Mostly <em class=\"calibre10\">Enterobius vermicularis</em> (pinworm) – can contribute by causing obstruction of the appendix</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">ESBL: extended spectrum beta-lactamases.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-891\"></a>Table 31.2 – Microbiology tests to consider in severe cases of appendicitis as indicated in the WHO EDL <em class=\"calibre10\">(6)</em></strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Diagnostic test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Purpose of the test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Settings where the test should be available</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Blood cultures and antimicrobial susceptibility testing</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To detect bacterial bloodstream infections</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Microscopy, culture and antimicrobial susceptibility testing of abscess fluid material when this can be drained</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Not routinely recommended, but may be used in specific cases to identify bacterial and fungal species for selection of appropriate antimicrobial regimens</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">EDL: Model List of Essential In Vitro Diagnostics.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-892\"></a>Table 31.3 – Laboratory tests (other than microbiology) that may help identify an alternative cause of abdominal pain that could mimic appendicitis as indicated in the WHO EDL <em class=\"calibre10\">(6)</em></strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Diagnostic test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Purpose of the test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Settings where the test should be available</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Pregnancy test</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">In the context of suspected appendicitis the purpose of the test is to exclude an ectopic pregnancy</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Community settings and health facilities without laboratories<sup class=\"calibre30\">a</sup></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Urinalysis test (dipstick)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To exclude a urinary tract infection</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Community settings and health facilities without laboratories<sup class=\"calibre30\">a</sup></p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">EDL: Model List of Essential In Vitro Diagnostics.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> Community and health settings without laboratories are settings such as health posts and centres, doctors’ offices, outreach clinics and ambulatory care. These tests are also assumed to be available at health care facilities with laboratories.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-500\" role=\"doc-pagebreak\" title=\"443\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-893\"></a>Table 31.4 – Laboratory tests (other than microbiology) that may help assess the severity of disease and identify a bacterial infection as indicated in the WHO EDL <em class=\"calibre10\">(6)</em></strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Diagnostic test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Purpose of the test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Settings where the test should be available</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">White blood cell count</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To help in the diagnosis of infections</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">C-reactive protein</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To detect inflammation as an indicator of various conditions (e.g. sepsis)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Procalcitonin</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To guide antibiotic therapy or discontinuation in sepsis</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Only in tertiary care facilities</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">EDL: Model List of Essential In Vitro Diagnostics.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-502\" role=\"doc-pagebreak\" title=\"445\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-894\"></a>Table 31.5 – Empiric antibiotic treatment for acute appendicitis</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color2\" colspan=\"4\">\n<p class=\"box_tit1\"><img alt=\"Imagem\" class=\"calibre26\" src=\"images/000166.jpg\"/> <strong class=\"calibre5\">Note</strong></p>\n<p class=\"box_p1\">Mild cases are defined as patients who are not critically ill with no signs of sepsis or septic shock.</p>\n<p class=\"box_p1\">Severe cases are defined as patients who are critically ill with signs of sepsis or septic shock.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\" colspan=\"4\">\n<p class=\"box_tit1\"><img alt=\"Imagem\" class=\"calibre26\" src=\"images/000133.jpg\"/> <strong class=\"calibre5\">Important</strong></p>\n<p class=\"box_p1\">Where more than one antibiotic is recommended for an infection, they are listed in alphabetical order and they should be considered equal treatment options, unless otherwise indicated.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Severity</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Adults</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Children</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Total treatment duration</strong></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Mild cases</strong></p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\"><strong class=\"calibre5\">First choice</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Amoxicillin+clavulanic acid</span><sup class=\"calibre30\">a</sup></p>\n<p class=\"box_p1\">IV: 1 g + 200 mg given every 8 hours</p>\n<p class=\"box_p1\">Oral: 875 + 125 mg given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Cefotaxime</span> (IV): 2 g given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">AND</strong> <span class=\"back_verde\">Metronidazole</span> (IV/oral): 500 mg given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Ceftriaxone</span> (IV): 2 g given once a day</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">AND</strong> <span class=\"back_verde\">Metronidazole</span> (IV/oral): 500 mg given every 8 hours</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\"><strong class=\"calibre5\">First choice</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Amoxicillin+clavulanic acid</span><sup class=\"calibre30\">a,c</sup></p>\n<p class=\"box_p1\">IV:</p>\n<p class=\"box_p1\">First week of life: 50 mg/kg of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p1\">Beyond first week of life: 50 mg/kg of amoxicillin/dose given every 8 hours</p>\n<p class=\"box_p1\">Oral: 80–90 mg/kg/day of amoxicillin component</p>\n<p class=\"box_p1\">Oral weight bands:</p>\n<p class=\"box_p1\">3–&lt; 6 kg: 250 mg of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p1\">6–&lt; 10 kg: 375 mg of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 500 mg of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 750 mg of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p1\">≥ 20 kg: 500 mg of amoxicillin/dose given every 8 hours or 1 g of amoxicillin/dose given every 12 hours</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Uncomplicated cases treated with appendectomy</strong>: stop antibiotics after surgery if adequate control of the source of infection has been achieved and symptoms have resolved.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\"><span class=\"calibre6\" id=\"calibre_link-503\" role=\"doc-pagebreak\" title=\"446\" type=\"pagebreak\"></span><strong class=\"calibre5\">Mild cases</strong></p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Second choice</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Ciprofloxacin</span><sup class=\"calibre30\">b</sup> (oral): 500 mg given</p>\n<p class=\"box_p1\">every 12 hours <strong class=\"calibre5\">AND</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Metronidazole</span> (IV/oral): 500 mg given every 8 hours</p>\n<p class=\"box_p1\">(Ciprofloxacin and metronidazole have excellent oral bioavailability and the IV route should be reserved for patients with impaired gastrointestinal function.)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Ampicillin</span> (IV):</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">First week of life: 50 mg/kg/dose given every 12 hours</li>\n<li class=\"box_li1\">Beyond first week of life: 50 mg/kg/dose given every 8 hours</li>\n</ul>\n<p class=\"box_p3\"><strong class=\"calibre5\">AND</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Gentamicin</span> (IV):</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">Neonates: 5 mg/kg given once daily</li>\n<li class=\"box_li1\">Children: 7.5 mg/kg given once daily</li>\n</ul>\n<p class=\"box_p3\"><strong class=\"calibre5\">AND</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Metronidazole</span> (IV/oral):</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">Neonates: 7.5 mg/kg/dose given every 12 hours (for IV starting with a loading dose of 15 mg/kg)</li>\n<li class=\"box_li1\">Children: 7.5 mg/kg/dose given every 8 hours</li>\n</ul>\n<p class=\"box_p1\">Oral weight bands:</p>\n<p class=\"box_p1\">3–&lt; 6 kg: 30 mg given every 8 hours</p>\n<p class=\"box_p1\">6–&lt; 10 kg: 50 mg given every 8 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 100 mg given every 8 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 150 mg given every 8 hours</p>\n<p class=\"box_p1\">20–&lt; 30 kg: 200 mg given every 8 hours</p>\n<p class=\"box_p1\">≥ 30 kg: use adult dose</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Complicated cases treated with appendectomy</strong>: 5 days if adequate control of the source of infection has been achieved and symptoms have resolved.</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Uncomplicated cases treated with antibiotics alone</strong>: 7 days with close clinical monitoring and re-evaluation for surgery if symptoms do not resolve.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\"><span class=\"calibre6\" id=\"calibre_link-504\" role=\"doc-pagebreak\" title=\"447\" type=\"pagebreak\"></span><strong class=\"calibre5\">Mild cases</strong></p>\n</td>\n<td class=\"color\"></td>\n<td class=\"color\">\n<p class=\"box_p1\"><span class=\"back_amarelo\">Cefotaxime</span> (IV): 50 mg/kg/dose given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">AND</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Metronidazole</span> (IV/oral):</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">Neonates: 7.5 mg/kg/dose given every 12 hours (for IV starting with a loading dose of 15 mg/kg)</li>\n<li class=\"box_li1\">Children: 7.5 mg/kg/dose given every 8 hours</li>\n</ul>\n<p class=\"box_p1\">Oral weight bands</p>\n<p class=\"box_p1\">3–&lt; 6 kg: 30 mg given every 8 hours</p>\n<p class=\"box_p1\">6–&lt; 10 kg: 50 mg given every 8 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 100 mg given every 8 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 150 mg given every 8 hours</p>\n<p class=\"box_p1\">20–&lt; 30 kg: 200 mg given every 8 hours</p>\n<p class=\"box_p1\">≥ 30 kg: use adult dose</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n</td>\n<td class=\"color\"></td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\"><span class=\"calibre6\" id=\"calibre_link-505\" role=\"doc-pagebreak\" title=\"448\" type=\"pagebreak\"></span><strong class=\"calibre5\">Mild cases</strong></p>\n</td>\n<td class=\"color\"></td>\n<td class=\"color\">\n<p class=\"box_p1\"><span class=\"back_amarelo\">Ceftriaxone</span> (IV): 80 mg/kg/dose given once a day</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">AND</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Metronidazole</span> (IV/oral):</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">Neonates: 7.5 mg/kg/dose given every 12 hours (for IV starting with a loading dose of 15 mg/kg)</li>\n<li class=\"box_li1\">Children: 7.5 mg/kg/dose given every 8 hours</li>\n</ul>\n<p class=\"box_p1\">Oral weight bands</p>\n<p class=\"box_p1\">3–&lt; 6 kg: 30 mg given every 8 hours</p>\n<p class=\"box_p1\">6–&lt; 10 kg: 50 mg given every 8 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 100 mg given every 8 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 150 mg given every 8 hours</p>\n<p class=\"box_p1\">20–&lt; 30 kg: 200 mg given every 8 hours</p>\n<p class=\"box_p1\">≥ 30 kg: use adult dose</p>\n</td>\n<td class=\"color\"></td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\"><span class=\"calibre6\" id=\"calibre_link-506\" role=\"doc-pagebreak\" title=\"449\" type=\"pagebreak\"></span><strong class=\"calibre5\">Mild cases</strong></p>\n</td>\n<td class=\"color\"></td>\n<td class=\"color\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Second choice</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Ciprofloxacin</span> (IV/oral): 15 mg/kg/dose, given every 12 hours</p>\n<p class=\"box_p1\">Oral weight bands</p>\n<p class=\"box_p1\">3–&lt; 6 kg: 50 mg given every 12 hours</p>\n<p class=\"box_p1\">6–&lt; 10 kg: 100 mg given every 12 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 150 mg given every 12 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 200 mg given every 12 hours</p>\n<p class=\"box_p1\">20–&lt; 30 kg: 300 mg given every 12 hours</p>\n<p class=\"box_p1\">≥ 30 kg: use adult dose</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">AND</strong></p>\n</td>\n<td class=\"color\"></td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\"><span class=\"calibre6\" id=\"calibre_link-507\" role=\"doc-pagebreak\" title=\"450\" type=\"pagebreak\"></span><strong class=\"calibre5\">Mild cases</strong></p>\n</td>\n<td class=\"color\"></td>\n<td class=\"color\">\n<p class=\"box_p1\"><span class=\"back_verde\">Metronidazole</span> (IV/oral):</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">Neonates: 7.5 mg/kg/dose given every 12 hours (for IV starting with a loading dose of 15 mg/kg)</li>\n<li class=\"box_li1\">Children: 7.5 mg/kg/dose given every 8 hours</li>\n</ul>\n<p class=\"box_p1\">Oral weight bands</p>\n<p class=\"box_p1\">3–&lt; 6 kg: 30 mg given every 8 hours</p>\n<p class=\"box_p1\">6–&lt; 10 kg: 50 mg given every 8 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 100 mg given every 8 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 150 mg given every 8 hours</p>\n<p class=\"box_p1\">20–&lt; 30 kg: 200 mg given every 8 hours</p>\n<p class=\"box_p1\">≥ 30 kg: use adult dose</p>\n<p class=\"box_p1\">(Ciprofloxacin and metronidazole have excellent oral bioavailability and the IV route should be reserved for patients with impaired gastrointestinal function)</p>\n</td>\n<td class=\"color\"></td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"calibre6\" id=\"calibre_link-508\" role=\"doc-pagebreak\" title=\"451\" type=\"pagebreak\"></span><strong class=\"calibre5\">Severe cases</strong></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">First choice</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Cefotaxime</span> (IV): 2 g given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">AND</strong> <span class=\"back_verde\">Metronidazole</span> (IV/oral): 500 mg given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Ceftriaxone</span> (IV): 2 g given once a day</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">AND</strong> <span class=\"back_verde\">Metronidazole</span> (IV/oral): 500 mg given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Piperacillin+tazobactam</span><sup class=\"calibre30\">d</sup> (IV): 4 g + 500 mg given every 6 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Second choice</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Meropenem</span><sup class=\"calibre30\">e</sup> (IV): 1 g given every 8 hours</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">First choice</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Ampicillin</span> (IV):</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">First week of life: 50 mg/kg/dose given every 12 hours</li>\n<li class=\"box_li1\">Beyond first week of life: 50 mg/kg/dose given every 8 hours</li>\n</ul>\n<p class=\"box_p3\"><strong class=\"calibre5\">AND</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Gentamicin</span> (IV):</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">Neonates: 5 mg/kg given once a day</li>\n<li class=\"box_li1\">Children: 7.5 mg/kg given once a day</li>\n</ul>\n<p class=\"box_p3\"><strong class=\"calibre5\">AND</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Metronidazole</span> (IV/oral)</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">Neonates: 7.5 mg/kg/dose given every 12 hours (for IV starting with a loading dose of 15 mg/kg)</li>\n<li class=\"box_li1\">Children: 7.5 mg/kg/dose given every 8 hours</li>\n</ul>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Piperacillin+tazobactam</span>(IV): 100 mg/kg/dose of piperacillin component given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Second choice</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Meropenem</span><sup class=\"calibre30\">d</sup> (IV): 20 mg/kg/dose given every 8 hours</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Uncomplicated cases treated with appendectomy</strong>: stop antibiotics after surgery if adequate control of the source of infection has been achieved and symptoms have resolved.</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Complicated cases treated with appendectomy</strong>: 5 days if adequate control of the source of infection has been achieved and symptoms have resolved.</p>\n<p class=\"box_p1\"><strong class=\"calibre5\">Uncomplicated cases treated with antibiotics alone</strong>: 7 days with close clinical monitoring and re-evaluation for surgery if symptoms do not resolve.</p>\n<span class=\"calibre6\" id=\"calibre_link-509\" role=\"doc-pagebreak\" title=\"452\" type=\"pagebreak\"></span> </td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"4\">\n<p class=\"legenda\">IV: intravenous.</p>\n<p class=\"legenda\">Note: All dosages are for normal renal and hepatic function.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> Prevalence of resistance to amoxicillin+clavulanic acid among <em class=\"calibre10\">Escherichia coli</em> isolates is high in some settings and this option should be considered taking local microbiology data into consideration where available.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">b</sup> The use of fluoroquinolones (such as ciprofloxacin) can be associated with important side–effects including: (i) mental health disturbances such as disorientation, agitation, nervousness, memory impairment and delirium; (ii) serious blood sugar disturbances such as hypoglycaemic coma; (iii) increased risk of tendinitis and tendon rupture; (iv) worsening symptoms in those with myasthenia gravis; and (v) potential irreversible neuropathy (serious nerve damage).</p>\n<p class=\"legenda\"><sup class=\"calibre30\">c</sup> Oral liquid formulations must be refrigerated after reconstitution as clavulanic acid is rapidly metabolized in high ambient temperatures.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">d</sup> Of note, piperacillin+tazobactam offers anti-<em class=\"calibre10\">Enterococcus</em> coverage, which the other options listed for adults do not. Ampicillin would be another appropriate option, but it was not listed in this table as it is not currently in the EML for this indication, while it is listed for children.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">e</sup> Meropenem should not be considered for routine use for all severe cases but only in complicated cases (i.e. abscess and/or peritonitis) in settings with a high prevalence of extended-spectrum beta-lactamase-producing Enterobacterales or in patients with known prior colonization, treated with multiple antibiotic courses or at risk of infections with pathogens resistant to the first-choice option. Empiric use of a Reserve antibiotic could be considered exceptionally in very select cases of seriously ill patients with peritonitis failing to respond to carbapenems or that have previously been treated for infections caused by carbapenem-resistant pathogens or that are known to be colonized with multidrug-resistant Gram-negative bacteria known to be susceptible to the selected Reserve antibiotic. Please refer to the chapter on Reserve antibiotics for the definition and list of Reserve antibiotics included in the EML and EMLc.</p>\n<p class=\"legenda\">Legend: ACCESS antibiotics are indicated in green, WATCH antibiotics in orange and RESERVE antibiotics in red.</p>\n</td>\n</tr>\n</tfoot>\n</table>"
        ]
    },
    {
        "name": "Intra-abdominal infections – acute diverticulitis",
        "tables": [
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-515\" role=\"doc-pagebreak\" title=\"458\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-895\"></a>Table 32.1 – Pathogens most frequently associated with acute diverticulitis (in descending order of frequency)</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Bacteria</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Fungi</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Parasites</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Enterobacterales (mostly <em class=\"calibre10\">Escherichia coli</em>) and other Gram-negative bacteria such as <em class=\"calibre10\">Pseudomonas aeruginosa</em> and <em class=\"calibre10\">Acinetobacter baumannii</em> (including multidrug-resistant strains such as those producing ESBL and carbapenemases)</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Streptococcus</em> spp. (e.g. of the <em class=\"calibre10\">Streptococcus anginosus</em> group – old name: <em class=\"calibre10\">Streptococcus milleri</em>)</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Enterococcus</em> spp.</p>\n<p class=\"box_p1\">Anaerobes (mostly <em class=\"calibre10\">Bacteroides</em> spp.)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Mostly <em class=\"calibre10\">Candida albicans</em></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><em class=\"calibre10\">Enterobius vermicularis</em> (pinworm)</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">ESBL: extended spectrum beta-lactamases.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-516\" role=\"doc-pagebreak\" title=\"459\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-896\"></a>Table 32.2 – Microbiology tests to consider in severe cases as indicated in the EDL <em class=\"calibre10\">(6)</em></strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Diagnostic test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Purpose of the test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Settings where the test should be available</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Blood cultures and antimicrobial susceptibility testing</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To detect bacterial bloodstream infections</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Microscopy, culture and antimicrobial susceptibility testing of abscess fluid material when this can be drained</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">First step to detect and identify bacterial and fungal species for selection of appropriate antimicrobial regimens</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">EDL: Model List of Essential In Vitro Diagnostics.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-897\"></a>Table 32.3 – Laboratory tests (other than microbiology) that may help assess the severity of disease and the identification of a bacterial infection as indicated in the WHO EDL <em class=\"calibre10\">(6)</em></strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Diagnostic test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Purpose of the test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Settings where the test should be available</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">White blood cell count</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To help in the diagnosis of infections</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">C-reactive protein</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To detect inflammation as an indicator of various conditions (e.g. sepsis)<sup class=\"calibre30\">a</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Procalcitonin</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To guide antibiotic therapy or discontinuation in sepsis</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Only in tertiary care facilities</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">EDL: Model List of Essential In Vitro Diagnostics.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> A cut-off value of 150–170 mg/L for C-reactive protein is sometimes used to discriminate between mild/uncomplicated cases and severe/complicated cases <em class=\"calibre10\">(327,328)</em>.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-519\" role=\"doc-pagebreak\" title=\"462\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-898\"></a>Table 32.4 – Empiric antibiotic treatment for acute diverticulitis</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color2\" colspan=\"3\">\n<p class=\"box_tit1\"><img alt=\"Imagem\" class=\"calibre26\" src=\"images/000166.jpg\"/> <strong class=\"calibre5\">Note</strong></p>\n<p class=\"box_p1\">Mild cases are defined as patients who are not critically ill with no signs of sepsis or septic shock.</p>\n<p class=\"box_p1\">Severe cases are defined as patients who are critically ill with signs of sepsis or septic shock.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color1\" colspan=\"3\">\n<p class=\"box_tit1\"><img alt=\"Imagem\" class=\"calibre26\" src=\"images/000133.jpg\"/> <strong class=\"calibre5\">Important</strong></p>\n<p class=\"box_p1\">Antibiotics are listed in alphabetical order but they should all be considered equal treatment options, unless otherwise indicated.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Severity</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Adults</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Total treatment duration</strong></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Mild cases</p>\n<p class=\"box_p1\">These can be uncomplicated cases that did not resolve spontaneously after 2–3 days without antibiotics or complicated cases with mild symptoms.</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">First choice</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Amoxicillin+clavulanic acid</span></p>\n<p class=\"box_p1\">IV: 1 g + 200 mg given every 8 hours</p>\n<p class=\"box_p1\">Oral: 875 + 125 mg given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Cefotaxime</span> (IV): 2 g given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">AND</strong> <span class=\"back_verde\">Metronidazole</span> (IV/oral): 500 mg given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Ceftriaxone</span> (IV): 2 g given once a day</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">AND</strong> <span class=\"back_verde\">Metronidazole</span> (IV/oral): 500 mg given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Second choice</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Ciprofloxacin</span><sup class=\"calibre30\">a</sup> (oral): 500 mg given every 12 hours <strong class=\"calibre5\">AND</strong> <span class=\"back_verde\">Metronidazole</span> (IV/oral): 500 mg given every 8 hours</p>\n<p class=\"box_p1\">(Ciprofloxacin and metronidazole have excellent oral bioavailability and the IV route should be reserved for patients with impaired gastrointestinal function.)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Continue for 4 days after control of the source of infection is achieved provided that there is good clinical recovery.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"calibre6\" id=\"calibre_link-520\" role=\"doc-pagebreak\" title=\"463\" type=\"pagebreak\"></span>Severe cases</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">First choice</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Cefotaxime</span> (IV): 2 g given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">AND</strong> <span class=\"back_verde\">Metronidazole</span> (IV/oral): 500 mg given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Ceftriaxone</span> (IV): 2 g given once a day</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">AND</strong> <span class=\"back_verde\">Metronidazole</span> (IV/oral): 500 mg given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Piperacillin+tazobactam</span><sup class=\"calibre30\">b</sup> (IV): 4 g + 500 mg given every 6 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Second choice</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Meropenem</span><sup class=\"calibre30\">c</sup> (IV): 1 g given every 8 hours</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Continue for 4 days after control of the source of infection is achieved provided that there is good clinical recovery.</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">EML: Model List of Essential Medicines; IV: intravenous.</p>\n<p class=\"legenda\">Note: All dosages are for normal renal and hepatic function.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> The use of fluoroquinolones (such as ciprofloxacin) can be associated with important side-effects including: (i) mental health disturbances such as disorientation, agitation, nervousness, memory impairment and delirium; (ii) serious blood sugar disturbances such as hypoglycaemic coma; (iii) increased risk of tendinitis and tendon rupture; (iv) worsening symptoms in those with myasthenia gravis; and (v) potential irreversible neuropathy (serious nerve damage).</p>\n<p class=\"legenda\"><sup class=\"calibre30\">b</sup> Of note, piperacillin+tazobactam offers anti-<em class=\"calibre10\">Enterococcus</em> coverage, which the other options listed for adults do not. Ampicillin would be another appropriate option, but it was not listed in this table as it is not currently in the EML for this indication, while it is listed for children.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">c</sup> Meropenem should not be considered for routine use for all severe cases but only in complicated cases (i.e. abscess and/or peritonitis) in settings with a high prevalence of extended-spectrum beta-lactamase-producing Enterobacterales or in patients with known prior colonization, treated with multiple antibiotic courses or at risk of infections with pathogens resistant to the first choice option. Empiric use of a Reserve antibiotic could be considered exceptionally in very select cases of seriously ill patients failing to respond to carbapenems or who have previously been treated for infections caused by carbapenem-resistant pathogens or who are known to be colonized with multidrug-resistant Gram-negative bacteria known to be susceptible to the selected Reserve antibiotic. Please refer to the chapter on Reserve antibiotics for the definition and list of Reserve antibiotics included in the WHO EML.</p>\n<p class=\"legenda\">Legend: ACCESS antibiotics are indicated in green, WATCH antibiotics in orange and RESERVE antibiotics in red.</p>\n</td>\n</tr>\n</tfoot>\n</table>"
        ]
    },
    {
        "name": "Intra-abdominal infections – Clostridioides difficile infection",
        "tables": [
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-899\"></a>Table 33.1 – Microbiology tests to consider if <em class=\"calibre10\">Clostridioides difficile</em> infection is suspected (no test for <em class=\"calibre10\">Clostridioides difficile</em> is listed in the third version of the EDL, 2021) <em class=\"calibre10\">(6)</em></strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Type of test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Purpose of the test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Comment</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color\">\n<ul class=\"tab\">\n<li class=\"box_li1\">Culture</li>\n<li class=\"box_li1\">NAAT</li>\n<li class=\"box_li1\">GDH antigen test</li>\n</ul>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To detect toxigenic <em class=\"calibre10\">Clostridioides difficile</em> strains</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Usually NAAT (culture would be the reference standard but it is complex to perform and has a long turnaround time). With NAAT<sup class=\"calibre30\">a</sup> , the main disadvantage is the high sensitivity of the test that could lead to over-diagnosis and overtreatment.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<ul class=\"tab\">\n<li class=\"box_li1\">GDH antigen test</li>\n</ul>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To detect <em class=\"calibre10\">Clostridioides difficile</em> toxigenic and non-toxigenic strains</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">The main disadvantage is that this test cannot predict the ability of the strain to produce toxins. However, a negative test will generally exclude <em class=\"calibre10\">Clostridioides difficile</em> infection.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<ul class=\"tab\">\n<li class=\"box_li1\"><span class=\"calibre6\" id=\"calibre_link-528\" role=\"doc-pagebreak\" title=\"471\" type=\"pagebreak\"></span>Cytotoxicity assay</li>\n<li class=\"box_li1\">Toxin A/B EIA</li>\n</ul>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To detect <em class=\"calibre10\">Clostridioides difficile</em> toxins</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Usually EIA (cytotoxicity assay would be the reference standard but it is hard to do and has a long turnaround time). With EIA, the main disadvantage is the low sensitivity (i.e. high risk of false negative results).</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">EDL: Model List of Essential In Vitro Diagnostics; EIA: enzyme immunoassay; GDH: glutamate dehydrogenase; NAAT: Nucleic acid amplification test.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> NAAT detect the presence of the gene for the toxin not its expression.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-900\"></a>Table 33.2 – Laboratory tests (other than microbiology) to consider if <em class=\"calibre10\">Clostridioides difficile</em> infection is suspected as indicated in the WHO EDL <em class=\"calibre10\">(6)</em></strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Diagnostic test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Purpose of the test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Settings where the test should be available</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">White blood cell count</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To help in the diagnosis of infections</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Creatinine</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To monitor kidney function for management of severe infections (i.e. sepsis) and adjustment of the antimicrobial regimen</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Electrolytes</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To monitor fluid, electrolytes and acid–base balance</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">EDL: Model List of Essential In Vitro Diagnostics.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-530\" role=\"doc-pagebreak\" title=\"473\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-901\"></a>Table 33.3 – Antibiotic treatment for a first episode of <em class=\"calibre10\">Clostridioides difficile</em>infection</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Adults</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Children</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Total treatment duration</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">First choice</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Metronidazole</span> (oral): 500 mg given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Second choice</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Vancomycin</span> (oral<sup class=\"calibre30\">a</sup> ): 125 mg given every 6 hours</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">First choice</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Metronidazole</span> (oral):</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">Neonates: 7.5 mg/kg/dose given every 12 hours</li>\n<li class=\"box_li1\">Children: 7.5 mg/kg/dose given every 8 hours</li>\n</ul>\n<p class=\"box_p1\">Oral weight bands:</p>\n<p class=\"box_p1\">3–&lt; 6 kg: 30 mg given every 8 hours</p>\n<p class=\"box_p1\">6–&lt; 10 kg: 50 mg given every 8 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 100 mg given every 8 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 150 mg given every 8 hours</p>\n<p class=\"box_p1\">20–&lt; 30 kg: 200 mg given every 8 hours</p>\n<p class=\"box_p1\">≥ 30 kg: use adult dose</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Second choice</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Vancomycin</span> (oral):</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">Neonates: 5–10 mg/kg/dose given every 6 hours</li>\n<li class=\"box_li1\">Children: 5–10 mg/kg/dose given every 6 hours</li>\n</ul>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">10 days</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">Note: All dosages are for normal renal and hepatic function.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> Oral vancomycin is preferable to metronidazole in severe cases. If needed, the dose could be increased to 500 mg given every 6 hours. In severe fulminant cases, intravenous metronidazole could be added to treatment with oral vancomycin.</p>\n<p class=\"legenda\">Legend: ACCESS antibiotics are indicated in green, WATCH antibiotics in orange and RESERVE antibiotics in red.</p>\n</td>\n</tr>\n</tfoot>\n</table>"
        ]
    },
    {
        "name": "Upper urinary tract infection",
        "tables": [
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-538\" role=\"doc-pagebreak\" title=\"481\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-903\"></a>Table 34.1 – Pathogens commonly causing upper urinary tract infections (in descending order of frequency)</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Most cases</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Enterobacterales (including multidrug-resistant strains such as those producing ESBL and carbapenemases)</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\"><em class=\"calibre10\">Escherichia coli</em> (&gt; 80% of cases)</li>\n<li class=\"box_li1\"><em class=\"calibre10\">Klebsiella pneumoniae</em></li>\n<li class=\"box_li1\"><em class=\"calibre10\">Proteus mirabilis</em></li>\n<li class=\"box_li1\">Other Enterobacterales</li>\n</ul>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">More rarely</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><em class=\"calibre10\">Enterococcus</em> spp.</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Streptococcus agalactiae</em> (group B <em class=\"calibre10\">Streptococcus</em>)</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Staphylococcus aureus</em> (rare in uncomplicated urinary tract infections, often in patients with urinary catheters; can be associated with bacteraemia)</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Additionally in patients with recent antibiotic exposure, hospitalization or instrumentation of the urinary tract (e.g. insertion of a catheter)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\"><em class=\"calibre10\">Pseudomonas aeruginosa</em></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Acinetobacter baumannii</em></p>\n<p class=\"box_p1\">(including multidrug-resistant strains)</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"2\">\n<p class=\"legenda\">ESBL: extended-spectrum beta-lactamases.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-540\" role=\"doc-pagebreak\" title=\"483\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-904\"></a>Table 34.2 – Microbiology tests for upper urinary tract infections as indicated in the WHO EDL <em class=\"calibre10\">(6)</em></strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Diagnostic test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Purpose of the test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Settings where the test should be available</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Urine culture and antimicrobial susceptibility testing</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Initial step to detect and identify bacterial and fungal species for selection of appropriate antimicrobial regimens</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Blood cultures and antimicrobial susceptibility testing</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To detect bacterial bloodstream infections</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">EDL: Model List of Essential In Vitro Diagnostics.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-905\"></a>Table 34.3 – Laboratory tests (other than microbiology) to consider for the diagnosis of upper urinary tract infections as indicated in the WHO EDL <em class=\"calibre10\">(6)</em></strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Diagnostic test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Purpose of the test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Settings where the test should be available</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Urinalysis test strips</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To detect urinary tract infections</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Community settings and health facilities without laboratories<sup class=\"calibre30\">a</sup></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Urine microscopy</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Presence or absence of: white blood cells, red blood cells; presence of casts and crystals in urine</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\"><span class=\"calibre6\" id=\"calibre_link-541\" role=\"doc-pagebreak\" title=\"484\" type=\"pagebreak\"></span>White blood cell count<sup class=\"calibre30\">b</sup></p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To aid in the diagnosis of infections</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">C-reactive protein<sup class=\"calibre30\">b</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To detect inflammation as an indicator of various conditions (e.g. sepsis)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Procalcitonin<sup class=\"calibre30\">b</sup></p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To guide antibiotic therapy or discontinuation in sepsis</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Only in tertiary care facilities</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">EDL: Model List of Essential In Vitro Diagnostics.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> Community and health settings without laboratories are settings such as health posts and centres, doctors’ offices, outreach clinics and ambulatory care. These tests are also assumed to be available at health care facilities with laboratories.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">b</sup> Only in severe cases when sepsis of urinary origin is suspected.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-542\" role=\"doc-pagebreak\" title=\"485\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-906\"></a>Table 34.4 – Medicines to consider for pain control of upper urinary tract infections</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color1\" colspan=\"3\">\n<p class=\"box_tit1\"><img alt=\"Imagem\" class=\"calibre26\" src=\"images/000133.jpg\"/> <strong class=\"calibre5\">Important</strong></p>\n<p class=\"box_p1\">Medicines are listed in alphabetical order but they should all be considered equal treatment options.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Medicine</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Formulation</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Dose and frequency</strong></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Ibuprofen<sup class=\"calibre30\">a</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Oral liquid: 200 mg/5 mL</p>\n<p class=\"box_p1\">Tablet: 200 mg; 400 mg; 600 mg</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Adults</strong>: 200–400 mg given every 6 to 8 hours (maximum dose of 2.4 g a day)</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Children</strong>: 5–10 mg/kg given every 6 to 8 hours (pain control/antipyretic treatment)</p>\n<p class=\"box_p1\">6–&lt; 10 kg: 50 mg given every 8 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 100 mg given every 8 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 150 mg given every 8 hours</p>\n<p class=\"box_p1\">20–&lt; 30 kg: 200 mg given every 8 hours</p>\n<p class=\"box_p1\">≥ 30 kg: use adult dose</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Paracetamol (acetaminophen)<sup class=\"calibre30\">b</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Oral liquid: 120 mg/5 mL; 125 mg/5 mL</p>\n<p class=\"box_p1\">Suppository: 100 mg</p>\n<p class=\"box_p1\">Tablet: 100 mg to 500 mg</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Adults</strong>: 500 mg–1 g given every 4 to 6 hours (maximum dose of 4 g a day)<sup class=\"calibre30\">c</sup></p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Children</strong>: 10–15 mg/kg given every 6 hours (pain control/antipyretic treatment)</p>\n<p class=\"box_p1\">3–&lt; 6 kg: 60 mg given every 6 hours</p>\n<p class=\"box_p1\">6 &lt;10 kg: 100 mg given every 6 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 150 mg given every 6 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 200 mg given every 6 hours</p>\n<p class=\"box_p1\">20–&lt; 30 kg: 300 mg given every 6 hours</p>\n<p class=\"box_p1\">≥ 30 kg: use adult dose</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> Not for children &lt; 3 months.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">b</sup> Not recommended for use as an anti-inflammatory as it has not be proven to have such an effect.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">c</sup> In patients with hepatic impairment or cirrhosis, maximum daily dose should be 2 g.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-907\"></a>Table 34.5 – Empiric antibiotic treatment for upper urinary tract infections</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color1\" colspan=\"4\">\n<p class=\"box_tit1\"><img alt=\"Imagem\" class=\"calibre26\" src=\"images/000133.jpg\"/> <strong class=\"calibre5\">Important</strong></p>\n<p class=\"box_p1\">Where more than one antibiotic is recommended for an infection, they are listed in alphabetical order and they should be considered equal treatment options, unless otherwise indicated.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Severity</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Adults</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Children</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Total treatment duration</strong></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Mild to moderate cases</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_amarelo\">Ciprofloxacin</span><sup class=\"calibre30\">a,b</sup> (oral): 500 mg given every 12 hours</p>\n<p class=\"box_p1\">(Ciprofloxacin has excellent oral bioavailability and the IV route should be reserved for patients with impaired gastrointestinal function.)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_amarelo\">Ciprofloxacin</span><sup class=\"calibre30\">a</sup> (IV/oral): 15 mg/kg/dose given every 12 hours</p>\n<p class=\"box_p1\">Oral weight bands:</p>\n<p class=\"box_p1\">3–&lt; 6 kg: 50 mg given every 12 hours</p>\n<p class=\"box_p1\">6–&lt; 10 kg: 100 mg given every 12 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 150 mg given every 12 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 200 mg given every 12 hours</p>\n<p class=\"box_p1\">20–&lt; 30 kg: 300 mg given every 12 hours</p>\n<p class=\"box_p1\">≥ 30 kg: use adult dose</p>\n<p class=\"box_p1\">(Ciprofloxacin has excellent oral bioavailability and the IV route should be reserved for patients with impaired gastrointestinal function.)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">7 days<sup class=\"calibre30\">c</sup></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"calibre6\" id=\"calibre_link-545\" role=\"doc-pagebreak\" title=\"488\" type=\"pagebreak\"></span>Severe cases</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_amarelo\">Cefotaxime</span><sup class=\"calibre30\">d</sup> (IV/IM): 1 g given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Ceftriaxone</span><sup class=\"calibre30\">d</sup> (IV/IM): 1 g given once a day</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">AND/OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Amikacin</span><sup class=\"calibre30\">e</sup> (IV): 15 mg/kg given once a day</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">AND/OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Gentamicin</span><sup class=\"calibre30\">e</sup> (IV): 5 mg/kg given once a day</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_amarelo\">Cefotaxime</span><sup class=\"calibre30\">d</sup> (IV/IM): 50mg/kg/dose given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Ceftriaxone</span><sup class=\"calibre30\">d</sup> (IV/IM): 80 mg/kg/dose given once a day</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">AND/OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Amikacin</span><sup class=\"calibre30\">e</sup> (IV): 15 mg/kg/dose given once a day</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">AND/OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Gentamicin</span><sup class=\"calibre30\">e</sup> (IV)</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">Neonates: 5 mg/kg/dose given once a day</li>\n<li class=\"box_li1\">Children: 7.5 mg/kg/dose given once a day</li>\n</ul>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">7 days</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"4\">\n<p class=\"legenda\">ESBL: extended-spectrum beta-lactamases; IM: intramuscular; IV: intravenous.</p>\n<p class=\"legenda\">Notes. All dosages are for normal renal and hepatic function.</p>\n<p class=\"legenda\"><em class=\"calibre10\">Escherichia coli</em> resistance rates to amoxicillin+clavulanic acid are lower than to amoxicillin alone. This combination still has activity against some ESBL-producing isolates and it can be considered an acceptable option, particularly in young children.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> Resistance to fluoroquinolones is increasing including in low-and middle-income countries and in children <em class=\"calibre10\">(343–345)</em>.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">b</sup> The use of fluoroquinolones (such as ciprofloxacin) can be associated with important side-effects including: (i) mental health disturbances such as disorientation, agitation, nervousness, memory impairment and delirium; (ii) serious blood sugar disturbances such as hypoglycaemic coma; (iii) increased risk of tendinitis and tendon rupture; (iv) worsening symptoms in those with myasthenia gravis; and (v) potential irreversible neuropathy (serious nerve damage).</p>\n<p class=\"legenda\"><sup class=\"calibre30\">c</sup> In men with upper urinary tract infections, prostatitis can also be present and longer treatment may therefore be warranted, but not universally as not each urinary tract infection episode in a male is associated with prostatitis.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">d</sup> Resistance to third-generation cephalosporins is increasing including in low- and middle-income countries and in children <em class=\"calibre10\">(343–345)</em>. In very sick patients, gentamicin (or amikacin) can be given in combination with ceftriaxone (or cefotaxime).</p>\n<p class=\"legenda\"><sup class=\"calibre30\">e</sup> Amikacin and gentamicin are still effective against isolates producing ESBL and are considered appropriate carbapenem-sparing options in settings where ESBL-producing isolates are very prevalent. Use of aminoglycosides can be associated with nephrotoxicity and/or ototoxicity, especially when used for more than 7 days.</p>\n<p class=\"legenda\">Legend: ACCESS antibiotics are indicated in green, WATCH antibiotics in orange and RESERVE antibiotics in red.</p>\n</td>\n</tr>\n</tfoot>\n</table>"
        ]
    },
    {
        "name": "Acute bacterial osteomyelitis",
        "tables": [
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-553\" role=\"doc-pagebreak\" title=\"496\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-908\"></a>Table 35.1 – Pathogens most frequently associated with acute osteomyelitis in children (in descending order of frequency)</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Pathogen</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Most common way of spreading</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Patients most at risk</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\"><em class=\"calibre10\">Staphylococcus aureus</em> (including MRSA)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Bloodborne or local spread</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Usually, no risk factors are identified but consider with penetrating injuries, recent surgical procedures or bite wounds</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><em class=\"calibre10\">Streptococcus</em> spp. (mostly <em class=\"calibre10\">Streptococcus pyogenes</em>, often called group A <em class=\"calibre10\">Streptococcus</em>, and less commonly <em class=\"calibre10\">Streptococcus pneumoniae</em>). <em class=\"calibre10\">Streptococcus agalactiae</em> (group B <em class=\"calibre10\">Streptococcus</em>) is a potential pathogen for neonates.</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Bloodborne</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Mostly no risk factor identified</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\"><em class=\"calibre10\">Kingella kingae</em> (a species of anaerobic Gram-negative bacilli)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Bloodborne</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Young children with generally mild disease</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><em class=\"calibre10\">Haemophilus influenzae</em> type b</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Bloodborne</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Young children not vaccinated against <em class=\"calibre10\">Haemophilus influenzae</em> type b</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Invasive non-typhoidal <em class=\"calibre10\">Salmonella</em></p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Bloodborne</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Children with sickle-cell disease</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Enterobacterales</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Bloodborne, local spread</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Neonates and immunocompromised children. Also consider in case of open fractures</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\"><em class=\"calibre10\">Acinetobacter baumannii</em></p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Bloodborne, local spread</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Consider in case of open fractures</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><em class=\"calibre10\">Pseudomonas aeruginosa</em></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Bloodborne or local spread</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Immunocompromised patients and immunocompetent children following wound puncture</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">MRSA: methicillin-resistant <em class=\"calibre10\">Staphylococcus aureus</em>.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-554\" role=\"doc-pagebreak\" title=\"497\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-909\"></a>Table 35.2 – Pathogens most frequently associated with acute osteomyelitis in adults (in descending order of frequency)</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Pathogen</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Most common way of spreading</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Patients most at risk</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\"><em class=\"calibre10\">Staphylococcus aureus</em> (including MRSA)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Bloodborne or local spread</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Usually, no risk factors are identified but consider with penetrating injuries, recent surgical procedures, bite wounds or injection drug use</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><em class=\"calibre10\">Staphylococcus</em> spp. other than <em class=\"calibre10\">Staphylococcus aureus</em></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Bloodborne or local spread</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Patients with recent prosthetic joint implants or arthroscopy or patients with bite wounds</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\"><em class=\"calibre10\">Streptococcus</em> spp.</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Bloodborne or local spread</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Splenic dysfunction</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\" colspan=\"3\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Less frequent pathogens (in alphabetical order)</strong></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\"><em class=\"calibre10\">Acinetobacter baumannii</em></p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Bloodborne, local spread</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Consider in case of open fractures</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Anaerobes</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Local spread</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Patients with bite wounds or recent abdominal surgery; diabetic foot infection</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\"><em class=\"calibre10\">Bartonella</em> spp.</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Bloodborne</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Patients with cat bite wounds</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><em class=\"calibre10\">Brucella</em> spp.</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Bloodborne</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Patients with occupational or domestic exposure to infected animals (e.g. farmers, sheep herders, veterinarians) or ingestion of contaminated food, mostly dairy products</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\"><span class=\"calibre6\" id=\"calibre_link-555\" role=\"doc-pagebreak\" title=\"498\" type=\"pagebreak\"></span><em class=\"calibre10\">Candida</em> spp.</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Bloodborne or local spread</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Immunocompromised patients, patients with invasive devices, patients who inject drugs (haematogenous spread) or patients with deep wounds (dissemination by local spread)</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><em class=\"calibre10\">Cryptococcus</em> spp.</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Bloodborne</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Immunocompromised patients</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Enterobacterales</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Bloodborne or local spread</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Patients with decubitus (pressure) ulcers, diabetic foot infections and burn wounds, especially if the wound is close to the perineum, and abdominal surgery</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><em class=\"calibre10\">Histoplasma</em> spp.</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Bloodborne</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Immunocompromised patients</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\"><em class=\"calibre10\">Mycobacterium tuberculosis</em></p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Bloodborne or local spread (e.g. from adjacent paravertebral lymph nodes)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Immunocompromised patients because of the risk of reactivation of tuberculosis. Often a cause of chronic rather than acute infection.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><em class=\"calibre10\">Pseudomonas aeruginosa</em></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Bloodborne or local spread</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Immunocompromised patients and following wound puncture, including injection drug use</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Invasive non-typhoidal <em class=\"calibre10\">Salmonella</em></p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Bloodborne</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Adults with sickle-cell disease</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">MRSA: methicillin-resistant <em class=\"calibre10\">Staphylococcus aureus</em>.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-557\" role=\"doc-pagebreak\" title=\"500\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-910\"></a>Table 35.3 – Microbiology tests to consider when osteomyelitis is suspected as indicated in the WHO EDL <em class=\"calibre10\">(6)</em></strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Diagnostic test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Purpose of the test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Settings where the test should be available</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Blood culture and antimicrobial susceptibility testing</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To detect bacterial bloodstream infections</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Bone biopsy for microscopy, culture<sup class=\"calibre30\">a</sup> and antimicrobial susceptibility testing</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Initial step in detection and identification of bacterial and fungal species for selection of appropriate antimicrobial regimens</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Microscopy, culture and antimicrobial susceptibility testing of deep samples of tissue and/or bone collected during debridement (i.e. when the surgeon removes as much of the diseased bone as possible)<sup class=\"calibre30\">a</sup></p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Initial step in detection and identification of bacterial and fungal species for selection of appropriate antimicrobial regimens</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">EDL: Model List of Essential In Vitro Diagnostics.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> Samples should be tested for special pathogens, such as mycobacteria, fungi and <em class=\"calibre10\">Brucella</em> spp., if compatible clinical/epidemiological features are evident.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-911\"></a>Table 35.4 – Laboratory tests (other than microbiology) to identify a bacterial infection, as indicated in the WHO EDL <em class=\"calibre10\">(6)</em></strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Diagnostic test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Purpose of the test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Settings where the test should be available</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">White blood count</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To help in the diagnosis of infections</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">C-reactive protein</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To detect inflammation as an indicator of various conditions</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\"><span class=\"calibre6\" id=\"calibre_link-558\" role=\"doc-pagebreak\" title=\"501\" type=\"pagebreak\"></span>Erythrocyte sedimentation rate</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Erythrocyte sedimentation rate could be used to complement C-reactive protein especially during follow-up when clinical improvements may be slower to detect than laboratory improvements</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Community settings and health facilities without laboratories<sup class=\"calibre30\">a</sup></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Procalcitonin</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To guide antibiotic therapy or discontinuation in sepsis</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Only in tertiary care facilities</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">EDL: Model List of Essential In Vitro Diagnostics.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> Community health settings without laboratories are settings such as health posts and centres, doctors’ offices, outreach clinics and ambulatory care. These tests are also assumed to be available at health care facilities with laboratories.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-561\" role=\"doc-pagebreak\" title=\"504\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-912\"></a>Table 35.5 – Empiric antibiotic treatment for osteomyelitis</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color1\" colspan=\"3\">\n<p class=\"box_tit1\"><img alt=\"Imagem\" class=\"calibre26\" src=\"images/000133.jpg\"/> <strong class=\"calibre5\">Important</strong></p>\n<p class=\"box_p1\">Where more than one antibiotic is recommended for an infection, they are listed in alphabetical order and they should be considered equal treatment options, unless otherwise indicated.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Adults</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Children</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Total treatment duration</strong></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">First choice</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Cloxacillin</span><sup class=\"calibre30\">a</sup> (IV): 2 g given every 6 hours</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">First choice</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Cloxacillin</span><sup class=\"calibre30\">a</sup></p>\n<p class=\"box_p1\">IV:</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">Neonates: 25–50 mg/kg/dose given every 12 hours</li>\n<li class=\"box_li1\">Children: 25 mg/kg/dose given every 6 hours</li>\n</ul>\n<p class=\"box_p1\">Oral: 15 mg/kg/dose given every 6 hours</p>\n<p class=\"box_p1\">Oral weight bands</p>\n<p class=\"box_p1\">3–&lt; 6 kg: 62.5 mg given every 6 hours</p>\n<p class=\"box_p1\">6–&lt; 10 kg: 125 mg given every 6 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 250 mg given every 6 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 375 mg given every 6 hours</p>\n<p class=\"box_p1\">≥ 20 kg: 500 mg given every 6 hours</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">3 weeks<sup class=\"calibre30\">b</sup> (in children with uncomplicated infections)</p>\n<p class=\"box_p1\"> </p>\n<p class=\"box_p1\">4–6 weeks<sup class=\"calibre30\">c</sup> (in adults)</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"calibre6\" id=\"calibre_link-562\" role=\"doc-pagebreak\" title=\"505\" type=\"pagebreak\"></span><strong class=\"calibre5\">Second choice</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Amoxicillin+clavulanic acid</span></p>\n<p class=\"box_p1\">(IV): 1g + 200 mg given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Cefazolin</span> (IV): 2 g given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Cefotaxime</span><sup class=\"calibre30\">d</sup> (IV) 2 g given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Ceftriaxone</span><sup class=\"calibre30\">d</sup> (IV): 2 g given once a day</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Clindamycin</span><sup class=\"calibre30\">e</sup> (IV/oral):600 mg given every 8 hours</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Second choice</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Amoxicillin+clavulanic acid</span><sup class=\"calibre30\">f</sup></p>\n<p class=\"box_p1\">IV:</p>\n<p class=\"box_p1\">First week of life: 50 mg/kg of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p1\">Beyond first week of life: 50 mg/kg of amoxicillin/dose given every 8 hours</p>\n<p class=\"box_p1\">Oral: 80–90 mg/kg/day of amoxicillin component</p>\n<p class=\"box_p1\">Oral weight bands</p>\n<p class=\"box_p1\">3–&lt; 6 kg: 250 mg of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p1\">6–&lt; 10 kg: 375 mg of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 500 mg of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 750 mg of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p1\">≥ 20kg: 500 mg of amoxicillin/dose given every 8 hours or 1 g of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Cefazolin</span> (IV): 25 mg/kg/dose given every 12 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Cefotaxime</span><sup class=\"calibre30\">d</sup> (IV): 50mg/kg/dose given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Ceftriaxone</span><sup class=\"calibre30\">d</sup> (IV): 80 mg/kg/dose given once a day</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Clindamycin</span><sup class=\"calibre30\">e</sup> (IV/oral):</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">Neonates: 5 mg/kg/dose given every 8 hours</li>\n<li class=\"box_li1\">Children: 10 mg/kg/dose given every 8 hours</li>\n</ul>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Same as above</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\"><span class=\"calibre6\" id=\"calibre_link-563\" role=\"doc-pagebreak\" title=\"506\" type=\"pagebreak\"></span>IV: intravenous; MRSA: methicillin-resistant <em class=\"calibre10\">Staphylococcus aureus</em>.</p>\n<p class=\"legenda\">Notes. All dosages are for normal renal and hepatic function.</p>\n<p class=\"legenda\">As mentioned in the text, empiric treatment should be avoided whenever possible in adults because there are many potential causative pathogens and high levels of resistance (e.g. MRSA) making it difficult to specify appropriate empiric treatment. In children, there is usually less variability in the most likely causative pathogens (in children the disease is mostly caused by spread of <em class=\"calibre10\">Staphylococcus</em> spp. and <em class=\"calibre10\">Streptococcus</em> spp. through the bloodstream) and therefore empiric treatment is common practice.</p>\n<p class=\"legenda\">In neonates, empirical antibiotic therapy should also cover Enterobacterales because infections caused by Gram-negative bacteria can occur in neonates, but <em class=\"calibre10\">Staphylococcus aureus</em> remains the most common pathogen. Therefore, in neonates, empiric use of cefotaxime (or ceftriaxone) is appropriate; ceftriaxone should be avoided in infants with hyperbilirubinaemia. In older children, bone infections caused by Enterobacterales are very rare.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> If cloxacillin is unavailable, any other IV antistaphylococcal penicillin could be used. For oral administration, dicloxacillin and flucloxacillin are preferred options within the class as they have better oral bioavailability. In adults, a higher dose (e.g. 12 g/day) could be considered given the concerns with bone penetration.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">b</sup> Three weeks of treatment (usually starting with 3–5 days IV treatment and then changing to oral treatment) are now commonly used in children with acute bloodborne osteomyelitis based on response to fever, ability to move the limb and reduction in levels of C-reactive protein (if available).</p>\n<p class=\"legenda\"><sup class=\"calibre30\">c</sup> Longer treatments may be required if implants or foreign material are present or in case of inadequate control at the source of infection; for example, where there is an abscess that has not been adequately drained.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">d</sup> Ceftriaxone or cefotaxime is preferred if invasive non-typhoidal <em class=\"calibre10\">Salmonella</em> or Enterobacterales infection are suspected. In neonates, cefotaxime is recommended in these cases.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">e</sup> Clindamycin is still an acceptable option when community-acquired MRSA is suspected or detected if antimicrobial susceptibility tests show that MRSA is sensitive to clindamycin or in settings where MRSA maintains high levels of susceptibility to clindamycin. Clindamycin can also be used when changing from the IV to the oral route, and in patients allergic to penicillin. In case of MRSA isolates resistant to clindamycin and in settings where the prevalence of community-acquired MRSA is high, the use of vancomycin could be considered when <em class=\"calibre10\">Staphylococcus aureus</em> is suspected. Oral options to consider to complete the course of treatment in case of MRSA or methicillin-susceptible <em class=\"calibre10\">Staphylococcus aureus</em> infections could be sulfamethoxazole+trimethoprim and doxycycline.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">f</sup> Oral liquid formulations must be refrigerated after reconstitution as clavulanic acid is rapidly metabolized in high ambient temperatures.</p>\n<p class=\"legenda\">Legend: ACCESS antibiotics are indicated in green, WATCH antibiotics in orange and RESERVE antibiotics in red.</p>\n</td>\n</tr>\n</tfoot>\n</table>"
        ]
    },
    {
        "name": "Septic arthritis",
        "tables": [
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-570\" role=\"doc-pagebreak\" title=\"513\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-913\"></a>Table 36.1 – Pathogens most frequently associated with acute septic arthritis in children (in descending order of frequency)</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Pathogen</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Most common mechanism of dissemination</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Patients most at risk</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\"><em class=\"calibre10\">Staphylococcus aureus</em> (including MRSA)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Bloodborne or by local spread</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Usually, no risk factors are identified but consider with penetrating injuries, recent surgical procedures or bite wounds</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><em class=\"calibre10\">Streptococcus pyogenes</em> (group A <em class=\"calibre10\">Streptococcus</em>) and less commonly <em class=\"calibre10\">Streptococcus pneumoniae Streptococcus agalactiae</em> (group B <em class=\"calibre10\">Streptococcus</em>) is a potential pathogen for neonates</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Bloodborne</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Usually, no risk factors are identified but consider with penetrating injuries or recent surgical procedures</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\"><em class=\"calibre10\">Kingella kingae</em> (a species of anaerobic Gram-negative bacilli)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Bloodborne</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Young children, usually with milder clinical disease</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><em class=\"calibre10\">Haemophilus influenzae</em> type b</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Bloodborne</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Young children not vaccinated against <em class=\"calibre10\">Haemophilus influenzae</em> type b</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Invasive non-typhoidal <em class=\"calibre10\">Salmonella</em></p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Bloodborne</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Children with sickle-cell disease</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Enterobacterales</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Bloodborne</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Neonates and immunocompromised children. Consider also in case of open skin wounds with exposed joint</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">MRSA: methicillin-resistant <em class=\"calibre10\">Staphylococcus aureus</em>.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-914\"></a>Table 36.2 – Pathogens most frequently associated with acute septic arthritis in adults</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Pathogen</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Main dissemination mechanism</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Patients most at risk</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\"><em class=\"calibre10\">Staphylococcus aureus</em> (including MRSA)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Bloodborne or by local spread</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Patients with penetrating injuries, recent surgical procedures, bite wounds or intravenous drug injection</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><em class=\"calibre10\">Staphylococcus</em> spp. other than <em class=\"calibre10\">Staphylococcus aureus</em></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Bloodborne or by local spread</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Patients who had implantation of prosthetic joint implants or arthroscopy, and patients with bite wounds</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\"><em class=\"calibre10\">Streptococcus</em> spp.</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Bloodborne or by local spread</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Splenic dysfunction (<em class=\"calibre10\">S. pneumoniae</em>)</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\" colspan=\"3\">\n<p class=\"box_p1\"><span class=\"calibre6\" id=\"calibre_link-571\" role=\"doc-pagebreak\" title=\"514\" type=\"pagebreak\"></span><strong class=\"calibre5\">Less frequent (in alphabetical order)</strong></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\"><em class=\"calibre10\">Acinetobacter baumannii</em></p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Bloodborne or by local spread</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Consider in case of open skin wounds with exposed joint</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Anaerobes</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">By local spread</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Patients with penetrating injuries (e.g. bite wounds)</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\"><em class=\"calibre10\">Bartonella</em> spp.</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Bloodborne</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Patients with cat bite wounds</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><em class=\"calibre10\">Brucella</em> spp.</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Bloodborne</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Patients with occupational or domestic exposure to infected animals (e.g. farmers, shepherds, veterinarians) or who have ingested contaminated food, mostly dairy products. Endemic in the Middle East and Mediterranean regions</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\"><em class=\"calibre10\">Candida</em> spp.</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Bloodborne or by local spread</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Immunocompromised patients, patients with invasive devices, patients who inject drugs (haematogenous spread) or patients with deep wounds (dissemination by local spread)</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><em class=\"calibre10\">Cryptococcus</em> spp.</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Bloodborne</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Immunocompromised patients</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Enterobacterales</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Bloodborne or by local spread</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Patients with decubitus or pressure ulcers, diabetic foot infections, burn wounds (especially if the wound is close to the perineum) and those having undergone recent abdominal surgery. Consider also in case of open skin wounds with exposed joint.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><em class=\"calibre10\">Histoplasma</em> spp.</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Bloodborne</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Immunocompromised patients</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\"><em class=\"calibre10\">Neisseria gonorrhoeae</em></p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Bloodborne</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Mostly women with disseminated gonococcal infection</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><em class=\"calibre10\">Mycobacterium tuberculosis</em></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Bloodborne</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Immunocompromised patients because of the risk of reactivation of tuberculosis</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\"><em class=\"calibre10\">Pseudomonas aeruginosa</em></p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Bloodborne or by local spread</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Immunocompromised patients and people who inject drugs</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">MRSA: methicillin-resistant <em class=\"calibre10\">Staphylococcus aureus</em>.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-573\" role=\"doc-pagebreak\" title=\"516\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-915\"></a>Table 36.3 – Microbiology tests to consider when septic arthritis is suspected, as indicated in the WHO EDL <em class=\"calibre10\">(6)</em></strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Diagnostic test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Purpose of the test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Settings where the test should be available</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Synovial fluid for microscopy, culture<sup class=\"calibre30\">a</sup> and antimicrobial susceptibility testing</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Initial step to detect and identify bacterial and fungal species for selection of appropriate antimicrobial regimens</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Blood cultures and antimicrobial susceptibility testing</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To detect bacterial bloodstream infections</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Microscopy, culture and antimicrobial susceptibility testing of deep samples collected at debridement in case of prosthetic joint implant</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Initial step to detect and identify bacterial and fungal species for selection of appropriate antimicrobial regimens</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Nucleic acid amplification test of urogenital specimens and urine for <em class=\"calibre10\">Neisseria gonorrhoeae</em> infection<sup class=\"calibre30\">b</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To diagnose gonorrhoeal urogenital disease and extragenital infection</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Synovial fluid for <em class=\"calibre10\">Mycobacterium tuberculosis</em> DNA</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To diagnose active tuberculosis and detect rifampicin resistance</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">EDL: Model List of Essential In Vitro Diagnostics.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> Examination for particular pathogens (e.g. mycobacteria, fungi, <em class=\"calibre10\">Brucella</em> spp.) should be done if clinical/epidemiological features are compatible. In cases of gonococcal arthritis, the culture of the synovial fluid is usually negative.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">b</sup> This test is not validated on the synovial fluid but is used in some settings.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-574\" role=\"doc-pagebreak\" title=\"517\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-916\"></a>Table 36.4 – Laboratory tests (other than microbiology) to consider to identify a bacterial joint infection, as indicated in the WHO EDL <em class=\"calibre10\">(6)</em></strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Diagnostic test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Purpose of the test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Settings where the test should be available</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">White blood count</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To help in the diagnosis of infections</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories but also in primary care settings</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">C-reactive protein</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To detect inflammation as an indicator of various conditions</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Procalcitonin</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To guide antibiotic therapy or discontinuation in sepsis</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Only in tertiary care facilities</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Erythrocyte sedimentation rate</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To detect inflammation as an indicator of various conditions when C-reactive protein is not available</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Community settings and health facilities without laboratories<sup class=\"calibre30\">a</sup></p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">EDL: Model List of Essential In Vitro Diagnostics.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> Community and health settings without laboratories are settings such as health posts and centres, doctors’ offices, outreach clinics and ambulatory care. These tests are also assumed to be available at health care facilities with laboratories.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-917\"></a>Table 36.5 – Synovial fluid examination</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Diagnostic test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Purpose of the test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Settings where the test should be available</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Synovial fluid: white cell count and crystals<sup class=\"calibre30\">a</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To detect the presence or absence of white blood cells and crystals</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> With septic arthritis, it is helpful to know the number of white blood cells in the synovial fluid and microscopy should also be done to investigate alternative diagnoses such as gout or chondrocalcinosis. Compared to non-infectious arthritis, acute bacterial infections are characterized by a much higher white cell count in the synovial fluid, usually &gt; 20 000 cells/μL (20 × 10<sup class=\"calibre30\">9</sup> cells/L) with &gt; 90% being neutrophils.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-577\" role=\"doc-pagebreak\" title=\"520\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-918\"></a>Table 36.6 – Empiric antibiotic treatment for septic arthritis</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color1\" colspan=\"3\">\n<p class=\"box_tit1\"><img alt=\"Imagem\" class=\"calibre26\" src=\"images/000133.jpg\"/> <strong class=\"calibre5\">Important</strong></p>\n<p class=\"box_p1\">Where more than one antibiotic is recommended for an infection, they are listed in alphabetical order and they should be considered equal treatment options, unless otherwise indicated.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Adults</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Children</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Total treatment duration</strong></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">First choice</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Cloxacillin</span><sup class=\"calibre30\">a</sup> (IV): 2 g given every 6 hours</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">First choice</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Cloxacillin</span><sup class=\"calibre30\">a</sup></p>\n<p class=\"box_p1\">IV:</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">Neonates: 25–50 mg/kg/dose given every 12 hours</li>\n<li class=\"box_li1\">Children: 25 mg/kg/dose given every 6 hours</li>\n</ul>\n<p class=\"box_p1\">Oral: 15 mg/kg/dose given every 6 hours</p>\n<p class=\"box_p1\">Oral weight bands</p>\n<p class=\"box_p1\">3–&lt; 6 kg: 62.5 mg given every 6 hours</p>\n<p class=\"box_p1\">6–&lt; 10 kg: 125 mg given every 6 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 250 mg given every 6 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 375 mg given every 6 hours</p>\n<p class=\"box_p1\">≥ 20 kg: 500 mg given every 6 hours</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Children: 3 weeks</p>\n<p class=\"box_p1\">Adults: 4–6 weeks<sup class=\"calibre30\">b</sup></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"calibre6\" id=\"calibre_link-578\" role=\"doc-pagebreak\" title=\"521\" type=\"pagebreak\"></span><strong class=\"calibre5\">Second choice</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Amoxicillin+clavulanic acid</span></p>\n<p class=\"box_p1\">(IV): 1g + 200 mg given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Cefazolin</span> (IV): 2 g given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Cefotaxime</span><sup class=\"calibre30\">c</sup> (IV) 2 g given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Ceftriaxone</span><sup class=\"calibre30\">c</sup> (IV): 2 g given once a day</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Clindamycin</span><sup class=\"calibre30\">d</sup> (IV/oral):600 mg given every 8 hours</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Second choice</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Amoxicillin+clavulanic acid</span><sup class=\"calibre30\">e</sup></p>\n<p class=\"box_p1\">IV:</p>\n<p class=\"box_p1\">First week of life: 50 mg/kg of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p1\">Beyond first week of life: 50 mg/kg of amoxicillin/dose given every 8 hours</p>\n<p class=\"box_p1\">Oral: 80–90 mg/kg/day of amoxicillin component</p>\n<p class=\"box_p1\">Oral weight bands</p>\n<p class=\"box_p1\">3–&lt; 6 kg: 250 mg of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p1\">6–&lt; 10 kg: 375 mg of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 500 mg of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 750 mg of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p1\">≥ 20kg: 500 mg of amoxicillin/dose given every 8 hours or 1 g of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Cefazolin</span> (IV): 25 mg/kg/dose given every 12 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Cefotaxime</span><sup class=\"calibre30\">c</sup> (IV): 50mg/kg/dose given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Ceftriaxone</span><sup class=\"calibre30\">c</sup> (IV): 80 mg/kg/dose given once a day</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Clindamycin</span><sup class=\"calibre30\">d</sup> (IV/oral):</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">Neonates: 5 mg/kg/dose given every 8 hours</li>\n<li class=\"box_li1\">Children: 10 mg/kg/dose given every 8 hours</li>\n</ul>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Children: 3 weeks</p>\n<p class=\"box_p1\"> </p>\n<p class=\"box_p1\">Adults: 4–6 weeks<sup class=\"calibre30\">b</sup></p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\"><span class=\"calibre6\" id=\"calibre_link-579\" role=\"doc-pagebreak\" title=\"522\" type=\"pagebreak\"></span>IV: intravenous; MRSA: methicillin-resistant <em class=\"calibre10\">Staphylococcus aureus</em>.</p>\n<p class=\"legenda\">Notes. All dosages are for normal renal and hepatic function.</p>\n<p class=\"legenda\">As mentioned in the text, targeted treatment is preferable whenever possible in adults because of the large number of potential causative pathogens, while in children empiric treatment is often given.</p>\n<p class=\"legenda\">In neonates, empirical antibiotic therapy should also cover Enterobacterales because infections caused by Gram-negative bacteria can occur, but <em class=\"calibre10\">Staphylococcus aureus</em> remains the most common pathogen. Therefore, in neonates, empiric use of cefotaxime (or ceftriaxone) is appropriate; ceftriaxone should be avoided in infants with hyperbilirubinaemia. In older children, joint infections caused by Enterobacterales are very rare.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> If cloxacillin is unavailable, any other IV antistaphylococcal penicillin could be used. For oral administration, dicloxacillin and flucloxacillin are preferred options within the class as they have better oral bioavailability. In adults, a higher dose (e.g. 12 g/day) could be considered given the concerns with bone penetration.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">b</sup> Shorter duration (10–14 days) in cases of gonococcal arthritis.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">c</sup> Ceftriaxone or cefotaxime is preferred in cases of suspected invasive non-typhoidal <em class=\"calibre10\">Salmonella</em> infection or Enterobacterales infection or gonococcal arthritis. In neonates, cefotaxime is recommended in these cases.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">d</sup> Clindamycin is still an acceptable option when community-acquired MRSA is suspected if antimicrobial susceptibility tests show that MRSA is sensitive to clindamycin or in settings where MRSA maintains high levels of susceptibility to clindamycin; suspicion should be based on local prevalence of community-acquired MRSA. Clindamycin can also be used when changing from the IV to oral route, and in patients allergic to penicillin. For severe disease potentially caused by MRSA, vancomycin can be considered in settings with local high prevalence of community-acquired MRSA, even though this is not a recommendation included in the current EML and EMLc <em class=\"calibre10\">(8,9)</em>. In case of MRSA and based on susceptibility results, alternative oral options that could be considered to complete the course of treatment include sulfamethoxazole+trimethoprim and doxycycline.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">e</sup> Oral liquid formulations must be refrigerated after reconstitution as clavulanic acid is rapidly metabolized in high ambient temperatures.</p>\n<p class=\"legenda\">Legend: ACCESS antibiotics are indicated in green, WATCH antibiotics in orange and RESERVE antibiotics in red.</p>\n</td>\n</tr>\n</tfoot>\n</table>"
        ]
    },
    {
        "name": "Skin and soft tissue infections – necrotizing fasciitis",
        "tables": [
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-586\" role=\"doc-pagebreak\" title=\"529\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-919\"></a>Table 37.1 – Pathogens most frequently associated with necrotizing fasciitis (in descending order of frequency)</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Monomicrobial (single pathogen)/type 2</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Polymicrobial (multiple pathogens)/type 1</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Most cases</strong></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Streptococcus pyogenes</em> (group A <em class=\"calibre10\">Streptococcus</em>) <em class=\"calibre10\">Streptococcus agalactiae</em> (group B <em class=\"calibre10\">Streptococcus</em>)</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Streptococcus dysgalactiae</em> (mostly in elderly people and patients with chronic illness)</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Less frequently</strong></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Staphylococcus aureus</em> (including MRSA)</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Pathogens to consider in cases with specific environmental exposure</strong></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Aeromonas hydrophila</em> (exposure to fresh water)</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Vibrio vulnificus</em> (exposure to seawater)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Combination of anaerobes</strong></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Bacteroides</em> spp.</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Clostridium perfringens</em></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Peptostreptococcus</em> spp. or oral anaerobic organisms when the head and/or neck are affected</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">and</strong></p>\n<p class=\"box_p1\">Enterobacterales</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Pseudomonas</em> spp.</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Streptococcus</em> spp.</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Staphylococcus aureus</em> (including MRSA)</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"2\">\n<p class=\"legenda\">MRSA: methicillin-resistant <em class=\"calibre10\">Staphylococcus aureus</em>; MSSA: methicillin-susceptible <em class=\"calibre10\">Staphylococcus aureus</em>.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-920\"></a>Table 37.2 – Microbiology tests to consider in a patient with suspected necrotizing fasciitis as indicated in the WHO EDL <em class=\"calibre10\">(6)</em></strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Diagnostic test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Purpose of the test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Settings where the test should be available</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Blood cultures and antimicrobial susceptibility testing</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To detect bacterial and fungal bloodstream infections</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Microscopy, culture and antimicrobial susceptibility testing of deep samples of tissue collected at debridement<sup class=\"calibre30\">a</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Initial step in detection and identification of bacterial and fungal species for selection of appropriate antimicrobial regimens</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">EDL: Model List of Essential In Vitro Diagnostics.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> Intraoperative tissue samples should also be sent for histopathology examination.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-921\"></a>Table 37.3 – Laboratory tests (other than microbiology) to consider to identify a bacterial infection as indicated in the WHO EDL <em class=\"calibre10\">(6)</em></strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Diagnostic test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Purpose of the test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Settings where the test should be available</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">White blood count</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To help in the diagnosis of infections</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories but also in primary care settings</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">C-reactive protein</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To detect inflammation as an indicator of various conditions</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Procalcitonin</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To guide antibiotic therapy or discontinuation in sepsis</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Only in tertiary health care facilities</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">EDL: Model List of Essential In Vitro Diagnostics.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-922\"></a>Table 37.4 – Laboratory tests (other than microbiology) to consider in a patient with suspected necrotizing fasciitis as indicated in the WHO EDL <em class=\"calibre10\">(6)</em></strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Diagnostic test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Purpose of the test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Settings where the test should be available</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Complete blood count</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To detect a wide range of disorders, including infections</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Creatinine</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To monitor kidney function for management of severe infections (i.e. sepsis) and adjustment of the antimicrobial regimen</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Electrolytes</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To monitor fluid, electrolyte and acid–base balance</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Glucose</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To diagnose intermediate hyperglycaemia and hypoglycaemia</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Community settings and health facilities without laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\"><span class=\"calibre6\" id=\"calibre_link-589\" role=\"doc-pagebreak\" title=\"532\" type=\"pagebreak\"></span>Haemoglobin</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To diagnose and monitor anaemia</p>\n<p class=\"box_p1\">Clinical marker for certain severe infections</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Community settings and health facilities without laboratories</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">EDL: Model List of Essential In Vitro Diagnostics.</p>\n<p class=\"legenda\">Note. If sepsis is suspected, additional tests may be needed; please refer to the chapter on sepsis.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-923\"></a>Table 37.5 – Empiric antibiotic treatment for suspected or confirmed necrotizing fasciitis</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Adults</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Children</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Total treatment duration</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_amarelo\">Piperacillin+tazobactam</span> (IV): 4 g + 500 mg given every 6 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">AND</strong> <span class=\"back_verde\">Clindamycin</span><sup class=\"calibre30\">a</sup> (IV): 900 mg given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">ADD</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Vancomycin</span> (IV) if MRSA is suspected: 15–20 mg/kg given every 12 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong> (If <em class=\"calibre10\">Streptococcus pyogenes</em> necrotizing fasciitis is considered unlikely):</p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Ceftriaxone</span> (IV): 2 g given once a day</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">AND</strong> <span class=\"back_verde\">Metronidazole</span> (IV): 500 mg given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">ADD</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Vancomycin</span> (IV) if MRSA is suspected: 15–20 mg/kg given every 12 hours</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_amarelo\">Piperacillin+tazobactam</span> (IV): 100 mg/kg/dose of piperacillin component given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">AND</strong> <span class=\"back_verde\">Clindamycin</span><sup class=\"calibre30\">a</sup> (IV):</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">Neonates: 5 mg/kg/dose given every 8 hours</li>\n<li class=\"box_li1\">Children: 10 mg/kg/dose given every 8 hours</li>\n</ul>\n<p class=\"box_p3\"><strong class=\"calibre5\">ADD</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Vancomycin</span> (IV) if MRSA is suspected:</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">Neonates: 15 mg/kg/dose given every 12 hours</li>\n<li class=\"box_li1\">Children: 15 mg/kg/dose given every 8 hours</li>\n</ul>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong> (If <em class=\"calibre10\">Streptococcus pyogenes</em> necrotizing fasciitis is considered unlikely):</p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Ceftriaxone</span> (IV): 80 mg/kg given once a day</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">AND</strong> <span class=\"back_verde\">Metronidazole</span> (IV/oral):</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">Neonates: 7.5 mg/kg/dose given every 12 hours (for IV starting with a loading dose of 15 mg/kg)</li>\n<li class=\"box_li1\">Children: 7.5 mg/kg/dose given every 8 hours</li>\n</ul>\n<span class=\"calibre6\" id=\"calibre_link-591\" role=\"doc-pagebreak\" title=\"534\" type=\"pagebreak\"></span>\n<p class=\"box_p1\">Oral weight bands:</p>\n<p class=\"box_p1\">3–&lt; 6 kg: 30 mg given every 8 hours</p>\n<p class=\"box_p1\">6–&lt; 10 kg: 50 mg given every 8 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 100 mg given every 8 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 150 mg given every 8 hours</p>\n<p class=\"box_p1\">20-&lt;30 kg: 200 mg given every 8 hours</p>\n<p class=\"box_p1\">≥ 30 kg: use adult dose</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">ADD</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Vancomycin</span> (IV) if MRSA is suspected:</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">Neonates: 15 mg/kg/dose given every 12 hours</li>\n<li class=\"box_li1\">Children: 15 mg/kg/dose given every 8 hours</li>\n</ul>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">2–3 weeks<sup class=\"calibre30\">b</sup></p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">IV: intravenous, MRSA: methicillin-resistant <em class=\"calibre10\">Staphylococcus aureus</em>.</p>\n<p class=\"legenda\">Note: All dosages are for normal renal and hepatic function.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> Clindamycin has the ability to suppress the expression of virulence factors in <em class=\"calibre10\">Staphylococcus aureus</em> (i.e. it has an anti-toxin effect).</p>\n<p class=\"legenda\"><sup class=\"calibre30\">b</sup> Knowledge on the most appropriate duration of treatment is limited. Therefore, duration is often individualized based on clinical response, on the success of surgical source control and, if available, changes in laboratory markers of infection. Usually total treatment duration is about 2–3 weeks.</p>\n<p class=\"legenda\">Legend: ACCESS antibiotics are indicated in green, WATCH antibiotics in orange and RESERVE antibiotics in red.</p>\n</td>\n</tr>\n</tfoot>\n</table>"
        ]
    },
    {
        "name": "Skin and soft tissue infections – pyomyositis",
        "tables": [
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-597\" role=\"doc-pagebreak\" title=\"540\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-924\"></a>Table 38.1 – Pathogens most frequently associated with pyomyositis (in descending order of frequency)</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Most cases</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">More rarely</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><em class=\"calibre10\">Staphylococcus aureus</em> (including MRSA)<sup class=\"calibre30\">a</sup></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Streptococcus pyogenes</em> (group A <em class=\"calibre10\">Streptococcus</em>)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><em class=\"calibre10\">Escherichia coli</em> (mostly in patients with cancer)</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Mycobacterium tuberculosis</em> and certain non-tuberculous mycobacteria</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"2\">\n<p class=\"legenda\">MRSA: methicillin-resistant <em class=\"calibre10\">Staphylococcus aureus</em>.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> Some strains can produce the Panton–Valentine leukocidin, a toxin associated with a higher pathogenic potential (i.e. the risk of causing a more severe disease). The possibility of <em class=\"calibre10\">Staphylococcus aureus</em> positive for Panton–Valentine leucocidin should be considered especially in case of recurrent skin infections. In these cases, topical decolonization measures might be considered to prevent recurrence and transmission to others.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-925\"></a>Table 38.2 – Microbiology tests to consider in a patient with suspected pyomyositis as indicated in the WHO EDL <em class=\"calibre10\">(6)</em></strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Diagnostic test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Purpose of the test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Settings where the test should be available</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Blood cultures and antimicrobial susceptibility testing</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To detect bacterial and fungal bloodstream infections</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Microscopy, culture and antimicrobial susceptibility testing of deep samples collected at aspiration/drainage of abscess</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Initial step to detect and identify bacterial and fungal species for selection of appropriate antimicrobial regimens</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">EDL: Model List of Essential In Vitro Diagnostics.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-926\"></a>Table 38.3 – Laboratory tests (other than microbiology) to consider to identify a bacterial infection as indicated in the WHO EDL <em class=\"calibre10\">(6)</em></strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Diagnostic test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Purpose of the test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Settings where the test should be available</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">White blood count</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To aid in the diagnosis of infections</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories but also in primary care settings</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">C-reactive protein</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To detect inflammation as an indicator of various conditions (e.g. sepsis)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Procalcitonin</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To guide antibiotic therapy or discontinuation in sepsis</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Only in tertiary and higher health care facilities</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">EDL: Model List of Essential In Vitro Diagnostics.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-600\" role=\"doc-pagebreak\" title=\"543\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-927\"></a>Table 38.4 – Empiric antibiotic treatment for pyomyositis</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color1\" colspan=\"3\">\n<p class=\"box_tit1\"><img alt=\"Imagem\" class=\"calibre26\" src=\"images/000133.jpg\"/> <strong class=\"calibre5\">Important</strong></p>\n<p class=\"box_p1\">Where more than one antibiotic is recommended for an infection, they are listed in alphabetical order and they should be considered equal treatment options, unless otherwise indicated.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Adults</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Children</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Total treatment duration</strong></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_verde\">Amoxicillin+clavulanic acid</span></p>\n<p class=\"box_p1\">IV: 1 g + 200 mg given every 8 hours</p>\n<p class=\"box_p1\">Oral: 875 mg + 125 mg given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Cefalexin</span> (oral): 500 mg given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Cloxacillin</span><sup class=\"calibre30\">a</sup></p>\n<p class=\"box_p1\">IV: 2 g given every 6 hours</p>\n<p class=\"box_p1\">Oral: 500 mg given every 6 hours</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_verde\">Amoxicillin+clavulanic acid</span><sup class=\"calibre30\">b</sup></p>\n<p class=\"box_p1\">IV:</p>\n<p class=\"box_p1\">First week of life: 50 mg/kg of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p1\">Beyond first week of life: 50 mg/kg of amoxicillin/dose given every 8 hours</p>\n<p class=\"box_p1\">Oral: 80–90 mg/kg/day of amoxicillin component</p>\n<p class=\"box_p1\">Oral weight bands:</p>\n<p class=\"box_p1\">3–&lt; 6 kg: 250 mg of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p1\">6–&lt; 10 kg: 375 mg of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 500 mg of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 750 mg of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p1\">≥ 20 kg: 500 mg of amoxicillin/dose given every 8 hours or 1 g of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Cefalexin</span> (oral): 25 mg/kg/dose given every 12 hours</p>\n<p class=\"box_p1\">Oral weight bands:</p>\n<p class=\"box_p1\">3–&lt; 6 kg: 125 mg given every 12 hours</p>\n<p class=\"box_p1\">6–&lt; 10 kg: 250 mg given every 12 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 375 mg given every 12 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg 500 mg given every 12 hours</p>\n<p class=\"box_p1\">20-&lt;30 kg: 625 mg given every 12 hours</p>\n<p class=\"box_p1\">≥ 30 kg: use adult dose</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<span class=\"calibre6\" id=\"calibre_link-601\" role=\"doc-pagebreak\" title=\"544\" type=\"pagebreak\"></span>\n<p class=\"box_p1\"><span class=\"back_verde\">Cloxacillin</span><sup class=\"calibre30\">a</sup></p>\n<p class=\"box_p1\">IV:</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">Neonates: 25–50 mg/kg/dose given every 12 hours</li>\n<li class=\"box_li1\">Children: 25 mg/kg/dose given every 6 hours</li>\n</ul>\n<p class=\"box_p1\">Oral: 15 mg/kg/dose given every 6 hours</p>\n<p class=\"box_p1\">Oral weight bands:</p>\n<p class=\"box_p1\">3–&lt; 6 kg: 62.5 mg given every 6 hours</p>\n<p class=\"box_p1\">6–&lt; 10 kg: 125 mg given every 6 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 250 mg given every 6 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 375 mg given every 6 hours</p>\n<p class=\"box_p1\">≥ 20 kg: 500 mg given every 6 hours</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">2–3 weeks</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">EML: Model List of Essential Medicines; IV: intravenous.</p>\n<p class=\"legenda\">Notes: All dosages are for normal renal and hepatic function.</p>\n<p class=\"legenda\">The recommendations given in the table are not included in the WHO EML but were extrapolated from the EML recommendations for skin and soft tissue infections <em class=\"calibre10\">(8)</em>.</p>\n<p class=\"legenda\">Vancomycin is not listed as first choice because in most settings methicillin-resistant <em class=\"calibre10\">Staphylococcus aureus</em> is not a frequent cause of community-acquired infections.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> If cloxacillin is unavailable, any other IV antistaphylococcal penicillin could be used. For oral administration, dicloxacillin and flucloxacillin are preferred options within the class as they have better oral bioavailability.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">b</sup> Oral liquid formulations must be refrigerated after reconstitution as clavulanic acid is rapidly metabolized in high ambient temperatures.</p>\n<p class=\"legenda\">Legend: ACCESS antibiotics are indicated in green, WATCH antibiotics in orange and RESERVE antibiotics in red.</p>\n</td>\n</tr>\n</tfoot>\n</table>"
        ]
    },
    {
        "name": "Febrile neutropenia",
        "tables": [
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-928\"></a>Table 39.1 – Pathogens most frequently associated with febrile neutropenia (in descending order of frequency)</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Bacteria</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Viruses</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Parasites</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><em class=\"calibre10\">Staphylococcus epidermidis</em></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Staphylococcus aureus</em> (including MRSA)</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Streptococcus</em> spp.</p>\n<p class=\"box_p1\">Other Gram-positive bacteria (e.g. <em class=\"calibre10\">Enterococcus</em> spp. including VRE)</p>\n<p class=\"box_p1\">Enterobacterales (including multidrug-resistant strains such as those producing ESBL and carbapenemases)</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Pseudomonas aeruginosa</em></p>\n<p class=\"box_p1\">Anaerobes</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Cytomegalovirus</p>\n<p class=\"box_p1\">Human herpesvirus 6</p>\n<p class=\"box_p1\">(Consider viruses in high-risk patients mostly because of reactivation of latent infections)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><em class=\"calibre10\">Candida</em> spp.</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Aspergillus</em> spp. (in case of prolonged neutropenia)</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">ESBL: extended-spectrum beta-lactamases; MRSA: methicillin-resistant <em class=\"calibre10\">Staphylococcus aureus</em>; VRE: vancomycin-resistant Enterococci.</p>\n<p class=\"legenda\">Notes. The risk of multidrug-resistant pathogens should always be carefully considered in patients with neutropenia because often infections in these patients are health care-associated.</p>\n<p class=\"legenda\">Most data come from tertiary care centres in high-income settings.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-611\" role=\"doc-pagebreak\" title=\"554\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-929\"></a>Table 39.2 – Microbiology tests to consider when febrile neutropenia is suspected depending on the most likely source of infection as indicated in the WHO EDL <em class=\"calibre10\">(6)</em></strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Test priority</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Diagnostic test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Purpose of the test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Settings where the test should be available</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Routine</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Blood cultures and antimicrobial susceptibility testing</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To detect bacterial and fungal bloodstream infections</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Routine</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Urine culture and antimicrobial susceptibility testing</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Initial step to detect and identify bacterial and fungal species for selection of appropriate antimicrobial regimens</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Consider in certain cases</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Sputum microscopy (Gram stain)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To assess microbial morphology and adequacy of the specimen for culture by identifying white blood cells and squamous epithelial cells</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Consider in certain cases</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Sputum culture and antimicrobial susceptibility testing</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Initial step to detect and identify bacterial and fungal species for selection of appropriate antimicrobial regimens</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Consider in certain cases (including for infection control purposes)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Nasopharyngeal swab for NAAT for influenza<sup class=\"calibre30\">a</sup></p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To diagnose seasonal influenza infection</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories but also in primary care settings</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Consider in certain cases (including for infection control purposes)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Nasopharyngeal swab for NAAT or antigen test for SARS-CoV-2</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To diagnose COVID-19</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories (NAAT) and primary care settings (antigen test)</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Consider in certain cases</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\"><em class=\"calibre10\">Aspergillus</em> antigen test</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To diagnose invasive aspergillosis in Immunocompromised patients</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"calibre6\" id=\"calibre_link-612\" role=\"doc-pagebreak\" title=\"555\" type=\"pagebreak\"></span>Consider in certain cases</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Cerebrospinal fluid microscopy</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To assess microbial morphology, number of white blood cells and red blood cells</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Consider in certain cases</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Cerebrospinal fluid Gram stain, bacterial culture and antimicrobial susceptibility testing</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Initial step to detect and identify bacterial and fungal species for selection of appropriate antimicrobial regimens</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Consider in certain cases</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Stool culture and antimicrobial susceptibility testing</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Initial step to detect and identify bacterial species for selection of appropriate antibiotic regimens</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Consider in certain cases</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\"><em class=\"calibre10\">Clostridioides difficile</em> testing (usually NAAT)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To diagnose <em class=\"calibre10\">Clostridioides difficile</em> infection</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">–<sup class=\"calibre30\">b</sup></p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"4\">\n<p class=\"legenda\">COVID-19: coronavirus disease 2019; EDL: Model List of Essential In Vitro Diagnostics; NAAT: nucleic acid amplification test; SARS CoV-2: severe acute respiratory syndrome coronavirus 2.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> Testing for respiratory viruses other than influenza (e.g. respiratory syncytial virus) could be considered based on availability and local epidemiology.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">b</sup> This test is not in the WHO EDL <em class=\"calibre10\">(6)</em>.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-613\" role=\"doc-pagebreak\" title=\"556\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-930\"></a>Table 39.3 – Laboratory tests to consider when febrile neutropenia is suspected as indicated in the WHO EDL <em class=\"calibre10\">(6)</em></strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Diagnostic test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Purpose of the test</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Settings where the test should be available</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Complete blood count</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To detect a wide range of disorders (e.g. severity of neutropenia, anaemia, thrombocytopenia), including infections</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">C-reactive protein<sup class=\"calibre30\">a</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To detect inflammation as an indicator of various conditions (e.g. sepsis)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Procalcitonin<sup class=\"calibre30\">a</sup></p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To guide antibiotic therapy or discontinuation in sepsis</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Only in tertiary care facilities</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Bilirubin</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To detect or monitor liver disease</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Community settings and health facilities without laboratories<sup class=\"calibre30\">b</sup></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Creatinine</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To monitor kidney function for management of severe infections (i.e. sepsis) and to adjust antimicrobial regimens</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Electrolytes</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To monitor fluid, electrolyte and acid–base balance</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Blood pH and gases</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">To assess lung function, metabolic or kidney disorders and monitor oxygen therapy</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Health care facilities with clinical laboratories</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Whole blood lactate</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">To assess metabolic acidosis, sepsis and dehydration</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Community settings and health facilities without laboratories<sup class=\"calibre30\">b</sup></p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">EDL: Model List of Essential In Vitro Diagnostics.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> Measurement of biomarkers on admission (C-reactive protein and procalcitonin) might help identify high-risk patients and predict severe outcomes, such as sepsis <em class=\"calibre10\">(368–370)</em>.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">b</sup> Community and health settings without laboratories are facilities such as health posts and centres, doctors’ offices, outreach clinics, ambulatory care and home-based and self-testing. These tests are assumed to be available at health care facilities with laboratories.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-616\" role=\"doc-pagebreak\" title=\"559\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-931\"></a>Table 39.4 – Initial empiric antibiotic treatment for febrile neutropenia (absolute neutrophil count &lt; 500 cells/μL (&lt; 0.5 x 10</strong><sup class=\"calibre30\">9</sup> <strong class=\"calibre5\">cells/L)) based on the patient’s initial risk assessment</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Patient risk</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Adults</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Children</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Total treatment duration</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Low risk: expected duration of neutropenia &lt; 7 days, no major comorbidities, no organ dysfunction, possible outpatient treatment</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_verde\">Amoxicillin+clavulanic acid</span></p>\n<p class=\"box_p1\">(oral): 500 mg+125mg given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">CONSIDER ADDING</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Ciprofloxacin</span><sup class=\"calibre30\">a</sup> (oral): 500 mg given every 12 hours</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_verde\">Amoxicillin+clavulanic acid</span><sup class=\"calibre30\">b</sup> (oral): 80–90 mg/kg/day of amoxicillin component</p>\n<p class=\"box_p1\">Oral weight bands:</p>\n<p class=\"box_p1\">3–&lt; 6 kg: 250 mg of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p1\">6–&lt; 10 kg: 375 mg of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 500 mg of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 750 mg of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p1\">≥ 20 kg: 500 mg of amoxicillin/dose given every 8 hours or 1 g of amoxicillin/dose given every 12 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">CONSIDER ADDING</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Ciprofloxacin</span> (oral) 15 mg/kg/dose given every 12 hours</p>\n<p class=\"box_p1\">Oral weight bands:</p>\n<p class=\"box_p1\">3–&lt; 6 kg: 50 mg given every 12 hours</p>\n<p class=\"box_p1\">6–&lt; 10 kg: 100 mg given every 12 hours</p>\n<p class=\"box_p1\">10–&lt; 15 kg: 150 mg given every 12 hours</p>\n<p class=\"box_p1\">15–&lt; 20 kg: 200 mg given every 12 hours</p>\n<p class=\"box_p1\">20–&lt;30 kg: 300 mg given every 12 hours</p>\n<p class=\"box_p1\">≥ 30 kg: use adult dose</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">7 days</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"calibre6\" id=\"calibre_link-617\" role=\"doc-pagebreak\" title=\"560\" type=\"pagebreak\"></span>High risk: expected duration of neutropenia &gt; 7 days, major comorbidities, organ dysfunction</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">First choice</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Piperacillin+tazobactam</span> (IV): 4g + 500 mg given every 6 hours</p>\n<p class=\"box_p1\"></p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Second choice</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Meropenem</span><sup class=\"calibre30\">c</sup> (IV): 1g given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">CONSIDER ADDING</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Amikacin</span><sup class=\"calibre30\">d</sup> (IV): 15 mg/kg given once a day</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">AND/OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Vancomycin</span><sup class=\"calibre30\">e</sup> (IV): 15–20 mg/kg given every 12 hours</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">First choice</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Piperacillin+tazobactam</span> (IV): 100 mg/kg/dose of piperacillin component given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">Second choice</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Meropenem</span><sup class=\"calibre30\">c</sup> (IV): 20 mg/kg/dose given every 8 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">CONSIDER ADDING</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Amikacin</span><sup class=\"calibre30\">d</sup> (IV): 15 mg/kg/dose given once a day</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">AND/OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_amarelo\">Vancomycin</span><sup class=\"calibre30\">e</sup> (IV):</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">Neonates: 15 mg/kg/dose given every 12 hours</li>\n<li class=\"box_li1\">Children: 15 mg/kg/dose given every 8 hours</li>\n</ul>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Until clinical signs of infection have resolved, including absence of fever for at least 48 hours.</p>\n<p class=\"box_p1\">If a pathogen is identified, the duration of therapy will be based on the particular pathogen and site of infection. If the patient still has neutropenia, he/she should be closely monitored for 24–48 hours and if fever returns, antibiotics should be restarted.</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"4\">\n<p class=\"legenda\"><span class=\"calibre6\" id=\"calibre_link-618\" role=\"doc-pagebreak\" title=\"561\" type=\"pagebreak\"></span>ESBL: extended-spectrum beta-lactamase; IV: intravenous; <em class=\"calibre10\">MRSA</em>: methicillin-resistant <em class=\"calibre10\">Staphylococcus aureus</em>.</p>\n<p class=\"legenda\">Note. All dosages are for normal renal and hepatic function.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> The use of fluoroquinolones (such as ciprofloxacin) can be associated with important side-effects including: (i) mental health disturbances such as disorientation, agitation, nervousness, memory impairment and delirium; (ii) serious blood sugar disturbances such as hypoglycaemic coma; (iii) increased risk of tendinitis and tendon rupture; (iv) worsening symptoms in those with myasthenia gravis; and (v) potential irreversible neuropathy (serious nerve damage).</p>\n<p class=\"legenda\"><sup class=\"calibre30\">b</sup> Oral liquid formulations must be refrigerated after reconstitution as clavulanic acid is rapidly metabolized in high ambient temperatures.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">c</sup> Empiric meropenem should only be considered in settings with a high prevalence of ESBL-producing Enterobacterales or in patients with known prior colonization or infection with resistant pathogens.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">d</sup> Consider adding amikacin in combination with piperacillin+tazobactam or meropenem when infections with resistant Gram-negative bacteria are suspected based on local epidemiology and clinical presentation; for example, severely ill patients including those who become clinically unstable after initial empiric monotherapy, and patients with known prior colonization or infection with ESBL-producing Enterobacterales. The need to continue combination treatment should be reassessed over time (e.g. after 48–72 hours) based on microbiology test results and clinical response.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">e</sup> Consider adding vancomycin in combination with piperacillin+tazobactam or meropenem when infection with MRSA is suspected (e.g. patients with MRSA colonization) or where a line infection is strongly suspected because of the risk of multidrug-resistant coagulase-negative <em class=\"calibre10\">Staphylococcus</em> infection. The need to continue combination treatment should be reassessed over time (e.g. after 48–72 hours) based on microbiology test results and clinical response.</p>\n<p class=\"legenda\">Legend: ACCESS antibiotics are highlighted in green, WATCH antibiotics in yellow and RESERVE antibiotics in red.</p>\n</td>\n</tr>\n</tfoot>\n</table>"
        ]
    },
    {
        "name": "Surgical prophylaxis",
        "tables": [
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-626\" role=\"doc-pagebreak\" title=\"569\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-932\"></a>Table 40.1 – Pathogens most frequently associated with surgical site infections by anatomical site of the procedure</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Type of procedure</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Pathogens most frequently associated with surgical site infections</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Cardiac procedures</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\"><em class=\"calibre10\">Staphylococcus aureus</em> and coagulase-negative staphylococci</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Cardiac device insertion procedures (e.g. pacemaker implantation)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><em class=\"calibre10\">Staphylococcus aureus</em> and coagulase-negative staphylococci</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Non-cardiac thoracic procedures (e.g. pulmonary resection)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\"><em class=\"calibre10\">Staphylococcus aureus</em> and coagulase-negative staphylococci</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Haemophilus influenzae</em></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Enterobacter cloacae</em></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Klebsiella pneumoniae</em></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Acinetobacter</em> spp.</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Pseudomonas aeruginosa</em></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Moraxella catarrhalis</em></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Gastroduodenal procedures</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><em class=\"calibre10\">Staphylococcus aureus</em> and coagulase-negative staphylococci</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Enterococcus</em> spp.</p>\n<p class=\"box_p1\">Enterobacterales</p>\n<p class=\"box_p1\">Anaerobes (<em class=\"calibre10\">Bacteroides</em> spp.)</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Biliary tract procedures</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Enterobacterales</p>\n<p class=\"box_p1\">Anaerobes</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Enterococcus</em> spp.</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Streptococcus</em> spp.</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Staphylococcus aureus</em> and coagulase-negative staphylococci</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Appendectomy</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><em class=\"calibre10\">Escherichia coli</em></p>\n<p class=\"box_p1\">Anaerobes (<em class=\"calibre10\">Bacteroides fragilis</em>)</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Small intestine procedures</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Enterobacterales</p>\n<p class=\"box_p1\">Anaerobes</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Enterococcus</em> spp.</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Streptococcus</em> spp.</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Staphylococcus aureus</em> and coagulase-negative staphylococci</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"calibre6\" id=\"calibre_link-627\" role=\"doc-pagebreak\" title=\"570\" type=\"pagebreak\"></span>Hernia repair procedures</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><em class=\"calibre10\">Enterococcus</em> spp.</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Streptococcus</em> spp.</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Staphylococcus aureus</em> and coagulase-negative staphylococci</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Colorectal procedures</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\"><em class=\"calibre10\">Escherichia coli</em></p>\n<p class=\"box_p1\">Anaerobes (<em class=\"calibre10\">Bacteroides fragilis</em>)</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Head and neck procedures</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><em class=\"calibre10\">Streptococcus</em> spp.</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Staphylococcus aureus</em> and coagulase-negative staphylococci</p>\n<p class=\"box_p1\">Enterobacterales</p>\n<p class=\"box_p1\">Anaerobes (from the oral microbiota)</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Neurosurgical procedures</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\"><em class=\"calibre10\">Staphylococcus aureus</em> and coagulase-negative staphylococci</p>\n<p class=\"box_p1\">Gram-negative bacteria</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Gynaecological procedures</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><em class=\"calibre10\">Streptococcus agalactiae</em> (group B streptococcus)</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Staphylococcus aureus</em></p>\n<p class=\"box_p1\"><em class=\"calibre10\">Enterococcus</em> spp.</p>\n<p class=\"box_p1\">Anaerobes</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Ophthalmic procedures</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\"><em class=\"calibre10\">Staphylococcus aureus</em> and coagulase-negative staphylococci</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Orthopaedic procedures</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><em class=\"calibre10\">Staphylococcus aureus</em> and coagulase-negative staphylococci</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Urological procedures</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">Enterobacterales (mostly <em class=\"calibre10\">Escherichia coli</em>)</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Enterococcus</em> spp.</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Vascular procedures</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><em class=\"calibre10\">Staphylococcus aureus</em> and coagulase-negative staphylococci</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"2\">\n<p class=\"legenda\">Note. This list is based on data from high-income settings and aims to give a general overview <em class=\"calibre10\">(380)</em>. The distribution of the pathogens most frequently associated with surgical site infections may vary in other settings.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-629\" role=\"doc-pagebreak\" title=\"572\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-933\"></a>Table 40.2 – Antibiotic prophylaxis before surgical procedures (all single dose)</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Type of procedure</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">First choice</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Second choice</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Clean procedure<sup class=\"calibre30\">a</sup></p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\"><span class=\"back_verde\">Cefazolin</span> (IV):</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">Children: 50 mg/kg</li>\n<li class=\"box_li1\">Adults: 2 g<sup class=\"calibre30\">b</sup></li>\n</ul>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\"><span class=\"back_amarelo\">Cefuroxime</span> (IV):</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">Children: 50 mg/kg</li>\n<li class=\"box_li1\">Adults: 1.5 g</li>\n</ul>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Clean contaminated procedure<sup class=\"calibre30\">c</sup> (except bowel surgery and urological procedures)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_verde\">Cefazolin</span> (IV):</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">Children: 50 mg/kg</li>\n<li class=\"box_li1\">Adults: 2 g<sup class=\"calibre30\">b</sup></li>\n</ul>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_amarelo\">Cefuroxime</span> (IV):</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">Children: 50 mg/kg</li>\n<li class=\"box_li1\">Adults: 1.5 g</li>\n</ul>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Contaminated procedure<sup class=\"calibre30\">d</sup></p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\"><span class=\"back_verde\">Cefazolin</span> (IV):</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">Children: 50 mg/kg</li>\n<li class=\"box_li1\">Adults: 2 g<sup class=\"calibre30\">b</sup></li>\n</ul>\n<p class=\"box_p3\"><strong class=\"calibre5\">AND</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Metronidazole</span> (IV):</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">Children: 7.5 mg/kg</li>\n<li class=\"box_li1\">Adults: 500 mg</li>\n</ul>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\"><span class=\"back_verde\">Amoxicillin+clavulanic acid</span> (IV):</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">Children: 50 mg/kg of amoxicillin component</li>\n<li class=\"box_li1\">Adults: 2 g + 200 mg</li>\n</ul>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Gentamicin</span><sup class=\"calibre30\">e</sup> (IV):</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">Neonates: 5 mg/kg</li>\n<li class=\"box_li1\">Children: 7.5 mg/kg</li>\n<li class=\"box_li1\">Adults: 5 mg/kg</li>\n</ul>\n<p class=\"box_p3\"><strong class=\"calibre5\">AND</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Metronidazole</span> (IV):</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">Children: 7.5 mg/kg</li>\n<li class=\"box_li1\">Adults: 500 mg</li>\n</ul>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Bowel surgery<sup class=\"calibre30\">f</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_verde\">Cefazolin</span> (IV):</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">Children: 50 mg/kg</li>\n<li class=\"box_li1\">Adults: 2 g<sup class=\"calibre30\">b</sup></li>\n</ul>\n<p class=\"box_p3\"><strong class=\"calibre5\">AND</strong></p>\n<p class=\"box_p1\"><span class=\"back_verde\">Metronidazole</span> (IV):</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">Children: 7.5 mg/kg</li>\n<li class=\"box_li1\">Adults: 500 mg</li>\n</ul>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"back_verde\">Amoxicillin+clavulanic acid</span> (IV):</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">Children: 50 mg/kg of amoxicillin component</li>\n<li class=\"box_li1\">Adults: 2 g + 200 mg</li>\n</ul>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Urologic procedures</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\"><span class=\"back_verde\">Cefazolin</span> (IV):</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">Children: 50 mg/kg</li>\n<li class=\"box_li1\">Adults: 2 g<sup class=\"calibre30\">b</sup></li>\n</ul>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\"><span class=\"back_verde\">Gentamicin</span> (IV):</p>\n<ul class=\"calibre22\">\n<li class=\"box_li1\">Neonates: 5 mg/kg</li>\n<li class=\"box_li1\">Children: 7.5 mg/kg</li>\n<li class=\"box_li1\">Adults: 5 mg/kg</li>\n</ul>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\"><span class=\"calibre6\" id=\"calibre_link-630\" role=\"doc-pagebreak\" title=\"573\" type=\"pagebreak\"></span>IV: intravenous.</p>\n<p class=\"legenda\">Note: All dosages are for normal renal and hepatic function.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> Surgical procedures where the respiratory, alimentary, genital or urinary tracts are not entered.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">b</sup> Higher doses of cefazolin (e.g. 3 g) may be required in obese patients, &gt; 120 kg.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">c</sup> Surgical procedures where the respiratory, alimentary, genital or urinary tracts are entered under controlled conditions and without unusual contamination. Operations involving the biliary tract, appendix, vagina and oropharynx are included in this category.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">d</sup> Operations with major (i.e. significant) interruptions in sterile technique (e.g. open cardiac massage) or substantial spillage from the gastrointestinal tract.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">e</sup> Gentamicin should be given in combination with metronidazole and not as a stand-alone option in contaminated surgical procedures because, if given alone, it provides insufficient coverage of anaerobic bacteria. Amikacin could be used instead of gentamicin based on local availability.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">f</sup> Bowel surgery includes appendectomy, small intestine and colorectal surgical procedures.</p>\n<p class=\"legenda\">Legend: ACCESS antibiotics are indicated in green, WATCH antibiotics in orange and RESERVE antibiotics in red.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-631\" role=\"doc-pagebreak\" title=\"574\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-934\"></a>Table 40.3 – Half-life of the antibiotics recommended for surgical prophylaxis in the WHO EML <em class=\"calibre10\">(8)</em></strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Antibiotic</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Half-life</strong><sup class=\"calibre32\">a</sup> <strong class=\"calibre5\">(hours)</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Amoxicillin+clavulanic acid</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">1–2</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Cefazolin</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">1.2–2.2</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Cefuroxime</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">1–2</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Gentamicin</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">2–3</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Metronidazole</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">6–8</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"2\">\n<p class=\"legenda\">EML: Model List of Essential Medicines.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> In adults with normal renal function</p>\n</td>\n</tr>\n</tfoot>\n</table>"
        ]
    },
    {
        "name": "Overview",
        "tables": [
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-937\"></a>Table 41.1 – Expected activity of Reserve antibiotics against third-generation cephalosporin- and carbapenem-resistant bacteria based on the type of beta-lactamase produced</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Type of beta-lactamase</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">ESBL</strong><sup class=\"calibre32\">a</sup></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">KPC</strong><sup class=\"calibre32\">b</sup></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">NDM, VIM, IMP</strong><sup class=\"calibre32\">b</sup></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">AmpC</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">OXA-48</strong><sup class=\"calibre32\">b</sup></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Non-fermenters</strong><sup class=\"calibre32\">c</sup></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Ambler class</strong><sup class=\"calibre30\">d</sup></p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">A<sup class=\"calibre30\">e</sup></p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">A<sup class=\"calibre30\">e</sup></p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">B</p>\n<p class=\"box_p1\">(MBLs)</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">C<sup class=\"calibre30\">e</sup></p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">D<sup class=\"calibre30\">e</sup></p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">NA</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">Cefiderocol</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">+</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">+</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">+</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">+</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">+</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">+<sup class=\"calibre30\">f</sup></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\" rowspan=\"2\">\n<p class=\"box_p1\">Ceftazidime+avibactam</p>\n</td>\n<td class=\"color\" rowspan=\"2\">\n<p class=\"box_p1\">+</p>\n</td>\n<td class=\"color\" rowspan=\"2\">\n<p class=\"box_p1\">+</p>\n</td>\n<td class=\"color\" rowspan=\"2\">\n<p class=\"box_p1\">–</p>\n</td>\n<td class=\"color\" rowspan=\"2\">\n<p class=\"box_p1\">+</p>\n</td>\n<td class=\"color\" rowspan=\"2\">\n<p class=\"box_p1\">+</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">–</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Acinetobacter baumannii</em></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">+</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Pseudomonas aeruginosa</em></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\" rowspan=\"2\">\n<p class=\"box_p1\">Fosfomycin (IV)</p>\n<p class=\"box_p1\">(consider using only in combination therapy)</p>\n</td>\n<td class=\"calibre29\" rowspan=\"2\">\n<p class=\"box_p1\">+</p>\n</td>\n<td class=\"calibre29\" rowspan=\"2\">\n<p class=\"box_p1\">+/–</p>\n</td>\n<td class=\"calibre29\" rowspan=\"2\">\n<p class=\"box_p1\">+/–</p>\n</td>\n<td class=\"calibre29\" rowspan=\"2\">\n<p class=\"box_p1\">+</p>\n</td>\n<td class=\"calibre29\" rowspan=\"2\">\n<p class=\"box_p1\">+/–</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">–</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Acinetobacter baumannii</em></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">+/–</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Pseudomonas aeruginosa</em></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Meropenem+vaborbactam</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">+</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">+</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">–</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">+</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">–</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">+/–</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><span class=\"calibre6\" id=\"calibre_link-637\" role=\"doc-pagebreak\" title=\"581\" type=\"pagebreak\"></span>Plazomicin</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">+</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">+</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">+/–</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">+</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">+</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">–</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"color\">\n<p class=\"box_p1\">Polymyxin B and colistin</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">+</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">+</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">+</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">+</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">+</p>\n</td>\n<td class=\"color\">\n<p class=\"box_p1\">+</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"7\">\n<p class=\"legenda\">AmpC: ampicillinase C; ESBL: extended-spectrum beta-lactamases; IMP: imipenemase; IV: intravenous; KPC: <em class=\"calibre10\">Klebsiella pneumoniae</em> carbapenemase; MBLs: metallo-beta-lactamases; NA: not applicable; NDM: New Delhi metallo-beta-lactamase; OXA-48: oxacillinase-48; VIM: Verona integron-encoded metallo-beta-lactamase.</p>\n<p class=\"legenda\"><strong class=\"calibre5\">Expected activity</strong>: + active; +/– possibly active; – not or insufficiently active.</p>\n<p class=\"legenda\">a ESBL are a group of different beta-lactamases conferring resistance to most beta-lactam antibiotics (with the notable exception of carbapenems).</p>\n<p class=\"legenda\"><sup class=\"calibre30\">b</sup> Carbapenemases.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">c</sup> Non-fermenters refer to bacteria that cannot catabolize glucose and thus are unable to ferment. The most relevant in this context are <em class=\"calibre10\">Acinetobacter baumannii</em> and <em class=\"calibre10\">Pseudomonas aeruginosa</em>. Please note when using this table, always consider that even when activity of a certain Reserve antibiotic is reported against carbapenem-resistant non-fermenters, this activity ultimately depends on the type of carbapenemase produced and the resistance mechanism. For plazomicin, some in vitro studies have shown activity against <em class=\"calibre10\">Pseudomonas aeruginosa</em> similar to amikacin <em class=\"calibre10\">(426)</em>.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">d</sup> The Ambler classification of beta-lactamases is the most widely used classification. According to this classification beta-lactamases are divided into four classes (A, B, C and D) based upon similarities in their amino acid sequence.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">e</sup> Ambler class A, C and D are serine beta-lactamases.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">f</sup> Higher mortality has been reported with carbapenem-resistant <em class=\"calibre10\">Acinetobacter baumannii</em> infections.</p>\n</td>\n</tr>\n</tfoot>\n</table>"
        ]
    },
    {
        "name": "Cefiderocol",
        "tables": [
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-641\" role=\"doc-pagebreak\" title=\"585\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-938\"></a>Table 42.1 – Expected activity of cefiderocol against third-generation cephalosporin and carbapenem-resistant bacteria based on the type of beta-lactamase produced</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Type of beta-lactamase</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">ESBL</strong><sup class=\"calibre32\">a</sup></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">KPC</strong><sup class=\"calibre32\">b</sup></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">NDM, VIM, IMP</strong><sup class=\"calibre32\">b</sup></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">AmpC</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">OXA-48</strong><sup class=\"calibre32\">b</sup></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Non-fermenters</strong><sup class=\"calibre32\">c</sup></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Ambler class</strong><sup class=\"calibre30\">d</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">A<sup class=\"calibre30\">e</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">A<sup class=\"calibre30\">e</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">B</p>\n<p class=\"box_p1\">(MBLs)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">C<sup class=\"calibre30\">e</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">D<sup class=\"calibre30\">e</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">NA</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Expected activity of cefiderocol</strong></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">+</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">+</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">+</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">+</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">+</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">+<sup class=\"calibre30\">f</sup></p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"7\">\n<p class=\"legenda\">AmpC: ampicillinase C; ESBL: extended-spectrum beta-lactamases; IMP: imipenemase; KPC: <em class=\"calibre10\">Klebsiella pneumoniae</em> carbapenemase; MBLs: metallo-beta-lactamases; NA: not applicable; NDM: New Delhi metallo-beta-lactamase; OXA-48: oxacillinase-48; VIM: Verona integron-encoded metallo-beta-lactamase.</p>\n<p class=\"legenda\"><strong class=\"calibre5\">Expected activity</strong>: + active.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> ESBL are a group of different beta-lactamases.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">b</sup> Carbapenemases.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">c</sup> Non-fermenters refer to bacteria that cannot catabolize glucose and thus are unable to ferment. The most relevant in this context are <em class=\"calibre10\">Acinetobacter baumannii</em> and <em class=\"calibre10\">Pseudomonas aeruginosa</em>. When using this table, always consider that even when activity of a certain Reserve antibiotic is reported against carbapenem-resistant non-fermenters, this ultimately depends on the type of carbapenemase produced and the resistance mechanism.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">d</sup> The Ambler classification of beta-lactamases is the most widely used classification. According to this classification beta-lactamases are divided into four classes (A, B, C and D) based upon similarities in their amino acid sequence.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">e</sup> Ambler class A, C and D are serine beta-lactamases.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">f</sup> Higher mortality has been reported with carbapenem-resistant <em class=\"calibre10\">Acinetobacter baumannii</em> infections.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-939\"></a>Table 42.2 – Cefiderocol suggested doses</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Dose in adults</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Dose in children</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Dose in neonates</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">2 g given every 8 hours</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">There are no data for children or neonates</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">There are no data for children or neonates</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">Note. All dosages are for normal renal and hepatic function.</p>\n</td>\n</tr>\n</tfoot>\n</table>"
        ]
    },
    {
        "name": "Ceftazidime+avibactam",
        "tables": [
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-940\"></a>Table 43.1 – Expected activity of ceftazidime+avibactam against third-generation cephalosporin- and carbapenem-resistant bacteria based on the type of beta-lactamase produced</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Type of beta-lactamase</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">ESBL</strong><sup class=\"calibre32\">a</sup></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">KPC</strong><sup class=\"calibre32\">b</sup></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">NDM, VIM, IMP</strong><sup class=\"calibre32\">b</sup></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">AmpC</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">OXA-48</strong><sup class=\"calibre32\">b</sup></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Non-fermenters</strong><sup class=\"calibre32\">c</sup></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Ambler class</strong><sup class=\"calibre30\">d</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">A<sup class=\"calibre30\">e</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">A<sup class=\"calibre30\">e</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">B</p>\n<p class=\"box_p1\">(MBLs)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">C<sup class=\"calibre30\">e</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">D<sup class=\"calibre30\">e</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">NA</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\" rowspan=\"2\">\n<p class=\"box_p3\"><strong class=\"calibre5\">Expected activity of ceftazidime+ avibactam</strong><sup class=\"calibre30\">f</sup></p>\n</td>\n<td class=\"calibre29\" rowspan=\"2\">\n<p class=\"box_p1\">+</p>\n</td>\n<td class=\"calibre29\" rowspan=\"2\">\n<p class=\"box_p1\">+</p>\n</td>\n<td class=\"calibre29\" rowspan=\"2\">\n<p class=\"box_p1\">–</p>\n</td>\n<td class=\"calibre29\" rowspan=\"2\">\n<p class=\"box_p1\">+</p>\n</td>\n<td class=\"calibre29\" rowspan=\"2\">\n<p class=\"box_p1\">+</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">–</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Acinetobacter baumannii</em></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">+</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Pseudomonas aeruginosa</em></p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"7\">\n<p class=\"legenda\">AmpC: ampicillinase C; ESBL: extended-spectrum beta-lactamases; IMP: imipenemase; KPC: <em class=\"calibre10\">Klebsiella pneumoniae</em> <em class=\"calibre10\">carbapenemase</em>; MBLs: metallo-beta-lactamases; NA: not applicable; NDM: New Delhi metallo-beta-lactamase; OXA-48: oxacillinase-48; VIM: Verona integron-encoded metallo-beta-lactamase.</p>\n<p class=\"legenda\"><strong class=\"calibre5\">Expected activity</strong>: + active; – not or insufficiently active.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> ESBL are a group of different beta-lactamases.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">b</sup> Carbapenemases.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">c</sup> Non-fermenters refer to bacteria that cannot catabolize glucose and thus are unable to ferment. The most relevant in this context are <em class=\"calibre10\">Acinetobacter baumannii</em> and <em class=\"calibre10\">Pseudomonas aeruginosa</em>. When using this table, always consider that even when activity of a certain Reserve antibiotic is reported against carbapenem-resistant non-fermenters, this ultimately depends on the type of carbapenemase produced and the resistance mechanism.</p>\n<p class=\"legenda\"><span class=\"calibre6\" id=\"calibre_link-648\" role=\"doc-pagebreak\" title=\"592\" type=\"pagebreak\"></span><sup class=\"calibre30\">d</sup> The Ambler classification of beta-lactamases is the most widely used classification. According to this classification beta-lactamases are divided into four classes (A, B, C and D) based upon similarities in their amino acid sequence.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">e</sup> Ambler class A, C and D are serine beta-lactamases.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">f</sup> Ceftazidime+avibactam co-prescribed with aztreonam retains activity against metallo-beta-lactamase-producing bacteria, however aztreonam is not currently listed in the WHO EML and EMLc.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-649\" role=\"doc-pagebreak\" title=\"593\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-941\"></a>Table 43.2 – Ceftazidime+avibactam suggested doses</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Dose in adults</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Dose in children</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">IV: 2.5 g (2 g ceftazidime + 500 mg avibactam) given every 8 hours</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">IV: 62.5 mg/kg/dose (50 mg/kg/dose ceftazidime + 12.5 mg/kg/dose avibactam); given every 8 hours</p>\n<p class=\"box_p1\">Max: 2 g ceftazidime + 500 mg avibactam per dose</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"2\">\n<p class=\"legenda\">IV: intravenous.</p>\n<p class=\"legenda\">Note. All dosages are for normal renal and hepatic function.</p>\n</td>\n</tr>\n</tfoot>\n</table>"
        ]
    },
    {
        "name": "Fosfomycin (intravenous)",
        "tables": [
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-942\"></a>Table 44.1 – Expected activity of intravenous fosfomycin against third-generation cephalosporin and carbapenem-resistant bacteria based on the type of beta-lactamase produced</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Type of beta-lactamase</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">ESBL</strong><sup class=\"calibre32\">a</sup></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">KPC</strong><sup class=\"calibre32\">b</sup></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">NDM, VIM, IMP</strong><sup class=\"calibre32\">b</sup></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">AmpC</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">OXA-48</strong><sup class=\"calibre32\">b</sup></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Non-fermenters</strong><sup class=\"calibre32\">c</sup></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Ambler class</strong><sup class=\"calibre30\">d</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">A<sup class=\"calibre30\">e</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">A<sup class=\"calibre30\">e</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">B</p>\n<p class=\"box_p1\">(MBLs)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">C<sup class=\"calibre30\">e</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">D<sup class=\"calibre30\">e</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">NA</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\" rowspan=\"2\">\n<p class=\"box_p3\"><strong class=\"calibre5\">Expected activity of IV fosfomycin</strong></p>\n<p class=\"box_p1\">(Consider using only in combination therapy)</p>\n</td>\n<td class=\"calibre29\" rowspan=\"2\">\n<p class=\"box_p1\">+</p>\n</td>\n<td class=\"calibre29\" rowspan=\"2\">\n<p class=\"box_p1\">+/–</p>\n</td>\n<td class=\"calibre29\" rowspan=\"2\">\n<p class=\"box_p1\">+/–</p>\n</td>\n<td class=\"calibre29\" rowspan=\"2\">\n<p class=\"box_p1\">+</p>\n</td>\n<td class=\"calibre29\" rowspan=\"2\">\n<p class=\"box_p1\">+/–</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">–</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Acinetobacter baumannii</em></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">+/–</p>\n<p class=\"box_p1\"><em class=\"calibre10\">Pseudomonas aeruginosa</em></p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"7\">\n<p class=\"legenda\">AmpC: ampicillinase C; ESBL: extended-spectrum beta-lactamases; IMP: imipenemase; IV: intravenous; KPC: <em class=\"calibre10\">Klebsiella pneumoniae</em> carbapenemase; MBLs: metallo-beta-lactamases; NA: not applicable; NDM: New Delhi metallo-beta-lactamase; OXA-48: oxacillinase-48; VIM: Verona integron-encoded metallo-beta-lactamase.</p>\n<p class=\"legenda\"><strong class=\"calibre5\">Expected activity</strong>: + active; +/– possibly active; – not or insufficiently active.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> ESBL are a group of different beta-lactamases.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">b</sup> Carbapenemases.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">c</sup> Non-fermenters refer to bacteria that cannot catabolize glucose and thus are unable to ferment. The most relevant in this context are <em class=\"calibre10\">Acinetobacter baumannii</em> and <em class=\"calibre10\">Pseudomonas aeruginosa</em>. When using this table, always consider that even when activity of a certain Reserve antibiotic is reported against carbapenem-resistant non-fermenters, this ultimately depends on the type of carbapenemase produced and the resistance mechanism.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">d</sup> The Ambler classification of beta-lactamases is the most widely used classification. According to this classification beta-lactamases are divided into four classes (A, B, C and D) based upon similarities in their amino acid sequence.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">e</sup> Ambler class A, C and D are serine beta-lactamases.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-655\" role=\"doc-pagebreak\" title=\"599\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-943\"></a>Table 44.2 – Fosfomycin suggested doses</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Dose in adults</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Dose in children</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">IV: 6 g given every 8 hours</p>\n<p class=\"box_p1\">(Note. Total daily dose may vary depending on the indication and may range between 12 g and 24 g per day divided every 8 to 12 hours.)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">IV: 200–400 mg/kg/day divided every 8 to 12 hours</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"2\">\n<p class=\"legenda\">IV: intravenous.</p>\n<p class=\"legenda\">Note. All dosages are for normal renal and hepatic function.</p>\n</td>\n</tr>\n</tfoot>\n</table>"
        ]
    },
    {
        "name": "Linezolid",
        "tables": [
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-944\"></a>Table 45.1 – Linezolid suggested doses</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Dose in adults</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Dose in children</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Dose in neonates</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">600 mg given every 12 hours</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">10 mg/kg/dose given every 8 hours</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">10 mg/kg/dose given every 12 hours (first week of life) or every 8 hours (&gt; first week of life)</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">Note. All dosages are for normal renal and hepatic function.</p>\n</td>\n</tr>\n</tfoot>\n</table>"
        ]
    },
    {
        "name": "Meropenem+vaborbactam",
        "tables": [
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-945\"></a>Table 46.1 – Expected activity of meropenem+vaborbactam against third-generation cephalosporin and carbapenem-resistant bacteria based on the type of beta-lactamase produced</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Type of beta-lactamase</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">ESBL</strong><sup class=\"calibre32\">a</sup></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">KPC</strong><sup class=\"calibre32\">b</sup></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">NDM, VIM, IMP</strong><sup class=\"calibre32\">b</sup></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">AmpC</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">OXA-48</strong><sup class=\"calibre32\">b</sup></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Non-fermenters</strong><sup class=\"calibre32\">c</sup></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Ambler class</strong><sup class=\"calibre30\">d</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">A<sup class=\"calibre30\">e</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">A<sup class=\"calibre30\">e</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">B</p>\n<p class=\"box_p1\">(MBLs)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">C<sup class=\"calibre30\">e</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">D<sup class=\"calibre30\">e</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">NA</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Expected activity of meropenem+ vaborbactam</strong></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">+</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">+</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">–</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">+</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">–</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">+/–</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"7\">\n<p class=\"legenda\">AmpC: ampicillinase C; ESBL: extended-spectrum beta-lactamases; IMP: imipenemase; KPC: <em class=\"calibre10\">Klebsiella pneumoniae</em> carbapenemase; MBLs: metallo-beta-lactamases; NA: not applicable; NDM: New Delhi metallo-beta-lactamase; OXA-48: oxacillinase-48; VIM: Verona integron-encoded metallo-beta-lactamase.</p>\n<p class=\"legenda\"><strong class=\"calibre5\">Expected activity</strong>: + active; +/– possibly active; – not or insufficiently active.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> ESBL are a group of different beta-lactamases.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">b</sup> Carbapenemases.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">c</sup> Non-fermenters refer to bacteria that cannot catabolize glucose and thus are unable to ferment. The most relevant in this context are <em class=\"calibre10\">Acinetobacter baumannii</em> and <em class=\"calibre10\">Pseudomonas aeruginosa</em>. When using this table, always consider that even when activity of a certain Reserve antibiotic is reported against carbapenem-resistant non-fermenters, this ultimately depends on the type of carbapenemase produced and the resistance mechanism.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">d</sup> The Ambler classification of beta-lactamases is the most widely used classification. According to this classification beta-lactamases are divided into four classes (A, B, C and D) based upon similarities in their amino acid sequence.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">e</sup> Ambler class A, C and D are serine beta-lactamases.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-946\"></a>Table 46.2 – Meropenem+vaborbactam suggested doses</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Dose in adults</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Dose in children</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Dose in neonates</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">IV: 4 g (2 g meropenem + 2 g vaborbactam) given every 8 hours</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Currently not licensed for children</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Currently not licensed for neonates</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">IV: intravenous.</p>\n<p class=\"legenda\">Note. All dosages are for normal renal and hepatic function.</p>\n</td>\n</tr>\n</tfoot>\n</table>"
        ]
    },
    {
        "name": "Plazomicin",
        "tables": [
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-947\"></a>Table 47.1 – Expected activity of plazomicin against third-generation cephalosporin and carbapenem-resistant bacteria based on the type of beta-lactamase produced</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Type of beta-lactamase</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">ESBL</strong><sup class=\"calibre32\">a</sup></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">KPC</strong><sup class=\"calibre32\">b</sup></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">NDM, VIM, IMP</strong><sup class=\"calibre32\">b</sup></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">AmpC</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">OXA-48</strong><sup class=\"calibre32\">b</sup></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Non-fermenters</strong><sup class=\"calibre32\">c</sup></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Ambler class</strong><sup class=\"calibre30\">d</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">A<sup class=\"calibre30\">e</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">A<sup class=\"calibre30\">e</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">B</p>\n<p class=\"box_p1\">(MBLs)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">C<sup class=\"calibre30\">e</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">D<sup class=\"calibre30\">e</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">NA</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Expected activity of plazomicin</strong></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">+</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">+</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">+/– <sup class=\"calibre30\">f</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">+</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">+</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">–</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"7\">\n<p class=\"legenda\">AmpC: ampicillinase C; ESBL: extended-spectrum beta-lactamases; IMP: imipenemase; KPC: <em class=\"calibre10\">Klebsiella pneumoniae</em> carbapenemase; MBLs: metallo-beta-lactamases; NA: not applicable; NDM: New Delhi metallo-beta-lactamase; OXA-48: oxacillinase-48; VIM: Verona integron-encoded metallo-beta-lactamase.</p>\n<p class=\"legenda\"><strong class=\"calibre5\">Expected activity</strong>: + active; +/– possibly active; – not or insufficiently active.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> ESBL are a group of different beta-lactamases.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">b</sup> Carbapenemases.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">c</sup> Non-fermenters refer to bacteria that cannot catabolize glucose and thus are unable to ferment. The most relevant in this context are <em class=\"calibre10\">Acinetobacter baumannii</em> and <em class=\"calibre10\">Pseudomonas aeruginosa</em>. When using this table, always consider that even when activity of a certain Reserve antibiotic is reported against carbapenem-resistant non-fermenters, this ultimately depends on the type of carbapenemase produced and the resistance mechanism. For plazomicin, some in vitro studies have shown activity against <em class=\"calibre10\">Pseudomonas aeruginosa</em> similar to amikacin <em class=\"calibre10\">(426)</em>.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">d</sup> The Ambler classification of beta-lactamases is the most widely used classification. According to this classification beta-lactamases are divided into four classes (A, B, C and D) based upon similarities in their amino acid sequence.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">e</sup> Ambler class A, C and D are serine beta-lactamases.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">f</sup> Susceptibility to plazomicin among strains producing metallo-beta-lactamases can be &gt; 50%.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-948\"></a>Table 47.2 – Plazomicin suggested doses</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Dose in adults</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Dose in children</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Dose in neonates</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\">IV: 15 mg/kg given once daily</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Currently not licensed for children</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Currently not licensed for neonates</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"3\">\n<p class=\"legenda\">IV: intravenous.</p>\n<p class=\"legenda\">Note. All dosages are for normal renal and hepatic function.</p>\n</td>\n</tr>\n</tfoot>\n</table>"
        ]
    },
    {
        "name": "Polymyxin B and colistin (polymyxin E)",
        "tables": [
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-677\" role=\"doc-pagebreak\" title=\"621\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-949\"></a>Table 48.1 – Expected activity of polymyxins against third-generation cephalosporin and carbapenem-resistant bacteria based on the type of beta-lactamase produced</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Type of beta-lactamase</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">ESBL</strong><sup class=\"calibre32\">a</sup></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">KPC</strong><sup class=\"calibre32\">b</sup></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">NDM, VIM, IMP</strong><sup class=\"calibre32\">b</sup></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">AmpC</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">OXA-48</strong><sup class=\"calibre32\">b</sup></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Non-fermenters</strong><sup class=\"calibre32\">c</sup></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Ambler class</strong><sup class=\"calibre30\">d</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">A<sup class=\"calibre30\">e</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">A<sup class=\"calibre30\">e</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">B</p>\n<p class=\"box_p1\">(MBLs)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">C<sup class=\"calibre30\">e</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">D<sup class=\"calibre30\">e</sup></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">NA</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Expected activity of polymyxin B and colistin</strong></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">+</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">+</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">+</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">+</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">+</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">+</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"7\">\n<p class=\"legenda\">AmpC: ampicillinase C; ESBL: extended-spectrum beta-lactamases; IMP: imipenemase; KPC: <em class=\"calibre10\">Klebsiella pneumoniae</em> carbapenemase; MBLs: metallo-beta-lactamases; NA: not applicable; NDM: New Delhi metallo-beta-lactamase; OXA-48: oxacillinase-48; VIM: Verona integron-encoded metallo-beta-lactamase.</p>\n<p class=\"legenda\"><strong class=\"calibre5\">Expected activity</strong>: + active.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> ESBL are a group of different beta-lactamases.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">b</sup> Carbapenemases.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">c</sup> Non-fermenters refer to bacteria that cannot catabolize glucose and thus are unable to ferment. The most relevant in this context are <em class=\"calibre10\">Acinetobacter baumannii</em> and <em class=\"calibre10\">Pseudomonas aeruginosa</em>. When using this table, always consider that even when activity of a certain Reserve antibiotic is reported against carbapenem-resistant non-fermenters, this ultimately depends on the type of carbapenemase produced and the resistance mechanism.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">d</sup> The Ambler classification of beta-lactamases is the most widely used classification. According to this classification beta-lactamases are divided into four classes (A, B, C and D) based upon similarities in their amino acid sequence.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">e</sup> Ambler class A, C and D are serine beta-lactamases.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><span class=\"calibre6\" id=\"calibre_link-679\" role=\"doc-pagebreak\" title=\"623\" type=\"pagebreak\"></span><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-950\"></a>Table 48.2 – Polymyxin B suggested doses</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<thead class=\"calibre27\">\n<tr class=\"calibre20\">\n<th class=\"calibre28\"></th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Dose in adults</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Dose in children</strong></p>\n</th>\n<th class=\"calibre28\">\n<p class=\"table_head\"><strong class=\"calibre5\">Dose in neonates</strong></p>\n</th>\n</tr>\n</thead>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Loading dose</strong></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">2.5 mg/kg (25 000 IU/kg)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">2.5 mg/kg (25 000 IU/kg)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">2.5 mg/kg (25 000 IU/kg)</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Maintenance dose</strong></p>\n<p class=\"box_p1\">(start 12 hours after the loading dose)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">1.5 mg/kg/dose (15 000 IU/kg/dose) given every 12 hours</p>\n<p class=\"box_p1\">Higher doses up to 2.5 –3 mg/kg/dose (25 000–30 000 IU/kg/dose) can be used but the maximum daily dose should not exceed 200 mg (2 000 000 IU)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">1.5 mg/kg/dose (15 000 IU/kg/dose) given every 12 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">In children &lt; 2 years of age</strong></p>\n<p class=\"box_p1\">0.75–2.25 mg/kg/dose (7 500 –22 500 IU/kg/dose) given every 12 hours</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">0.75–2.25 mg/kg/dose (7 500 – 22 500 IU/kg/dose) given every 12 hours</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"4\">\n<p class=\"legenda\">Note. All dosages are for normal renal and hepatic function.</p>\n<p class=\"legenda\">IU: international units.</p>\n</td>\n</tr>\n</tfoot>\n</table>",
            "<table class=\"noborder\">\n<caption class=\"table_titb\"><strong class=\"calibre5\"><a class=\"calibre6\" id=\"calibre_link-951\"></a>Table 48.3 – Colistin suggested doses</strong></caption>\n<colgroup class=\"calibre17\">\n<col class=\"calibre18\"/>\n<col class=\"calibre18\"/>\n</colgroup>\n<tbody class=\"calibre19\">\n<tr class=\"calibre20\">\n<td class=\"color2\" colspan=\"4\">\n<p class=\"box_tit1\"><img alt=\"Imagem\" class=\"calibre26\" src=\"images/000166.jpg\"/> <strong class=\"calibre5\">Note</strong></p>\n<p class=\"box_p1\">Doses are expressed in mg of CBA and in IU of colistimethate sodium<sup class=\"calibre30\">a</sup></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"colort\"></td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Dose in adults</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Dose in children</strong></p>\n</td>\n<td class=\"colort\">\n<p class=\"table_head\"><strong class=\"calibre5\">Dose in neonates</strong></p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Loading dose</strong></p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">300 mg CBA (9 million IU colistimethate sodium)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Insufficient data</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">Insufficient data</p>\n</td>\n</tr>\n<tr class=\"calibre20\">\n<td class=\"calibre29\">\n<p class=\"box_p1\"><strong class=\"calibre5\">Maintenance dose</strong></p>\n<p class=\"box_p1\">(start 12 hours after the loading dose)</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">150 mg CBA (4.5 million IU colistimethate sodium) given every 12 hours</p>\n<p class=\"box_p1\">Maximum daily dose should not exceed 300-400 mg CBA or 9–12 million IU colistimethate sodium</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">0.625–1.25 mg/kg/dose CBA (18 750–37 500 IU/kg/dose colistimethate sodium) given every 6 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\">1.25–2.5 mg/kg/dose CBA (37 500–75 000 IU/kg/dose colistimethate sodium) given every 12 hours</p>\n</td>\n<td class=\"calibre29\">\n<p class=\"box_p1\">0.625–1.25 mg/kg/dose CBA (18 750–37 500 IU/kg/dose colistimethate sodium) given every 6 hours</p>\n<p class=\"box_p3\"><strong class=\"calibre5\">OR</strong></p>\n<p class=\"box_p1\">1.25–2.5 mg/kg/dose CBA (37 500–75 000 IU/kg/dose colistimethate sodium) given every 12 hours</p>\n</td>\n</tr>\n</tbody>\n<tfoot class=\"calibre31\">\n<tr class=\"calibre20\">\n<td class=\"calibre21\" colspan=\"4\">\n<p class=\"legenda\">CBA: colistin base activity; IU: international units.</p>\n<p class=\"legenda\">Note. All dosages are for normal renal and hepatic function.</p>\n<p class=\"legenda\"><sup class=\"calibre30\">a</sup> 34 mg of CBA corresponds to 1 million IU of colistimethate sodium and to 80 mg of colistimethate sodium.</p>\n</td>\n</tr>\n</tfoot>\n</table>"
        ]
    }
]


    for (var i = 0; i < data.length; i++) {
        var tables = data[i].tables;
        var name = data[i].name;
        
        var div = document.createElement("div");
        var h1 = document.createElement("h1");
        var h1Text = document.createTextNode(name);
        h1.appendChild(h1Text);
        div.appendChild(h1);
        
        for (var j = 0; j < tables.length; j++) {
            var table = tables[j];
            var tableDiv = document.createElement("div");
            tableDiv.innerHTML = table;
            div.appendChild(tableDiv);
        }

        document.body.appendChild(div);

        // add a br tag
        document.body.appendChild(document.createElement("br"));
        document.body.appendChild(document.createElement("br"));
    }

    </script>
</body>
</html>